
<html lang="en"     class="pb-page"  data-request-id="beb4e496-7ac3-4f7f-8c52-b60a6fbe2775"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2010.53.issue-4;website:website:acspubs;article:article:10.1021/jm901132v;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Selectively Nonselective Kinase Inhibition: Striking the Right Balance" /></meta><meta name="dc.Creator" content="Richard  Morphy" /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 27, 2009" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm901132v" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2009 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm901132v" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm901132v" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm901132v" /></link>
        
    
    

<title>Selectively Nonselective Kinase Inhibition: Striking the Right Balance | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm901132v" /></meta><meta property="og:title" content="Selectively Nonselective Kinase Inhibition: Striking the Right Balance" /></meta><meta property="og:image" content="https://pubs.acs.org/pb-assets/images/CoverImages_2by1Scaled/jmcmar-1595795902140.png" /></meta><meta property="og:description" content="" /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm901132v"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm901132v">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm901132v&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm901132v&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm901132v&amp;href=/doi/10.1021/jm901132v" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2010</span><span class="cit-fg-volume">, 53</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1413-1437</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/53/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/jm900932g" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Selectively Nonselective Kinase Inhibition: Striking the Right Balance</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Morphy">Richard Morphy</a></span><span class="author-xref-symbol "><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info"><span class="aff-text">Medicinal Chemistry Department, Schering-Plough, Newhouse, Lanarkshire, ML1 5SH, U.K.</span></div><div class="corresp-info"><strong>†</strong>Contact information. Phone: 01698-736104. Fax: 01698-736187. E-mail: <a href="/cdn-cgi/l/email-protection#e193888289809385cf8c8e93918998a19291828e9391cf828e8c"><span class="__cf_email__" data-cfemail="dba9b2b8b3baa9bff5b6b4a9abb3a29ba8abb8b4a9abf5b8b4b6">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm901132v&amp;href=/doi/10.1021%2Fjm901132v" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2010</span></span><span class="cit-volume">, 53</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1413–1437</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 27, 2009</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 July 2009</li><li><span class="item_label"><b>Published</b> online</span>27 October 2009</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 February 2010</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm901132v" title="DOI URL">https://doi.org/10.1021/jm901132v</a></div><div class="article_header-article-copyright"><strong>Copyright © 2009 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1413%26pageCount%3D25%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRichard%2BMorphy%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D53%26issueNum%3D4%26contentID%3Djm901132v%26title%3DSelectively%2BNonselective%2BKinase%2BInhibition%253A%2BStriking%2Bthe%2BRight%2BBalance%26numPages%3D25%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1437%26publicationDate%3DFebruary%2B2010">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm901132v"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">11167</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">203</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm901132v" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Selectively Nonselective Kinase Inhibition: Striking the Right Balance&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Morphy&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2009&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;53&quot;,&quot;pages&quot;:&quot;1413-1437&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm901132v&quot;},&quot;abstract&quot;:&quot;&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm901132v&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901132v" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm901132v&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901132v" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm901132v&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901132v" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm901132v&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901132v&amp;href=/doi/10.1021/jm901132v" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm901132v" /></input><a href="/doi/pdf/10.1021/jm901132v" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm901132v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm901132v%26sid%3Dliteratum%253Aachs%26pmid%3D20166671%26genre%3Darticle%26aulast%3DMorphy%26date%3D2010%26atitle%3DSelectively%2BNonselective%2BKinase%2BInhibition%253A%2BStriking%2Bthe%2BRight%2BBalance%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D53%26issue%3D4%26spage%3D1413%26epage%3D1437%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291264" title="Kinase inhibitors">Kinase inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/53/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83042" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83042" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Protein kinases have become the second most exploited group of drug targets after G-protein-coupled receptors (GPCRs), accounting for 30% of drug discovery projects at many pharmaceutical companies with dozens of compounds in clinical development.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Most early kinase inhibitors exhibited poor selectivity between kinases, and the trend in recent years has been toward ever more selective inhibitors in an attempt to minimize the risk of side effects. The risk with highly selective inhibitors is that their efficacy for treating complex diseases like cancer might be compromised by the redundancies in signaling pathways. The increasing interest in multitarget drug discovery (MTDD<a class="ref internalNav" href="#fnabbrev" aria-label="a">a</a>) <div class="NLM_fn" id="fnabbrev">a<p class="last">Abbreviations: MTDD, multitarget drug discovery; MTD, multitarget drug; DML, designed multiple ligand; MKI, multikinase inhibitor; STD, single target drug; FBDD, fragment-based drug discovery; SPR, surface plasmon resonance ; AS−MS, affinity selection−mass spectrometry; PDB, Protein Data Bank; ITC, isothermal titration calorimetry; FDC, fixed dose combination.</p></div> stems from a belief that modulating more than one target can provide superior efficacy and safety profiles compared to single target drugs. Currently, there are two contrasting MTDD philosophies. The first involves combining agents that are selective for a single target to achieve an additive or synergistic effect. The second involves discovering agents that are simultaneously capable of addressing two or more targets. Although this perspective focuses primarily on the latter, the advantages and disadvantages of both approaches will be highlighted.</div><div class="NLM_p">Very few drugs are truly selective for a single target, and in reality most biologically active small molecules have a degree of promiscuity by their very nature. Many clinically useful drugs are now known to have multiple activities, but most of these multitarget drugs (MTDs) were discovered serendipitously and their mechanisms of action were only established retrospectively. The deliberate and prospective design of ligands that act in a “selectively nonselective” manner on multiple targets of therapeutic interest is an emerging trend in drug discovery.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> Increasing numbers of these so-called designed multiple ligands (DMLs) are being reported in the medicinal chemistry literature.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In particular, identifying multikinase inhibitors (MKIs) with specific multiple activity profiles is currently an area of great interest in the pharmaceutical industry, especially for the treatment of cancer. Five years ago there were few examples of DMLs in the medicinal chemistry literature for kinase targets, but the period since has witnessed an explosive growth in interest in this area.</div><div class="NLM_p">Marketed MKI drugs vary with respect to the number of kinases they are known to inhibit, with some inhibiting only a small number of kinases, whereas others appear to be highly promiscuous. These apparent differences in selectivity are to an extent influenced by the amount of selectivity screening that has been performed, with some inhibitors appearing to be more promiscuous simply on the basis of having been profiled more rigorously. As the title of this Perspective delineates, the aim for the medicinal chemist working in the MKI field should be to strike the right balance between the nonselectivity (promiscuity) that may be required for efficacy and the selectivity that is required for safety. At present it is difficult to intentionally design a MKI with activity only at the kinases of interest, but increasingly rational and elegant medicinal chemistry approaches are being applied to solving this difficult problem. This Perspective aims to capture the current state of the art and to explore the future challenges and strategies in this area. The terminology used herein, illustrated using known inhibitors, is summarized in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>.</div><figure id="fig1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0013.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Overview of the terminology used in this article with examples.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">2 The First Marketed Kinase Inhibitor Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65656" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65656" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3">2.1 BCR-ABL Inhibitors for Treating Chronic Myelogenous Leukemia (CML)</h3><div class="NLM_p">Since the launch of imatinib (Gleevec) <b>1</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) in 2001 for treating chronic myelogenous leukemia (CML), a number of other kinase inhibitors have been approved for the treatment of cancer. Imatinib was originally developed to selectively inhibit the platelet-derived growth factor receptors (PDGFR) α and β but was later found to inhibit several structurally related tyrosine kinases like c-Kit and BCR-ABL.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The multikinase activity of imatinib has led to its exploitation in different cancer types showing significant clinical activity against malignancies dependent on all three of the receptors: BCR-ABL in CML, c-Kit in gastrointestinal stromal tumors (GIST), and PDGFR in dermatofibroma sarcoma protuberans (DFSP).</div><div class="NLM_p">While imatinib is extremely effective in treating chronic CML, patients with late-stage disease often have a less durable response due to acquired resistance, attributable to mutations in the ABL kinase domain that prevent the binding of imatinib.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The newer BCR-ABL1 inhibitors, nilotinib (Tasigna) <b>2</b> and dasatinib (Sprycel) <b>3</b>, are not only significantly more potent against the wild-type form of the kinase but also inhibit virtually all the known mutants, with the exception of the problematic ABL1 “T315I” mutant which increases the size of the gatekeeper residue from threonine to isoleucine (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> One MKI that inhibits the T315I mutant is the aurora kinase inhibitor VX-680/MK-0457 whose binding mode evades these gatekeeper mutations, leading to its successful use in imatinib-resistant CML patients.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">Drug resistant mutant kinases will likely present an ever greater challenge in the future because of natural selection pressures as ever larger patient populations are treated. As well as being active against multiple forms of BCR-ABL, dasatinib <b>3</b> and bosutinib <b>4</b> also inhibit a second family of kinases, SRC. Dual SRC/ABL inhibitors may have two separate roles in overcoming imatinib resistance, first combating BCR-ABL mutations by hitting multiple mutant forms of the same target and second hitting a second target, SRC, that has also been implicated in BCR-ABL signaling. Bosutinib is now in phase III clinical trials, and phase II studies have shown good activity in patients resistant to imatinib or other tyrosine kinase inhibitors.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><figure id="fig2" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0012.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Kinase inhibitors used for treating cancer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.2 Treatment of Solid Tumors</h3><div class="NLM_p">Where a specific target exists within a solid carcinoma, a highly target-selective drug might be useful.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The monoclonal antibody cetuximab (Erbitux) is a single target drug (STD, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) that acts selectively via the epidermal growth factor receptor tyrosine kinase (EGFR). It is used to treat metastatic colorectal cancer and head and neck cancer. Similarly, the small molecule kinase inhibitors gefitinib (Iressa) <b>7</b> and erlotinib (Tarceva) <b>8</b>, which are highly selective for EGFR, are used as a monotherapy for patients with non-small-cell lung cancer (NSCLC) who have activating mutations of EGFR. While the efficacy of gefitinib and erlotinib is generally regarded as being driven by inhibition of a single kinase, there is evidence that these inhibitors interact with other kinases at physiological concentrations and it is unknown if these contribute to the therapeutic effect.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Truly target-specific small molecule kinase inhibitors probably do not yet exist, and even if they are achievable, their value in the cancer area is questionable.</div><div class="NLM_p">Clinical experience suggests that selective targeting of a single kinase will produce fewer successful results in solid carcinomas than in leukemias and lymphomas and for shorter durations when they occur. A comparison of imatinib in CML and GIST demonstrates its superior response in the former condition.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The 10% major response rate for non-small-cell lung cancer is disappointing compared with the 90% response rate to imatinib for CML. Most solid tumors are not “addicted” to a single pathway for survival in the way that CML is “addicted” to the BCR-ABL pathway. There is increasing evidence that inhibiting multiple targets produces greater benefit over single-target inhibition where no specific pathway drives tumor proliferation and survival. Structural and architectural factors that are absent from leukemia have a profound influence on drug penetration into three-dimensional tumors. Once tumors grow beyond ∼2 mm<sup>3</sup>, a new network of blood vessels is required to sustain them (angiogenesis) and there appears to be an advantage to multitargeted agents that target the vasculature in addition to the tumor itself. In theory, the stable genome of endothelial cells compared to tumor cells should make resistance to an antiangiogenic drug less likely than for a drug that targets the tumor itself.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">The signaling pathways generated by receptor tyrosine kinases that are activated by vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) collectively control angiogenesis as well as tumor growth and survival. Combined inhibition of VEGF and PDGF receptors might result in broader antitumor efficacy, since multitargeted inhibitors should help to overcome the redundancies in signaling pathways.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14, 15)</a> The recent approval of the multitargeted agents, sunitinib (Sutent) <b>5</b><a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and sorafenib (Nexavar) <b>6</b>,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> demonstrates that clinical benefit in the treatment of solid tumors with manageable side effects is possible with broad-acting kinase inhibitors (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). While both sunitinib and sorafenib have a much wider spectrum of activities than imatinib, these two agents differ both in their potency against their targets and in their spectrum of activities. Which of these drugs proves to be ultimately superior will require testing in a wider range of cancer types, especially common forms such as breast and lung cancer. The future challenge will be to ascertain which specific spectrum of targets produces a significant clinical benefit with respect to specific tumor types. One of the main concerns with MKIs is their safety window, so it is encouraging that these broad spectrum inhibitors seem to be generally well tolerated with the most common side effects being generally manageable, e.g., gastrointestinal toxicities, skin reaction, and hypertension for sunitinib and rash and diarrhea for sorafenib.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p last">The first generation of multikinase drugs to show activity in the clinic were not intentionally designed to have their particular multitarget profiles. Indeed many MKIs were originally envisaged as single kinase inhibitors until they were found to inhibit other kinases as well. For example, sorafenib <b>6</b> was originally developed as a mutant B-RAF inhibitor<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> but was later found to inhibit tyrosine kinases as well, whereas bosutinib <b>4</b> was originally identified as a SRC inhibitor and was later found to have ABL-inhibitory activity<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and another ABL-inhibitor dasatinib <b>3</b> was derived from a LCK inhibitor program.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Sunitinib was initially envisaged as a dual VEGFR and PDGFR inhibitor<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> but has been found to have one of the most promiscuous MKI profiles.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The risk with such unintentional MKIs is that they are more likely to hit other, perhaps unknown, kinases associated with undue host toxicity. To minimize this risk, the next generation of MKIs with predefined profiles are increasingly being sought. For a MKI to be defined as a “designed” multiple ligand (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), it must address only those desired kinases that are associated with the disease while avoiding undesired kinases that are associated with side effects.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">3 New Generation of Designed MKIs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48253" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48253" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">3.1 Discovery of Lapatanib</h3><div class="NLM_p">The first marketed MKI drug that comes close to fulfilling the definition of a designed multiple ligand is lapatinib (Tykerb) <b>9</b>. Here, the advantage of a dual inhibitor was rationalized prospectively and the optimization was conducted in such a way as to balance the desired activities and exclude undesired side activities.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> EGFR and ErbB2 are both overexpressed in many cancer cell types. Because of their differing receptor expression patterns in human tumors, the inhibition of both kinases was anticipated to provide a broad profile of anticancer activity.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p">The starting point was a series of 4-anilinoquinazolines with a structure similar to those of the selective EGFR inhibitors gefitinib <b>7</b> and erlotinib <b>8</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). It was found that increasing the size of the group on the aniline, by replacing the 4′-fluorine with a benzyloxy group, introduced potent erbB2 activity <b>9</b>. A wide variety of linear substituents were tolerated on the furan, and a range of substituent patterns gave good isolated enzyme activity, but the 2,5-disubstituted furan ring spacer was found to give especially good activity in cells. A sulfonylamine group was introduced to improve aqueous solubility.</div><div class="NLM_p">The crystal structure of lapatinib bound to EGFR revealed a closed (“unactivated”) conformation with a large back pocket containing the benzyloxyaniline headgroup associated with high ErbB2 potency.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The quinazoline functions as the hinge-binder, and the heteroaryl linker and hydrophilic side chain extend into a solvent exposed region. This unusual conformation (αC-Glu-out conformation) was found to be associated with a slow off-rate that in turn produced a prolonged inhibition of signal transduction in tumor cells with a half-life of 5 h (compared to <10 min for erlotinib), which is assumed to contribute to lapatinib’s impressive efficacy. Another unusual feature of lapatinib is the cleanness of its dual activity profile. It did not show any activity in a panel of 119 kinases at Ambit.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_p">Lapatinib was efficacious in the HN5 and BT474 cancer cell lines overexpressing EGFR and erbB2 respectively. In vivo efficacy was also demonstrated against the same cell lines grown as subcutaneous xenograft models. Lapatinib was approved in 2007 for the treatment of breast cancer, and studies in many other conditions are now ongoing.</div><div class="NLM_p last">Analogues of lapatinib with alternative hinge-binding cores have recently appeared in the literature. For example, an arylaminopyrimidine-5-carbaldehyde oxime scaffold effectively mimics the well-known quinazoline core of gefinitib <b>7</b> and lapatinib <b>9</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The amino group forms an intramolecular hydrogen bond with the oxime nitrogen atom, mimicking the quinazoline phenyl ring. Like lapatinib, compound <b>10</b> was found to be highly selective for the EGFR subfamily.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">3.2 Other EGFR Family Inhibitors</h3><div class="NLM_p">The development of lapatinib has stimulated much activity in the EGFR family area, and there has been increasing interest in combining activity at EGFR family receptors with activity at other kinases. Vandetanib <b>11</b> (Zactima) inhibits both the EGFR and VEGFR pathways with triple inhibition of EGFR, ErbB2, and VEGFR-2 (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The recent literature has suggested that a combination of selective EGFR and insulin-like growth factor receptor 1 (IGF1R) inhibitors (gefitinib and NVP-ADW742, respectively) affords a synergistic decrease in cellular proliferation across a diverse set of cancer cell lines compared to the single agents.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> A group at Abbott aiming to develop a dual inhibitor started from compound <b>12</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>) that showed potent IGF-1R inhibitory properties but displayed poor cellular activity versus EGFR and ErbB-2. Identifying 2-OMe as the preferred substituent on the benzimidazole and a methyl-substituted piperazine provided balanced inhibition of IGF-1R, EGFR, and ErbB-2 in both isolated enzyme and cellular assays. In a murine PD model, triple inhibitor compound <b>13</b> completely inhibited receptor phosphorylation of both IGF-1R and EGFR. The compound showed modest oral bioavailability of 12% in the mouse, which is consistent with its high molecular weight of 610.</div><figure id="fig3" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. EGFR family inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">4 Lead Generation Approaches</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70735" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70735" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Increasingly rational approaches are being followed in the development of MKIs. Lapatinib itself was discovered by starting from an EGFR-selective compound and then increasing activity at erbB2 to achieve a balanced inhibitory profile. Indeed the most common approach to discovering MKIs is the cross-screening of focused sets of compounds originating from “selective” kinase programs.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">4.1 Focused Screening</h3><div class="NLM_p">In focused screening, compound classes that are already known to be active against one of the targets of interest are screened against another target. This simplifies the logistics of screening against multiple targets and improves screening hit rates. The large number of kinase projects in many companies lends itself to a large-scale chemogenomics effort whereby chemotypes for one target are recycled as screening hits for others. The value of serendipitous cross-screening for MKIs has been vindicated by the history of the development of the dual ABL/SRC inhibitors starting from compounds designed as selective SRC inhibitors.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The task of developing these MKIs was aided by the fact that the SARs for the two enzymes have been observed to be similar, with the most potent SRC inhibitors also being the most potent ABL inhibitors.</div><div class="NLM_p">The big advantage of cross-screening is the high hit rate due to the high similarity of the ATP binding site between kinases, and in a recent GSK study, at least one hit was found against every kinase when a kinase-like library was screened.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> For most targets, multiple active compounds covering different chemotypes were found. This hit rate is very high compared to that normally obtained from diverse or focused screening. Certain motifs within MKIs have been correlated with promiscuous inhibition across kinase families, and a five point pharmacophore combination has been proposed.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> This suggests that starting from scaffolds that fit this pharmacophore, two strategies might be pursued, incorporating additional components to render it selectively nonselective or excising moieties responsible for the undesired interactions, hoping the desired activities are retained.</div><div class="NLM_p last">A major disadvantage of cross-screening is that the intellectual property (IP) space is becoming increasingly congested for compounds that bind at the ATP site. One way around this is to use “scaffold-swapping” in which structural information is used to guide the replacement of the hinge-binding scaffold with a novel heterocycle.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> A second way is to use diversity-based screening as described below.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">4.2 Diversity-Based Screening</h3><div class="NLM_p">Diversity-based screening can generate novel chemotypes, possibly binding to sites other than the ATP-site. To date, there have been few reported examples of MKIs being discovered via diversity-based HTS approaches, which could be due to the complexity of screening large numbers of compounds at multiple targets. It could be due, however, to the fact that HTS is a relatively new lead discovery paradigm and there is an inevitable time lag to publication. Perhaps the best known example of a multikinase drug being derived from HTS is sorafenib, although, as mentioned earlier, this compound was originally developed as a B-RAF inhibitor and its multitarget profile was not conceived prospectively. In a more recent HTS example, dual AKT inhibitors were discovered by a team at Merck.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Increased AKT1 and AKT2 kinase activity has been observed in various cancer cell types such as breast, ovarian, pancreatic, and prostate cancers. An AKT1-selective inhibitor was obtained from the HTS screen, and analogue synthesis also produced an AKT2 selective inhibitor. A mixture of the two selective inhibitors was shown to induce a superior apoptotic response compared to either inhibitor alone, and this provided the team with the motivation to develop a dual inhibitor <b>14</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). The allosteric mechanism of action within the series gave good selectivity over other kinases. Importantly, these AKT inhibitors displayed selectivity versus the closely related AGC family (PKA, PKC, SGK) of kinases as well as selectivity with respect to the individual AKT isozymes.</div><div class="NLM_p">Further work from the same group describes efforts to improve physical properties, thereby enhancing cellular potency.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Increasing the basicity of the heterocyclic core, by moving from a quinoxaline to a pyridine template <b>15</b>, improved aqueous solubility and cell permeability and reduced molecular weight (MW). Unfortunately compounds from the series showed hERG activity.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Introducing a tricyclic triazole scaffold in <b>16</b> significantly reduced hERG binding affinity and provided more potent and balanced activity against AKT1 and AKT2, which was important for in vivo efficacy. These inhibitors do not seem to be ATP or substrate competitive and appear to occupy a novel allosteric binding site, the so-called pleckstrin homology domain. Another member of this series, the pan-AKT inhibitor <b>17</b> (MK-2206), is reported to be in phase 1 clinical trials for the potential oral treatment of solid tumors.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><div class="NLM_p">There are a range of biophysical affinity-based methods that also have applicability in the search for MKIs, such as NMR, surface plasmon resonance (SPR), and mass spectrometry. For example, affinity selection−mass spectrometry (AS−MS) techniques enable the screening of large compound libraries as potential ligands for any binding site on the protein surface and not just the “active site,” enabling the discovery of ligands that act through allosteric binding and other mechanisms.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> It has also been suggested that fragment methods could be useful for the discovery of DMLs.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><figure id="fig4" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0010.jpeg" id="gr4" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">4.3 Framework Combination</h3><div class="NLM_p last">A knowledge-based approach, known as framework combination, is another lead generation strategy for DMLs frequently reported in the literature.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> This approach is based on a hybridizing of the frameworks and the underlying pharmacophores of two molecules, each selective for a different target of interest, into a single molecule with both activities. There are a large number of literature examples of the framework combination approach being applied to other proteomic families like GPCRs, transporters, nuclear receptors, proteases, and oxidases. The rarity of the framework combination approach for kinases probably reflects the fact that obtaining selective ligands for kinases is still a major challenge, and this step precedes the rational “designing in” of multiple activities, driven by knowledge of the selective ligand SARs. Whether this approach will be applied in the kinase area is uncertain, and it is likely that the predominance of screening approaches will endure.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">5 Challenges of Lead Optimization</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50853" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50853" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Medicinal chemists working on a DML project must optimize the desired ratio of activities, remove any undesired activities associated with side effects, and attain the pharmacokinetic (PK) profile required for oral administration. The last two goals are also common to most single target projects, but it is their combination with the multiactivity goal that creates the added challenge in MTDD.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">5.1 Importance of Appropriately Balanced Potency</h3><div class="NLM_p">In any multitarget project, establishing an optimal ratio of the desired activities is critical in order to maximize efficacy and safety. For most multikinase cancer drugs, it is not clear to what extent the inhibition of each kinase contributes to the overall therapeutic effect. Moreover, it is possible that the efficacy of some of these drugs is being primarily driven by targets other than the designated targets. This lack of knowledge concerning how these drugs are actually working greatly complicates clinical development and makes the identification of groups of patients who are more likely to respond very difficult. Even for relatively selective dual inhibitors such as lapatinib, can we be sure that both targets are being inhibited to the appropriate extent in patients?<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> There is a distinct lack of available biomarkers to indicate whether an agent is hitting each intended target to an appropriate degree or indeed whether unintended targets are also being hit. An unbalanced potency against the various targets might lead to inadequate inhibition of one or more targets with a consequential reduction in efficacy. Even worse, the result of suboptimal inhibition might be the more rapid or more complete emergence of therapeutic resistance. The optimal balance of inhibitory activity is not necessary equivalent for each target, although in most published work in this field the aim has been to achieve equal or similar activity for all targets in the first instance. This is normally to provide a clear if somewhat arbitrary goal for the medicinal chemist. Without extensive testing in predictive animal models, and ultimately clinical feedback, determining the optimal balance of activities will be guesswork. There will be an optimal level of inhibition for each kinase in a multitarget profile that is associated with maximum efficacy and safety. These occupancy relationships are rarely discussed in the literature and in most cases are probably unknown.</div><div class="NLM_p">Knowledge generated during clinical studies can help researchers to identify an optimal profile. The wider availability of target engagement biomarkers, such as PET ligands, that provide occupancy data associated with efficacy and adverse effects mediated through on-target and off-target activities will aid future developments in the field of MTDD. Matching individual MKI drugs to individual patients is important to maximize efficacy, since kinase expression profiles differ between cancer patients.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div><div class="NLM_p last">As the number of targets to be balanced increases, the complexity of the task will increase supraproportionally. Furthermore, measuring the potency balance in both biochemical and cell-based assays is important to avoid misleading effects. Another complication facing the medicinal chemist is the possibility of active metabolites that have a significantly different profile from the parent compound. There are several examples of MTDs that give rise to metabolites that are thought to contribute to their efficacy.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> For the currently marketed MKI drugs, it is unclear to what extent this is an issue. The des-benzyl metabolite of lapatinib is known to lack activity at the erbB2 receptor.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> The des-ethyl metabolite of sunitinib is described as having a profile similar to that of sunitinib itself toward VEGFR, PDGFR, and KIT, but given the highly complex profile of the parent compound, it is difficult to be sure that there is no contribution to the efficacy or safety profile from such metabolites.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">5.2 Physicochemical Properties of MKIs</h3><div class="NLM_p">The detrimental influence of high MW and lipophilicity (cLogP) on the PK behavior of orally administered drugs has been the subject of intense interest since the publication of the “rule-of-5” (RO5) in 1997.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> A comparison of the physical properties of DMLs in general, relative to marketed drugs or preclinical compounds, indicated that DMLs have poorer properties.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46, 47)</a> Many kinase ligands are extended linear structures because they need to reach away from the ATP hinge region to neighboring regions that provide selectivity. A few MKIs such as the highly promiscuous sunitinib <b>5</b> are relatively small, but many others such as imatinib <b>1</b> and lapatinib <b>9</b> which are more selective are significant larger. Another example is the VEGFR ligand <b>19</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) that was produced from a HTS-derived hinge-binding template <b>18</b> and elaborated with H-bonding and hydrophobic functionality to access additional binding sites.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div><figure id="fig5" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0009.jpeg" id="gr5" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0008.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. ATP and inhibitor binding sites of kinases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Since only a limited number of kinase drugs have been approved thus far and these are heavily biased toward oncology, it has been argued that the optimal physical property profile for kinase inhibitors is still evolving. The average MW of oral drugs in general tends to decrease with progression through clinical development,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> whereas the average MW of kinase drug candidates shows the opposite trend.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> However, the optimal properties that determine absorption across the gut wall should be independent of target family, and consequently, kinase inhibitor design should be influenced by the property profiles of oral drugs in general and not just kinase drugs. The unusual MW trend for kinase inhibitors may be related more to the fact that larger compounds are more potent and selective inhibitors and therefore more likely to progress to the later phases.</div><div class="NLM_p">The high cLogP of many MKIs is a consequence of the primarily hydrophobic binding pockets adjacent to the small polar hinge recognition site (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). There are many examples in the kinase inhibitor literature of trying to reduce cLogP, since this property is a primary determinant of drug metabolism, distribution, and off-target activity. For example, the cLogP of lapatinib analogues needed to be reduced to reduce plasma protein binding.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div><div class="NLM_p">Lipophilicity and the presence of a positive charge in a molecule have been shown to be positively correlated with undesired promiscuity.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52, 53)</a> Reducing cLogP for multitarget ligands has been shown to have a beneficial effect on off-target activities such as hERG blockade.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div><div class="NLM_p">Most MKIs have low brain exposure which may be an advantage in some cases, but it is an issue for treating brain metastases which can arise from tumors in the periphery. Lapatinib <b>9</b> is a substrate for the efflux transporters P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) at the blood−brain barrier, which is consistent with its relatively high MW (581) and cLogP (5.1).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Nonetheless, lapatinib has been shown in clinical studies to reduce CNS tumor growth possibly via disruption of the blood−brain barrier by tumors or via inhibition of efflux by lapatinib upon repeat dosing.</div><div class="NLM_p last">The inherently challenging physicochemical property profiles of MKIs are less problematic if the goal of a project is a parenterally administered drug or a biochemical probe rather than an oral drug. Intravenous agents can be an option for treating certain forms of cancer, as illustrated by compound <b>21</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). The development of high quality pharmacological tools to explore and validate the potential therapeutic value of novel target combinations is an important area of future research in this field. Establishing the ground rules for designing such chemical probes is the subject of much current interest within the chemical biology community.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> The ideal set of properties for probe compounds remains to be defined, but certainly potency in cellular assays and the wider selectivity profile of these tools will be more important than oral drug developability criteria.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">5.3 Selectivity Challenge</h3><div class="NLM_p">Gaining selectivity for a single kinase, or in the case of MKIs a limited subset, is widely recognized as the principal challenge facing medicinal chemists working in the kinase field. The risk of a MKI project is that such compounds are by their very nature probably more likely to hit a wider range of kinases. Several recent papers describe the profiling of large numbers of compounds against large numbers of kinases. A recent report looked at the selectivity of approved kinase drugs and candidates across 317 different kinases.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The most selective of the currently approved multikinase drugs was lapatinib <b>9</b>, and the least selective was sunitinib <b>5</b>; the latter bound >15% of kinases tested with <i>K</i><sub>d</sub> < 100 nM. Fedorov et al. profiled a diverse set of 156 commercially available, widely used kinase inhibitors against 60 serine/threonine kinases.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Bamborough et al. screened 577 diverse compounds versus 203 protein kinases and found that two-thirds of the compounds bound to more than 10 kinases, thereby clearly illustrating the extent of the selectivity challenge in the kinase area.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> These screening exercises have provided many useful insights and lessons for medicinal chemists engaged in kinase drug discovery.</div><div class="NLM_p">In cases where a large number of closely related kinase isozymes exist, some of which may be critical to normal cellular function, the task of achieving wider selectivity will be particularly intricate. At the present time, it is difficult, if not impossible, to rationally design a compound with absolute selectivity for two or three kinases and with no affinity for any off-target. So this current reality has led to a more pragmatic approach whereby MKIs are developed that are deemed to be “selective enough” to be progressed into toxicity testing in animal studies. Even if absolute selectivity cannot be achieved, it would be worthwhile to determine if particular off-target activities are detrimental before terminating the development of an otherwise promising lead compound. The consequences of inhibiting most kinases are poorly understood, raising the question of how to proceed if an off-target activity is detected.</div><div class="NLM_p">Studying clinical drugs can reveal which kinases can safely be inhibited and which are critical to normal cellular function and should be avoided. Off-target kinases that are significantly inhibited by clinical compounds without overt safety concerns could be classified as posing lower selectivity risks. Unanticipated activities, even for well studied inhibitors, are still being found via panel screening.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> For example, the receptor tyrosine kinase DDR1 was recently reported as a novel target of imatinib <b>1</b>.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Although sunitinib <b>5</b> was originally viewed as a dual VEGFR2 and PDGFRβ inhibitor, it was later found to inhibit no less than eight kinases with IC<sub>50</sub> values of less than 100 nM and yet still has an acceptable side effect profile in man. It is also instructive to look at selective kinase inhibitors that failed for safety reasons in the clinic, which could give an indication of kinases to avoid.</div><div class="NLM_p">Kinase selectivity should thus be treated in the same manner as any other off-target activity that might translate into undesirable biology. If an inhibitor hits a target in vitro, it does not mean that it will be an issue in vivo. It will depend upon the administered dose required to achieve efficacy compared to that producing unacceptable side effects.</div><div class="NLM_p">It remains to be seen whether such a pragmatic approach to kinase selectivity profiles can be extended beyond oncology to non-life-threatening disease areas such as inflammation, where side effect liabilities will be particularly critical (see section<a class="ref internalNav" href="#sec10" aria-label=" 10"> 10</a>). Cardiotoxicity associated with multikinase inhibition is one area of concern.<a onclick="showRef(event, 'ref6 ref61'); return false;" href="javascript:void(0);" class="ref ref6 ref61">(6, 61)</a> Imatinib has been reported to have mechanism-based cardiotoxic effects traceable to its impact on the C-ABL kinase, and nilotinib carries a black box warning for possible heart complications.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Often it is not clear which kinases are responsible for the cardiotoxicity because of the complex profiles of MKIs, but hypothetical mechanisms have been proposed.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> MKI-associated cardiac complications represent a potentially serious toxicity and underscore the need for careful monitoring of cardiac function in cancer patients.</div><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16">5.3.1 Measuring Selectivity and Off-Target Risk</h4><div class="NLM_p">The measurement of selectivity in the kinase inhibitor field is a controversial issue, in part resulting from the empirical nature of the assays used and their lack of standardization. To avoid arriving at erroneous conclusions, selectivity should be evaluated not just at the protein level but also at the whole cell level and preferably also at the level of the whole organism.</div><div class="NLM_p">Initially, kinase inhibitors are typically evaluated at the protein level for their potential to inhibit kinase-catalyzed phosphotransfer from ATP to a substrate protein or peptide. Kinase selectivity profiles can be determined by a number of service providers using kinase enzymatic or binding assays for most of the known kinases. These studies provide a useful glimpse of potential off-target activity with the caveat that the kinase assays are often run under varying nonphysiological conditions using multiple ATP/<i>K</i><sub>m</sub> ratios, primarily truncated protein constructs (usually only the kinase domain) and artificial substrates. It is thus necessary to confirm on-target versus off-target kinase activity in a more physiological context through further analysis in cell-based and ultimately in vivo settings.</div><div class="NLM_p">There are dangers in comparing IC<sub>50</sub> values that have been determined using different concentrations of ATP, substrate, or enzyme. Some service providers tailor the ATP concentration to the <i>K</i><sub>m</sub> of each individual kinase, whereas others use a fixed ATP concentration closer to the much higher physiological intracellular level of around 1 mM. It is important to be aware of these differences when comparing selectivity data, since drastic shifts in IC<sub>50</sub>s for an ATP competitive inhibitor can occur. In one example of a dual PIM1/PIM2 inhibitor, the compound appeared either PIM2-selective, if an ATP concentration close to the <i>K</i><sub>m</sub> was used, or PIM1-selective if a fixed concentration of 100 μM ATP was used.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><div class="NLM_p">In many published studies describing MKI specificity, only a small number of closely related kinases were selected, and this may lead to erroneous conclusions about an inhibitor’s perceived selectivity. Screening as large and diverse a panel as possible will help to minimize safety risks, but even then there will be kinases that are missed, so extended postmarketing surveillance of MKI drugs will be needed to pick up any side effects.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Since MKIs are still relatively new to the market, some rare but severe side effects might still be discovered with more prolonged use.</div><div class="NLM_p">With over 500 human kinases known, it is an expensive, if not impractical, task at present to determine the full selectivity profile of every active compound in a lead optimization series. Since similar compounds on the whole have a tendency to show similar profiles, this is probably not even necessary. On the other hand, small structural differences can make significant differences to selectivity, so as well as looking at a wide kinase panel at the start of a project, medicinal chemists should check selectivity periodically during the optimization process. Although costs are coming down with increasing automation, the relatively high costs associated with these commercial services means that compounds are typically screened at a single concentration of 1 or 10 μM and then further evaluated in dose−response studies against selected kinases of interest. It has been suggested that large panel screens provide redundant information and that relatively small panels if judiciously selected can give a good impression of the selectivity and promiscuity of compounds across the human kinome.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></div><div class="NLM_p">Another method for examining the wider selectivity of novel kinase inhibitors is chemical proteomics, whereby a nonselective kinase inhibitor is immobilized on a bead and captures on the surface any targets to which it is capable of binding. In this way, new information about the binding profiles of several well-known clinically used kinase inhibitors, such as imatinib, has also been revealed.<a onclick="showRef(event, 'ref60 ref65'); return false;" href="javascript:void(0);" class="ref ref60 ref65">(60, 65)</a> Chemical proteomics has the advantage that it can be performed using extracts from diseased cells and tumor tissue, including from human subjects. The attraction of such selectivity screening relates not just to safety but also to the potential to discover cross-reactivity at targets associated with efficacy. Chemical proteomics, when integrated with the biochemical screening of MKIs in large assay panels, can help elucidate the true mechanism of action of MKIs in clinically relevant samples.</div><div class="NLM_p">During the course of compound optimization, the importance of monitoring structure−activity relationships in both biochemical and cellular kinase assays cannot be overemphasized, since disconnects between the two types of assays are extremely common for a variety of reasons.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> The concentration of ATP, substrate, or enzyme is probably not in its physiological context. Cell permeability and intracellular accumulation of the inhibitor can sometimes account for differences between biochemical and cellular assays. In other cases it appears that the physiologically relevant form of the kinase is not accurately reflected by the biochemical kinase assay, especially when only the truncated kinase domain is used. For example, the IGF1R inhibitor AEW541 displayed almost identical potency for inhibition of IGF1R (IC<sub>50</sub> = 150 nM) and insulin receptor (IC<sub>50</sub> = 140 nM) in biochemical kinase assays. However, in cellular assays the compound was 25-fold more selective for IGF1R versus the insulin receptor (EC<sub>50</sub>, IGFR = 86 nM).<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a></div><div class="NLM_p">The cellular selectivity of kinase inhibitors can be evaluated using cell lines that have been engineered to report on the inhibition of a particular kinase such as the murine Ba/F3 cell line.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Model cell lines, though very useful for guiding chemical optimization, can sometimes give misleading information if the kinase expression profile differs from diseased human tumor cells. The kinase target signature of bosutinib, determined via chemical proteomics and a large-scale kinase inhibition panel, varied between cells obtained from patients with CML and a model cell line for CML, the K562 cell line.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> This signifies the added value of generating such profiles in disease-specific primary cell populations.</div><div class="NLM_p last">Evaluation of kinase inhibitor selectivity in vivo remains a significant hurdle. It is clear that we need new methods to globally monitor the changes in phosphorylation that result from kinase inhibition at the level of the whole organism and the relationship to efficacy and toxicity. The concentrations of protein kinases and inhibitors in specific tissues may exceed concentrations tested in vitro leading to unexpected inhibition of multiple kinases in vivo and the irrelevance of carefully crafted in vitro selectivity profiles.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17">5.3.2 Chemical Strategies To Design Out Undesired Activities</h4><div class="NLM_p">Focused screening frequently produces nonselective inhibitors with undesired kinase activities. There are as yet few literature examples of a prospective approach to rationally design out side activities, although such an approach is undoubtedly occurring in many laboratories.</div><div class="NLM_p">Undesired off-target activities fall into two general categories, kinase selectivity issues and non-kinase selectivity issues. In the latter category, binding to promiscuous proteins such as the cytochrome P450s and the hERG channel frequently correlates with lipophilicity, so reducing the global cLogP of a molecule is usually a favored approach. Given the high cLogP of many kinase inhibitors, hERG binding can become a major issue. In the AKT1/AKT2 example above, activity at the hERG ion channel was particularly challenging to remove.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Improving kinase selectivity is less likely to be solved by such an approach and instead benefits from a more precise understanding of the differences in the pharmacophores between the desired and undesired targets. Biostructural information can be extremely useful for rationally removing side activities as illustrated in the following example.</div><div class="NLM_p">In a report from Heerding et al. at GSK, the discovery of a pan-AKT inhibitor is described.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> The starting compound <b>20</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>) was a modest inhibitor of the AKTs, with only 1μM potency for AKT2 and poor selectivity over the related AGC family kinases, MSK1 and ROCK1. A significant feature of this work is that a model of the AKT2 active site was used to guide potency improvements at the AKTs while at the same time reducing activity at ROCK and RSK1. A 2-methyl-3-butyn-2-ol group was used to extend the compound through a narrow opening into the back pocket of AKT2, a change that was not well tolerated by ROCK and MSK1 because of differences in the residues lining the pocket. Side activity at ROCK and MSK1 kinases was removed by incorporation of an additional group into <b>20</b> to give compound <b>21</b>. Compound <b>21</b> was cocrystallized with AKT2 which confirmed the binding mode predicted by the docking study with a key H-bond between the N5 of the oxadiazole and Ala232 in the AKT2 hinge region. While this compound shows good selectivity over ROCK and MSK1, it still shows activity at other AGC kinases, including PKA and PKC isozymes, and AMPK and DAPK3 from the CAMK family. This example shows how MKI design is evolving with the use of biostructural information from the desired and undesired binding sites to improve selectivity. At the same time it demonstrates the difficulty medicinal chemists face when trying to improve selectivity over multiple off-targets. Although compound <b>21</b> had poor oral exposure, it was progressed into clinical trials as an intravenous agent (GSK690693) to treat patients with solid tumors or hematological malignancies.</div><figure id="fig7" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Fernández et al. use nonconserved patterns of shielding of hydrogen bonds between amino acids (“dehydrons”) as a basis to design out undesired activities. Addition of an extra methyl group to imatinib removed activity at BCR-ABL while retaining activity at c-KIT <b>22</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> The aim was to reduce the risk of BCR-ABL-mediated cardiotoxicity while maintaining c-KIT-mediated efficacy against gastrointestinal stromal tumors (GIST). At the same time, activity at JNK1 was introduced to reinforce the prevention of cardiotoxicity. It has been proposed by the same group that a simple modification to sunitinib (N-methylation, <b>23</b>) will improve its selectivity over AMPK2 and RSK, targets associated with cardiotoxicity.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> This evolution of a strategy of identifying kinase off-targets associated with toxicity and then rationally designing that activity out is still at an early stage but mirrors that ongoing in the psychiatry disease area. Here, “dirty” monoaminergic-based schizophrenia drugs such as clozapine are being cleaned of activities associated with side effects such as activities at the adrenergic α1 receptor associated with CV side effects and the histamine H<sub>1</sub> receptor associated with weight gain.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></div><div class="NLM_p last">As the number of targets in a profile increases, the complexity of the task of balancing the desired activities while removing undesired activities increases exponentially. This is made somewhat easier if the desired targets are pharmacophorically similar to each other but pharmacophorically dissimilar to the undesired targets. By gaining knowledge of the individual kinase SARs and maximizing the use of biostructural and pharmacophore information for each target, a more efficient path to a ligand with a selectively nonselective profile can be followed. The inherent challenge of achieving finely tuned kinase activity profiles will without doubt be facilitated by the kinase SAR knowledge derived from the screening of many kinase inhibitors against large-scale panels of kinases and a chemogenomic analysis of the resulting data.<a onclick="showRef(event, 'ref31 ref57'); return false;" href="javascript:void(0);" class="ref ref31 ref57">(31, 57)</a></div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">5.4 Fragment Approach</h3><div class="NLM_p">Fragment based drug discovery (FBDD) has become very popular over recent years as a means of providing compounds with high “ligand efficiency” in terms of their binding energy per heavy atom.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Given the physicochemical issues with some MKIs, a FBDD approach to the discovery of DMLs with improved physicochemical properties has clear attractions.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Supporting evidence for the relevance of such an approach is provided by recent reports that smaller ligands are more likely to bind to multiple targets than larger ones.<a onclick="showRef(event, 'ref39 ref75 ref76'); return false;" href="javascript:void(0);" class="ref ref39 ref75 ref76">(39, 75, 76)</a></div><div class="NLM_p">In a fragment-based approach to MTDD, any of a number of biophysical methods that have been applied to single-target FBDD could be considered, such as NMR, high throughput crystallography, mass spectrometry, or SPR. Alternatively, high concentration biochemical screens could be performed. A basic core scaffold that is capable of binding to both targets would be sought (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>). Subsequent “growing” of the fragment, guided by biostructural data, could provide high affinity and ligand efficiency at both targets. A recent example is the use of a FBDD approach to pan-PPAR inhibitors.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><div class="NLM_p">In the MKI field, one viable approach could be to screen for a hinge-binding fragment and then grow the compound into the neighboring back pockets to increase potency and selectivity (“front-to-back” approach). Care needs to be taken to avoid growing fragments into excessively decorated, high MW compounds which may provide better potency and selectivity but at the expense of poor PK. Encouragingly, Hajduk et al. found that most hinge-binding fragments exhibit at least some level of selectivity even without decoration.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> An alternative to screening for hinge-binding fragments is the so-called “back-to-front” approach whereby a fragment is selected that is shown by X-ray crystallography to bind in the neighboring hydrophobic pockets (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). This fragment is then grown into a potent inhibitor by adding only the necessary groups to provide the essential interactions in the kinase active site and thereby provide more druglike final structures.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> This approach was used by Pargellis et al. to discover a deep pocket-binding fragment that was later extended into the ATP-site to give the p38 inhibitor BIRB-0796.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></div><div class="NLM_p">If improving the affinity of a fragment for two or more targets simultaneously proves to be impossible, there exists a tantalizing possibility that the high-affinity binding that is characteristically required for target-selective agents may not be essential for a multiple ligand by virtue of the synergy that can exist between the targets.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><figure id="fig8" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Fragment-based approach to MTDD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">5.5 Usefulness of Biostructural, Calorimetric, and Kinetic Data in MKI Discovery</h3><div class="NLM_p">One advantage for medicinal chemists working in the multitarget kinase area, compared to those working on membrane targets like GPCRs, is the availability of three-dimensional protein structures for many of the targets. These valuable assets should enable a more rational approach to both the lead generation and optimization of MKIs. In lead generation, large-scale multitarget virtual screening is a promising protein structure-based method that complements diversity-based screening.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> In lead optimization, access to X-ray information can help guide the process of improving activity and selectivity as illustrated by the pan-AKT inhibitor <b>21</b> above (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). The availability of multiple crystal structures of kinases in various conformational states can further enhance the value of crystallography and pave the way for designing MKIs with more finely tuned multitarget profiles.</div><div class="NLM_p">However, there are limits to the value of biostructural information. Although many cocomplex structures of MKIs have been solved, in most cases it is difficult to understand the structural basis of the observed selectivity or promiscuity. Indeed, predicting kinase selectivity from structures in the Protein Data Bank (PDB) is complicated by the wide range of dynamic flexibility (plasticity) of kinase structures for different inhibitor classes. In a recent article, Hajduk et al. conclude that guidance from crystallography and modeling is very useful for driving initial potency gains, but exploiting the subtle differences between the kinases structures to achieve selectivity could only be achieved in some cases by the fine-tuning of substitution patterns through an empirical medicinal chemistry approach.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Part of the problem is that there are, as yet, few examples in the PDB of the same compound bound to different kinases. However, from the limited number of structures available, we already know that the same compound can bind to two different kinases in different modes, illustrating the complexity and subtlety of kinase−inhibitor interactions. For example, imatinib binds to ABL and SYK kinases in quite different modes.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Small fragments are known to be able to adopt different binding modes with different kinases.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> A fragment-based approach to MTDD may be complicated by the fact that hits may bind to each kinase differently, so a crystal structure of each protein−ligand complex would be needed to guide the optimization process.</div><div class="NLM_p last">Other techniques can complement the use of crystallography in lead generation and optimization such as calorimetric and kinetic analyses of inhibitor binding and catalytic activity. Isothermal titration calorimetry (ITC) is useful for determining the enthalpic and entropic contributions to inhibitor binding. It has been suggested that enzyme inhibitors that are discovered via an enthalpy-driven optimization approach can have advantages over entropy-driven inhibitors by adopting a higher quality fit to the binding site with optimal alignment of hydrogen bonds specific for the desired target.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> It is tempting to speculate that enthalpy-driven MKIs may be more likely to attain selectivity for the desired over the undesired targets. Kinase inhibitors that exhibit unusually slow off-rates have been attracting increasing attention in recent years because of their potential to have a prolonged duration of action even when the compound clears rapidly from the systemic circulation.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Techniques such as SPR can be used to study the kinetics of binding to multiple targets.</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">6 Influence of Binding Mode on Selectivity and the Feasibility of MKI Design</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40487" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40487" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">There are a number of different ways of classifying kinase inhibitors, and the best way of doing so is a topic of ongoing debate within the kinase community. A commonly employed classification scheme stratifies inhibitors depending upon whether they are ATP-competitive, the activity state of the kinase, and their reversibility (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). In this section, the influence of these factors on selectivity and promiscuity is discussed.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Classification Scheme for Kinase Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top"><th align="center">kinase class</th><th align="center">ATP-competitive</th><th align="center">activated state</th><th align="center">reversibility</th></tr></thead><tbody><tr valign="top"><td align="left">activated (type 1)</td><td align="left">√</td><td align="left">√</td><td align="left">√</td></tr><tr valign="top"><td align="left">unactivated (type 2)</td><td align="left">√</td><td align="left">x</td><td align="left">√</td></tr><tr valign="top"><td align="left">allosteric (type 3)</td><td align="left">x</td><td align="left">√/x</td><td align="left">√</td></tr><tr valign="top"><td align="left">covalent irreversible</td><td align="left">√/x</td><td align="left">√/x</td><td align="left">x</td></tr></tbody></table></div></div><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">6.1 Activated State Inhibitors</h3><div class="NLM_p">Classical kinase inhibitors, sometimes known as type 1 inhibitors, bind in the ATP-binding site and are ATP-competitive, with the kinase in its activated state. At least one hydrogen bond is formed with the hinge region as well as one or more interactions with the surrounding front, ribose, or back pockets, which are largely hydrophobic in nature (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>).<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> The gatekeeper residue controls access to the second hydrophobic back pocket, and most ATP-competitive kinase inhibitors exploit this pocket to gain extra potency. Sunitinib’s especially broad activity is likely to be connected with the fact that it binds in the ATP site without extending into the more kinase-specific regions of the binding site. In contrast, the high selectivity of gefitinib <b>2</b> for EGFR is most likely due to its ability to exploit the back pocket which is occupied by the 3-chloro substituent. Not all type 1 kinase inhibitors can access the back pocket due to the potential blocking effect of the gatekeeper residue.</div><div class="NLM_p last">A potential advantage of type 1 inhibition is that the activated state will certainly be present in diseased cells because kinases are constitutively active in cancer and the cells may be less likely to become resistant because of conserved nature of the activated state. The high degree of conservation of the activated conformation between kinases should make it easier to obtain the desired multiple activities, but at the same time the likelihood of low selectivity may also be higher. Most compounds in development are of the type 1 variety, and for many kinases activated state binders may be the only option given that there is no evidence so far that they are able to adopt unactivated conformations. A recent review describes the most common hinge-binding scaffolds present in ATP-competitive MKIs.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">6.2 Unactivated State Inhibitors</h3><div class="NLM_p">Some MKIs bind to an extended ATP-binding site of an “unactivated” (sometimes called an “inactive”) form of the kinase.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> These so-called type 2 inhibitors open up a new hydrophobic pocket in the back of the protein (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>) and form new hydrogen bond interactions. The clinical importance of type 2 compounds is illustrated by the fact that five out of eight approved kinase inhibitors bind to unactivated states: imatinib, nilotinib, sorafenib, sunitinib, and lapatinib.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a></div><div class="NLM_p">Two prominent examples are the “DFG-out” and the “helix-C-out (αC-Glu-out)” unactivated conformations. The “DFG-out” state is so called because the phenylalanine of the DFG motif flips “out” toward the solvent, blocking access of ATP and creating a new pocket for compounds to bind. Examples of the “DFG-out” state are the interaction between c-ABL and imatinib and nilotinib, as well as sorafenib binding to VEGFR and Raf-1.<a onclick="showRef(event, 'ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref88 ref89">(88, 89)</a> The C-helix-out conformation retains the general DFG-in form but leads to inactivation by rotating and shifting the C-helix outward, which opens up an additional pocket.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> The C-helix-out form is most commonly associated with EGFR and binds lapatinib <b>9</b>.</div><div class="NLM_p">There has been a noticeable trend in the pharmaceutical industry toward identifying type 2 unactivated state binders driven by a desire for higher efficacy, selectivity, and a better IP position than is possible for a type 1 inhibitor. Higher affinity may arise from binding to the new pockets opened up by the conformational rearrangement. The fact that there is less conservation among the unactivated conformations of different kinases may lead to better selectivity, and the high selectivity of imatinib and lapatinib has been rationalized in this way. However, the common belief that type 2 inhibitors are more selective is challenged by compounds such as <b>24</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>) that binds to the DFG-out state but is less selective than <b>25</b> which binds in the DFG-in mode.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The DFG pocket itself is actually highly conserved between kinases, and any selectivity advantage may be more due to the fact that not all kinases can adopt the DFG-out conformation. Aurora inhibitors that preferentially bind either activated or unactivated conformations have been reported to show good selectivity, suggesting that both conformations can contain unique motifs that can be exploited.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a></div><div class="NLM_p">The different conformations of a kinase are essentially different drug targets, so the best option for a medicinal chemist is to keep an open mind with respect to which type of inhibitor affords the best opportunity for a particular multitarget profile. Researchers at ARIAD Pharmaceuticals described two parallel projects to obtain both type 1<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> and type 2<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> dual SRC/ABL inhibitors from the same chemical series, represented by <b>26</b> and <b>27</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>), respectively. Interestingly, most type 2 ABL inhibitors like imatinib do not bind to SRC because of differences in the hydrogen bonding requirements in the hinge region in the DFG-out conformation. Nonetheless, compound <b>27</b> possesses good activity against SRC (IC<sub>50</sub> = 8 nM) and wild-type ABL (IC<sub>50</sub> = 25 nM) and has some activity against the normally intractable ABL T315I mutant (IC<sub>50</sub> = 478 nM).</div><div class="NLM_p">Both imatinib and lapatinib arose from starting compounds that were classical type 1 ATP site inhibitors.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> In each case, enlargement of the structures caused the switch of the kinase conformation with the <i>N</i>-methylpiperazinomethyl and 3-fluorobenzyl moieties being the responsible groups in imatinib and lapatinib, respectively. Similarly, the type 2 dual SRC/ABL inhibitor <b>27</b> is noticeably larger than the type 1 inhibitor <b>26</b>, with the diarylamide group considered as a privileged DFG-out inducing fragment (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>).<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a></div><div class="NLM_p">Kinase inhibitors that are deliberately designed to target multiple mutated isoforms can, in a broad definition of the term, also be regarded as DMLs, and one strategy is to design type 2 inhibitors that bind away from the mutation-prone gatekeeper region. Mutation-resistant type 2 SRC inhibitors have been rationally designed by hybridizing hinge-binding (type 1) and allosteric (type 3) fragments using crystal structures to design a linker that evades gatekeeper mutations.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a></div><div class="NLM_p">Structural biology will be the key to developing a better understanding of the different structural/conformational states that different kinases can display and assessing which enzymes can be successfully bridged with a MKI while attaining acceptable wider kinase selectivity. It is not clear for the five marketed drugs that bind to an unactivated state that the same conformation is adopted for all the kinases in each profile. There is emerging evidence from X-ray structures that this may not necessarily be the case. Imatinib binds to cKit and ABL in the same DFG-out conformation but to SYK in the DFG-in mode.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> BMS-599626 inhibits EGFR in an ATP-competitive manner but inhibits erbB2 in a non-ATP-competitive manner, suggesting that the binding modes are significantly different despite the two binding sites being very similar.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Another complication is that an inhibitor can bind to the same kinase in different modes. Sunitinib and dasatinib are able to bind to both activated and unactivated states.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a></div><div class="NLM_p">The above observations serve to illustrate some general and important points for MKI design. In addition to the activated state, a wide range of unactivated states may be available and new inhibitors may bind to one state preferentially or to several, and this may in itself differ between the different kinases in the profile. The biostructural situation is potentially highly complex and difficult to predict with small changes in structure being enough to shift the binding mode as illustrated by compounds <b>24</b> and <b>25</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>). The importance of having regular access to X-ray structures during an optimization program is paramount.</div><figure id="fig9" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Inhibitors with different binding modes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">6.3 Allosteric Inhibitors</h3><div class="NLM_p">Allosteric kinase inhibitors, sometimes known as type 3 inhibitors, target sites on the protein outside the ATP site, even though in some cases they may bind in proximity to it. Unlike lapatinib, which is a type 2 ligand that extends into the ATP region, some DFG-out and αC-Glu-out ligands do not and have been described as allosteric.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Compounds that bind to unactivated states can be either ATP-competitive or not depending upon their binding mode. Drawing a distinction between type 2 and type 3 inhibitors is sometimes complicated by the fact that inhibitors that bind outside the ATP site can still be ATP-competitive in kinetic experiments.</div><div class="NLM_p">Compared to ATP site inhibitors, there are as yet relatively few examples of allosteric inhibitors, but there has been a consistent effort to develop such inhibitors,<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> and novel assay systems are being developed to specifically detect binding outside the ATP pocket.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Among the best known allosteric inhibitors are MEK inhibitors such as CI-1040 (PD184352), many of which are highly selective because of the uniqueness of their binding site.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a></div><div class="NLM_p">It is unknown at the present time whether targeting allosteric sites will offer any advantages in terms of the discovery of selectively nonselective MKIs. These alternative binding sites can be more structurally distinct than the ATP binding site, so type 3 inhibitors may be more likely to be selective in a broad kinase panel than type 1 inhibitors but less likely to hit all the kinases of interest in the first place. However, it is conceivable that two kinases that cannot be bridged with an ATP-competitive inhibitor could share sufficient structural similarity at an allosteric site to allow development of a dual inhibitor. At present, the structure-based design of allosteric MKIs is hampered by a lack of examples in the PDB.</div><div class="NLM_p">Historically, there has been a problem in obtaining druglike, small molecule substrate mimetics, since these protein−protein binding sites are usually solvent-exposed and rather featureless surface patches. However, some of these sites have been shown to be druggable with nonpeptidic small molecules, for example, the non-ATP-competitive inhibitor <b>28</b> of BCR-ABL (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>), ON012380, that can override imatinib resistance.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></div><div class="NLM_p last">Allosteric inhibitors do not need to out-compete millimolar levels of ATP inside the cell but rather (protein) substrates that are present at much lower concentrations. Thus, it has been argued that acceptable in vivo potency can arise from surprisingly low levels of affinity compared to ATP-competitive inhibitors.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Currently we have only limited knowledge of the diversity of allosteric kinase pockets. The use of biophysical screening methods such as AS−MS has the clear potential to identify multitarget hits binding to novel sites, with a profoundly different selectivity profile from ATP-competitive hits.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Relatively unexplored binding sites certainly exist at least for some kinases, such as conserved binding sites for common regulatory molecules, and perhaps these will in the future be exploited for MKI design. For example, a novel binding site in p38 that binds a wide range of regulatory lipid-like molecules has been reported.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Compounds <b>14</b>−<b>17</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>) bind to an unusual allosteric binding site associated with the pleckstrin homology domain (PH domain) of AKT kinases, and this confers exceptionally good selectivity over other related kinases.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> The JNK inhibitor <b>29</b> targets a specialized protein interaction site, thereby mimicking the binding of JNK to its partner, the JNK-interacting protein 1 (JIP1) (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>).<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></div></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25">6.4 Covalent Inhibitors</h3><div class="NLM_p">No consensus exists in the literature concerning the use of covalent, irreversible inhibitors compared to fully reversible inhibitors. Although toxicity risks may be amplified, it has been suggested that selective covalent binding may be a positive contributor to compound potency as a result of prolonged inhibition of the enzyme, the ability to effectively compete with high concentrations of ATP, and increased activity against mutant kinases.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div><div class="NLM_p">The most extensively studied covalent inhibitor, canertinib (CI-1033) <b>30</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>), is a dual inhibitor of EGFR and erbB2 with a structure similar to that of gefitinib <b>7</b>. The thiol group of Cys 797 in the EGFR enzyme catalytic site is trapped by a Michael addition reaction to the acrylamide moiety. Preclinical studies suggest that irreversible EGFR/erbB2 inhibitors may have activity in tumors refractory to erlotinib or gefitinib, although this has yet to be borne out in the clinic.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a></div><div class="NLM_p last">In terms of the scope for designing irreversible MKIs, a recent analysis suggested that there are over 200 kinases (∼40% of the kinome) with cysteines accessible to targeting with an irreversible inhibitor.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Irreversible dual inhibitors of EGFR and VEGFR-2, such as <b>31</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>), have been reported incorporating two independent reactive centers each targeting different cysteine residues in the kinase domains.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> A potential issue arises in the design of a covalently bound irreversible MKI if the reactivity of the covalent warhead varies between the different kinases resulting in unbalanced activity.</div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">7 Current Scope and Future Feasibility of Multikinase Inhibition</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74702" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74702" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">7.1 State of the Art</h3><div class="NLM_p">Over the past few years, the medicinal chemistry literature describing multikinase inhibition has grown enormously and an ever increasing number of target combinations of postulated disease relevance have been proposed (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>). This network of connections gives a flavor of the historical activity in the MKI field but will certainly not be comprehensive given the extensive and fast moving nature of this research. Because of its pivotal role in angiogenesis, most work has involved combining VEGFR-2 inhibition with other activities and there are a total of 19 connections from VEGFR-2 in this network. Most of these combinations comprise closely related tyrosine kinase receptors, although a small number of them bridge more distantly related kinases and some even cross the barrier between kinases and another target family. It is probable that the currently exemplified combinations represent merely the tip of a large iceberg of conceivable disease-relevant combinations. An important question to ask therefore is “Where do the outer limits of MTDD lie?” MTDD is frequently a difficult and resource-intensive endeavor for medicinal chemists, so it is important to assess the feasibility of any given project at an early stage to avoid frustration and wasted resources. The feasibility of a particular profile should be dependent on the similarity of the binding sites of the desired and undesired targets. The similarity between kinases can be assessed from the protein perspective, using either the full or a partial (e.g. ATP-site) sequence identity, or from the ligand perspective, using “SAR” or “chemogenomic” similarity-based methods.</div><figure id="fig10" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0004.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Network of disease-associated MKI connections.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">7.2 Feasibility of Combinations within the Kinase Superfamily</h3><div class="NLM_p">Recent studies have compared how the sequence-based similarity of kinases aligns with SAR-based similarity. Vieth et al. found that clustering based on ATP-site sequence identity correlated reasonably well with clustering based on SAR similarity for kinases with >60% sequence identity.<a onclick="showRef(event, 'ref106 ref107'); return false;" href="javascript:void(0);" class="ref ref106 ref107">(106, 107)</a> Similarly, Bamborough et al. found that compounds that inhibit one kinase will often show activity against others from the same branch, provided that these kinases are related by over 40−50% sequence identity in their kinase domains.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a>For example, high sequence identity (83%) and high SAR similarity are observed between EGFR and ErbB2. This suggests that these two kinases are highly likely to bind similar ligands and that the search for a dual inhibitor like lapatinib was a sound decision based on good feasibility. The threshold above which sequence identity and SAR similarity converge seems to be unusually low for tyrosine kinases compared to other kinases, explaining the broad inhibitory profiles of many of the approved tyrosine kinase inhibitor drugs.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><div class="NLM_p">Kinases with dissimilar sequences can show high SAR similarity, but this is rare and not readily predictable.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a>It is also rare for closely related kinases to show low SAR similarity. The implication of these two observations for the feasibility of MKI design seems clear and intuitive. The medicinal chemist’s job will be easier if the desired kinases are closely related and the undesired kinases are unrelated by sequence to the desired ones. Bamborough et al. also found that where inhibitors do hit more distant kinases they tend to be broadly nonselective pan-kinase inhibitors.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Several caveats apply to this study which used nonphysiological conditions with truncated kinase domains immobilized onto beads in the absence of ATP. Also, the conclusions could be influenced by the historical bias of the kinase library studied. Only the screening of even larger compound sets against the wider kinome may reveal hidden connections between distant kinases. It would clearly be a generic problem for medicinal chemists trying to bridge dissimilar kinases if the only way to do so was using a nonselective compound with a concomitant risk of side effects. There were exceptions though such as the two dissimilar pairs, LKB1/AAK1 and RIPK2/LCK. Compound <b>32</b> is a moderately potent LKB1/AAK1 dual inhibitor that is fairly selective over other kinases (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>).</div><div class="NLM_p">Vieth et al. found other examples where sequence identity and SAR similarity diverge; e.g., ABL clusters next to PKCα in SAR space, despite low sequence identity.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> The explanation for these unexpected connections between kinases is unclear. It is possible that compounds such as <b>32</b> depend strongly on individual residues for their interactions with the ATP sites of LKB1 and AAK1 which are lost when whole sequences are compared. Differences in the size of the gatekeeper residue could be a principal cause of the discrepancies between sequence and SAR similarity, since this residue is a very important determinant of selectivity. Inhibitors of tyrosine kinases show a higher tendency to cross-react with other members of the subfamily compared to other branches of the kinome, such as the MAPK region of the CMGC branch.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> This could be due to the fact that tyrosine kinases have a more highly conserved gatekeeper residue compared to other subfamilies. In contrast, p38α and p38γ show low SAR similarity despite high sequence identity, which is consistent with their different gatekeeper residues, threonine and methionine, respectively. The fact that so many of the current MKIs are tyrosine kinase inhibitors is consistent with the hypothesis that it should be unusually easy to develop MKIs for this subfamily and unusually hard for the CMGC branch. The counterside is that broader selectivity may be harder for multityrosine kinase inhibitors but the experience of lapatinib, reported to bind to only 3 out of 290 kinases, shows it is possible.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><div class="NLM_p">In essence, the identity of the gatekeeper could be a key determinant of the feasibility of a particular MKI profile, especially where the kinases have relatively low sequence similarity. Nonetheless, kinase pairs with unexpectedly high SAR similarities remain highly unpredictable. It is possible that unusual conformational features such as dynamic flexibility, which are not obvious from either their sequence or gatekeeper identities, are responsible. Activities at two kinases that are not closely related by sequence can sometimes be combined if both enzymes can adopt the same type 2 conformation. For example, dual  activities have been observed for EphA1 and FRK but not for EphA1 and SYK despite the latter pair having more similar sequence identities. The explanation for this unusual combination could be due to the fact that both EphA1 and FRK can both adopt the DFG-out conformation whereas SYK cannot.</div><figure id="fig11" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0003.jpeg" id="gr11" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As a result of the high degree of conservation of the ATP-binding site, it is very common to find cross-reactivity among protein kinase inhibitors and tyrosine kinase inhibitors appear to be particularly prone to cross-reactivity.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> There are many examples of compounds that inhibit both tyrosine kinases and serine/threonine kinases, so there is no significant barrier to MKI design between these two subfamilies (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>). Sorafenib inhibits the serine/threonine kinase Raf-1 and several tyrosine kinases.</div><div class="NLM_p">Another family of kinases that share a similar function to the protein kinases are the lipid kinases such as phosphatidylinositol-3-OH kinases (PI3Ks). The pyrazolopyrimidine ligand <b>33</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>) is active at both tyrosine kinases (BCR-ABL, SRC, VERGFR2, PDGFR) and PI3Ks (p110α) despite the fact that these two families lack significant sequence similarity.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> PI3K signaling is a common mechanism of tumor resistance to tyrosine kinase inhibitors,<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> and preclinical studies have shown efficacy by combining inhibitors of these two families.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> The compounds from this class were inactive at serine/threonine kinases despite the fact that tyrosine kinases are structurally more similar to serine/threonine kinases than to lipid kinases.</div><div class="NLM_p">While most tyrosine kinase inhibitor templates lack activity against lipid kinases, there appears to be something special about this pyrazolopyrimidine chemotype that allows binding to both families. The surprising activity profile of <b>33</b> was also rationalized on the basis of the properties of the gatekeeper residues. The small threonine gatekeeper in tyrosine kinases allows the azaindole substituent of <b>33</b> to reach its deep hydrophobic pocket. In both serine/threonine and lipid kinases the gatekeeper is a bulkier isoleucine residue, but only in the case of the PI3Ks can the inhibitor circumvent this residue and gain access to the hydrophobic pocket. This sort of detailed structural understanding will be increasingly necessary to rationally design kinase inhibitors with specific selective profiles.</div><div class="NLM_p">Identifying such privileged, polymodal templates that can provide a diversity of low energy interactions could be the key to bridging more distant targets, and a fragment-based approach to MTDD has a particular appeal in this respect.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Vieth et al. also proposed that the SAR similarity relationships between kinases can be predicted more effectively by looking at the similarity between their constituent fragments within their ligands rather than by looking at sequence comparisons.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></div><div class="NLM_p">Another factor that should influence the feasibility of designing a particular multikinase profile is the widely differing hit rate among kinases in focused or diversity-based screening. In their broad kinase panel screen, Bamborough et al. identified tyrosine kinases that bound many compounds from many chemotypes such as PDGFRα/β, KIT, and FLT3, whereas some others such as ZAP70 bound no compounds at all.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Similarly some serine/threonine kinases like MST1, LOOK, and DRAK1 are highly sensitive to inhibition, while for others like ERK1/2, it is very difficult to find inhibitors. While the reasons for these widely different hit rates are not clear at the structural level, some kinases are clearly more tolerant while some have more restrictive binding requirements. It seems logical to propose that those kinases that are less stringent in terms of their SAR requirements will be those that are easier to combine with other kinases of interest. Those refractory kinases with high SAR stringency will be more difficult to combine and may only be inhibited by highly nonselective ligands that also hit undesired kinases.</div><div class="NLM_p last">In summary, taking a chemogenomics-type approach to kinase inhibition can help expand our knowledge of the complex inter-relationships within the kinome. This work is still at an embryonic stage, and the associations made so far are necessarily tentative. A larger data set from more panel screening data is needed to firm up these associations and facilitate the in silico predictions of cross-reactivities. Surprises can arise in terms of both desired and undesired kinase activities, and account should be taken of SAR similarity, as well as sequence. This SAR information could be useful at the earliest stages of target profile selection to choose target combinations with a good chance of finding MKIs with acceptable wider selectivity. If it transpires that two targets cannot be addressed because of high SAR dissimilarity and/or stringency, then the medicinal chemist could look elsewhere in the same signaling pathway for an alternative combination.</div></div><div id="sec7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29">7.3 Feasibility between the Kinase and Other Proteomic Superfamilies</h3><div class="NLM_p">The debate surrounding the selectivity and promiscuity of kinase inhibitors is dominated, not surprisingly, by the issue of intrasuperfamily similarity. However, this debate often ignores the fact that kinase inhibitors have some of the greatest intersuperfamily promiscuity.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> MKIs frequently possess off-target activity at non-kinase targets which needs to be designed out during the optimization phase. Although it has the potential to amplify the risk of off-target effects, on the positive side, the general promiscuity of protein kinase inhibitors also provides an opportunity to design unusual combinations of activities that span different proteomic families. It is also possible that the antitumor efficacy of clinically used kinase inhibitors is in part due to non-kinase activities that may only be discovered serendipitously and retrospectively. Two such examples of non-kinase activity are the recent disclosures that both imatinib and nilotinib strongly inhibit several human carbonic anhydrase (hCA) isoforms<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> and the drug-metabolizing oxidoreductase NQO2.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Thus far, the literature contains few examples of ligands that were deliberately designed to selectively target a kinase and a non-kinase. In part, this may be due to medicinal chemists having steered clear of such an endeavor, regarding this as an especially daunting task given the current state of the art in kinase inhibitor research.</div><div class="NLM_p">Dual inhibitors of VEGFR-2 and dihydrofolate reductase (DHFR) are potential antitumor agents.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Pyrimidines such as <b>36</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>) were designed by combining structural features of the DHFR inhibitor TMQ <b>34</b> and the VEGFR-2 inhibitor SU5416 <b>35</b>. The design was facilitated by modeling of the ligands into the ATP-site of VEGFR-2 and the active site of DHFR. Efforts are currently underway to improve the relatively weak activity, but the authors made the point that if there is a strong synergistic effect, a multitarget drug need not be highly potent. Thus, even the low DHFR inhibitory activity of <b>36</b> perhaps acts synergistically with the kinase inhibitory activity to provide a viable antitumor effect.</div><div class="NLM_p">Since the approval of the histone deacetylase (HDAC) inhibitor SAHA, there has been interest in combining HDAC and kinase inhibition. A combination of a HDAC inhibitor with imatinib showed synergistic effects in terms of inducing apoptosis in CML cell lines and overcame imatinib resistance due to the mutant BCR-ABL T315I protein.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> A dual inhibitor <b>37</b> was designed by incorporating, into the structure of imatinib <b>1</b>, a hydroxamic acid warhead that complexes the Zn<sup>2+</sup> ion in the active site of HDAC. A triple inhibitor <b>38</b> of HDAC, EGFR, and erbB2 has been reported with low nanomolar activity against all three enzymes and reasonable selectivity in a 72-kinase panel.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Compound <b>38</b>, obtained by adding a hydroxamic acid to the EGFR inhibitor erlotinib <b>8</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), is reported to be in clinical development for the treatment of solid tumors.</div><div class="NLM_p">On the basis that both c-SRC kinase and nitric oxide synthase (iNOS) are key regulatory enzymes in tumorigenesis, dual inhibitors of both enzymes were designed in the hope that they would be more effective than single inhibitors and could be beneficial to overcome drug resistance. Starting from a SRC inhibitor template, the 4-aniline-3-quinolinecarbonitrile skeleton of bosutinib <b>4</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), the existing 4-anilines were replaced with groups that have selective inhibition against iNOS such as 2-aminothiazole. Although compounds such as <b>39</b> showed good inhibition of SRC (IC<sub>50</sub> = 15 nM), the iNOS inhibition was much weaker (IC<sub>50</sub> = 313 μM). This may imply that the inhibition mechanism of compound <b>39</b> is mainly dominated by the inhibition of SRC kinase with no evidence that the dual profile is beneficial in this case.</div><div class="NLM_p">The challenge of trying to get a balanced profile and good physicochemical properties in an inhibitor spanning dissimilar target families will be profound, and compromises may need to be made where the pharmacophores are fundamentally different. The chance of success might be expected to be higher for a combination of a kinase with another protein with a nucleotide binding site. In addition to the 518 kinases encoded in the human genome, there are over 2000 other nucleotide-dependent enzymes, including polymerases, chaperones, motor proteins, reductases, and methyltransferases.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> There are also many nucleotide-binding receptors such as the adenosine and purinergic receptors. This cross-reactivity among nucleotide-binding proteins is backed up by screening evidence. Hopkins et al. found that kinase inhibitors frequently inhibit the phosphodiesterases (PDEs).<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Hajduk et al. reported that kinase-targeted libraries often exhibit increased hit rates against non-kinase targets, with an average enhancement of 3-fold compared to a random selection of compounds.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The conserved nature of ATP binding sites among other protein classes implies that exploiting the wide range of ATP competitive kinase inhibitors that are already available could provide starting points for the development of inhibitors that target kinases and other proteins simultaneously. Waldmann et al. screened tyrosine kinase inhibitors against the bacterial enzyme <span class="smallcaps smallerCapital">d</span>-alanine−<span class="smallcaps smallerCapital">d</span>-alanine ligase on the basis that the ATP binding sites were similar between these different target families and found some hits such as <b>40</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>).<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> An inhibitor of SRC, ABL, and LCK <b>41</b> was found to bind to the ATP binding site of another bacterial enzyme, biotin carboxylase.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a></div><figure id="fig12" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0002.jpeg" id="gr12" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">It is noticeable that all of the above examples are enzyme combinations, with kinase inhibition being combined with activity at DHFR, HDAC, or iNOS. Thus far, the literature contains no examples of deliberately combining activity at a kinase and a GPCR for a particular disease, but many accidental examples of such cross-reactivity are known. The prototypical ATP-competitive kinase inhibitor staurosporine has been found to show potent allosteric interactions at muscarinic M1 and M2 receptors.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> In fact, two of the target families that had the highest cross-target family promiscuity are kinases and the aminergic GPCRs, so it would not be a surprise for a kinase ligand to bind to an aminergic GPCR and vice versa.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> In fact, only ligands for the notoriously promiscuous cytochrome P450s appear to have higher promiscuity than the ligands for kinases and aminergic GPCRs. The high cross-target family promiscuity of kinase ligands is a double-edged sword. On the one hand it should provide an opportunity to discover unusual combinations of therapeutic relevance, but at the same time, the task of achieving sufficient wider selectivity over undesired targets could be complicated.</div></div><div id="sec7_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30">7.4 Predicting Unexpected Connections between Targets from Remote Target Families</h3><div class="NLM_p">A big challenge for the future development of MTDD is to correlate the promiscuity of targets and compounds with discrete structural features.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> The promiscuity of proteins could either be related to their having multiple discrete binding sites that coexist on the protein surface concurrently or be due to plasticity of the protein creating an assortment of competing sites that can bind ligands in low energy conformations. Protein promiscuity may be due to a binding site being able to accommodate multiple ligands in a variety of different binding modes with high affinity, perhaps due to the ability of water to act as a bridge in different ways between the protein and ligand. Promiscuity within a target family could be due to the overwhelming importance of a single interaction to the binding energy, such as the conserved salt bridge between the basic nitrogen of an aminergic GPCR agonist and the Asp residue in the transmembrane TM3 domain.</div><div class="NLM_p">The promiscuity of compounds is influenced by physicochemical properties, and the role of MW and cLogP has already been documented.<a onclick="showRef(event, 'ref39 ref52'); return false;" href="javascript:void(0);" class="ref ref39 ref52">(39, 52)</a> DMLs also seem to be more flexible than preclinical compounds in general.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a>An optimal level of flexibility may be important to allow the binding of compounds to different targets in different conformations. Imatinib is known to bind to NQO2 in a different conformation from BCR-ABL.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> ATP is known to bind in different conformations to different types of proteins in the PDB, and even within the kinase family there are differences, suggesting that similarity in protein function does not necessarily imply similarity in the binding mode of the endogenous ligand.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a></div><div class="NLM_p">The example above of compound <b>33</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>) that binds to two structurally unrelated kinases with different binding modes illustrates that certain scaffolds are capable of specific binding to different proteins by being able to form different interactions. To maximize the feasibility of a particular combination, proteins should be lenient in terms of their binding requirements and compound chemotypes should be amenable to binding to proteins in multiple ways.</div><div class="NLM_p">Although the DML field has expanded enormously over recent years, many new combinations await discovery. Given the number of possible permutations, even taking account of the medicinal chemistry challenges, there will likely be a larger number of druggable combinations than there are druggable single targets. New computational methods can help to define the true extent of the “opportunity space” for DMLs. In silico methods have been devised to compare crystal structures, looking for commonalities in binding sites that may provide opportunities for designing new combinations.<a onclick="showRef(event, 'ref122 ref123'); return false;" href="javascript:void(0);" class="ref ref122 ref123">(122, 123)</a> In the MKI area, protein structure-based search methods often suffer from the disadvantage that kinases readily change conformation, so comparing proteins by looking at ligand similarity is at least as appropriate. Similar compounds can bind distant kinases and structurally unrelated compounds can bind similar kinases, but this is relatively uncommon. Thus, it should be possible to assess the feasibility of bridging two kinases by looking at the similarity of their known inhibitors. The work of Bamborough et al. implies that if two inhibitors of different kinases have a Tanimoto coefficient above 0.6 (<i>T</i><sub>c</sub> > 0.6), there is a good chance that they will also hit the other kinase.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Ligand-based similarity methods have also been used by other groups to study ligands from a wider range of targets from diverse proteomic families to produce a map of polypharmacology space.<a onclick="showRef(event, 'ref75 ref124 ref125'); return false;" href="javascript:void(0);" class="ref ref75 ref124 ref125">(75, 124, 125)</a> These maps can reveal relationships between targets that are unexpected from sequence data alone and help identify novel target combinations for which it may be possible to find a multitarget agent.</div><div class="NLM_p">Although they have great potential, it is still early days for such predictive approaches. It is difficult to know how generally useful they will be for assessing the feasibility of those unexpected combinations where the targets are not obviously related by structure or function, and yet it is still possible to obtain a druglike DML. The discovery that imatinib and nilotinib inhibit CA I and CA II carbonic anhydrases would not currently be predicted on the basis of the structures of either the proteins or their known ligands.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> These kinase inhibitors lack the typical warheads, such as sulphonamides, associated with CA inhibition.</div><div class="NLM_p last">Likewise, chemical similarity does not always translate into biological similarity, so the fact that two targets have similar ligands does not guarantee success. Fusing multiple prediction methods that use different measures of compound similarity is likely to improve the overall success rates of in silico lead identification.</div></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">8 Network Pharmacology</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47685" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47685" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In addition to assessing the feasibility of a particular combination from a medicinal chemistry perspective, the second critical determinant of success in MTDD is discovering and validating novel combinations from the disease perspective. Network pharmacology is an emerging and exciting discipline that has the potential to transform the way we discover MTDs.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a></div><div class="NLM_p">There are emerging signs of a change in mindset in drug discovery from targeting single targets to targeting disease-relevant pathways. Signaling pathways are not strictly linear processes but rather involve a complex network of interconnected circuits. When only a single pathway is targeted, redundancy and crosstalk between these pathways allow for compensatory effects by alternative pathways. Systems-level and individual target-based research should not be regarded as competing fields. They are complementary. By adopting a single-target mindset, we can better understand how an individual target contributes to the operation of a system as a whole. In addition to biological approaches such as gene knock outs and knock downs, chemical biology approaches using highly selective chemical probes can reveal the contribution of each component to the therapeutic efficacy and safety of a multitarget drug.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Isobolographic analyses of the effect on efficacy of different doses of selective ligands can help to identify the individual target contributions.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a></div><div class="NLM_p">The targeting of aberrant network states may represent a powerful new paradigm in MTDD. Although the majority of the protein inventory in a cancer cell is the same as a normal cell, the differences in the topology of the biological networks could be targeted to provide an improved therapeutic index.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> We need to ascertain where the best places to intervene in a network are, from the perspective of efficacy, safety, and druggability.</div><div class="NLM_p">Known MKIs achieve their superior antitumor effects by simultaneous disruption of different targets in the same pathway or of multiple targets in different pathways. The terms “single-spectrum” and “extended-spectrum” inhibitors have been used to describe agents that respectively target kinases in the same or different signaling pathways.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Lapatinib is an example of the former, inhibiting two kinases in the EGFR pathway, EGFR and ErbB2. The blockade of several targets in the same pathway can be useful for overcoming the onset of resistance to inhibition of one component in a pathway. However, it may be necessary to block more than one pathway to prevent signaling simply being redirected via an alternative pathway. Vandetanib <b>11</b> is an extended-spectrum  agent that blocks both the EGFR and VEGFR pathways with triple inhibition of EGFR, ErbB2, and VEGFR-2.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> As well as affecting tumor cell proliferation, EGFR stimulation increases angiogenesis, so this combination is potentially synergistic. Another example of an inhibitor that acts on two separate pathways is XL880 which as well as inhibiting multiple receptor tyrosine kinases (RTKs) involved in angiogenesis (VEGFR, PDGFR, c-Kit, Flt3, and Tie-2) also inhibits c-MET, which is indicative of tumor aggressiveness and poor prognosis.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Sorafenib has a unique profile among the approved inhibitors, with activity at an intracellular serine/threonine kinase (B-RAF), hence blocking the MEK/ERK pathway and the cell surface RTKs (VEGFR, PDGFR, c-Kit, and RET).</div><div class="NLM_p">The literature now contains numerous examples where selective inhibition of one kinase appears to lead to compensatory changes in the activity of another target or pathway that counteracts the intended antitumor effect. Developing a network-based understanding of which targets are involved in these feedback loops can lead to the rational design of new MKI profiles. Paradoxically, several kinase inhibitors, such as the allosteric mTORC1 inhibitor, rapamycin, and the ATP-competitive AKT inhibitor, A-443654, have been found to activate rather than inhibit the target pathway owing to inhibition of a negative feedback loop.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Because activation of these pathways promotes tumor growth, it is crucial to understand which pathways may have active feedback loops and which kinases are responsible for their control. Selective inhibition of mTOR may lead to PI3 kinase (PI3K) activation which can be overcome with combined inhibition of mTOR and p110α.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> The efficacy of EGFR/erbB2 inhibitors in treating erbB2-positive breast cancer is reduced by compensatory changes in the phosphorylation of erbB3 that lead to the restoration of PI3K/AKT-mediated signaling.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Combining EGFR inhibition with PI3K/mTOR inhibition is a promising approach for improving efficacy.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Similarly it has been suggested that MET inhibition should be combined with EGFR inhibition to overcome resistance to gefitinib in lung cancer patients due to MET-induced activation of the PI3K/AKT-mediated pathway.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a></div><div class="NLM_p last">A better understanding of the role of feedback loops within networks is already helping to avoid safety issues with kinase inhibitors for chronic, nononcology diseases. One of the potential safety issues with p38 inhibitors is the possibility of tumorigenic side effects via the p38a-TAB1 feedback loop.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> This potential risk may be avoided by targeting targets downstream of p38 such as MAPK-activated protein kinase 2 (MK2).<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">9 Combinations of Selective Inhibitors as an Alternative Approach to MKIs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34113" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34113" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The development of exquisitely selective single target kinase inhibitors, rather than selectively nonselective MKIs, is currently the primary focus in many companies. Single target agents can be effective in treating tumors that are “addicted” to a single oncogenic kinase, the best known example being CML which is dependent on the sustained activation of BCR-ABL. Some selective agents, such as gefitinib <b>7</b>, show good efficacy but only in a small subset of patients with EGFR mutations. Thus, there is a general recognition that in many, if not most, cases achieving sufficient efficacy will demand their combination with other agents. Where two or more agents, that are highly selective for a single target, need to be dosed separately in the form of two (or more) individual medications, there is a risk of poor patient compliance due to complex dosing regimens. However, this will be less of a concern for life-threatening diseases such as cancer, especially where patients are hospitalised. Indeed, there are currently a large number of cancer trials ongoing combining small molecule kinase inhibitors as well as combinations of small molecule inhibitors and monoclonal antibodies. To make dosing regimes simpler and improve compliance, particularly for less severe diseases, several small molecules can be coformulated in a single tablet.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Recently this fixed dose combination (FDC) approach has started to be applied in the kinase area. For example, AstraZeneca and Merck are developing a combination of the allosteric AKT inhibitor <b>17</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>) and the MEK1/2 inhibitor AZD6244.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a></div><div class="NLM_p">The question is often asked whether FDCs or DMLs are the preferred approach to MTDD. The answer is not clear at present and is unlikely to be resolved in the near future. Arguing at this point in time that one approach is always better than the other risks stifling the important intellectual debate that needs to take place. In reality, there is almost certainly room for both in the armamentarium of modern drug development. DMLs and FDCs have their own distinctive advantages and disadvantages, and which is preferred will depend upon a diverse range of considerations from the feasibility of the DML approach at the drug discovery stage to the individual needs of the particular patient in the clinic.</div><div class="NLM_p">An advantage of drug combinations is the ability to titrate the dose for optimal inhibition of each target. While it is not possible with a FDC to fine-tune an exact ratio for an individual, a number of different dose combinations are usually made available based upon the most common doses of the individual drugs. One limitation of FDCs is that concomitant administration of two or more agents may result in drug−drug interactions and unacceptable additive toxicities.</div><div class="NLM_p">For some disease-relevant target combinations, the medicinal chemist will struggle to achieve the requisite multitarget profile. Particularly where the targets in a combination are distantly related, the danger of the DML approach is that obtaining the multiple activities in a single molecule will only be achieved at the expense of either poor physicochemical properties and low oral bioavailability or poor selectivity and high toxicity. In such cases, a more practical and safer approach might be the combined administration of two highly target-selective compounds. Together they could provide the desired balance of activities, with a wider selectivity profile that translates into an optimal therapeutic window in man.</div><div class="NLM_p">The question then arises as to how many single agents can be combined in a single tablet. Most current FDCs contain two agents only, but advances in formulation technology are expanding the number of drugs that can be combined. The so-called polypill combines five medicines for treating cardiovascular disease in a single tablet with a similar additive effect to each drug separately and no unexpected interactions between the drugs.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> However, the difficulties of formulating multicomponent capsules over extended periods of time should not be underestimated and can be very costly and time-consuming.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> For example, some components may well require different conditions for stability from others, such as a different pH, to avoid problems with chemical degradation.</div><div class="NLM_p">Another issue with FDCs is the ownership of the IP if the individual drugs are derived from different companies. The AstraZeneca and Merck collaboration combining their MEK and AKT inhibitors is a new type of intercompany collaboration. Rather than combining an experimental therapy with an approved drug as is more common to enhance the drug’s therapeutic effect, the two companies are coming together at an earlier stage and planning a phase I trial.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Whether this type of agreement marks the start of a new trend in clinical research collaboration remains to be seen.</div><div class="NLM_p last">Even many of the broad spectrum MKIs such as sunitinib and sorafenib may need to be combined with other agents, since neither appears to be curative when used alone. There are several clinical trials ongoing combining these agents with other drugs, for example, combining sunitinib with chemotherapy, combining lapatinib with trastuzumab, and combining sorafenib with bevacizumab, to add another level of inhibition by removing VEGF from the blood. So in the future, a third hybrid strategy could well emerge in addition to conventional DMLs and FDCs in which combinations of DMLs are given to further enhance efficacy.</div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">10 Noncancer Application of MKIs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84615" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84615" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All kinase inhibitors, approved in the U.S. and Europe, are used in the cancer area, and there is only one nononcology kinase inhibitor, fasudil, used in Japan for the treatment of cerebral vasospasms and ischemia. However, many pharmaceutical companies are putting a significant effort into exploiting this target family in other therapeutic areas. The risk to benefit ratio needs to be appropriate for the disease being studied, and for most other diseases this will inevitably mean cleaner selectivity and side effect profiles will be required. For the current generation of multitargeted anticancer agents, it is not entirely clear which targets are driving efficacy. For less serious and chronic diseases, the clinical development of MKIs without such knowledge is much less likely and the discovery of biomarkers relating target engagement to efficacy will be even more important.</div><div class="NLM_p">The second most important area for kinase inhibitors after cancer is inflammatory disease, and many kinase inhibitors that modulate proinflammatory pathways have entered clinical trials.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> However, many have been discontinued, and this is probably related to inadequate selectivity. As a result, the emphasis is presently on obtaining highly selective single kinase inhibitors rather than MKIs. Whereas the side effects of MKIs may be tolerable in the cancer disease area, combinations of highly selective kinase inhibitors may ultimately prove to be a more valid approach clinically for some nononcology applications.</div><div class="NLM_p">Activation of p38 kinases causes downstream up-regulation of cytokine production (TNFα and IL-1) and therefore plays a pivotal role in inflammatory conditions such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Many pharmaceutical companies have sought increasingly selective p38 inhibitors over the past decade or so, but disappointingly, none of them have yet progressed to the market. The p38 family is closely related to the Jun N-terminal kinase (JNK) families, so it is perhaps not surprising that some p38 inhibitors also inhibit the JNK pathway. Dual p38/JNK3 inhibitor <b>42</b> developed by Vertex as potential therapies for stroke may address both the inflammatory (p38) and antiapoptotic (JNK3) components of the disease (Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>).<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a></div><div class="NLM_p">While inhibition of the p38 MAPK pathway remains a major focus of research in the pharmaceutical industry, there is an increasing trend to move away from direct inhibition of p38 kinase, because of concerns over its multifarious roles in cellular signaling, and toward inhibition of downstream targets such as MK2.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> This may provide a more measured and safer way of inhibiting the production of pro-inflammatory cytokines such as TNF-α. Since MK3 has a parallel role to MK2 in its inflammatory function, it has been proposed that MK2/MK3 dual inhibitors may provide a superior anti-inflammatory effect compared with MK2 inhibition alone.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a></div><div class="NLM_p">Like many forms of cancer, Alzheimer’s disease is a terminal disease with few treatment options at present, and therefore, the MKI approach may be highly appropriate. Both hyperphosphorylation of tau (leading to neurofibrillary tangles) and amyloid-β production (leading to amyloid plaques) are mediated by a small set of kinases, such as CDK1, CDK5, GSK3, and CK1.<a onclick="showRef(event, 'ref141 ref142 ref143 ref144'); return false;" href="javascript:void(0);" class="ref ref141 ref142 ref143 ref144">(141-144)</a> Multitarget inhibitors acting on this selection of kinases could therefore have great therapeutic value. The GSK3 kinases are more closely associated with the cyclin-dependent kinase (CDK) sub-branch than its location on the phylogenetic tree would suggest, and most CDK inhibitors have been found to be good inhibitors of GSK3β due to the similarity of the ATP binding domains.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Oumata et al. prepared trisubstituted purines <b>43</b> that were evaluated as inhibitors of CDK1, CDK5, GSK-3, and CK1, and Chioua et al. described pyrazolopyridine <b>44</b> as a prototypical inhibitor of CDK5, GSK-3, and DYRK1A (Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>).<a onclick="showRef(event, 'ref145 ref146'); return false;" href="javascript:void(0);" class="ref ref145 ref146">(145, 146)</a></div><figure id="fig13" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0001.jpeg" id="gr13" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec11" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">11 Summary</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27376" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27376" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">MKIs can deliver superior efficacy compared to inhibitors with high specificity for a single kinase, and the recent introduction of several MKIs to the market opens the door to a new era of safer and effective anticancer therapy. The key to combining high efficacy with acceptable safety is to inhibit multiple targets in a selectively nonselective fashion. Strategies for intentionally designing MKIs are emerging, but the field is still in its infancy and we are as medicinal chemists currently on the steepest part of the learning curve. MTDD can be time-consuming and expensive, and we need to become more proficient first at identifying disease-relevant target combinations and second at discovering MKIs that combine optimal physicochemical and biological properties. Bold and innovative medicinal chemistry strategies are required to tackle “difficult combinations” where the disease rationale is compelling but where it is a struggle to combine all the desired attributes of an oral MKI drug into a single molecule. At present it is unclear to what extent MKIs with highly tuned selectivity profiles can be rationally designed, particularly for targets that are unrelated by sequence. In addition to the well-known selectivity challenge, the physicochemical property profiles of ATP-competitive MKIs can be inherently challenging and limited scope for patentability can also be a serious hindrance. On the plus side, the amount of kinase-specific structural information is growing very rapidly, and ultimately this may reveal distinct features and design rules that enable a medicinal chemist to rationally modify and refine the profile of MKIs. In addition, increasing SAR knowledge is emerging from large scale panel screening with the binding profiles starting to reveal to medicinal chemists how chemical structure affects cross-reactivity across large parts of the kinome.</div><div class="NLM_p">The merit of MKIs compared with single kinase inhibitors is a subject of controversy in drug discovery that is unlikely to be resolved in the near future. At the start of a new MTDD project, a rigorous debate needs to take place as to whether it makes more sense to seek a combination of highly selective agents or a DML. Many factors need to be taken into account in this decision such as the number, similarity, and promiscuity of the targets in the profile and the disease area.</div><div class="NLM_p">Conformational plasticity and the occurrence of multiple binding modes complicate the in silico prediction of kinase polypharmacology based solely upon protein structure. The use of ligand-based similarity to assess the feasibility of a given combination can add real value. Currently, serendipity plays a significant role in MKI discovery and many, if not most, MKIs have been discovered by chance during the search for selective inhibitors. Medicinal chemists need to be alert to the possibilities when a surprising combination is found by chance. To exploit such serendipity, you need a good appreciation of when you have a sufficiently high quality starting compound and then you need to be able to make and test sufficient analogues to explore your new disease-based hypothesis.</div><div class="NLM_p last">MKIs are costly to develop and are consequently priced at a premium level, so they will need to show clear improvements in order to get reimbursement. There have already been problems with reimbursement for some MKIs in some markets due to concerns from funding bodies over insufficient efficacy. The true value of MKIs relative to other anticancer drugs still has to be established, and the results from recent clinical trials have been mixed. Despite the broad activity profile of many MKIs, the patient response can be inconsistent and unpredictable. The identification of predictive biomarkers of response or resistance is a critical step to ascertain which specific combination of targets produces a significant clinical benefit with respect to specific tumor types. More clinical feedback is needed to facilitate the design of the next generation of inhibitors with more precisely defined profiles. Although it might seem immeasurably distant at the present time, the ultimate goal should be to derive the prerequisite knowledge and tools so that MTDD becomes a rational endeavor rather than a black box approach that relies upon serendipity. This will help banish claims that MKIs are merely “dirty”, nonspecific drugs with insufficient specificity for treating a wider range of human diseases.</div></div><div class="NLM_back"><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75178" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75178" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Morphy</span> - <span class="hlFld-Affiliation affiliation">Medicinal Chemistry Department, Schering-Plough, Newhouse, Lanarkshire, ML1 5SH, U.K.</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#97e5fef4fff6e5f3b9faf8e5e7ffeed7e4e7f4f8e5e7b9f4f8fa"><span class="__cf_email__" data-cfemail="a7d5cec4cfc6d5c389cac8d5d7cfdee7d4d7c4c8d5d789c4c8ca">[email protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li></li></ul></div><div class="testing" data-doi="10.1021/jm901132v" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="bio"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">Biography</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30801" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30801" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="" data-index="" class="article__inlineFigure"><h2 class="fig-label"></h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id="><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Richard Morphy</b> completed his Ph.D. at Durham University (U.K.) under the direction of Professor David Parker working on macrocycle synthesis and conjugation to monoclonal antibodies. In 1989 he joined Celltech Ltd. in Slough (U.K.) as a medicinal chemist working on a variety of oncology and inflammation projects. In 1995, he joined Organon Laboratories in Scotland as a team leader in the CNS area, and he is currently a section head in the Medicinal Chemistry Department at Schering Plough’s Newhouse site. His involvement with a number of CNS and non-CNS projects over the years has led to a keen interest in the challenging area of discovering multitarget ligands.</p></figure></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81443" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81443" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 146 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Cohen, P.</span><span> </span><span class="NLM_article-title">Protein kinases: the major drug targets of the twenty-first century?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=309-315&author=P.+Cohen&title=Protein+kinases%3A+the+major+drug+targets+of+the+twenty-first+century%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DProtein%2520kinases%253A%2520the%2520major%2520drug%2520targets%2520of%2520the%2520twenty-first%2520century%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D309%26epage%3D315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">From magic bullets to designed multiple ligands</span> <span class="citation_source-journal">Drug Discovery Today.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">641</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+magic+bullets+to+designed+multiple+ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0lhDkiRh5NdPcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520magic%2520bullets%2520to%2520designed%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today.%26date%3D2004%26volume%3D9%26spage%3D641%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Millan, M. J.</span><span> </span><span class="NLM_article-title">Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2Fj.pharmthera.2005.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=16522330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtFCqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2006&pages=135-370&author=M.+J.+Millan&title=Multi-target+strategies+for+the+improved+treatment+of+depressive+states%3A+conceptual+foundations+and+neuronal+substrates%2C+drug+discovery+and+therapeutic+application"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application</span></div><div class="casAuthors">Millan, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-370</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Major depression is a debilitating and recurrent disorder with a substantial lifetime risk and a high social cost.  Depressed patients generally display co-morbid symptoms, and depression frequently accompanies other serious disorders.  Currently available drugs display limited efficacy and a pronounced delay to onset of action, and all provoke distressing side effects.  Cloning of the human genome has fuelled expectations that symptomatic treatment may soon become more rapid and effective, and that depressive states may ultimately be "prevented" or "cured".  In pursuing these objectives, in particular for genome-derived, non-monoaminergic targets, "specificity" of drug actions is often emphasized.  That is, priority is afforded to agents that interact exclusively with a single site hypothesized as critically involved in the pathogenesis and/or control of depression.  Certain highly selective drugs may prove effective, and they remain indispensable in the exptl. (and clin.) evaluation of the significance of novel mechanisms.  However, by analogy to other multifactorial disorders, "multi-target" agents may be better adapted to the improved treatment of depressive states.  Support for this contention is garnered from a broad palette of observations, ranging from mechanisms of action of adjunctive drug combinations and electroconvulsive therapy to "network theory" anal. of the etiol. and management of depressive states.  The review also outlines opportunities to be exploited, and challenges to be addressed, in the discovery and characterization of drugs recognizing multiple targets.  Finally, a diversity of multi-target strategies is proposed for the more efficacious and rapid control of core and co-morbid symptoms of depression, together with improved tolerance relative to currently available agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxf3nCB4E-O7Vg90H21EOLACvtfcHk0lhDkiRh5NdPcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtFCqtr4%253D&md5=dbca7f1b7bba52c69d9c6b95eea01d69</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2005.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2005.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26atitle%3DMulti-target%2520strategies%2520for%2520the%2520improved%2520treatment%2520of%2520depressive%2520states%253A%2520conceptual%2520foundations%2520and%2520neuronal%2520substrates%252C%2520drug%2520discovery%2520and%2520therapeutic%2520application%26jtitle%3DPharmacol.%2520Ther.%26date%3D2006%26volume%3D110%26spage%3D135%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6523</span><span class="NLM_x">–</span> <span class="NLM_lpage">6543</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0lij4JNwolHt0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eder, J. P.</span><span> </span><span class="NLM_article-title">Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1013</span><span class="NLM_x">–</span> <span class="NLM_lpage">1028</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=1013-1028&author=P.+M.+LoRussoauthor=J.+P.+Eder&title=Therapeutic+potential+of+novel+selective-spectrum+kinase+inhibitors+in+oncology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DEder%26aufirst%3DJ.%2BP.%26atitle%3DTherapeutic%2520potential%2520of%2520novel%2520selective-spectrum%2520kinase%2520inhibitors%2520in%2520oncology%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D17%26spage%3D1013%26epage%3D1028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Daub, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Specht, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Strategies to overcome resistance to targeted protein kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1001</span><span class="NLM_x">–</span> <span class="NLM_lpage">1010</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=1001-1010&author=H.+Daubauthor=K.+Spechtauthor=A.+Ullrich&title=Strategies+to+overcome+resistance+to+targeted+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDaub%26aufirst%3DH.%26aulast%3DSpecht%26aufirst%3DK.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DStrategies%2520to%2520overcome%2520resistance%2520to%2520targeted%2520protein%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D12%26spage%3D1001%26epage%3D1010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soverini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarani, M.</span><span> </span><span class="NLM_article-title">Dual tyrosine kinase inhibitors in chronic myeloid leukemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1872</span><span class="NLM_x">–</span> <span class="NLM_lpage">1879</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1872-1879&author=G.+Martinelliauthor=S.+Soveriniauthor=G.+Rostiauthor=M.+Baccarani&title=Dual+tyrosine+kinase+inhibitors+in+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DSoverini%26aufirst%3DS.%26aulast%3DRosti%26aufirst%3DG.%26aulast%3DBaccarani%26aufirst%3DM.%26atitle%3DDual%2520tyrosine%2520kinase%2520inhibitors%2520in%2520chronic%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2005%26volume%3D19%26spage%3D1872%26epage%3D1879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Deininger, M. W.</span><span> </span><span class="NLM_article-title">Nilotinib</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">4027</span><span class="NLM_x">–</span> <span class="NLM_lpage">4031</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1158%2F1078-0432.CCR-07-5015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=18593977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvFyltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=4027-4031&author=M.+W.+Deininger&title=Nilotinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Nilotinib</span></div><div class="casAuthors">Deininger, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4027-4031</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review on the development of nilotinib.  Topics discussed include current landscape of chronic myeloid leukemia (CML) therapy, preclin. profiling, clin. activity, toxicity, pharmacokinetics, and selection of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnU21REG8aPrVg90H21EOLACvtfcHk0lij4JNwolHt0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvFyltbc%253D&md5=9f2f33d264c28bbe84e70a72d6e425ee</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-5015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-5015%26sid%3Dliteratum%253Aachs%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DNilotinib%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D4027%26epage%3D4031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedman, S. J.</span><span> </span><span class="NLM_article-title">MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">500</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=500-502&author=F.+J.+Gilesauthor=J.+Cortesauthor=D.+Jonesauthor=D.+Bergstromauthor=H.+Kantarjianauthor=S.+J.+Freedman&title=MK-0457%2C+a+novel+kinase+inhibitor%2C+is+active+in+patients+with+chronic+myeloid+leukemia+or+acute+lymphocytic+leukemia+with+the+T315I+BCR-ABL+mutation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DBergstrom%26aufirst%3DD.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DFreedman%26aufirst%3DS.%2BJ.%26atitle%3DMK-0457%252C%2520a%2520novel%2520kinase%2520inhibitor%252C%2520is%2520active%2520in%2520patients%2520with%2520chronic%2520myeloid%2520leukemia%2520or%2520acute%2520lymphocytic%2520leukemia%2520with%2520the%2520T315I%2520BCR-ABL%2520mutation%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D500%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruemmendorf, T.</span><span> </span><span class="NLM_article-title">Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated among patients with AP and BP CML and Ph_ ALL</span> <span class="citation_source-journal">Blood (ASH Annu. Meet. Abstr.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">473</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=473&author=C.+Gambacorti-Passeriniauthor=H.+Kantarjianauthor=T.+Bruemmendorf&title=Bosutinib+%28SKI-606%29+demonstrates+clinical+activity+and+is+well+tolerated+among+patients+with+AP+and+BP+CML+and+Ph_+ALL"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DBruemmendorf%26aufirst%3DT.%26atitle%3DBosutinib%2520%2528SKI-606%2529%2520demonstrates%2520clinical%2520activity%2520and%2520is%2520well%2520tolerated%2520among%2520patients%2520with%2520AP%2520and%2520BP%2520CML%2520and%2520Ph_%2520ALL%26jtitle%3DBlood%2520%2528ASH%2520Annu.%2520Meet.%2520Abstr.%2529%26date%3D2007%26volume%3D110%26spage%3D473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Blackledge, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Averbuch, S.</span><span> </span><span class="NLM_article-title">Gefitinib (“Iressa”, ZD1839) and new epidermal growth factor receptor inhibitors</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">566</span><span class="NLM_x">–</span> <span class="NLM_lpage">572</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fsj.bjc.6601550" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=14760365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2cXoslKjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2004&pages=566-572&author=G.+Blackledgeauthor=S.+Averbuch&title=Gefitinib+%28%E2%80%9CIressa%E2%80%9D%2C+ZD1839%29+and+new+epidermal+growth+factor+receptor+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib ( Iressa', ZD1839) and new epidermal growth factor receptor inhibitors</span></div><div class="casAuthors">Blackledge, G.; Averbuch, S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">566-572</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) is a promising target for cancer therapy and a no. of EGFR-targeted agents have been developed.  Those most advanced in development are the EGFR tyrosine kinase inhibitors gefitinib ('Tarceva', ZD1839) and erlotinib ('Tarceva', OSI-774), and the monoclonal antibody cetuximab ('Erbitux', IMC-C225).  This review provides a clin. overview of these agents, highlighting their antitumor activities in different tumor types.  Epidermal growth factor receptor-targeted agents are generally well tolerated and are not typically assocd. with the severe adverse events often seen with cytotoxic chemotherapy.  Gefitinib is the agent with the most extensive clin. experience, particularly in non-small-cell lung cancer (NSCLC). Recently, gefitinib became the first-approved EGFR-targeted agent, for use in patients with previously treated advanced NSCLC in Japan, the USA and other countries.  Further studies are required to explore the full potential of these novel agents either as monotherapy or combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFcx_HdnziB7Vg90H21EOLACvtfcHk0lhpu-QX1Tk82g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXoslKjsA%253D%253D&md5=6fb4274fbf9f2a674053bb6030348167</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6601550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6601550%26sid%3Dliteratum%253Aachs%26aulast%3DBlackledge%26aufirst%3DG.%26aulast%3DAverbuch%26aufirst%3DS.%26atitle%3DGefitinib%2520%2528%25E2%2580%259CIressa%25E2%2580%259D%252C%2520ZD1839%2529%2520and%2520new%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitors%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2004%26volume%3D90%26spage%3D566%26epage%3D572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Rix, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span> </span><span class="NLM_article-title">Target profiling of small molecules by chemical proteomics</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">616</span><span class="NLM_x">–</span> <span class="NLM_lpage">625</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnchembio.216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=19690537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWhsb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=616-625&author=U.+Rixauthor=G.+Superti-Furga&title=Target+profiling+of+small+molecules+by+chemical+proteomics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Target profiling of small molecules by chemical proteomics</span></div><div class="casAuthors">Rix, Uwe; Superti-Furga, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">616-624</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The medical and pharmaceutical communities are facing a dire need for new druggable targets, while, paradoxically, the targets of some drugs that are in clin. use or development remain elusive.  Many compds. have been more promiscuous than originally anticipated, which can potentially lead to side effects, but which may also open up addnl. medical uses.  As we move toward systems biol. and personalized medicine, comprehensively detg. small mol.-target interaction profiles and mapping these on signaling and metabolic pathways will become increasingly necessary.  Chem. proteomics is a powerful mass spectrometry-based affinity chromatog. approach for identifying proteome-wide small mol.-protein interactions.  Here we will provide a crit. overview of the basic concepts and recent advances in chem. proteomics and review recent applications, with a particular emphasis on kinase inhibitors and natural products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBJz9OMT5Rp7Vg90H21EOLACvtfcHk0lhpu-QX1Tk82g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWhsb7K&md5=b357080902ea5e6cd6ab51792f327d0b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.216%26sid%3Dliteratum%253Aachs%26aulast%3DRix%26aufirst%3DU.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DTarget%2520profiling%2520of%2520small%2520molecules%2520by%2520chemical%2520proteomics%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D616%26epage%3D625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Kerbel, R. S.</span><span> </span><span class="NLM_article-title">Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents</span> <span class="citation_source-journal">BioEssays</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1991&pages=31-36&author=R.+S.+Kerbel&title=Inhibition+of+tumor+angiogenesis+as+a+strategy+to+circumvent+acquired+resistance+to+anti-cancer+therapeutic+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKerbel%26aufirst%3DR.%2BS.%26atitle%3DInhibition%2520of%2520tumor%2520angiogenesis%2520as%2520a%2520strategy%2520to%2520circumvent%2520acquired%2520resistance%2520to%2520anti-cancer%2520therapeutic%2520agents%26jtitle%3DBioEssays%26date%3D1991%26volume%3D13%26spage%3D31%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Boyer, S. J.</span><span> </span><span class="NLM_article-title">Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">973</span><span class="NLM_x">–</span> <span class="NLM_lpage">1000</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.2174%2F1568026023393273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=12171566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtVOitbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=973-1000&author=S.+J.+Boyer&title=Small+molecule+inhibitors+of+KDR+%28VEGFR-2%29+kinase%3A+an+overview+of+structure+activity+relationships"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships</span></div><div class="casAuthors">Boyer, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Hilversum, Netherlands)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">973-1000</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The Kinase insert Domain contg. Receptor (KDR), alternatively referred to as VEGFR-2, is a receptor for Vascular Endothelial Growth Factors (VEGFs) and functions as a key regulator of angiogenesis, the process by which new capillaries are created from preexisting blood vessels.  The induction of angiogenesis, or the "angiogenic switch," is a crit. step in tumor progression, and inhibitors of KDR have been demonstrated both to induce tumor regression and reduce metastatic potential in preclin. models.  In the last few years, medicinal chemists have expanded the kinase selectivity profile of known inhibitor classes to include KDR, and also identified novel classes of KDR inhibitors.  This review presents structure activity relationships (SAR) of small mol. inhibitors of KDR, with an emphasis on the pharmacophore elements of the scaffolds employed.  Binding hypotheses based on x-ray crystallog. analyses will also be described.  Addnl., the efficacy of representative compds. in in vitro and in vivo models of tumor progression and angiogenesis are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8iX5xdLgktLVg90H21EOLACvtfcHk0lhpu-QX1Tk82g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtVOitbw%253D&md5=4c4445eac589bded1baed3140b918be8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F1568026023393273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026023393273%26sid%3Dliteratum%253Aachs%26aulast%3DBoyer%26aufirst%3DS.%2BJ.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520KDR%2520%2528VEGFR-2%2529%2520kinase%253A%2520an%2520overview%2520of%2520structure%2520activity%2520relationships%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2002%26volume%3D2%26spage%3D973%26epage%3D1000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H.-J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazlauskas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavenee, W. K.</span><span> </span><span class="NLM_article-title">Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1464</span><span class="NLM_x">–</span> <span class="NLM_lpage">1472</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=1464-1472&author=D.+Wangauthor=H.-J.+S.+Huangauthor=A.+Kazlauskasauthor=W.+K.+Cavenee&title=Induction+of+vascular+endothelial+growth+factor+expression+in+endothelial+cells+by+platelet-derived+growth+factor+through+the+activation+of+phosphatidylinositol+3-kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DH.-J.%2BS.%26aulast%3DKazlauskas%26aufirst%3DA.%26aulast%3DCavenee%26aufirst%3DW.%2BK.%26atitle%3DInduction%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520expression%2520in%2520endothelial%2520cells%2520by%2520platelet-derived%2520growth%2520factor%2520through%2520the%2520activation%2520of%2520phosphatidylinositol%25203-kinase%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D1464%26epage%3D1472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Mendel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreck, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngai, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carver, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haznedar, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sukbuntherng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span> </span><span class="NLM_article-title">In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">337</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=12538485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1OrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=327-337&author=D.+B.+Mendelauthor=A.+D.+Lairdauthor=X.+Xinauthor=S.+G.+Louieauthor=J.+G.+Christensenauthor=G.+Liauthor=R.+E.+Schreckauthor=T.+J.+Abramsauthor=T.+J.+Ngaiauthor=L.+B.+Leeauthor=L.+J.+Murrayauthor=J.+Carverauthor=E.+Chanauthor=K.+G.+Mossauthor=J.+O.+Haznedarauthor=J.+Sukbuntherngauthor=R.+A.+Blakeauthor=L.+Sunauthor=C.+Tangauthor=T.+Millerauthor=S.+Shirazianauthor=G.+McMahonauthor=J.+M.+Cherrington&title=In+vivo+antitumor+activity+of+SU11248%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+growth+factor+and+platelet-derived+growth+factor+receptors%3A+determination+of+a+pharmacokinetic%2Fpharmacodynamic+relationship"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship</span></div><div class="casAuthors">Mendel, Dirk B.; Laird, A. Douglas; Xin, Xiaohua; Louie, Sharianne G.; Christensen, James G.; Li, Guangmin; Schreck, Randall E.; Abrams, Tinya J.; Ngai, Theresa J.; Lee, Leslie B.; Murray, Lesley J.; Carver, Jeremy; Chan, Emily; Moss, Katherine G.; Haznedar, Joshua O.; Sukbuntherng, Juthamas; Blake, Robert A.; Sun, Li; Tang, Cho; Miller, Todd; Shirazian, Sheri; McMahon, Gerald; Cherrington, Julie M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">327-337</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">One challenging aspect in the clin. development of molecularly targeted therapies, which represent a new and promising approach to treating cancers, has been the identification of a biol. active dose rather than a max. tolerated dose.  The goal of the present study was to identify a pharmacokinetic/pharmacodynamic relationship in preclin. models that could be used to help guide selection of a clin. dose.  SU11248, a novel small mol. receptor tyrosine kinase inhibitor with direct antitumor as well as antiangiogenic activity via targeting the vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), KIT, and FLT3 receptor tyrosine kinases, was used as the pharmacol. agent in these studies.  In mouse xenograft models, SU11248 exhibited broad and potent antitumor activity causing regression, growth arrest, or substantially reduced growth of various established xenografts derived from human or rat tumor cell lines.  To predict the target SU11248 exposure required to achieve antitumor activity in mouse xenograft models, we directly measured target phosphorylation in tumor xenografts before and after SU11248 treatment and correlated this with plasma inhibitor levels.  In target modulation studies in vivo, SU11248 selectively inhibited Flk-1/KDR (VEGF receptor 2) and PDGF receptor β phosphorylation (in a time- and dose-dependent manner) when plasma concns. of inhibitor reached or exceeded 50-100 ng/mL.  Similar results were obtained in a functional assay of VEGF-induced vascular permeability in vivo.  Const. inhibition of VEGFR2 and PDGF receptor β phosphorylation was not required for efficacy; at highly efficacious doses, inhibition was sustained for 12 h of a 24-h dosing interval.  The pharmacokinetic/pharmacodynamic relationship established for SU11248 in these preclin. studies has aided in the design, selection, and evaluation of dosing regimens being tested in human trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH8BrUNdo50rVg90H21EOLACvtfcHk0lg_VIJvrGdoZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1OrtA%253D%253D&md5=faafdec68a96d6cdf02ab347f69422b6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMendel%26aufirst%3DD.%2BB.%26aulast%3DLaird%26aufirst%3DA.%2BD.%26aulast%3DXin%26aufirst%3DX.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DSchreck%26aufirst%3DR.%2BE.%26aulast%3DAbrams%26aufirst%3DT.%2BJ.%26aulast%3DNgai%26aufirst%3DT.%2BJ.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26aulast%3DCarver%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DMoss%26aufirst%3DK.%2BG.%26aulast%3DHaznedar%26aufirst%3DJ.%2BO.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26atitle%3DIn%2520vivo%2520antitumor%2520activity%2520of%2520SU11248%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520growth%2520factor%2520and%2520platelet-derived%2520growth%2520factor%2520receptors%253A%2520determination%2520of%2520a%2520pharmacokinetic%252Fpharmacodynamic%2520relationship%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D327%26epage%3D337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNabola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shujath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gawlak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eveleigh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auclair, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gedrich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voznesensky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, P. A.</span><span> </span><span class="NLM_article-title">BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">7099</span><span class="NLM_x">–</span> <span class="NLM_lpage">7109</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7099-7109&author=S.+M.+Wilhelmauthor=C.+Carterauthor=L.+Tangauthor=D.+Wilkieauthor=A.+McNabolaauthor=H.+Rongauthor=C.+Chenauthor=X.+Zhangauthor=P.+Vincentauthor=M.+McHughauthor=Y.+Caoauthor=J.+Shujathauthor=S.+Gawlakauthor=D.+Eveleighauthor=B.+Rowleyauthor=L.+Liuauthor=L.+Adnaneauthor=M.+Lynchauthor=D.+Auclairauthor=I.+Taylorauthor=R.+Gedrichauthor=A.+Voznesenskyauthor=B.+Riedlauthor=L.+E.+Postauthor=G.+Bollagauthor=P.+A.+Trail&title=BAY+43-9006+exhibits+broad+spectrum+oral+antitumor+activity+and+targets+the+RAF%2FMEK%2FERK+pathway+and+receptor+tyrosine+kinases+involved+in+tumor+progression+and+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DWilkie%26aufirst%3DD.%26aulast%3DMcNabola%26aufirst%3DA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DVincent%26aufirst%3DP.%26aulast%3DMcHugh%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DShujath%26aufirst%3DJ.%26aulast%3DGawlak%26aufirst%3DS.%26aulast%3DEveleigh%26aufirst%3DD.%26aulast%3DRowley%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DAuclair%26aufirst%3DD.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DGedrich%26aufirst%3DR.%26aulast%3DVoznesensky%26aufirst%3DA.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DPost%26aufirst%3DL.%2BE.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DBAY%252043-9006%2520exhibits%2520broad%2520spectrum%2520oral%2520antitumor%2520activity%2520and%2520targets%2520the%2520RAF%252FMEK%252FERK%2520pathway%2520and%2520receptor%2520tyrosine%2520kinases%2520involved%2520in%2520tumor%2520progression%2520and%2520angiogenesis%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D7099%26epage%3D7109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Sathornsumetee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reardon, D. A.</span><span> </span><span class="NLM_article-title">Targeting multiple kinases in glioblastoma multiforme</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">292</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=277-292&author=S.+Sathornsumeteeauthor=D.+A.+Reardon&title=Targeting+multiple+kinases+in+glioblastoma+multiforme"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSathornsumetee%26aufirst%3DS.%26aulast%3DReardon%26aufirst%3DD.%2BA.%26atitle%3DTargeting%2520multiple%2520kinases%2520in%2520glioblastoma%2520multiforme%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D277%26epage%3D292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowinger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simantov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, S.</span><span> </span><span class="NLM_article-title">Discovery and development of sorafenib: a multikinase inhibitor for treating cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnrd2130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17016424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVajsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=835-844&author=S.+Wilhelmauthor=C.+Carterauthor=M.+Lynchauthor=T.+Lowingerauthor=J.+Dumasauthor=R.+A.+Smithauthor=B.+Schwartzauthor=R.+Simantovauthor=S.+Kelley&title=Discovery+and+development+of+sorafenib%3A+a+multikinase+inhibitor+for+treating+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of sorafenib: a multikinase inhibitor for treating cancer</span></div><div class="casAuthors">Wilhelm, Scott; Carter, Christopher; Lynch, Mark; Lowinger, Timothy; Dumas, Jacques; Smith, Roger A.; Schwartz, Brian; Simantov, Ronit; Kelley, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">835-844</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the mol. revolution of the 1980s, knowledge of the etiol. of cancer has increased considerably, which has led to the discovery and development of targeted therapies tailored to inhibit cancer-specific pathways.  The introduction and refinement of rapid, high-throughput screening technologies over the past decade has greatly facilitated this targeted discovery and development process.  Here, the authors describe the discovery and continuing development of sorafenib (previously known as BAY 43-9006), the first oral multikinase inhibitor that targets Raf and affects tumor signaling and the tumor vasculature.  The discovery cycle of sorafenib (Nexavar; Bayer Pharmaceuticals) - from initial screening for a lead compd. to FDA approval for the treatment of advanced renal cell carcinoma in Dec. 2005 - was completed in just 11 years, with approval being received ∼5 years after the initiation of the first Phase I trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6WjjfgNSCtbVg90H21EOLACvtfcHk0lg_VIJvrGdoZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVajsbbM&md5=490d4995170f3a7270ae9bbdd24b12e5</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrd2130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2130%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DLowinger%26aufirst%3DT.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DSimantov%26aufirst%3DR.%26aulast%3DKelley%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520development%2520of%2520sorafenib%253A%2520a%2520multikinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D835%26epage%3D844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Golas, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etienne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span> </span><span class="NLM_article-title">SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of SRC and ABL kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">381</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=12543790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1Krsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=375-381&author=J.+M.+Golasauthor=K.+Arndtauthor=C.+Etienneauthor=J.+Lucasauthor=D.+Nardinauthor=J.+Gibbonsauthor=P.+Frostauthor=F.+Yeauthor=D.+H.+Boschelliauthor=F.+Boschelli&title=SKI-606%2C+a+4-anilino-3-quinolinecarbonitrile+dual+inhibitor+of+SRC+and+ABL+kinases%2C+is+a+potent+antiproliferative+agent+against+chronic+myelogenous+leukemia+cells+in+culture+and+causes+regression+of+K562+xenografts+in+nude+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">SKI-606, a 4-Anilino-3-quinolinecarbonitrile Dual Inhibitor of Src and Abl Kinases, Is a Potent Antiproliferative Agent against Chronic Myelogenous Leukemia Cells in Culture and Causes Regression of K562 Xenografts in Nude Mice</span></div><div class="casAuthors">Golas, Jennifer M.; Arndt, Kim; Etienne, Carlo; Lucas, Judy; Nardin, Danielle; Gibbons, James; Frost, Philip; Ye, Fei; Boschelli, Diane H.; Boschelli, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">375-381</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Constitutive tyrosine kinase activity of Bcr-Abl promotes proliferation and survival of chronic myelogenous leukemia (CML) cells.  Inhibition of Bcr-Abl tyrosine kinase activity or signaling proteins activated by Bcr-Abl in CML cells blocks proliferation and causes apoptotic cell death.  The selective Abl kinase inhibitor, STI-571 (marketed as Gleevec), is toxic to CML cells in culture, causes regression of CML tumors in nude mice, and is currently used to treat CML patients.  Here we describe a p.o. active, dual Src/Abl kinase inhibitor with potent antiproliferative activity against CML cells in culture.  This 4-anilino-3-quinolinecarbonitrile (SKI-606) ablates tyrosine phosphorylation of Bcr-Abl in CML cells and of v-Abl expressed in fibroblasts.  SKI-606 inhibits phosphorylation of cellular proteins, including STAT5, at concns. that inhibit proliferation in CML cells.  Phosphorylation of the autoactivation site of the Src family kinases Lyn and/or Hck is also reduced by treatment with SKI-606.  Once daily oral administration of this compd. at 100 mg/kg for 5 days causes complete regression of large K562 xenografts in nude mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ0DM9Z0QjjLVg90H21EOLACvtfcHk0ljLxyJT6AfPJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1Krsg%253D%253D&md5=e7b5e5ffee0238543dc9c31b7e86b3d2</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGolas%26aufirst%3DJ.%2BM.%26aulast%3DArndt%26aufirst%3DK.%26aulast%3DEtienne%26aufirst%3DC.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DNardin%26aufirst%3DD.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DFrost%26aufirst%3DP.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DBoschelli%26aufirst%3DF.%26atitle%3DSKI-606%252C%2520a%25204-anilino-3-quinolinecarbonitrile%2520dual%2520inhibitor%2520of%2520SRC%2520and%2520ABL%2520kinases%252C%2520is%2520a%2520potent%2520antiproliferative%2520agent%2520against%2520chronic%2520myelogenous%2520leukemia%2520cells%2520in%2520culture%2520and%2520causes%2520regression%2520of%2520K562%2520xenografts%2520in%2520nude%2520mice%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D375%26epage%3D381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0ljLxyJT6AfPJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nematalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sistla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4-dimethyl-1<i>H</i>-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">–</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.+Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=A.+Sistlaauthor=T.+C.+Luuauthor=F.+Tangauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-fluoro-2-oxo-1%2C2-dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.%2BY.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DA.%26aulast%3DLuu%26aufirst%3DT.%2BC.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-fluoro-2-oxo-1%252C2-dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D27%26spage%3D1116%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaneda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inigo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual SRC/ABL kinase inhibitor with potent antitumor activity in preclinical assays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6658</span><span class="NLM_x">–</span> <span class="NLM_lpage">6661</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049486a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6658-6661&author=L.+J.+Lombardoauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=J.+C.+Barrishauthor=K.+Behniaauthor=S.+Castanedaauthor=L.+A.+Corneliusauthor=J.+Dasauthor=A.+M.+Doweykoauthor=C.+Fairchildauthor=J.+T.+Huntauthor=I.+Inigoauthor=K.+Johnstonauthor=A.+Kamathauthor=D.+Kanauthor=H.+Kleiauthor=P.+Maratheauthor=S.+Pangauthor=R.+Petersonauthor=S.+Pittauthor=G.+L.+Schievenauthor=R.+J.+Schmidtauthor=J.+Tokarskiauthor=M.+L.+Wenauthor=J.+Wityakauthor=R.+M.+Borzilleri&title=Discovery+of+N-%282-chloro-6-methyl-phenyl%29-2-%286-%284-%282-hydroxyethyl%29-piperazin-1-yl%29-2-methylpyrimidin-4-ylamino%29thiazole-5-carboxamide+%28BMS-354825%29%2C+a+dual+SRC%2FABL+kinase+inhibitor+with+potent+antitumor+activity+in+preclinical+assays"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm049486a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049486a%26sid%3Dliteratum%253Aachs%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DCastaneda%26aufirst%3DS.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DFairchild%26aufirst%3DC.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DInigo%26aufirst%3DI.%26aulast%3DJohnston%26aufirst%3DK.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DKan%26aufirst%3DD.%26aulast%3DKlei%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DPeterson%26aufirst%3DR.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DTokarski%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DM.%2BL.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520N-%25282-chloro-6-methyl-phenyl%2529-2-%25286-%25284-%25282-hydroxyethyl%2529-piperazin-1-yl%2529-2-methylpyrimidin-4-ylamino%2529thiazole-5-carboxamide%2520%2528BMS-354825%2529%252C%2520a%2520dual%2520SRC%252FABL%2520kinase%2520inhibitor%2520with%2520potent%2520antitumor%2520activity%2520in%2520preclinical%2520assays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6658%26epage%3D6661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Lackey, K. E.</span><span> </span><span class="NLM_article-title">Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">435</span><span class="NLM_x">–</span> <span class="NLM_lpage">460</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.2174%2F156802606776743156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=16719802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtV2juro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=435-460&author=K.+E.+Lackey&title=Lessons+from+the+drug+discovery+of+lapatinib%2C+a+dual+ErbB1%2F2+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons from the drug discovery of Lapatinib, a dual ErbB1/2 tyrosine Kinase inhibitor</span></div><div class="casAuthors">Lackey, Karen E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">435-460</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein Kinases offer many opportunities for drug intervention points since phosphorylation is the most common post-translational modification.  Phosphorylation regulates activity, location, degrdn., and conformation and the aberrant activity is implicated in many diseases, including cancer, inflammation, cardiovascular, and central nervous system diseases.  The focus of this review will be on the generation of highly effective signaling inhibitors targeting members of the erbB family of receptor tyrosine kinases, EGFR and ErbB-2, also known as transmembrane Type 1 receptor tyrosine kinases of the HER family of receptors.  Ligand binding to the receptor causes a conformational change which activates the tyrosine kinase domain leading to autophosphorylation.  This autophosphorylation activates the RAS/mitogen-activated protein (MAP) kinase and phosphoinositol-3-kinase (PI3K) pathways leading to a myriad of signaling and cellular activities.  Type 1 receptors are overexpressed in a variety of cancers and generally correlate with poor prognosis.  For this reason, scientists at GlaxoSmithKline and many others in the scientific community target the ATP binding site of the intracellular portion of the protein to block the aberrant signaling event.  This review intends to cover the lessons learned in the discovery of Lapatinib (GW572016, GW2016) by pulling together the various different publications that have been generated in distinct disciplines on aspects of the drug discovery program.  Data analyses and correlation of assay data to help with the design of drug-like mols. are included and demonstrate a break from the traditional focus on abs. potency as a guiding factor in lead compd. selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnKhQE45WWsbVg90H21EOLACvtfcHk0lgZ-490KHWrXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtV2juro%253D&md5=5bb70c03abc1fb8c301cac0f5f713fbe</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F156802606776743156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802606776743156%26sid%3Dliteratum%253Aachs%26aulast%3DLackey%26aufirst%3DK.%2BE.%26atitle%3DLessons%2520from%2520the%2520drug%2520discovery%2520of%2520lapatinib%252C%2520a%2520dual%2520ErbB1%252F2%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2006%26volume%3D6%26spage%3D435%26epage%3D460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Zhang, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guntrip, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanderwall, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span> </span><span class="NLM_article-title">Synthesis and SAR of potent EGFR/erbB2 dual inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=111-114&author=Y.+M.+Zhangauthor=S.+Cockerillauthor=S.+B.+Guntripauthor=D.+Rusnakauthor=K.+Smithauthor=D.+Vanderwallauthor=E.+Woodauthor=K.+Lackey&title=Synthesis+and+SAR+of+potent+EGFR%2FerbB2+dual+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%2BM.%26aulast%3DCockerill%26aufirst%3DS.%26aulast%3DGuntrip%26aufirst%3DS.%2BB.%26aulast%3DRusnak%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DK.%26aulast%3DVanderwall%26aufirst%3DD.%26aulast%3DWood%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520potent%2520EGFR%252FerbB2%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D111%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Normanno, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianco, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strizzi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maiello, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luca, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caponigro, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salomon, D. S.</span><span> </span><span class="NLM_article-title">The ErbB receptors and their ligands in cancer: an overview</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.2174%2F1389450053765879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=15857286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktlansb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=243-257&author=N.+Normannoauthor=C.+Biancoauthor=L.+Strizziauthor=M.+Mancinoauthor=M.+R.+Maielloauthor=A.+D.+Lucaauthor=F.+Caponigroauthor=D.+S.+Salomon&title=The+ErbB+receptors+and+their+ligands+in+cancer%3A+an+overview"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The ErbB receptors and their ligands in cancer: An overview</span></div><div class="casAuthors">Normanno, N.; Bianco, C.; Strizzi, L.; Mancino, M.; Maiello, M. R.; De Luca, A.; Caponigro, F.; Salomon, D. S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">243-257</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">This review article provides an overview on the most recent advances on the role of ErbB receptors and growth factors of the epidermal growth factor (EGF)-family of peptides in cancer pathogenesis and progression.  The ErbB tyrosine kinases and the EGF-like peptides form a complex system.  In fact, the interactions occurring between receptors and ligands of these families affect the type and the duration of the intracellular signals that derive from receptor activation.  Interestingly, activation of ErbB receptors is also driven by different classes of membrane receptor, suggesting that ErbB kinases can amplify growth promoting signals carried by different pathways.  The importance of ErbB receptors and EGF-like peptides in development of organs and tissues has been demonstrated by using different mouse models.  In vitro and in vivo studies have also shown that ErbB receptors and their ligands can act as transforming genes.  However, evidence suggests that cooperation of different receptors and ligands is necessary to induce a fully transformed phenotype.  Indeed, co-expression of different ErbB receptors and EGF-like growth factors is a common phenomenon in human primary carcinomas.  This observation suggests that the growth and the survival of carcinoma cells is sustained by a network of receptors/ligands of the ErbB family.  In this respect, the contemporary expression of different ErbB tyrosine kinases and/or EGF-like growth factors in human carcinomas might also affect tumor response to target based agents directed against the ErbB receptor/ligand system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr40R-_wweKqbVg90H21EOLACvtfcHk0lgH7pYREJkD-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktlansb8%253D&md5=40abc678c508a318878d76da7c866420</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2174%2F1389450053765879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450053765879%26sid%3Dliteratum%253Aachs%26aulast%3DNormanno%26aufirst%3DN.%26aulast%3DBianco%26aufirst%3DC.%26aulast%3DStrizzi%26aufirst%3DL.%26aulast%3DMancino%26aufirst%3DM.%26aulast%3DMaiello%26aufirst%3DM.%2BR.%26aulast%3DLuca%26aufirst%3DA.%2BD.%26aulast%3DCaponigro%26aufirst%3DF.%26aulast%3DSalomon%26aufirst%3DD.%2BS.%26atitle%3DThe%2520ErbB%2520receptors%2520and%2520their%2520ligands%2520in%2520cancer%253A%2520an%2520overview%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2005%26volume%3D6%26spage%3D243%26epage%3D257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Petrov, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K. E.</span><span> </span><span class="NLM_article-title">Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4686</span><span class="NLM_x">–</span> <span class="NLM_lpage">4691</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2Fj.bmcl.2006.05.090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=16777410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFOlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4686-4691&author=K.+G.+Petrovauthor=Y.+M.+Zhangauthor=M.+Carterauthor=G.+S.+Cockerillauthor=S.+Dickersonauthor=C.+A.+Gauthierauthor=Y.+Guoauthor=R.+A.+Mookauthor=D.+W.+Rusnakauthor=A.+L.+Walkerauthor=E.+R.+Woodauthor=K.+E.+Lackey&title=Optimization+and+SAR+for+dual+ErbB-1%2FErbB-2+tyrosine+kinase+inhibition+in+the+6-furanylquinazoline+series"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series</span></div><div class="casAuthors">Petrov, Kimberly G.; Zhang, Yue-Mei; Carter, Malcolm; Cockerill, G. Stuart; Dickerson, Scott; Gauthier, Cassandra A.; Guo, Yu; Mook, Robert A.; Rusnak, David W.; Walker, Ann L.; Wood, Edgar R.; Lackey, Karen E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4686-4691</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthetic modifications on a 6-furanylquinazoline scaffold to optimize the dual ErbB-1/ErbB-2 tyrosine kinase inhibition afforded consistent SAR whereby a 4-(3-fluorobenzyloxy)-3-haloanilino structure provided the best enzyme potency and cellular selectivity.  Changes made to the 6-furanyl group had little impact on the enzyme activity, but appeared to dramatically affect the cellular efficacy.  The discovery of lapatinib emerged from this work.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtejUjyH9in7Vg90H21EOLACvtfcHk0lgH7pYREJkD-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFOlu7o%253D&md5=946712927ab1a7940ea3ef2fea7574b5</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.05.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.05.090%26sid%3Dliteratum%253Aachs%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DZhang%26aufirst%3DY.%2BM.%26aulast%3DCarter%26aufirst%3DM.%26aulast%3DCockerill%26aufirst%3DG.%2BS.%26aulast%3DDickerson%26aufirst%3DS.%26aulast%3DGauthier%26aufirst%3DC.%2BA.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DWalker%26aufirst%3DA.%2BL.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DLackey%26aufirst%3DK.%2BE.%26atitle%3DOptimization%2520and%2520SAR%2520for%2520dual%2520ErbB-1%252FErbB-2%2520tyrosine%2520kinase%2520inhibition%2520in%2520the%25206-furanylquinazoline%2520series%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4686%26epage%3D4691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Xu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Searle, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abad, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neeper, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struble, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emanuel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruninger, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandey, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno-Mazza, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuentes-Pesquera, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span> </span><span class="NLM_article-title">Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3495</span><span class="NLM_x">–</span> <span class="NLM_lpage">3499</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3495-3499&author=G.+Xuauthor=L.+L.+Searleauthor=T.+V.+Hughesauthor=A.+K.+Beckauthor=P.+J.+Connollyauthor=M.+C.+Abadauthor=M.+P.+Neeperauthor=G.+T.+Strubleauthor=B.+A.+Springerauthor=S.+L.+Emanuelauthor=R.+H.+Gruningerauthor=N.+Pandeyauthor=M.+Adamsauthor=S.+Moreno-Mazzaauthor=A.+R.+Fuentes-Pesqueraauthor=S.+A.+Middletonauthor=L.+M.+Greenberger&title=Discovery+of+novel+4-amino-6-arylaminopyrimidine-5-carbaldehyde+oximes+as+dual+inhibitors+of+EGFR+and+ErbB-2+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DG.%26aulast%3DSearle%26aufirst%3DL.%2BL.%26aulast%3DHughes%26aufirst%3DT.%2BV.%26aulast%3DBeck%26aufirst%3DA.%2BK.%26aulast%3DConnolly%26aufirst%3DP.%2BJ.%26aulast%3DAbad%26aufirst%3DM.%2BC.%26aulast%3DNeeper%26aufirst%3DM.%2BP.%26aulast%3DStruble%26aufirst%3DG.%2BT.%26aulast%3DSpringer%26aufirst%3DB.%2BA.%26aulast%3DEmanuel%26aufirst%3DS.%2BL.%26aulast%3DGruninger%26aufirst%3DR.%2BH.%26aulast%3DPandey%26aufirst%3DN.%26aulast%3DAdams%26aufirst%3DM.%26aulast%3DMoreno-Mazza%26aufirst%3DS.%26aulast%3DFuentes-Pesquera%26aufirst%3DA.%2BR.%26aulast%3DMiddleton%26aufirst%3DS.%2BA.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26atitle%3DDiscovery%2520of%2520novel%25204-amino-6-arylaminopyrimidine-5-carbaldehyde%2520oximes%2520as%2520dual%2520inhibitors%2520of%2520EGFR%2520and%2520ErbB-2%2520protein%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3495%26epage%3D3499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Hubbard, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamaung, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidanze, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palazzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilsbacher, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheppard, G. S.</span><span> </span><span class="NLM_article-title">Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1718</span><span class="NLM_x">–</span> <span class="NLM_lpage">1721</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1718-1721&author=R.+D.+Hubbardauthor=N.+Y.+Bamaungauthor=S.+D.+Fidanzeauthor=S.+A.+Ericksonauthor=F.+Palazzoauthor=J.+L.+Wilsbacherauthor=Q.+Zhangauthor=L.+A.+Tuckerauthor=X.+Huauthor=P.+Kovarauthor=D.+J.+Osterlingauthor=E.+F.+Johnsonauthor=J.+Bouskaauthor=J.+Wangauthor=S.+K.+Davidsenauthor=R.+L.+Bellauthor=G.+S.+Sheppard&title=Development+of+multitargeted+inhibitors+of+both+the+insulin-like+growth+factor+receptor+%28IGF-IR%29+and+members+of+the+epidermal+growth+factor+family+of+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DR.%2BD.%26aulast%3DBamaung%26aufirst%3DN.%2BY.%26aulast%3DFidanze%26aufirst%3DS.%2BD.%26aulast%3DErickson%26aufirst%3DS.%2BA.%26aulast%3DPalazzo%26aufirst%3DF.%26aulast%3DWilsbacher%26aufirst%3DJ.%2BL.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DTucker%26aufirst%3DL.%2BA.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DKovar%26aufirst%3DP.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DBouska%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DBell%26aufirst%3DR.%2BL.%26aulast%3DSheppard%26aufirst%3DG.%2BS.%26atitle%3DDevelopment%2520of%2520multitargeted%2520inhibitors%2520of%2520both%2520the%2520insulin-like%2520growth%2520factor%2520receptor%2520%2528IGF-IR%2529%2520and%2520members%2520of%2520the%2520epidermal%2520growth%2520factor%2520family%2520of%2520receptor%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1718%26epage%3D1721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Boschelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span> </span><span class="NLM_article-title">7-Alkoxy-4-phenylamino-3-quinolinecarbonitriles as dual inhibitors of SRC and ABL kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1599</span><span class="NLM_x">–</span> <span class="NLM_lpage">1601</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0499458" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1599-1601&author=D.+Boschelliauthor=Y.+Wangauthor=S.+Johnsonauthor=B.+Wuauthor=F.+Yeauthor=A.+Sosaauthor=J.+Golasauthor=F.+Boschelli&title=7-Alkoxy-4-phenylamino-3-quinolinecarbonitriles+as+dual+inhibitors+of+SRC+and+ABL+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm0499458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0499458%26sid%3Dliteratum%253Aachs%26aulast%3DBoschelli%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DSosa%26aufirst%3DA.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DBoschelli%26aufirst%3DF.%26atitle%3D7-Alkoxy-4-phenylamino-3-quinolinecarbonitriles%2520as%2520dual%2520inhibitors%2520of%2520SRC%2520and%2520ABL%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1599%26epage%3D1601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Bamborough, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, K.</span><span> </span><span class="NLM_article-title">Assessment of chemical coverage of kinome space and its implications for kinase drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">7898</span><span class="NLM_x">–</span> <span class="NLM_lpage">7914</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8011036" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVequ7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7898-7914&author=P.+Bamboroughauthor=D.+Drewryauthor=G.+Harperauthor=G.+K.+Smithauthor=K.+Schneider&title=Assessment+of+chemical+coverage+of+kinome+space+and+its+implications+for+kinase+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of Chemical Coverage of Kinome Space and Its Implications for Kinase Drug Discovery</span></div><div class="casAuthors">Bamborough, Paul; Drewry, David; Harper, Gavin; Smith, Gary K.; Schneider, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7898-7914</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">More than 500 compds. chosen to represent kinase inhibitor space have been screened against a panel of over 200 protein kinases.  Significant results include the identification of hits against new kinases including PIM1 and MPSK1, and the expansion of the inhibition profiles of several literature compds.  A detailed anal. of the data through the use of affinity fingerprints has produced findings with implications for biol. target selection, the choice of tool compds. for target validation, and lead discovery and optimization.  In a detailed examn. of the tyrosine kinases, interesting relationships have been found between targets and compds.  Taken together, these results show how broad cross-profiling can provide important insights to assist kinase drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBRI-arQk3t7Vg90H21EOLACvtfcHk0lgGBnmGor-HqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVequ7zI&md5=8d98c80fb157b987a19e32a1efb53103</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm8011036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8011036%26sid%3Dliteratum%253Aachs%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DDrewry%26aufirst%3DD.%26aulast%3DHarper%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DG.%2BK.%26aulast%3DSchneider%26aufirst%3DK.%26atitle%3DAssessment%2520of%2520chemical%2520coverage%2520of%2520kinome%2520space%2520and%2520its%2520implications%2520for%2520kinase%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7898%26epage%3D7914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Aronov, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murcko, M. A.</span><span> </span><span class="NLM_article-title">Toward a pharmacophore for kinase frequent hitters</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">5616</span><span class="NLM_x">–</span> <span class="NLM_lpage">5619</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049793g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=5616-5619&author=A.+M.+Aronovauthor=M.+A.+Murcko&title=Toward+a+pharmacophore+for+kinase+frequent+hitters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm049793g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049793g%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26aulast%3DMurcko%26aufirst%3DM.%2BA.%26atitle%3DToward%2520a%2520pharmacophore%2520for%2520kinase%2520frequent%2520hitters%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D5616%26epage%3D5619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Akritopoulou-Zanze, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajduk, P. J.</span><span> </span><span class="NLM_article-title">Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">297</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=291-297&author=I.+Akritopoulou-Zanzeauthor=P.+J.+Hajduk&title=Kinase-targeted+libraries%3A+the+design+and+synthesis+of+novel%2C+potent%2C+and+selective+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAkritopoulou-Zanze%26aufirst%3DI.%26aulast%3DHajduk%26aufirst%3DP.%2BJ.%26atitle%3DKinase-targeted%2520libraries%253A%2520the%2520design%2520and%2520synthesis%2520of%2520novel%252C%2520potent%252C%2520and%2520selective%2520kinase%2520inhibitors%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D291%26epage%3D297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Lindsley, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leister, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Defeo-Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huff, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, M. E.</span><span> </span><span class="NLM_article-title">Allosteric AKT (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">764</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=761-764&author=C.+W.+Lindsleyauthor=Z.+Zhaoauthor=W.+H.+Leisterauthor=R.+G.+Robinsonauthor=S.+F.+Barnettauthor=D.+Defeo-Jonesauthor=R.+E.+Jonesauthor=G.+D.+Hartmanauthor=J.+R.+Huffauthor=H.+E.+Huberauthor=M.+E.+Duggan&title=Allosteric+AKT+%28PKB%29+inhibitors%3A+discovery+and+SAR+of+isozyme+selective+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLeister%26aufirst%3DW.%2BH.%26aulast%3DRobinson%26aufirst%3DR.%2BG.%26aulast%3DBarnett%26aufirst%3DS.%2BF.%26aulast%3DDefeo-Jones%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DR.%2BE.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DHuff%26aufirst%3DJ.%2BR.%26aulast%3DHuber%26aufirst%3DH.%2BE.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DAllosteric%2520AKT%2520%2528PKB%2529%2520inhibitors%253A%2520discovery%2520and%2520SAR%2520of%2520isozyme%2520selective%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D761%26epage%3D764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leister, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Defeo-Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huff, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span> </span><span class="NLM_article-title">Discovery of 2,3,5-trisubstituted pyridine derivatives as potent AKT1 and AKT2 dual inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">909</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2Fj.bmcl.2004.12.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=15686884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2MXos1elug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=905-909&author=Z.+Zhaoauthor=W.+H.+Leisterauthor=R.+G.+Robinsonauthor=S.+F.+Barnettauthor=D.+Defeo-Jonesauthor=R.+E.+Jonesauthor=G.+D.+Hartmanauthor=J.+R.+Huffauthor=H.+E.+Huberauthor=M.+E.+Dugganauthor=C.+W.+Lindsley&title=Discovery+of+2%2C3%2C5-trisubstituted+pyridine+derivatives+as+potent+AKT1+and+AKT2+dual+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors</span></div><div class="casAuthors">Zhao, Zhijian; Leister, William H.; Robinson, Ronald G.; Barnett, Stanley F.; Defeo-Jones, Deborah; Jones, Raymond E.; Hartman, George D.; Huff, Joel R.; Huber, Hans E.; Duggan, Mark E.; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">905-909</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This letter describes the discovery of a novel series of dual Akt1/Akt2 kinase inhibitors, based on a 2,3,5-trisubstituted pyridine scaffold.  Compds. from this series, which contain a 5-tetrazolyl moiety, exhibit more potent inhibition of Akt2 than Akt1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJOzjnuD-86LVg90H21EOLACvtfcHk0lgGBnmGor-HqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXos1elug%253D%253D&md5=a61e2d83a2d7ffdb660255e341deaa9c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.12.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.12.062%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLeister%26aufirst%3DW.%2BH.%26aulast%3DRobinson%26aufirst%3DR.%2BG.%26aulast%3DBarnett%26aufirst%3DS.%2BF.%26aulast%3DDefeo-Jones%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DR.%2BE.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DHuff%26aufirst%3DJ.%2BR.%26aulast%3DHuber%26aufirst%3DH.%2BE.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DDiscovery%2520of%25202%252C3%252C5-trisubstituted%2520pyridine%2520derivatives%2520as%2520potent%2520AKT1%2520and%2520AKT2%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D905%26epage%3D909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Defeo-Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leander, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosford, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasit, P.</span><span> </span><span class="NLM_article-title">Allosteric inhibitors of AKT1 and AKT2: discovery of [1,2,4]triazolo[3,4-<i>f</i>][1,6]naphthyridines with potent and balanced activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">834</span><span class="NLM_x">–</span> <span class="NLM_lpage">836</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=834-836&author=Y.+Liauthor=J.+Liangauthor=T.+Siuauthor=E.+Huauthor=M.+A.+Rossiauthor=S.+F.+Barnettauthor=D.+Defeo-Jonesauthor=R.+E.+Jonesauthor=R.+G.+Robinsonauthor=K.+Leanderauthor=H.+E.+Huberauthor=S.+Mittalauthor=N.+Cosfordauthor=P.+Prasit&title=Allosteric+inhibitors+of+AKT1+and+AKT2%3A+discovery+of+%5B1%2C2%2C4%5Dtriazolo%5B3%2C4-f%5D%5B1%2C6%5Dnaphthyridines+with+potent+and+balanced+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DSiu%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DE.%26aulast%3DRossi%26aufirst%3DM.%2BA.%26aulast%3DBarnett%26aufirst%3DS.%2BF.%26aulast%3DDefeo-Jones%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DR.%2BE.%26aulast%3DRobinson%26aufirst%3DR.%2BG.%26aulast%3DLeander%26aufirst%3DK.%26aulast%3DHuber%26aufirst%3DH.%2BE.%26aulast%3DMittal%26aufirst%3DS.%26aulast%3DCosford%26aufirst%3DN.%26aulast%3DPrasit%26aufirst%3DP.%26atitle%3DAllosteric%2520inhibitors%2520of%2520AKT1%2520and%2520AKT2%253A%2520discovery%2520of%2520%255B1%252C2%252C4%255Dtriazolo%255B3%252C4-f%255D%255B1%252C6%255Dnaphthyridines%2520with%2520potent%2520and%2520balanced%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D834%26epage%3D836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span>NCT00670488: MK2206 in Patients with Locally Advanced or Metastatic Solid Tumors. <a href="http://www.clinicaltrials.gov" class="extLink">www.clinicaltrials.gov</a>,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NCT00670488%3A+MK2206+in+Patients+with+Locally+Advanced+or+Metastatic+Solid+Tumors.+www.clinicaltrials.gov%2C+2008."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Annis, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Athanasopoulos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felsch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalghatgi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orminati, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosner, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipps, G. W.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thaddupathy, G. R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyler, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilenchik, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, E. A.</span><span> </span><span class="NLM_article-title">An affinity selection-mass spectrometry method for the identification of small molecule ligands from self-encoded combinatorial libraries. Discovery of a novel antagonist of <i>E. coli</i> dihydrofolate reductase</span> <span class="citation_source-journal">Int. J. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">238</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">83</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=238&publication_year=2004&pages=77-83&author=D.+A.+Annisauthor=J.+Athanasopoulosauthor=P.+Curranauthor=J.+Felschauthor=K.+Kalghatgiauthor=W.+H.+Leeauthor=H.+Nashauthor=J.-P.+Orminatiauthor=K.+E.+Rosnerauthor=G.+W.+Shippsauthor=G.+R.+A.+Thaddupathyauthor=A.+N.+Tylerauthor=L.+Vilenchikauthor=E.+A.+Winter&title=An+affinity+selection-mass+spectrometry+method+for+the+identification+of+small+molecule+ligands+from+self-encoded+combinatorial+libraries.+Discovery+of+a+novel+antagonist+of+E.+coli+dihydrofolate+reductase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAnnis%26aufirst%3DD.%2BA.%26aulast%3DAthanasopoulos%26aufirst%3DJ.%26aulast%3DCurran%26aufirst%3DP.%26aulast%3DFelsch%26aufirst%3DJ.%26aulast%3DKalghatgi%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DW.%2BH.%26aulast%3DNash%26aufirst%3DH.%26aulast%3DOrminati%26aufirst%3DJ.-P.%26aulast%3DRosner%26aufirst%3DK.%2BE.%26aulast%3DShipps%26aufirst%3DG.%2BW.%26aulast%3DThaddupathy%26aufirst%3DG.%2BR.%2BA.%26aulast%3DTyler%26aufirst%3DA.%2BN.%26aulast%3DVilenchik%26aufirst%3DL.%26aulast%3DWinter%26aufirst%3DE.%2BA.%26atitle%3DAn%2520affinity%2520selection-mass%2520spectrometry%2520method%2520for%2520the%2520identification%2520of%2520small%2520molecule%2520ligands%2520from%2520self-encoded%2520combinatorial%2520libraries.%2520Discovery%2520of%2520a%2520novel%2520antagonist%2520of%2520E.%2520coli%2520dihydrofolate%2520reductase%26jtitle%3DInt.%2520J.%2520Mass%2520Spectrom.%26date%3D2004%26volume%3D238%26spage%3D77%26epage%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">Fragments, network biology and designing multiple ligands</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">156</span><span class="NLM_x">–</span> <span class="NLM_lpage">160</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=156-160&author=R.+Morphyauthor=Z.+Rankovic&title=Fragments%2C+network+biology+and+designing+multiple+ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFragments%252C%2520network%2520biology%2520and%2520designing%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D156%26epage%3D160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">McNeil, C.</span><span> </span><span class="NLM_article-title">Two targets, one drug for new EGFR inhibitors</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">1102</span><span class="NLM_x">–</span> <span class="NLM_lpage">1103</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1093%2Fjnci%2Fdjj350" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=16912259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A280%3ADC%252BD28vovVSqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2006&pages=1102-1103&author=C.+McNeil&title=Two+targets%2C+one+drug+for+new+EGFR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Two targets, one drug for new EGFR inhibitors</span></div><div class="casAuthors">McNeil Caroline</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1102-3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcbGu8z0PtTq69lAbTj9rGfW6udTcc2eZKiKeiM1IeRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vovVSqtQ%253D%253D&md5=d18909cf12038eac649b05345b4bd51c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjj350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjj350%26sid%3Dliteratum%253Aachs%26aulast%3DMcNeil%26aufirst%3DC.%26atitle%3DTwo%2520targets%252C%2520one%2520drug%2520for%2520new%2520EGFR%2520inhibitors%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2006%26volume%3D98%26spage%3D1102%26epage%3D1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Factors underlying sensitivity of cancers to small-molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">709</span><span class="NLM_x">–</span> <span class="NLM_lpage">723</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=709-723&author=P.+A.+J%C3%A4nneauthor=N.+Grayauthor=J.+Settleman&title=Factors+underlying+sensitivity+of+cancers+to+small-molecule+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DFactors%2520underlying%2520sensitivity%2520of%2520cancers%2520to%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D709%26epage%3D723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguiz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title"><i>N</i>-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">2303</span><span class="NLM_x">–</span> <span class="NLM_lpage">2312</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2008&pages=2303-2312&author=N.+H.+Jensenauthor=R.+M.+Rodriguizauthor=M.+G.+Caronauthor=W.+C.+Wetselauthor=R.+B.+Rothmanauthor=B.+L.+Roth&title=N-Desalkylquetiapine%2C+a+potent+norepinephrine+reuptake+inhibitor+and+partial+5-HT1A+agonist%2C+as+a+putative+mediator+of+quetiapine%27s+antidepressant+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DN-Desalkylquetiapine%252C%2520a%2520potent%2520norepinephrine%2520reuptake%2520inhibitor%2520and%2520partial%25205-HT1A%2520agonist%252C%2520as%2520a%2520putative%2520mediator%2520of%2520quetiapine%2527s%2520antidepressant%2520activity%26jtitle%3DNeuropsychopharmacology%26date%3D2008%26volume%3D33%26spage%3D2303%26epage%3D2312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Medina, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodin, S.</span><span> </span><span class="NLM_article-title">Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1426</span><span class="NLM_x">–</span> <span class="NLM_lpage">1447</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2Fj.clinthera.2008.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=18803986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtF2rtLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2008&pages=1426-1447&author=P.+J.+Medinaauthor=S.+Goodin&title=Lapatinib%3A+a+dual+inhibitor+of+human+epidermal+growth+factor+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases</span></div><div class="casAuthors">Medina, Patrick J.; Goodin, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1426-1447</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Background: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.  It is indicated for use in combination with capecitabine for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress HER2 (ErbB2) and who have received previous treatment that included an anthracycline, a taxane, and trastuzumab.  Objective: This review summarizes the pharmacol., pharmacokinetics, clin. efficacy, and safety profile of lapatinib, and its current and potential role in the treatment of breast cancer and other malignancies.  Methods: Relevant English-language publications were identified through searches of MEDLINE (1966-May 2008), the American Society of Clin. Oncol. abstrs. database (2000-2007), abstrs. from the San Antonio Breast Cancer Symposium (2005-2007), and the FDA Web site (Jan. 2008).  Search terms included lapatinib, GW572016, HER2, EGFR, receptor tyrosine kinase, dual-receptor blockade, adverse events, and clin. trials.  Results: The Tmax of lapatinib after oral administration is 3 to 4 h.  Dividing the dose or administering it with food, particularly a high-fat meal, increases the AUC >2-fold.  Lapatinib is metabolized primarily by the cytochrome P 450 3A4 isoenzyme, with 1 metabolite remaining active against EGFR but not HER2.  Due to drug accumulation, the t1/2 of lapatinib is 24 h with continuous dosing.  In a Phase III trial comparing lapatinib and capecitabine with capecitabine alone in women with HER2-pos., locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of lapatinib and capecitabine was assocd. with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, resp.; P = NS) and a significant increase in time to progression (6.2 vs 4.3 mo; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).  Lapatinib has been reported to have antitumor activity in Phase II trials when used as first-line therapy for MBC, in patients with inflammatory breast cancer, and in patients with central nervous system metastases.  Phase II trials in other solid tumor types found modest activity.  The approved dosing of lapatinib is 1250 mg PO QD given continuously in combination with capecitabine 2000 mg/m2 daily administered in 2 divided doses on days 1 to 14 of a 21-day cycle.  The most common clin. toxicities of all grades assocd. with lapatinib used in combination with capecitabine in the pivotal clin. trial were diarrhea (65%), hand-foot syndrome (53%), nausea (44%), rash (29%), and fatigue (24%).  Cardiac toxicity appears to be less frequent with lapatinib than with trastuzumab.  Conclusions: Lapatinib is a dual inhibitor of the EGFR and HER2 tyrosine kinases.  It is approved by the FDA for use in combination with capecitabine for the treatment of HER2-pos. MBC that has progressed with std. treatment.  In clin. trials, this combination was assocd. with a significant improvement in the time to progression in patients with MBC.  Lapatinib's efficacy in other malignancies that overexpress EGFR and/or HER2 is under evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCjQ3-xYaNcbVg90H21EOLACvtfcHk0li2wdk1Uty1AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtF2rtLfL&md5=e2e7505d278f03060c4bf664994f1ae1</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2008.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2008.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DMedina%26aufirst%3DP.%2BJ.%26aulast%3DGoodin%26aufirst%3DS.%26atitle%3DLapatinib%253A%2520a%2520dual%2520inhibitor%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinases%26jtitle%3DClin.%2520Ther.%26date%3D2008%26volume%3D30%26spage%3D1426%26epage%3D1447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Houk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bello, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amantea, M.</span><span> </span><span class="NLM_article-title">A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2497</span><span class="NLM_x">–</span> <span class="NLM_lpage">2506</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1158%2F1078-0432.CCR-08-1893" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=19258444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvVWksLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=2497-2506&author=B.+E.+Houkauthor=C.+L.+Belloauthor=D.+Kangauthor=M.+Amantea&title=A+population+pharmacokinetic+meta-analysis+of+sunitinib+malate+%28SU11248%29+and+its+primary+metabolite+%28SU12662%29+in+healthy+volunteers+and+oncology+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients</span></div><div class="casAuthors">Houk, Brett E.; Bello, Carlo L.; Kang, Dongwoo; Amantea, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2497-2506</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor approved for advanced renal cell carcinoma and imatinib-resistant or imatinib-intolerant gastrointestinal stromal tumor.  Following administration, sunitinib is metabolized by cytochrome P 450 3A4 to an active metabolite (SU12662).  The objective of this anal. was to assess sunitinib and SU12662 pharmacokinetics and to identify covariates that might explain variability in exposure following oral administration.  Exptl. Design: Data from 590 subjects (73 volunteers and 517 patients) in 14 studies were analyzed.  Plasma concn.-time data were analyzed using nonlinear mixed-effects modeling to est. population pharmacokinetic parameters, as well as relationships between these parameters and gender, race, age, wt., creatinine clearance, Eastern Cooperative Oncol. Group score, and tumor type.  Simulations were done to det. the predicted effect of these covariates on exposure.  Results: Sep. models were developed for sunitinib and SU12662 (each a two-compartment model with first-order absorption and elimination).  Sunitinib parameters were estd. as CL/F, 51.8 L/h and Vd/Fcentral, 2,030 L.  SU12662 parameters were estd. as CL/F, 29.6 L/h and Vd/Fcentral, 3,080 L.  Tumor type (except acute myeloid leukemia), Asian race, gender, body wt., and elevated Eastern Cooperative Oncol. Group score described a portion of the variability in CL/F for sunitinib and metabolite; gender and body wt. explained some of the variability in Vd/Fcentral for sunitinib and metabolite.  Among patients, the predicted changes in sunitinib and metabolite AUC and Cmax as a result of the individual covariates ranged up to 17%.  Conclusion: The magnitude of the predicted changes in exposure with the covariates studied minimizes the necessity for dose adjustment in any of these subpopulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrSL9u0xSIEbVg90H21EOLACvtfcHk0li2wdk1Uty1AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvVWksLg%253D&md5=f970bf4524041d44f349f03aed344595</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1893%26sid%3Dliteratum%253Aachs%26aulast%3DHouk%26aufirst%3DB.%2BE.%26aulast%3DBello%26aufirst%3DC.%2BL.%26aulast%3DKang%26aufirst%3DD.%26aulast%3DAmantea%26aufirst%3DM.%26atitle%3DA%2520population%2520pharmacokinetic%2520meta-analysis%2520of%2520sunitinib%2520malate%2520%2528SU11248%2529%2520and%2520its%2520primary%2520metabolite%2520%2528SU12662%2529%2520in%2520healthy%2520volunteers%2520and%2520oncology%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D2497%26epage%3D2506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Lipinski, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominy, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, P. J.</span><span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0li2wdk1Uty1AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26spage%3D3%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Morphy, J. R.</span><span> </span><span class="NLM_article-title">The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2969</span><span class="NLM_x">–</span> <span class="NLM_lpage">2978</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0512185" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtlOit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=2969-2978&author=J.+R.+Morphy&title=The+influence+of+target+family+and+functional+activity+on+the+physicochemical+properties+of+pre-clinical+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The Influence of Target Family and Functional Activity on the Physicochemical Properties of Pre-Clinical Compounds</span></div><div class="casAuthors">Morphy, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2969-2978</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The target families of greatest interest in drug discovery can be differentiated on the basis of the physicochem. properties of their preclin. ligands.  The ligands for peptidergic targets, such as peptide G protein-coupled receptors (GPCRs) and integrin receptors, possess significantly higher median property values than those for aminergic targets, such as monoamine transporters and GPCRs.  The ligands for peptide GPCRs were found to be less efficient, in terms of their binding energy per unit of mol. wt. or lipophilicity, than ligands for monoamine GPCRs.  The changes in the property values during the optimization process were found to vary only slightly across the target families, with the main determinant of the drug-likeness of the optimized compds. being the profile of the starting compds.  Agonists for monoamine GPCRs, opioid receptors and ion channels were typically smaller and less lipophilic than the antagonists, but there was no difference between the agonists and the antagonists for peptide GPCRs and nuclear receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0EegclZUHNbVg90H21EOLACvtfcHk0lj_IQbiS-s-pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtlOit7g%253D&md5=fcf63bff570d58d56492b46ddecb5eb1</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm0512185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0512185%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520influence%2520of%2520target%2520family%2520and%2520functional%2520activity%2520on%2520the%2520physicochemical%2520properties%2520of%2520pre-clinical%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D2969%26epage%3D2978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Morphy, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">The physicochemical challenges of designing multiple ligands</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4961</span><span class="NLM_x">–</span> <span class="NLM_lpage">4970</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0603015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4961-4970&author=J.+R.+Morphyauthor=Z.+Rankovic&title=The+physicochemical+challenges+of+designing+multiple+ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The Physicochemical Challenges of Designing Multiple Ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4961-4970</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compds. designed to bind more than one target can provide a therapeutic benefit relative to highly target-selective ligands.  The physicochem. properties of designed multiple ligands were found to be less druglike than those for preclin. compds. in general.  These properties are controlled by the superfamily to which the targets belong and the lead discovery strategy that was followed.  The properties for peptide G-protein-coupled receptor (GPCR) ligands were the least favorable for oral delivery, whereas transporter, monoamine GPCR, and oxidase ligands were the most druglike.  The lead discovery strategy, framework combination or screening, exerts a profound influence on the property values.  Combining the frameworks from two selective ligands often results in large, complex dual ligands, but druglike ligands can be achieved if the degree of framework overlap is maximized and the size of the selective ligands minimized.  For some target combinations, a screening approach may provide a route to smaller, less complex leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonGHbXyxgv4LVg90H21EOLACvtfcHk0lj_IQbiS-s-pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D&md5=c7a227848516d0aa58ed037a582943fe</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm0603015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603015%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DJ.%2BR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DThe%2520physicochemical%2520challenges%2520of%2520designing%2520multiple%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4961%26epage%3D4970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Dinges, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akritopoulou-Zanze, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumeister, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunha, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Djuric, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gracias, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafferty, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowin, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. Q.</span><span> </span><span class="NLM_article-title">1,4-Dihydroindeno[1,2-<i>c</i>]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4266</span><span class="NLM_x">–</span> <span class="NLM_lpage">4271</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4266-4271&author=J.+Dingesauthor=K.+L.+Ashworthauthor=I.+Akritopoulou-Zanzeauthor=L.+D.+Arnoldauthor=S.+A.+Baumeisterauthor=P.+F.+Bousquetauthor=G.+A.+Cunhaauthor=S.+K.+Davidsenauthor=S.+W.+Djuricauthor=V.+J.+Graciasauthor=M.+R.+Michaelidesauthor=P.+Raffertyauthor=T.+J.+Sowinauthor=K.+D.+Stewartauthor=Z.+Xiaauthor=H.+Q.+Zhang&title=1%2C4-Dihydroindeno%5B1%2C2-c%5Dpyrazoles+as+novel+multitargeted+receptor+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDinges%26aufirst%3DJ.%26aulast%3DAshworth%26aufirst%3DK.%2BL.%26aulast%3DAkritopoulou-Zanze%26aufirst%3DI.%26aulast%3DArnold%26aufirst%3DL.%2BD.%26aulast%3DBaumeister%26aufirst%3DS.%2BA.%26aulast%3DBousquet%26aufirst%3DP.%2BF.%26aulast%3DCunha%26aufirst%3DG.%2BA.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DDjuric%26aufirst%3DS.%2BW.%26aulast%3DGracias%26aufirst%3DV.%2BJ.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26aulast%3DRafferty%26aufirst%3DP.%26aulast%3DSowin%26aufirst%3DT.%2BJ.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DH.%2BQ.%26atitle%3D1%252C4-Dihydroindeno%255B1%252C2-c%255Dpyrazoles%2520as%2520novel%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4266%26epage%3D4271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. M.</span><span> </span><span class="NLM_article-title">Time-related differences in the physical property profiles of oral drugs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6338</span><span class="NLM_x">–</span> <span class="NLM_lpage">6348</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049717d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpt1Sksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6338-6348&author=P.+D.+Leesonauthor=A.+M.+Davis&title=Time-related+differences+in+the+physical+property+profiles+of+oral+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Time-Related Differences in the Physical Property Profiles of Oral Drugs</span></div><div class="casAuthors">Leeson, Paul D.; Davis, Andrew M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">6338-6348</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Comparisons of the calcd. physicochem. properties of oral drugs launched prior to 1983 (864 drugs) and between 1983 and 2002 (329 drugs) show that mean values of lipophilicity, percent polar surface area and H-bond donor count are the same, suggesting that these are the most important oral drug-like phys. properties.  In contrast, mean values of mol. wt. and the nos. of O + N atoms, H-bond acceptors, and rotatable bonds and rings have increased in 1983-2002 drugs (by 13-29%).  Anal. of the 1983-2002 oral drugs by therapy area shows that anti-infectives and nervous system drugs have the most extreme phys. property profiles.  Cardiovascular drugs show increasing mol. wt. with year of publication, primarily a consequence of focusing on clin. proven mechanisms, with limited chem. diversity.  Drug classes other than anti-infectives show comparable distributions of lipophilicity, suggesting that this property in oral drugs is important irresp. of the drug's target.  The results suggest that the balance between polar and nonpolar drug properties is an important, unchanging feature of oral drug mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtNkiWH6Bl6bVg90H21EOLACvtfcHk0lj_IQbiS-s-pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpt1Sksbg%253D&md5=edd5cceab1ccfe3542cb4df180e3c160</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm049717d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049717d%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DDavis%26aufirst%3DA.%2BM.%26atitle%3DTime-related%2520differences%2520in%2520the%2520physical%2520property%2520profiles%2520of%2520oral%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6338%26epage%3D6348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Vieth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, R. M.</span><span> </span><span class="NLM_article-title">Kinomics: characterizing the therapeutically validated kinase space</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">839</span><span class="NLM_x">–</span> <span class="NLM_lpage">846</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=839-846&author=M.+Viethauthor=J.+J.+Sutherlandauthor=D.+H.+Robertsonauthor=R.+M.+Campbell&title=Kinomics%3A+characterizing+the+therapeutically+validated+kinase+space"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVieth%26aufirst%3DM.%26aulast%3DSutherland%26aufirst%3DJ.%2BJ.%26aulast%3DRobertson%26aufirst%3DD.%2BH.%26aulast%3DCampbell%26aufirst%3DR.%2BM.%26atitle%3DKinomics%253A%2520characterizing%2520the%2520therapeutically%2520validated%2520kinase%2520space%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D839%26epage%3D846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Waterson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornberger, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sammond, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickson, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caferro, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinkle, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spehar, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehling, D. E.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1332</span><span class="NLM_x">–</span> <span class="NLM_lpage">1336</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1332-1336&author=A.+G.+Watersonauthor=K.+G.+Petrovauthor=K.+R.+Hornbergerauthor=R.+D.+Hubbardauthor=D.+M.+Sammondauthor=S.+C.+Smithauthor=H.+D.+Dicksonauthor=T.+R.+Caferroauthor=K.+W.+Hinkleauthor=K.+L.+Stevensauthor=S.+H.+Dickersonauthor=D.+W.+Rusnakauthor=G.+M.+Speharauthor=E.+R.+Woodauthor=R.+J.+Griffinauthor=D.+E.+Uehling&title=Synthesis+and+evaluation+of+aniline+headgroups+for+alkynyl+thienopyrimidine+dual+EGFR%2FErbB-2+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DHornberger%26aufirst%3DK.%2BR.%26aulast%3DHubbard%26aufirst%3DR.%2BD.%26aulast%3DSammond%26aufirst%3DD.%2BM.%26aulast%3DSmith%26aufirst%3DS.%2BC.%26aulast%3DDickson%26aufirst%3DH.%2BD.%26aulast%3DCaferro%26aufirst%3DT.%2BR.%26aulast%3DHinkle%26aufirst%3DK.%2BW.%26aulast%3DStevens%26aufirst%3DK.%2BL.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DSpehar%26aufirst%3DG.%2BM.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DUehling%26aufirst%3DD.%2BE.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520aniline%2520headgroups%2520for%2520alkynyl%2520thienopyrimidine%2520dual%2520EGFR%252FErbB-2%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1332%26epage%3D1336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0ljLG9z25V1BrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Peters, J. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnider, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattei, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span> </span><span class="NLM_article-title">Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">680</span><span class="NLM_x">–</span> <span class="NLM_lpage">686</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=680-686&author=J.+U.+Petersauthor=P.+Schniderauthor=P.+Matteiauthor=M.+Kansy&title=Pharmacological+promiscuity%3A+dependence+on+compound+properties+and+target+specificity+in+a+set+of+recent+Roche+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26aulast%3DSchnider%26aufirst%3DP.%26aulast%3DMattei%26aufirst%3DP.%26aulast%3DKansy%26aufirst%3DM.%26atitle%3DPharmacological%2520promiscuity%253A%2520dependence%2520on%2520compound%2520properties%2520and%2520target%2520specificity%2520in%2520a%2520set%2520of%2520recent%2520Roche%2520compounds%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D680%26epage%3D686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Whitlock, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fish, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fray, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stobie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakenhut, F.</span><span> </span><span class="NLM_article-title">Pyridyl-phenyl ether monoamine reuptake inhibitors: impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2896</span><span class="NLM_x">–</span> <span class="NLM_lpage">2899</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2Fj.bmcl.2008.03.082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=18417343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvVWjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2896-2899&author=G.+A.+Whitlockauthor=P.+V.+Fishauthor=M.+J.+Frayauthor=A.+Stobieauthor=F.+Wakenhut&title=Pyridyl-phenyl+ether+monoamine+reuptake+inhibitors%3A+impact+of+lipophilicity+on+dual+SNRI+pharmacology+and+off-target+promiscuity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity</span></div><div class="casAuthors">Whitlock, Gavin A.; Fish, Paul V.; Fray, M. Jonathan; Stobie, Alan; Wakenhut, Florian</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2896-2899</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A novel series of pyridyl-Ph ethers are disclosed, which possess dual 5-HT and NA reuptake pharmacol. with good selectivity over dopamine reuptake inhibition.  An anal. of the relationship between lipophilicity and pharmacol. highlighted that potent dual SNRI activity was only achievable at c log P > 3.5.  The series was found to possess significant polypharmacol. issues, and we concluded that this off-target promiscuity was related to lipophilicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq5leMowQeALVg90H21EOLACvtfcHk0ljLG9z25V1BrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvVWjsL0%253D&md5=0558e1795ceabcbda51c84708bca12ee</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.03.082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.03.082%26sid%3Dliteratum%253Aachs%26aulast%3DWhitlock%26aufirst%3DG.%2BA.%26aulast%3DFish%26aufirst%3DP.%2BV.%26aulast%3DFray%26aufirst%3DM.%2BJ.%26aulast%3DStobie%26aufirst%3DA.%26aulast%3DWakenhut%26aufirst%3DF.%26atitle%3DPyridyl-phenyl%2520ether%2520monoamine%2520reuptake%2520inhibitors%253A%2520impact%2520of%2520lipophilicity%2520on%2520dual%2520SNRI%2520pharmacology%2520and%2520off-target%2520promiscuity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D2896%26epage%3D2899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Polli, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmon, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castellino, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Mara, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">John-Williams, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serabjit-Singh, C. J.</span><span> </span><span class="NLM_article-title">The role of efflux and uptake transporters in [<i>N</i>-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">701</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=695-701&author=J.+W.+Polliauthor=J.+E.+Humphreysauthor=K.+A.+Harmonauthor=S.+Castellinoauthor=M.+J.+O%27Maraauthor=K.+L.+Olsonauthor=L.+S.+John-Williamsauthor=K.+M.+Kochauthor=C.+J.+Serabjit-Singh&title=The+role+of+efflux+and+uptake+transporters+in+%5BN-%7B3-chloro-4-%5B%283-fluorobenzyl%29oxy%5Dphenyl%7D-6-%5B5-%28%7B%5B2-%28methylsulfonyl%29ethyl%5Damino%7Dmethyl%29-2-furyl%5D-4-quinazolinamine+%28GW572016%2C+lapatinib%29+disposition+and+drug+interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26aulast%3DHumphreys%26aufirst%3DJ.%2BE.%26aulast%3DHarmon%26aufirst%3DK.%2BA.%26aulast%3DCastellino%26aufirst%3DS.%26aulast%3DO%2527Mara%26aufirst%3DM.%2BJ.%26aulast%3DOlson%26aufirst%3DK.%2BL.%26aulast%3DJohn-Williams%26aufirst%3DL.%2BS.%26aulast%3DKoch%26aufirst%3DK.%2BM.%26aulast%3DSerabjit-Singh%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520role%2520of%2520efflux%2520and%2520uptake%2520transporters%2520in%2520%255BN-%257B3-chloro-4-%255B%25283-fluorobenzyl%2529oxy%255Dphenyl%257D-6-%255B5-%2528%257B%255B2-%2528methylsulfonyl%2529ethyl%255Damino%257Dmethyl%2529-2-furyl%255D-4-quinazolinamine%2520%2528GW572016%252C%2520lapatinib%2529%2520disposition%2520and%2520drug%2520interactions%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D695%26epage%3D701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Oprea, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bologa, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curpan, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glen, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipinski, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostopovici-Halip, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rishton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ursu, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sklar, L. A.</span><span> </span><span class="NLM_article-title">A crowdsourcing evaluation of the NIH chemical probes</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnchembio0709-441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=19536101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsVags7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=441-447&author=T.+I.+Opreaauthor=C.+G.+Bologaauthor=S.+Boyerauthor=R.+F.+Curpanauthor=R.+C.+Glenauthor=A.+L.+Hopkinsauthor=C.+A.+Lipinskiauthor=G.+R.+Marshallauthor=Y.+C.+Martinauthor=L.+Ostopovici-Halipauthor=G.+Rishtonauthor=O.+Ursuauthor=R.+J.+Vazauthor=C.+Wallerauthor=H.+Waldmannauthor=L.+A.+Sklar&title=A+crowdsourcing+evaluation+of+the+NIH+chemical+probes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A crowdsourcing evaluation of the NIH chemical probes</span></div><div class="casAuthors">Oprea, Tudor I.; Bologa, Cristian G.; Boyer, Scott; Curpan, Ramona F.; Glen, Robert C.; Hopkins, Andrew L.; Lipinski, Christopher A.; Marshall, Garland R.; Martin, Yvonne C.; Ostopovici-Halip, Liliana; Rishton, Gilbert; Ursu, Oleg; Vaz, Roy J.; Waller, Chris; Waldmann, Herbert; Sklar, Larry A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">441-447</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with commentary.  Between 2004 and 2008, the US National Institutes of Health Mol. Libraries and Imaging initiative pilot phase funded 10 high-throughput screening centers, resulting in the deposition of 691 assays into PubChem and the nomination of 64 chem. probes.  We crowdsourced the Mol. Libraries and Imaging initiative output to 11 experts, who expressed medium or high levels of confidence in 48 of these 64 probes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2vr16pYCeybVg90H21EOLACvtfcHk0ljSw4I45Y_39g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsVags7k%253D&md5=adc3ed5b33cbd233ec6160c5465651b7</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnchembio0709-441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio0709-441%26sid%3Dliteratum%253Aachs%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DBologa%26aufirst%3DC.%2BG.%26aulast%3DBoyer%26aufirst%3DS.%26aulast%3DCurpan%26aufirst%3DR.%2BF.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DMarshall%26aufirst%3DG.%2BR.%26aulast%3DMartin%26aufirst%3DY.%2BC.%26aulast%3DOstopovici-Halip%26aufirst%3DL.%26aulast%3DRishton%26aufirst%3DG.%26aulast%3DUrsu%26aufirst%3DO.%26aulast%3DVaz%26aufirst%3DR.%2BJ.%26aulast%3DWaller%26aufirst%3DC.%26aulast%3DWaldmann%26aufirst%3DH.%26aulast%3DSklar%26aufirst%3DL.%2BA.%26atitle%3DA%2520crowdsourcing%2520evaluation%2520of%2520the%2520NIH%2520chemical%2520probes%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D441%26epage%3D447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsden, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pogacic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rellos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullock, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwaller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundström, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">20523</span><span class="NLM_x">–</span> <span class="NLM_lpage">20528</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=20523-20528&author=O.+Fedorovauthor=B.+Marsdenauthor=V.+Pogacicauthor=P.+Rellosauthor=S.+M%C3%BCllerauthor=A.+N.+Bullockauthor=J.+Schwallerauthor=M.+Sundstr%C3%B6mauthor=S.+Knapp&title=A+systematic+interaction+map+of+validated+kinase+inhibitors+with+Ser%2FThr+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DMarsden%26aufirst%3DB.%26aulast%3DPogacic%26aufirst%3DV.%26aulast%3DRellos%26aufirst%3DP.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DSchwaller%26aufirst%3DJ.%26aulast%3DSundstr%25C3%25B6m%26aufirst%3DM.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DA%2520systematic%2520interaction%2520map%2520of%2520validated%2520kinase%2520inhibitors%2520with%2520Ser%252FThr%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D20523%26epage%3D20528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Bamborough, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, K.</span><span> </span><span class="NLM_article-title">Assessment of chemical coverage of kinome space and its implications for kinase drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">7898</span><span class="NLM_x">–</span> <span class="NLM_lpage">7914</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8011036" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVequ7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7898-7914&author=P.+Bamboroughauthor=D.+Drewryauthor=G.+Harperauthor=G.+K.+Smithauthor=K.+Schneider&title=Assessment+of+chemical+coverage+of+kinome+space+and+its+implications+for+kinase+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of Chemical Coverage of Kinome Space and Its Implications for Kinase Drug Discovery</span></div><div class="casAuthors">Bamborough, Paul; Drewry, David; Harper, Gavin; Smith, Gary K.; Schneider, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7898-7914</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">More than 500 compds. chosen to represent kinase inhibitor space have been screened against a panel of over 200 protein kinases.  Significant results include the identification of hits against new kinases including PIM1 and MPSK1, and the expansion of the inhibition profiles of several literature compds.  A detailed anal. of the data through the use of affinity fingerprints has produced findings with implications for biol. target selection, the choice of tool compds. for target validation, and lead discovery and optimization.  In a detailed examn. of the tyrosine kinases, interesting relationships have been found between targets and compds.  Taken together, these results show how broad cross-profiling can provide important insights to assist kinase drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBRI-arQk3t7Vg90H21EOLACvtfcHk0ljSw4I45Y_39g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVequ7zI&md5=8d98c80fb157b987a19e32a1efb53103</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm8011036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8011036%26sid%3Dliteratum%253Aachs%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DDrewry%26aufirst%3DD.%26aulast%3DHarper%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DG.%2BK.%26aulast%3DSchneider%26aufirst%3DK.%26atitle%3DAssessment%2520of%2520chemical%2520coverage%2520of%2520kinome%2520space%2520and%2520its%2520implications%2520for%2520kinase%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7898%26epage%3D7914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lélias, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule−kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule%E2%88%92kinase+interaction+map+for+clinical+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule%25E2%2588%2592kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Bantscheff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberhard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastuck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boesche, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hobson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reader, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweetman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouwmeester, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopf, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neubauer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsden, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuster, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewes, G.</span><span> </span><span class="NLM_article-title">Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1035</span><span class="NLM_x">–</span> <span class="NLM_lpage">1044</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnbt1328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17721511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVWksLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=1035-1044&author=M.+Bantscheffauthor=D.+Eberhardauthor=Y.+Abrahamauthor=S.+Bastuckauthor=M.+Boescheauthor=S.+Hobsonauthor=T.+Mathiesonauthor=J.+Perrinauthor=M.+Raidaauthor=C.+Rauauthor=V.+Readerauthor=G.+Sweetmanauthor=A.+Bauerauthor=T.+Bouwmeesterauthor=C.+Hopfauthor=U.+Kruseauthor=G.+Neubauerauthor=N.+Ramsdenauthor=J.+Rickauthor=B.+Kusterauthor=G.+Drewes&title=Quantitative+chemical+proteomics+reveals+mechanisms+of+action+of+clinical+ABL+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors</span></div><div class="casAuthors">Bantscheff, Marcus; Eberhard, Dirk; Abraham, Yann; Bastuck, Sonja; Boesche, Markus; Hobson, Scott; Mathieson, Toby; Perrin, Jessica; Raida, Manfred; Rau, Christina; Reader, Valerie; Sweetman, Gavain; Bauer, Andreas; Bouwmeester, Tewis; Hopf, Carsten; Kruse, Ulrich; Neubauer, Gitte; Ramsden, Nigel; Rick, Jens; Kuster, Bernhard; Drewes, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1035-1044</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors describe a chem. proteomics approach to profile the interaction of small mols. with hundreds of endogenously expressed protein kinases and purine-binding proteins.  This subproteome is captured by immobilized nonselective kinase inhibitors (kinobeads), and the bound proteins are quantified in parallel by mass spectrometry using isobaric tags for relative and abs. quantification (iTRAQ).  By measuring the competition with the affinity matrix, the authors assess the binding of drugs to their targets in cell lysates and in cells.  By mapping drug-induced changes in the phosphorylation state of the captured proteome, the authors also analyze signaling pathways downstream of target kinases.  Quant. profiling of the drugs imatinib (Gleevec), dasatinib (Sprycel) and bosutinib in K562 cells confirms known targets including ABL and SRC family kinases and identifies the receptor tyrosine kinase DDR1 and the oxidoreductase NQO2 as novel targets of imatinib.  The data suggest that the approach is a valuable tool for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsC3OpIuhl8LVg90H21EOLACvtfcHk0lhPrUzI0y1ruA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVWksLvF&md5=ed20d4684a8a6733aba24ca64602bae8</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnbt1328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1328%26sid%3Dliteratum%253Aachs%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DEberhard%26aufirst%3DD.%26aulast%3DAbraham%26aufirst%3DY.%26aulast%3DBastuck%26aufirst%3DS.%26aulast%3DBoesche%26aufirst%3DM.%26aulast%3DHobson%26aufirst%3DS.%26aulast%3DMathieson%26aufirst%3DT.%26aulast%3DPerrin%26aufirst%3DJ.%26aulast%3DRaida%26aufirst%3DM.%26aulast%3DRau%26aufirst%3DC.%26aulast%3DReader%26aufirst%3DV.%26aulast%3DSweetman%26aufirst%3DG.%26aulast%3DBauer%26aufirst%3DA.%26aulast%3DBouwmeester%26aufirst%3DT.%26aulast%3DHopf%26aufirst%3DC.%26aulast%3DKruse%26aufirst%3DU.%26aulast%3DNeubauer%26aufirst%3DG.%26aulast%3DRamsden%26aufirst%3DN.%26aulast%3DRick%26aufirst%3DJ.%26aulast%3DKuster%26aufirst%3DB.%26aulast%3DDrewes%26aufirst%3DG.%26atitle%3DQuantitative%2520chemical%2520proteomics%2520reveals%2520mechanisms%2520of%2520action%2520of%2520clinical%2520ABL%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D1035%26epage%3D1044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Force, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Etten, R. A.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">332</span><span class="NLM_x">–</span> <span class="NLM_lpage">344</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnrc2106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17457301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksFSiu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=332-344&author=T.+Forceauthor=D.+S.+Krauseauthor=R.+A.+Van+Etten&title=Molecular+mechanisms+of+cardiotoxicity+of+tyrosine+kinase+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition</span></div><div class="casAuthors">Force, Thomas; Krause, Daniela S.; Van Etten, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">332-344</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer therapy has progressed remarkably in recent years.  In no area has this been more apparent than in the development of 'targeted therapies', particularly those using drugs that inhibit the activity of certain tyrosine kinases, activating mutations or amplifications of which are causal, or strongly contributory, to tumorigenesis.  However, some of these therapies have been assocd. with toxicity to the heart.  Here we summarize what is known about the cardiotoxicity of cancer drugs that target tyrosine kinases.  We focus on basic mechanisms through which interruption of specific signalling pathways leads to cardiomyocyte dysfunction and/or death, and contrast this with therapeutic responses in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIyJIGdG9hv7Vg90H21EOLACvtfcHk0lhPrUzI0y1ruA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksFSiu7w%253D&md5=b574f420e2a09de9bae3aa2313e76c3e</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fnrc2106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2106%26sid%3Dliteratum%253Aachs%26aulast%3DForce%26aufirst%3DT.%26aulast%3DKrause%26aufirst%3DD.%2BS.%26aulast%3DVan%2BEtten%26aufirst%3DR.%2BA.%26atitle%3DMolecular%2520mechanisms%2520of%2520cardiotoxicity%2520of%2520tyrosine%2520kinase%2520inhibition%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D332%26epage%3D344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Kerkelä, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grazette, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yacobi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iliescu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patten, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beahm, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shevtsov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesant, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clubb, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenzweig, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salomon, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Etten, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alroy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durand, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Force, T.</span><span> </span><span class="NLM_article-title">Cardiotoxicity of the cancer therapeutic agent imatinib mesylate</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">908</span><span class="NLM_x">–</span> <span class="NLM_lpage">916</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnm1446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=16862153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A280%3ADC%252BD28rhtlKrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=908-916&author=R.+Kerkel%C3%A4author=L.+Grazetteauthor=R.+Yacobiauthor=C.+Iliescuauthor=R.+Pattenauthor=C.+Beahmauthor=B.+Waltersauthor=S.+Shevtsovauthor=S.+Pesantauthor=F.+J.+Clubbauthor=A.+Rosenzweigauthor=R.+N.+Salomonauthor=R.+A.+Van+Ettenauthor=J.+Alroyauthor=J.+B.+Durandauthor=T.+Force&title=Cardiotoxicity+of+the+cancer+therapeutic+agent+imatinib+mesylate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiotoxicity of the cancer therapeutic agent imatinib mesylate</span></div><div class="casAuthors">Kerkela Risto; Grazette Luanda; Yacobi Rinat; Iliescu Cezar; Patten Richard; Beahm Cara; Walters Brian; Shevtsov Sergei; Pesant Stephanie; Clubb Fred J; Rosenzweig Anthony; Salomon Robert N; Van Etten Richard A; Alroy Joseph; Durand Jean-Bernard; Force Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">908-16</span>
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    </div><div class="casAbstract">Imatinib mesylate (Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia.  Here we report ten individuals who developed severe congestive heart failure while on imatinib and we show that imatinib-treated mice develop left ventricular contractile dysfunction.  Transmission electron micrographs from humans and mice treated with imatinib show mitochondrial abnormalities and accumulation of membrane whorls in both vacuoles and the sarco- (endo-) plasmic reticulum, findings suggestive of a toxic myopathy.  With imatinib treatment, cardiomyocytes in culture show activation of the endoplasmic reticulum (ER) stress response, collapse of the mitochondrial membrane potential, release of cytochrome c into the cytosol, reduction in cellular ATP content and cell death.  Retroviral gene transfer of an imatinib-resistant mutant of c-Abl, alleviation of ER stress or inhibition of Jun amino-terminal kinases, which are activated as a consequence of ER stress, largely rescues cardiomyocytes from imatinib-induced death.  Thus, cardiotoxicity is an unanticipated side effect of inhibition of c-Abl by imatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGHOTag-dpJhjv2lLSLOxFfW6udTcc2ebQoDh447mUjrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rhtlKrtg%253D%253D&md5=4012ddd42a942f1441abb54df1894db8</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fnm1446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1446%26sid%3Dliteratum%253Aachs%26aulast%3DKerkel%25C3%25A4%26aufirst%3DR.%26aulast%3DGrazette%26aufirst%3DL.%26aulast%3DYacobi%26aufirst%3DR.%26aulast%3DIliescu%26aufirst%3DC.%26aulast%3DPatten%26aufirst%3DR.%26aulast%3DBeahm%26aufirst%3DC.%26aulast%3DWalters%26aufirst%3DB.%26aulast%3DShevtsov%26aufirst%3DS.%26aulast%3DPesant%26aufirst%3DS.%26aulast%3DClubb%26aufirst%3DF.%2BJ.%26aulast%3DRosenzweig%26aufirst%3DA.%26aulast%3DSalomon%26aufirst%3DR.%2BN.%26aulast%3DVan%2BEtten%26aufirst%3DR.%2BA.%26aulast%3DAlroy%26aufirst%3DJ.%26aulast%3DDurand%26aufirst%3DJ.%2BB.%26aulast%3DForce%26aufirst%3DT.%26atitle%3DCardiotoxicity%2520of%2520the%2520cancer%2520therapeutic%2520agent%2520imatinib%2520mesylate%26jtitle%3DNat.%2520Med.%26date%3D2006%26volume%3D12%26spage%3D908%26epage%3D916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Qian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cywin, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farmer, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashem, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magboo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pack, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prokopowicz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welzel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morwick, T.</span><span> </span><span class="NLM_article-title">Hit to lead account of the discovery of a new class of inhibitors of PIM kinases and crystallographic studies revealing an unusual kinase binding mode</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1814</span><span class="NLM_x">–</span> <span class="NLM_lpage">1827</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801242y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1814-1827&author=K.+Qianauthor=L.+Wangauthor=C.+L.+Cywinauthor=B.+T.+Farmerauthor=E.+Hickeyauthor=C.+Homonauthor=S.+Jakesauthor=M.+A.+Kashemauthor=G.+Leeauthor=S.+Leonardauthor=J.+Liauthor=R.+Magbooauthor=W.+Maoauthor=E.+Packauthor=C.+Pengauthor=A.+Prokopowiczauthor=M.+Welzelauthor=J.+Wolakauthor=T.+Morwick&title=Hit+to+lead+account+of+the+discovery+of+a+new+class+of+inhibitors+of+PIM+kinases+and+crystallographic+studies+revealing+an+unusual+kinase+binding+mode"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm801242y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801242y%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DCywin%26aufirst%3DC.%2BL.%26aulast%3DFarmer%26aufirst%3DB.%2BT.%26aulast%3DHickey%26aufirst%3DE.%26aulast%3DHomon%26aufirst%3DC.%26aulast%3DJakes%26aufirst%3DS.%26aulast%3DKashem%26aufirst%3DM.%2BA.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DLeonard%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMagboo%26aufirst%3DR.%26aulast%3DMao%26aufirst%3DW.%26aulast%3DPack%26aufirst%3DE.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DProkopowicz%26aufirst%3DA.%26aulast%3DWelzel%26aufirst%3DM.%26aulast%3DWolak%26aufirst%3DJ.%26aulast%3DMorwick%26aufirst%3DT.%26atitle%3DHit%2520to%2520lead%2520account%2520of%2520the%2520discovery%2520of%2520a%2520new%2520class%2520of%2520inhibitors%2520of%2520PIM%2520kinases%2520and%2520crystallographic%2520studies%2520revealing%2520an%2520unusual%2520kinase%2520binding%2520mode%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1814%26epage%3D1827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Brandt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, J.</span><span> </span><span class="NLM_article-title">Small kinase assay panels can provide a measure of selectivity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5861</span><span class="NLM_x">–</span> <span class="NLM_lpage">5863</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5861-5863&author=P.+Brandtauthor=A.+J.+Jensenauthor=J.+Nilsson&title=Small+kinase+assay+panels+can+provide+a+measure+of+selectivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrandt%26aufirst%3DP.%26aulast%3DJensen%26aufirst%3DA.%2BJ.%26aulast%3DNilsson%26aufirst%3DJ.%26atitle%3DSmall%2520kinase%2520assay%2520panels%2520can%2520provide%2520a%2520measure%2520of%2520selectivity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5861%26epage%3D5863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Rix, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hantschel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dürnberger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remsing, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planyavsky, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernbach, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaupe, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colinge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Köcher, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span> </span><span class="NLM_article-title">Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">4055</span><span class="NLM_x">–</span> <span class="NLM_lpage">4063</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1182%2Fblood-2007-07-102061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17720881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtl2qsb%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=4055-4063&author=U.+Rixauthor=O.+Hantschelauthor=G.+D%C3%BCrnbergerauthor=L.+Remsingauthor=M.+Planyavskyauthor=N.+V.+Fernbachauthor=I.+Kaupeauthor=K.+L.+Bennettauthor=P.+Valentauthor=J.+Colingeauthor=T.+K%C3%B6cherauthor=G.+Superti-Furga&title=Chemical+proteomic+profiles+of+the+BCR-ABL+inhibitors+imatinib%2C+nilotinib%2C+and+dasatinib+reveal+novel+kinase+and+nonkinase+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets</span></div><div class="casAuthors">Rix, Uwe; Hantschel, Oliver; Duernberger, Gerhard; Rix, Lily L. Remsing; Planyavsky, Melanie; Fernbach, Nora V.; Kaupe, Ines; Bennett, Keiryn L.; Valent, Peter; Colinge, Jacques; Koecher, Thomas; Superti-Furga, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4055-4063</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The BCR-ABL tyrosine kinase inhibitor imatinib represents the current front-line therapy in chronic myeloid leukemia.  Because many patients develop imatinib resistance, 2 second-generation drugs, nilotinib and dasatinib, displaying increased potency against BCR-ABL were developed.  To predict potential side effects and novel medical uses, we generated comprehensive drug-protein interaction profiles by chem. proteomics for all 3 drugs.  Our studies yielded 4 major findings: (1) The interaction profiles of the 3 drugs displayed strong differences and only a small overlap covering the ABL kinases.  (2) Dasatinib bound in excess of 30 Tyr and Ser/Thr kinases, including major regulators of the immune system, suggesting that dasatinib might have a particular impact on immune function.  (3) Despite the high specificity of nilotinib, the receptor tyrosine kinase DDR1 was identified and validated as an addnl. major target.  (4) The oxidoreductase NQO2 was bound and inhibited by imatinib and nilotinib at physiol. relevant drug concns., representing the 1st nonkinase target of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe8e6qqCnkrrVg90H21EOLACvtfcHk0lgMRnY0yLkJaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtl2qsb%252FF&md5=ff968982e9c20806c0c5fe9612f88407</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-07-102061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-07-102061%26sid%3Dliteratum%253Aachs%26aulast%3DRix%26aufirst%3DU.%26aulast%3DHantschel%26aufirst%3DO.%26aulast%3DD%25C3%25BCrnberger%26aufirst%3DG.%26aulast%3DRemsing%26aufirst%3DL.%26aulast%3DPlanyavsky%26aufirst%3DM.%26aulast%3DFernbach%26aufirst%3DN.%2BV.%26aulast%3DKaupe%26aufirst%3DI.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DColinge%26aufirst%3DJ.%26aulast%3DK%25C3%25B6cher%26aufirst%3DT.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DChemical%2520proteomic%2520profiles%2520of%2520the%2520BCR-ABL%2520inhibitors%2520imatinib%252C%2520nilotinib%252C%2520and%2520dasatinib%2520reveal%2520novel%2520kinase%2520and%2520nonkinase%2520targets%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D4055%26epage%3D4063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Targeting cancer with small molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+cancer+with+small+molecule+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0lgMRnY0yLkJaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520cancer%2520with%2520small%2520molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer.%26date%3D2009%26volume%3D9%26spage%3D28%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Scotlandi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manara, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoletti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lollini, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perdichizzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Echeverría, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picci, P.</span><span> </span><span class="NLM_article-title">Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">3868</span><span class="NLM_x">–</span> <span class="NLM_lpage">3876</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=3868-3876&author=K.+Scotlandiauthor=M.+C.+Manaraauthor=G.+Nicolettiauthor=P.+L.+Lolliniauthor=S.+Lukasauthor=S.+Beniniauthor=S.+Crociauthor=S.+Perdichizziauthor=D.+Zambelliauthor=M.+Serraauthor=C.+Garc%C3%ADa-Echeverr%C3%ADaauthor=F.+Hofmannauthor=P.+Picci&title=Antitumor+activity+of+the+insulin-like+growth+factor-I+receptor+kinase+inhibitor+NVP-AEW541+in+musculoskeletal+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScotlandi%26aufirst%3DK.%26aulast%3DManara%26aufirst%3DM.%2BC.%26aulast%3DNicoletti%26aufirst%3DG.%26aulast%3DLollini%26aufirst%3DP.%2BL.%26aulast%3DLukas%26aufirst%3DS.%26aulast%3DBenini%26aufirst%3DS.%26aulast%3DCroci%26aufirst%3DS.%26aulast%3DPerdichizzi%26aufirst%3DS.%26aulast%3DZambelli%26aufirst%3DD.%26aulast%3DSerra%26aufirst%3DM.%26aulast%3DGarc%25C3%25ADa-Echeverr%25C3%25ADa%26aufirst%3DC.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DPicci%26aufirst%3DP.%26atitle%3DAntitumor%2520activity%2520of%2520the%2520insulin-like%2520growth%2520factor-I%2520receptor%2520kinase%2520inhibitor%2520NVP-AEW541%2520in%2520musculoskeletal%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D3868%26epage%3D3876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrián, F.</span><span> </span><span class="NLM_article-title">Ba/F3 cells and their use in kinase drug discovery</span> <span class="citation_source-journal">Curr. Opin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1097%2FCCO.0b013e328011a25f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17133113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Cnt7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=55-60&author=M.+Warmuthauthor=S.+Kimauthor=X.+J.+Guauthor=G.+Xiaauthor=F.+Adri%C3%A1n&title=Ba%2FF3+cells+and+their+use+in+kinase+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Ba/F3 cells and their use in kinase drug discovery</span></div><div class="casAuthors">Warmuth, Markus; Kim, Sungjoon; Gu, Xiang-ju; Xia, Gang; Adrian, Francisco</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-60</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Purpose of review: Due to their ability to function as dominant oncogenes, protein kinases have become favored targets in the quest for 'molecularly-targeted' cancer chemotherapeutics.  The discovery of a large no. of cancer-assocd. mutations in the kinome, and the progress in developing specific small-mol. kinase inhibitors has increased the need for accurate, reproducible, and efficient kinase activity-dependent cellular assay systems.  Recent findings: Ba/F3, a murine interleukin-3 dependent pro-B cell line is increasingly popular as a model system for assessing both the potency and downstream signaling of kinase oncogenes, and the ability of small-mol. kinase inhibitors to block kinase activity.  Facilitated by their growth properties, Ba/F3 cells have recently been adapted to high-throughput assay formats for compd. profiling.  Further, several published approaches show promise in predicting resistance to small-mol. kinase inhibitors elicited by point mutations interfering with inhibitor binding.  Summary: Ba/F3 cells are an increasingly popular tool in kinase drug discovery.  The ability to test the transforming capacity of newly identified kinase mutations, and to profile drug candidates and compd. libraries in high-throughput fashion, combined with the use of Ba/F3 cells to predict clin. resistance will greatly facilitate developments in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXQmhiRwGlDLVg90H21EOLACvtfcHk0lgWPwarCL5EXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Cnt7%252FL&md5=a7f8d84dfedea69d408edb571e2eead9</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1097%2FCCO.0b013e328011a25f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0b013e328011a25f%26sid%3Dliteratum%253Aachs%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DX.%2BJ.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DAdri%25C3%25A1n%26aufirst%3DF.%26atitle%3DBa%252FF3%2520cells%2520and%2520their%2520use%2520in%2520kinase%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2007%26volume%3D19%26spage%3D55%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Remsing Rix, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colinge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hantschel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stranzl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgartner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augustin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Till, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span> </span><span class="NLM_article-title">Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">485</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fleu.2008.334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=19039322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVKhu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=477-485&author=L.+L.+Remsing+Rixauthor=U.+Rixauthor=J.+Colingeauthor=O.+Hantschelauthor=K.+L.+Bennettauthor=T.+Stranzlauthor=A.+M%C3%BCllerauthor=C.+Baumgartnerauthor=P.+Valentauthor=M.+Augustinauthor=J.+H.+Tillauthor=G.+Superti-Furga&title=Global+target+profile+of+the+kinase+inhibitor+bosutinib+in+primary+chronic+myeloid+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells</span></div><div class="casAuthors">Remsing Rix, L. L.; Rix, U.; Colinge, J.; Hantschel, O.; Bennett, K. L.; Stranzl, T.; Mueller, A.; Baumgartner, C.; Valent, P.; Augustin, M.; Till, J. H.; Superti-Furga, G.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">477-485</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The detailed mol. mechanism of action of second-generation BCR-ABL tyrosine kinase inhibitors, including perturbed targets and pathways, should contribute to rationalized therapy in chronic myeloid leukemia (CML) or in other affected diseases.  Here, we characterized the target profile of the dual SRC/ABL inhibitor bosutinib employing a two-tiered approach using chem. proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel.  The combined strategy resulted in a global survey of bosutinib targets comprised of over 45 novel tyrosine and serine/threonine kinases.  We have found clear differences in the target patterns of bosutinib in primary CML cells vs. the K562 cell line.  A comparison of bosutinib with dasatinib across the whole kinase panel revealed overlapping, but distinct, inhibition profiles.  Common among those were the SRC, ABL and TEC family kinases.  Bosutinib did not inhibit KIT or platelet-derived growth factor receptor, but prominently targeted the apoptosis-linked STE20 kinases.  Although in vivo bosutinib is inactive against ABL T315I, we found this clin. important mutant to be enzymically inhibited in the mid-nanomolar range.  Finally, bosutinib is the first kinase inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation.  Leukemia (2009) 23, 477-485; doi:10.1038/leu.2008.334; published online 27 Nov. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8u0ixFotIMLVg90H21EOLACvtfcHk0lgWPwarCL5EXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVKhu7w%253D&md5=b0d56d468ef66ddc2a6f012d08f8c1a4</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fleu.2008.334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2008.334%26sid%3Dliteratum%253Aachs%26aulast%3DRemsing%2BRix%26aufirst%3DL.%2BL.%26aulast%3DRix%26aufirst%3DU.%26aulast%3DColinge%26aufirst%3DJ.%26aulast%3DHantschel%26aufirst%3DO.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DStranzl%26aufirst%3DT.%26aulast%3DM%25C3%25BCller%26aufirst%3DA.%26aulast%3DBaumgartner%26aufirst%3DC.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DAugustin%26aufirst%3DM.%26aulast%3DTill%26aufirst%3DJ.%2BH.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DGlobal%2520target%2520profile%2520of%2520the%2520kinase%2520inhibitor%2520bosutinib%2520in%2520primary%2520chronic%2520myeloid%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D477%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Heerding, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leber, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keenan, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafrance, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safonov, I. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takata, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venslavsky, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choudhry, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaber, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tummino, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strum, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duckett, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberwein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knick, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lansing, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McConnell, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minthorn, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Concha, N. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span> </span><span class="NLM_article-title">Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3<i>S</i>)-3-piperidinylmethyl]oxy}-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5663</span><span class="NLM_x">–</span> <span class="NLM_lpage">5679</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8004527" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5663-5679&author=D.+A.+Heerdingauthor=N.+Rhodesauthor=J.+D.+Leberauthor=T.+J.+Clarkauthor=R.+M.+Keenanauthor=L.+V.+Lafranceauthor=M.+Liauthor=I.+G.+Safonovauthor=D.+T.+Takataauthor=J.+W.+Venslavskyauthor=D.+S.+Yamashitaauthor=A.+E.+Choudhryauthor=R.+A.+Copelandauthor=Z.+Laiauthor=M.+D.+Schaberauthor=P.+J.+Tumminoauthor=S.+L.+Strumauthor=E.+R.+Woodauthor=D.+R.+Duckettauthor=D.+Eberweinauthor=V.+B.+Knickauthor=T.+J.+Lansingauthor=R.+T.+McConnellauthor=S.+Zhangauthor=E.+A.+Minthornauthor=N.+O.+Conchaauthor=G.+L.+Warrenauthor=R.+Kumar&title=Identification+of+4-%282-%284-amino-1%2C2%2C5-oxadiazol-3-yl%29-1-ethyl-7-%7B%5B%283S%29-3-piperidinylmethyl%5Doxy%7D-1H-imidazo%5B4%2C5-c%5Dpyridin-4-yl%29-2-methyl-3-butyn-2-ol+%28GSK690693%29%2C+a+novel+inhibitor+of+AKT+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Fjm8004527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8004527%26sid%3Dliteratum%253Aachs%26aulast%3DHeerding%26aufirst%3DD.%2BA.%26aulast%3DRhodes%26aufirst%3DN.%26aulast%3DLeber%26aufirst%3DJ.%2BD.%26aulast%3DClark%26aufirst%3DT.%2BJ.%26aulast%3DKeenan%26aufirst%3DR.%2BM.%26aulast%3DLafrance%26aufirst%3DL.%2BV.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DSafonov%26aufirst%3DI.%2BG.%26aulast%3DTakata%26aufirst%3DD.%2BT.%26aulast%3DVenslavsky%26aufirst%3DJ.%2BW.%26aulast%3DYamashita%26aufirst%3DD.%2BS.%26aulast%3DChoudhry%26aufirst%3DA.%2BE.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DStrum%26aufirst%3DS.%2BL.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DDuckett%26aufirst%3DD.%2BR.%26aulast%3DEberwein%26aufirst%3DD.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLansing%26aufirst%3DT.%2BJ.%26aulast%3DMcConnell%26aufirst%3DR.%2BT.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DMinthorn%26aufirst%3DE.%2BA.%26aulast%3DConcha%26aufirst%3DN.%2BO.%26aulast%3DWarren%26aufirst%3DG.%2BL.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DIdentification%2520of%25204-%25282-%25284-amino-1%252C2%252C5-oxadiazol-3-yl%2529-1-ethyl-7-%257B%255B%25283S%2529-3-piperidinylmethyl%255Doxy%257D-1H-imidazo%255B4%252C5-c%255Dpyridin-4-yl%2529-2-methyl-3-butyn-2-ol%2520%2528GSK690693%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520AKT%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5663%26epage%3D5679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Fernández, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanguino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozturk, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crespo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wulf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shavrin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trent, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangala, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bankson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelovani, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samarel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sood, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Berestein, G.</span><span> </span><span class="NLM_article-title">An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">4044</span><span class="NLM_x">–</span> <span class="NLM_lpage">4054</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=4044-4054&author=A.+Fern%C3%A1ndezauthor=A.+Sanguinoauthor=Z.+Pengauthor=E.+Ozturkauthor=J.+Chenauthor=A.+Crespoauthor=S.+Wulfauthor=A.+Shavrinauthor=C.+Qinauthor=J.+Maauthor=J.+Trentauthor=Y.+Linauthor=H.+D.+Hanauthor=L.+S.+Mangalaauthor=J.+A.+Banksonauthor=J.+Gelovaniauthor=A.+Samarelauthor=W.+Bornmannauthor=A.+K.+Soodauthor=G.+Lopez-Berestein&title=An+anticancer+C-Kit+kinase+inhibitor+is+reengineered+to+make+it+more+active+and+less+cardiotoxic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DA.%26aulast%3DSanguino%26aufirst%3DA.%26aulast%3DPeng%26aufirst%3DZ.%26aulast%3DOzturk%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCrespo%26aufirst%3DA.%26aulast%3DWulf%26aufirst%3DS.%26aulast%3DShavrin%26aufirst%3DA.%26aulast%3DQin%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DTrent%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DH.%2BD.%26aulast%3DMangala%26aufirst%3DL.%2BS.%26aulast%3DBankson%26aufirst%3DJ.%2BA.%26aulast%3DGelovani%26aufirst%3DJ.%26aulast%3DSamarel%26aufirst%3DA.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DSood%26aufirst%3DA.%2BK.%26aulast%3DLopez-Berestein%26aufirst%3DG.%26atitle%3DAn%2520anticancer%2520C-Kit%2520kinase%2520inhibitor%2520is%2520reengineered%2520to%2520make%2520it%2520more%2520active%2520and%2520less%2520cardiotoxic%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26spage%3D4044%26epage%3D4054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Fernández, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crespo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiwari, A.</span><span> </span><span class="NLM_article-title">Is there a case for selectively promiscuous anticancer drugs?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">5</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1-5&author=A.+Fern%C3%A1ndezauthor=A.+Crespoauthor=A.+Tiwari&title=Is+there+a+case+for+selectively+promiscuous+anticancer+drugs%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DA.%26aulast%3DCrespo%26aufirst%3DA.%26aulast%3DTiwari%26aufirst%3DA.%26atitle%3DIs%2520there%2520a%2520case%2520for%2520selectively%2520promiscuous%2520anticancer%2520drugs%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D1%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Von Coburg, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kottke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weizel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ligneau, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, H.</span><span> </span><span class="NLM_article-title">Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">538</span><span class="NLM_x">–</span> <span class="NLM_lpage">542</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=538-542&author=Y.+Von+Coburgauthor=T.+Kottkeauthor=L.+Weizelauthor=X.+Ligneauauthor=H.+Stark&title=Potential+utility+of+histamine+H3+receptor+antagonist+pharmacophore+in+antipsychotics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVon%2BCoburg%26aufirst%3DY.%26aulast%3DKottke%26aufirst%3DT.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DLigneau%26aufirst%3DX.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DPotential%2520utility%2520of%2520histamine%2520H3%2520receptor%2520antagonist%2520pharmacophore%2520in%2520antipsychotics%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D538%26epage%3D542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chessari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tisi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhead, A. J.</span><span> </span><span class="NLM_article-title">Recent developments in fragment-based drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3661</span><span class="NLM_x">–</span> <span class="NLM_lpage">3680</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8000373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3661-3680&author=M.+Congreveauthor=G.+Chessariauthor=D.+Tisiauthor=A.+J.+Woodhead&title=Recent+developments+in+fragment-based+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fjm8000373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8000373%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DTisi%26aufirst%3DD.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26atitle%3DRecent%2520developments%2520in%2520fragment-based%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3661%26epage%3D3680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Paolini, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapland, R. H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Hoorn, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Global mapping of pharmacological space</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">805</span><span class="NLM_x">–</span> <span class="NLM_lpage">815</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnbt1228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=16841068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFansb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=805-815&author=G.+V.+Paoliniauthor=R.+H.+B.+Shaplandauthor=W.+P.+van+Hoornauthor=J.+S.+Masonauthor=A.+L.+Hopkins&title=Global+mapping+of+pharmacological+space"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Global mapping of pharmacological space</span></div><div class="casAuthors">Paolini, Gaia V.; Shapland, Richard H. B.; van Hoorn, Willem P.; Mason, Jonathan S.; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">805-815</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We present the global mapping of pharmacol. space by the integration of several vast sources of medicinal chem. structure-activity relationships (SAR) data.  Our comprehensive mapping of pharmacol. space enables us to identify confidently the human targets for which chem. tools and drugs have been discovered to date.  The integration of SAR data from diverse sources by unique canonical chem. structure, protein sequence and disease indication enables the construction of a ligand-target matrix to explore the global relationships between chem. structure and biol. targets.  Using the data matrix, we are able to catalog the links between proteins in chem. space as a polypharmacol. interaction network.  We demonstrate that probabilistic models can be used to predict pharmacol. from a large knowledge base.  The relationships between proteins, chem. structures and drug-like properties provide a framework for developing a probabilistic approach to drug discovery that can be exploited to increase research productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV_CE47zZq8LVg90H21EOLACvtfcHk0lhBfazNVQR7Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFansb8%253D&md5=f559b34692cc903a1b503deb07030c5d</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1038%2Fnbt1228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1228%26sid%3Dliteratum%253Aachs%26aulast%3DPaolini%26aufirst%3DG.%2BV.%26aulast%3DShapland%26aufirst%3DR.%2BH.%2BB.%26aulast%3Dvan%2BHoorn%26aufirst%3DW.%2BP.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DGlobal%2520mapping%2520of%2520pharmacological%2520space%26jtitle%3DNat.%2520Biotechnol.%26date%3D2006%26volume%3D24%26spage%3D805%26epage%3D815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Radhakrishnan, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tidor, B.</span><span> </span><span class="NLM_article-title">Specificity in molecular design: a physical framework for probing the determinants of binding specificity and promiscuity in a biological environment</span> <span class="citation_source-journal">J. Phys. Chem. B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">13419</span><span class="NLM_x">–</span> <span class="NLM_lpage">13435</span></span><div class="citationLinks">[<a href="/doi/10.1021/jp074285e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2007&pages=13419-13435&author=M.+L.+Radhakrishnanauthor=B.+Tidor&title=Specificity+in+molecular+design%3A+a+physical+framework+for+probing+the+determinants+of+binding+specificity+and+promiscuity+in+a+biological+environment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fjp074285e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp074285e%26sid%3Dliteratum%253Aachs%26aulast%3DRadhakrishnan%26aufirst%3DM.%2BL.%26aulast%3DTidor%26aufirst%3DB.%26atitle%3DSpecificity%2520in%2520molecular%2520design%253A%2520a%2520physical%2520framework%2520for%2520probing%2520the%2520determinants%2520of%2520binding%2520specificity%2520and%2520promiscuity%2520in%2520a%2520biological%2520environment%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2007%26volume%3D111%26spage%3D13419%26epage%3D13435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehra, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perreault, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erbe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krupka, H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">England, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plotnikov, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Will, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Signaevsky, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kral, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantwell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settachatgull, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Womack, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milburn, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vlasuk, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobin, J. F.</span><span> </span><span class="NLM_article-title">Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">262</span><span class="NLM_x">–</span> <span class="NLM_lpage">267</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1073%2Fpnas.0811325106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=19116277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltF2rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=262-267&author=D.+R.+Artisauthor=J.+J.+Linauthor=C.+Zhangauthor=W.+Wangauthor=U.+Mehraauthor=M.+Perreaultauthor=D.+Erbeauthor=H.+I.+Krupkaauthor=B.+P.+Englandauthor=J.+Arnoldauthor=A.+N.+Plotnikovauthor=A.+Marimuthuauthor=H.+Nguyenauthor=S.+Willauthor=M.+Signaevskyauthor=J.+Kralauthor=J.+Cantwellauthor=C.+Settachatgullauthor=D.+S.+Yanauthor=D.+Fongauthor=A.+Ohauthor=S.+Shiauthor=P.+Womackauthor=B.+Powellauthor=G.+Habetsauthor=B.+L.+Westauthor=K.+Y.+Zhangauthor=M.+V.+Milburnauthor=G.+P.+Vlasukauthor=K.+P.+Hirthauthor=K.+Nolopauthor=G.+Bollagauthor=P.+N.+Ibrahimauthor=J.+F.+Tobin&title=Scaffold-based+discovery+of+indeglitazar%2C+a+PPAR+pan-active+anti-diabetic+agent"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent</span></div><div class="casAuthors">Artis, Dean R.; Lin, Jack J.; Zhang, Chao; Wang, Weiru; Mehra, Upasana; Perreault, Mylene; Erbe, David; Krupka, Heike I.; England, Bruce P.; Arnold, James; Plotnikov, Alexander N.; Marimuthu, Adhirai; Nguyen, Hoa; Will, Sarah; Signaevsky, Maxime; Kral, John; Cantwell, John; Settachatgull, Alvin; Yan, Douglas S.; Fong, Daniel; Oh, Angela; Shi, Shenghua; Womack, Patrick; Powell, Benjamin; Habets, Gaston; West, Brian L.; Zhang, Kam Y. J.; Milburn, Michael V.; Vlasuk, George P.; Hirth, K. Peter; Nolop, Keith; Bollag, Gideon; Ibrahim, Prabha N.; Tobin, James F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">262-267</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">In a search for more effective anti-diabetic treatment, we used a process coupling low-affinity biochem. screening with high-throughput co-crystallog. in the design of a series of compds. that selectively modulate the activities of all three peroxisome proliferator-activated receptors (PPARs), PPARα, PPARγ, and PPARδ.  Transcriptional transactivation assays were used to select compds. from this chem. series with a bias toward partial agonism toward PPARγ, to circumvent the clin. obsd. side effects of full PPARγ agonists.  Co-crystallog. characterization of the lead mol., indeglitazar, in complex with each of the 3 PPARs revealed the structural basis for its PPAR pan-activity and its partial agonistic response toward PPARγ.  Compared with full PPARγ-agonists, indeglitazar is less potent in promoting adipocyte differentiation and only partially effective in stimulating adiponectin gene expression.  Evaluation of the compd. in vivo confirmed the reduced adiponectin response in animal models of obesity and diabetes while revealing strong beneficial effects on glucose, triglycerides, cholesterol, body wt., and other metabolic parameters.  Indeglitazar has now progressed to Phase II clin. evaluations for Type 2 diabetes mellitus (T2DM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiPwFlRHVN2bVg90H21EOLACvtfcHk0liDEFbApOG1Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltF2rtg%253D%253D&md5=29503488bc79c51644c81d83add9040a</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0811325106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0811325106%26sid%3Dliteratum%253Aachs%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DMehra%26aufirst%3DU.%26aulast%3DPerreault%26aufirst%3DM.%26aulast%3DErbe%26aufirst%3DD.%26aulast%3DKrupka%26aufirst%3DH.%2BI.%26aulast%3DEngland%26aufirst%3DB.%2BP.%26aulast%3DArnold%26aufirst%3DJ.%26aulast%3DPlotnikov%26aufirst%3DA.%2BN.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DWill%26aufirst%3DS.%26aulast%3DSignaevsky%26aufirst%3DM.%26aulast%3DKral%26aufirst%3DJ.%26aulast%3DCantwell%26aufirst%3DJ.%26aulast%3DSettachatgull%26aufirst%3DC.%26aulast%3DYan%26aufirst%3DD.%2BS.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DWomack%26aufirst%3DP.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DVlasuk%26aufirst%3DG.%2BP.%26aulast%3DHirth%26aufirst%3DK.%2BP.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DTobin%26aufirst%3DJ.%2BF.%26atitle%3DScaffold-based%2520discovery%2520of%2520indeglitazar%252C%2520a%2520PPAR%2520pan-active%2520anti-diabetic%2520agent%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D262%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Mueller, G.</span> (Proteros) From Kinase Inhibitor Chemistry. Presented at CHI's Inaugural Meeting, Charting the Chemical Space, San Diego, CA, April 7−8,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Mueller%2C+G.+%28Proteros%29+From+Kinase+Inhibitor+Chemistry.+Presented+at+CHI%27s+Inaugural+Meeting%2C+Charting+the+Chemical+Space%2C+San+Diego%2C+CA%2C+April+7%E2%88%928%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DMueller%26aufirst%3DG.%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Pargellis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Churchill, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pav, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regan, J.</span><span> </span><span class="NLM_article-title">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnsb770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=11896401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=268-272&author=C.+Pargellisauthor=L.+Tongauthor=L.+Churchillauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=P.+M.+Grobauthor=E.+R.+Hickeyauthor=N.+Mossauthor=S.+Pavauthor=J.+Regan&title=Inhibition+of+p38+MAP+kinase+by+utilizing+a+novel+allosteric+binding+site"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span></div><div class="casAuthors">Pargellis, Christopher; Tong, Liang; Churchill, Laurie; Cirillo, Pier F.; Gilmore, Thomas; Graham, Anne G.; Grob, Peter M.; Hickey, Eugene R.; Moss, Neil; Pav, Susan; Regan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-272</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The p38 MAP kinase plays a crucial role in regulating the prodn. of proinflammatory cytokines, such as tumor necrosis factor and interleukin-1.  Blocking this kinase may offer an effective therapy for treating many inflammatory diseases.  Here we report a new allosteric binding site for a diaryl urea class of highly potent and selective inhibitors against human p38 MAP kinase.  The formation of this binding site requires a large conformational change not obsd. previously for any of the protein Ser/Thr kinases.  This change is in the highly conserved Asp-Phe-Gly motif within the active site of the kinase.  Soln. studies demonstrate that this class of compds. has slow binding kinetics, consistent with the requirement for conformational change.  Improving interactions in this allosteric pocket, as well as establishing binding interactions in the ATP pocket, enhanced the affinity of the inhibitors by 12,000-fold.  One of the most potent compds. in this series, BIRB 796, has picomolar affinity for the kinase and low nanomolar inhibitory activity in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT8_QT7_pbYrVg90H21EOLACvtfcHk0liDEFbApOG1Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D&md5=68850ecdbe08df4285ba38cfa2c93ea4</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1038%2Fnsb770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb770%26sid%3Dliteratum%253Aachs%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DRegan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520p38%2520MAP%2520kinase%2520by%2520utilizing%2520a%2520novel%2520allosteric%2520binding%2520site%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D268%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, L.</span><span> </span><span class="NLM_article-title">Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">7882</span><span class="NLM_x">–</span> <span class="NLM_lpage">7888</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8010096" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7882-7888&author=D.+Weiauthor=X.+Jiangauthor=L.+Zhouauthor=J.+Chenauthor=Z.+Chenauthor=C.+Heauthor=K.+Yangauthor=Y.+Liuauthor=J.+Peiauthor=L.+Lai&title=Discovery+of+multitarget+inhibitors+by+combining+molecular+docking+with+common+pharmacophore+matching"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjm8010096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010096%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520multitarget%2520inhibitors%2520by%2520combining%2520molecular%2520docking%2520with%2520common%2520pharmacophore%2520matching%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7882%26epage%3D7888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Alton, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunney, E. A.</span><span> </span><span class="NLM_article-title">Targeting the unactivated conformations of protein kinases for small molecule drug discovery</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">595</span><span class="NLM_x">–</span> <span class="NLM_lpage">605</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=595-605&author=G.+R.+Altonauthor=E.+A.+Lunney&title=Targeting+the+unactivated+conformations+of+protein+kinases+for+small+molecule+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlton%26aufirst%3DG.%2BR.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26atitle%3DTargeting%2520the%2520unactivated%2520conformations%2520of%2520protein%2520kinases%2520for%2520small%2520molecule%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D595%26epage%3D605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Freire, E.</span><span> </span><span class="NLM_article-title">Do enthalpy and entropy distinguish first in class from best in class?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">869</span><span class="NLM_x">–</span> <span class="NLM_lpage">874</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2Fj.drudis.2008.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=18703160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFCgu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=869-874&author=E.+Freire&title=Do+enthalpy+and+entropy+distinguish+first+in+class+from+best+in+class%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Do enthalpy and entropy distinguish first in class from best in class?</span></div><div class="casAuthors">Freire, Ernesto</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">19/20</span>),
    <span class="NLM_cas:pages">869-874</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  A drug mol. should bind to its target with high affinity and selectivity.  Because the binding affinity is a combined function of the binding enthalpy and the binding entropy, extremely high affinity requires that both terms contribute favorably to binding.  The binding enthalpy, however, is notoriously more difficult to optimize than the binding entropy, a fact that has resulted in thermodynamically unbalanced mols. that do not achieve optimal potency.  In fact, with current technologies, the enthalpic optimization of drug candidates may take years and only appear in second-generation products.  Within that context, it is not surprising that structure/activity relationships (SARs) that explicitly incorporate the interplay between enthalpy and entropy and accelerate the optimization process are being developed and gaining popularity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5swEhu922BbVg90H21EOLACvtfcHk0lhpqboTV6DguA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFCgu7fN&md5=357358107c5686a1863a83291c1cdd92</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2008.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2008.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DFreire%26aufirst%3DE.%26atitle%3DDo%2520enthalpy%2520and%2520entropy%2520distinguish%2520first%2520in%2520class%2520from%2520best%2520in%2520class%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2008%26volume%3D13%26spage%3D869%26epage%3D874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pompliano, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meek, T. D.</span><span> </span><span class="NLM_article-title">Drug−target residence time and its implications for lead optimization</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug%E2%88%92target+residence+time+and+its+implications+for+lead+optimization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug%25E2%2588%2592target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Backes, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zech, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, G.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1409</span><span class="NLM_x">–</span> <span class="NLM_lpage">1425</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1517%2F17460440802579975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=23506106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvFCmtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1409-1425&author=A.+C.+Backesauthor=B.+Zechauthor=B.+Felberauthor=B.+Kleblauthor=G.+M%C3%BCller&title=Small-molecule+inhibitors+binding+to+protein+kinases.+Part+I%3A+exceptions+from+the+traditional+pharmacophore+approach+of+type+I+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition</span></div><div class="casAuthors">Backes, A. C.; Zech, B.; Felber, B.; Klebl, B.; Mueller, G.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1409-1425</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Protein kinases are essential enzymes propagating cellular signal transduction processes and consequently have emerged as central targets for drug discovery against a wide range of diseases with a strong historical focus on oncol. disorders.  A large no. of high-resoln. crystal structures of various ATP-competitive inhibitors in complex with their target protein kinases have been detd. and present a wealth of detailed information about binding modes, inhibition mechanisms and assocd. structure-activity relationships of target-bound small mols.  Objective: In this first part of a two-part review, exceptions to the type I binding mode of kinase inhibitors that follow the traditional pharmacophore model are discussed, highlighting unexpected structural features.  Methods: The scope of this review covers published crystal structures of protein kinases in complex with various ligands.  Results: Structural parameters of both inhibitors and kinases contribute to the complexity of designing kinase inhibitors.  The continued study of high-resoln. structures of ligand-enzyme complexes in combination with a more dynamic understanding of accessible conformational states of the target proteins, supported by detailed kinetic studies, will in the long-term help in developing new low-mol. wt. kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgxVqECguWJbVg90H21EOLACvtfcHk0lhpqboTV6DguA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvFCmtrk%253D&md5=705fa7e531ceced90ed86d0d2658766e</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1517%2F17460440802579975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460440802579975%26sid%3Dliteratum%253Aachs%26aulast%3DBackes%26aufirst%3DA.%2BC.%26aulast%3DZech%26aufirst%3DB.%26aulast%3DFelber%26aufirst%3DB.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DG.%26atitle%3DSmall-molecule%2520inhibitors%2520binding%2520to%2520protein%2520kinases.%2520Part%2520I%253A%2520exceptions%2520from%2520the%2520traditional%2520pharmacophore%2520approach%2520of%2520type%2520I%2520inhibition%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D1409%26epage%3D1425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Krug, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilgeroth, A.</span><span> </span><span class="NLM_article-title">Recent advances in the development of multi-kinase inhibitors</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1312</span><span class="NLM_x">–</span> <span class="NLM_lpage">1327</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1312-1327&author=M.+Krugauthor=A.+Hilgeroth&title=Recent+advances+in+the+development+of+multi-kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrug%26aufirst%3DM.%26aulast%3DHilgeroth%26aufirst%3DA.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520of%2520multi-kinase%2520inhibitors%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D1312%26epage%3D1327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Backes, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zech, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, G .</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1427</span><span class="NLM_x">–</span> <span class="NLM_lpage">1449</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1427-1449&author=A.+C.+Backesauthor=B.+Zechauthor=B.+Felberauthor=B.+Kleblauthor=G+.+M%C3%BCller&title=Small-molecule+inhibitors+binding+to+protein+kinase.+Part+II%3A+the+novel+pharmacophore+approach+of+type+II+and+type+III+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBackes%26aufirst%3DA.%2BC.%26aulast%3DZech%26aufirst%3DB.%26aulast%3DFelber%26aufirst%3DB.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DG%2B.%26atitle%3DSmall-molecule%2520inhibitors%2520binding%2520to%2520protein%2520kinase.%2520Part%2520II%253A%2520the%2520novel%2520pharmacophore%2520approach%2520of%2520type%2520II%2520and%2520type%2520III%2520inhibition%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D1427%26epage%3D1449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Bikker, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span> </span><span class="NLM_article-title">Kinase domain mutations in cancer: implications for small molecule drug design strategies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1493</span><span class="NLM_x">–</span> <span class="NLM_lpage">1509</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8010542" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVCisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1493-1509&author=J.+A.+Bikkerauthor=N.+Brooijmansauthor=A.+Wissnerauthor=T.+S.+Mansour&title=Kinase+domain+mutations+in+cancer%3A+implications+for+small+molecule+drug+design+strategies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies</span></div><div class="casAuthors">Bikker, Jack A.; Brooijmans, Natasja; Wissner, Allan; Mansour, Tarek S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1493-1509</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review will provide a brief overview of kinase structure and function as it pertains to drug discovery, describe the location and importance of clin. mutations, and review the emerging understanding of their impact based on sequence homol., protein crystal complexes, and biochem./biophys. information.  Underlying this discussion is our appreciation that the current clin. arsenal of small mol. kinase inhibitors only contains the first weapons to be deployed in a long war against drug resistance mutations occurring in multiple kinases that target multiple cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBBjVt8P6JI7Vg90H21EOLACvtfcHk0lgHmKnplz5MOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVCisr0%253D&md5=fa09d8a6e553ccd1bb1f093176ecb366</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fjm8010542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010542%26sid%3Dliteratum%253Aachs%26aulast%3DBikker%26aufirst%3DJ.%2BA.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DKinase%2520domain%2520mutations%2520in%2520cancer%253A%2520implications%2520for%2520small%2520molecule%2520drug%2520design%2520strategies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1493%26epage%3D1509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structures of the kinase domain of c-ABL in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+structures+of+the+kinase+domain+of+c-ABL+in+complex+with+the+small+molecule+inhibitors+PD173955+and+imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0lgHmKnplz5MOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520kinase%2520domain%2520of%2520c-ABL%2520in%2520complex%2520with%2520the%2520small%2520molecule%2520inhibitors%2520PD173955%2520and%2520imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Wan, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">764</span><span class="NLM_x">–</span> <span class="NLM_lpage">766</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=764-766&author=P.+T.+Wanauthor=M.+J.+Garnettauthor=S.+M.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=C.+M.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Marais&title=Mechanism+of+activation+of+the+RAF-ERK+signaling+pathway+by+oncogenic+mutations+of+B-RAF"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMechanism%2520of%2520activation%2520of%2520the%2520RAF-ERK%2520signaling%2520pathway%2520by%2520oncogenic%2520mutations%2520of%2520B-RAF%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D764%26epage%3D766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuck, L.</span><span> </span><span class="NLM_article-title">A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">66452</span><span class="NLM_x">–</span> <span class="NLM_lpage">66659</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=66452-66659&author=E.+R.+Woodauthor=A.+T.+Tuesdaleauthor=O.+B.+McDonaldauthor=D.+Yanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilbmerauthor=L.+Shewchuck&title=A+unique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTuesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilbmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuck%26aufirst%3DL.%26atitle%3DA%2520unique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D66452%26epage%3D66659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Pollard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortimore, M.</span><span> </span><span class="NLM_article-title">Discovery and development of aurora kinase inhibitors as anticancer agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2629</span><span class="NLM_x">–</span> <span class="NLM_lpage">2651</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8012129" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjs1Gmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2629-2651&author=J.+R.+Pollardauthor=M.+Mortimore&title=Discovery+and+development+of+aurora+kinase+inhibitors+as+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Aurora Kinase Inhibitors as Anticancer Agents</span></div><div class="casAuthors">Pollard, John R.; Mortimore, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2629-2651</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This article summarizes the roles that each of the Aurora kinases plays in mitosis and cancer biol. and discusses how different Aurora inhibition selectivity profiles impact the cellular and in vivo behavior of the drug candidates.  In addn., the wealth of structural biol. information for the Aurora kinases is reviewed.  This will be used to provide a rationale for the cross-reactivity profiles of some the Aurora kinase drug candidates and will review current theories for how selectivity within the Aurora kinase family has been achieved.  Finally the discovery and development of the clin. candidates targeting Aurora kinases will be summarized together with a brief discussion of notable structure-activity relationships (SAR).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojisjXqX2odrVg90H21EOLACvtfcHk0ljh7tQpexdNTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjs1Gmtbc%253D&md5=bb59ec8929dd81ae89e606cfb84f18df</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Fjm8012129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8012129%26sid%3Dliteratum%253Aachs%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DMortimore%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520development%2520of%2520aurora%2520kinase%2520inhibitors%2520as%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2629%26epage%3D2651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broudy, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span> </span><span class="NLM_article-title">Novel N9-arenethenyl purines as potent dual SRC/ABL tyrosine kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4907</span><span class="NLM_x">–</span> <span class="NLM_lpage">4912</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4907-4912&author=Y.+Wangauthor=W.+C.+Shakespeareauthor=W.+S.+Huangauthor=R.+Sundaramoorthiauthor=S.+Lentiniauthor=S.+Dasauthor=S.+Liuauthor=G.+Bandaauthor=D.+Wenauthor=X.+Zhuauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=D.+Dalgarnoauthor=T.+Clacksonauthor=T.+K.+Sawyer&title=Novel+N9-arenethenyl+purines+as+potent+dual+SRC%2FABL+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DLentini%26aufirst%3DS.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26atitle%3DNovel%2520N9-arenethenyl%2520purines%2520as%2520potent%2520dual%2520SRC%252FABL%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4907%26epage%3D4912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broudy, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iuliucci, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">9-(Arenethenyl)purines as dual SRC/ABL kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4743</span><span class="NLM_x">–</span> <span class="NLM_lpage">4756</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900166t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4743-4756&author=W.+S.+Huangauthor=X.+Zhuauthor=Y.+Wangauthor=M.+Azamauthor=D.+Wenauthor=R.+Sundaramoorthiauthor=R.+M.+Thomasauthor=S.+Liuauthor=G.+Bandaauthor=S.+P.+Lentiniauthor=S.+Dasauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=G.+Q.+Daleyauthor=J.+Iuliucciauthor=D.+C.+Dalgarnoauthor=T.+Clacksonauthor=T.+K.+Sawyerauthor=W.+C.+Shakespeare&title=9-%28Arenethenyl%29purines+as+dual+SRC%2FABL+kinase+inhibitors+targeting+the+inactive+conformation%3A+design%2C+synthesis%2C+and+biological+evaluation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Fjm900166t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900166t%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DIuliucci%26aufirst%3DJ.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3D9-%2528Arenethenyl%2529purines%2520as%2520dual%2520SRC%252FABL%2520kinase%2520inhibitors%2520targeting%2520the%2520inactive%2520conformation%253A%2520design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4743%26epage%3D4756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grtter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robubi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3915</span><span class="NLM_x">–</span> <span class="NLM_lpage">3926</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9002928" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtlWgtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3915-3926&author=M.+Getlikauthor=C.+Grtterauthor=J.+R.+Simardauthor=S.+Klterauthor=M.+Rabillerauthor=H.+B.+Rodeauthor=A.+Robubiauthor=D.+Rauh&title=Hybrid+compound+design+to+overcome+the+gatekeeper+T338M+mutation+in+cSrc"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc</span></div><div class="casAuthors">Getlik, Matthaeus; Gruetter, Christian; Simard, Jeffrey R.; Kluter, Sabine; Rabiller, Matthias; Rode, Haridas B.; Robubi, Armin; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3915-3926</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The emergence of drug resistance remains a fundamental challenge in the development of kinase inhibitors that are effective over long-term treatments.  Allosteric inhibitors that bind to sites lying outside the highly conserved ATP pocket are thought to be more selective than ATP-competitive inhibitors and may circumvent some mechanisms of drug resistance.  Crystal structures of type I and allosteric type III inhibitors in complex with the tyrosine kinase cSrc allowed to develop these scaffolds into potent type II kinase inhibitors.  One of these compds., I (RL46), disrupts FAK-mediated focal adhesions in cancer cells via direct inhibition of cSrc.  Details gleaned from crystal structures revealed a key feature of a subset of these compds., a surprising flexibility in the vicinity of the gatekeeper residue that allows these compds. to overcome a dasatinib-resistant gatekeeper mutation emerging in cSrc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-72ZDo25pC7Vg90H21EOLACvtfcHk0lhc7srPJqHxBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtlWgtbY%253D&md5=3ff187e49298ec4690c76a2bc2100274</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Fjm9002928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9002928%26sid%3Dliteratum%253Aachs%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DGrtter%26aufirst%3DC.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DKlter%26aufirst%3DS.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DRobubi%26aufirst%3DA.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DHybrid%2520compound%2520design%2520to%2520overcome%2520the%2520gatekeeper%2520T338M%2520mutation%2520in%2520cSrc%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3915%26epage%3D3926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smykla, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span> </span><span class="NLM_article-title">Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">6186</span><span class="NLM_x">–</span> <span class="NLM_lpage">6193</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1158%2F1078-0432.CCR-06-0642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17062696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWhsbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=6186-6193&author=T.+W.+Wongauthor=F.+Y.+Leeauthor=C.+Yuauthor=F.+R.+Luoauthor=S.+Oppenheimerauthor=H.+Zhangauthor=R.+A.+Smyklaauthor=H.+Mastalerzauthor=B.+E.+Finkauthor=J.+T.+Hunt&title=Preclinical+antitumor+activity+of+BMS-599626%2C+a+pan-HER+kinase+inhibitor+that+inhibits+HER1%2FHER2+homodimer+and+heterodimer+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling</span></div><div class="casAuthors">Wong, Tai W.; Lee, Francis Y.; Yu, Chiang; Luo, Feng R.; Oppenheimer, Simone; Zhang, Hongjian; Smykla, Richard A.; Mastalerz, Harold; Fink, Brian E.; Hunt, John T.; Gavai, Ashvinikumar V.; Vite, Gregory D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">20, Pt. 1</span>),
    <span class="NLM_cas:pages">6186-6193</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The studies described here are intended to characterize the ability of BMS-599626, a small-mol. inhibitor of the human epidermal growth factor receptor (HER) kinase family, to modulate signaling and growth of tumor cells that depend on HER1 and/or HER2.  Exptl. Design: The potency and selectivity of BMS-599626 were assessed in biochem. assays using recombinant protein kinases, as well as in cell proliferation assays using tumor cell lines with varying degrees of dependence on HER1 or HER2 signaling.  Modulation of receptor signaling was detd. in cell assays by Western blot analyses of receptor autophosphorylation and downstream signaling.  The ability of BMS-599626 to inhibit receptor heterodimer signaling in tumor cells was studied by receptor coimmunopptn.  Antitumor activity of BMS-599626 was evaluated using a no. of different xenograft models that represent a spectrum of human tumors with HER1 or HER2 overexpression.  Results: BMS-599626 inhibited HER1 and HER2 with IC50 of 20 and 30 nmol/L, resp., and was highly selective when tested against a broad panel of diverse protein kinases.  Biochem. studies suggested that BMS-599626 inhibited HER1 and HER2 through distinct mechanisms.  BMS-599626 abrogated HER1 and HER2 signaling and inhibited the proliferation of tumor cell lines that are dependent on these receptors, with IC50 in the range of 0.24 to 1 μmol/L.  BMS-599626 was highly selective for tumor cells that depend on HER1/HER2 and had no effect on the proliferation of cell lines that do not express these receptors.  In tumor cells that are capable of forming HER1/HER2 heterodimers, BMS-599626 inhibited heterodimerization and downstream signaling.  BMS-599626 had antitumor activity in models that overexpress HER1 (GEO), as well as in models that have HER2 gene amplification (KPL4) or overexpression (Sal2), and there was good correlation between the inhibition of receptor signaling and antitumor activity.  Conclusions: BMS-599626 is a highly selective and potent inhibitor of HER1 and HER2 kinases and inhibits tumor cell proliferation through modulation of receptor signaling.  BMS-599626 inhibits HER1/HER2 receptor heterodimerization and provides an addnl. mechanism of inhibiting tumors in which receptor coexpression and heterodimerization play a major role in driving tumor growth.  The preclin. data support the advancement of BMS-599626 into clin. development for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVgsCF6GDMPbVg90H21EOLACvtfcHk0lhc7srPJqHxBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWhsbbK&md5=a8350e2eb304a091fa82f1159e44c119</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0642%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DF.%2BR.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSmykla%26aufirst%3DR.%2BA.%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DB.%2BE.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26atitle%3DPreclinical%2520antitumor%2520activity%2520of%2520BMS-599626%252C%2520a%2520pan-HER%2520kinase%2520inhibitor%2520that%2520inhibits%2520HER1%252FHER2%2520homodimer%2520and%2520heterodimer%2520signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D6186%26epage%3D6193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Bogoyevitch, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairlie, D. P.</span><span> </span><span class="NLM_article-title">A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">622</span><span class="NLM_x">–</span> <span class="NLM_lpage">633</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=622-633&author=M.+A.+Bogoyevitchauthor=D.+P.+Fairlie&title=A+new+paradigm+for+protein+kinase+inhibition%3A+blocking+phosphorylation+without+directly+targeting+ATP+binding"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBogoyevitch%26aufirst%3DM.%2BA.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26atitle%3DA%2520new%2520paradigm%2520for%2520protein%2520kinase%2520inhibition%253A%2520blocking%2520phosphorylation%2520without%2520directly%2520targeting%2520ATP%2520binding%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D622%26epage%3D633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Price, S.</span><span> </span><span class="NLM_article-title">Putative allosteric MEK1 and MEK2 inhibitors</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">603</span><span class="NLM_x">–</span> <span class="NLM_lpage">627</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1517%2F13543776.18.6.603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmt1Okt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=603-627&author=S.+Price&title=Putative+allosteric+MEK1+and+MEK2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Putative allosteric MEK1 and MEK2 inhibitors</span></div><div class="casAuthors">Price, Steve</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">603-627</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Over the last decade, the pharmaceutical industry has invested significantly in efforts to identify novel inhibitors of the mitogen-activated protein kinases MEK1 and MEK2.  Unsurprisingly, several ATP-competitive inhibitors have been identified, but the discovery of allosteric inhibitors has been the main focus for the development of novel therapies.  A no. of allosteric MEK1 and MEK2 inhibitors have been reported to exhibit exquisite selectivity when profiled against large panels of kinases.  Of the eight MEK inhibitors that have entered the clinic, it is believed that the majority, if not all, bind allosterically.  Objective: This review focuses on the patenting activity concerning putative allosteric MEK inhibitors, and their progression into the clinic.  Method: An anal. of the putative allosteric MEK inhibitor patent estate from the first-use application for PD-098059 in 1996 through to Feb. 2008 was undertaken.  An evaluation and summary of such therapies that have entered the clinic are provided.  Conclusion: The overwhelming majority of patents filed that describe putative allosteric MEK inhibitors are based on a diarylamine scaffold.  The ubiquitous expression of MEK throughout the body, and its central role in the cell signaling pathway, will undoubtedly ensure that inhibitors continue to be progressed into the clinic over the next decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrembLi7K41BrVg90H21EOLACvtfcHk0lhkjpabjb5Zdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmt1Okt74%253D&md5=0ae01171b408bcd941d692fe57ae57ae</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1517%2F13543776.18.6.603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.18.6.603%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DS.%26atitle%3DPutative%2520allosteric%2520MEK1%2520and%2520MEK2%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2008%26volume%3D18%26spage%3D603%26epage%3D627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Gumireddy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosenza, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">John, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robell, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">1992</span><span class="NLM_x">–</span> <span class="NLM_lpage">1997</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=1992-1997&author=K.+Gumireddyauthor=S.+J.+Bakerauthor=S.+C.+Cosenzaauthor=P.+Johnauthor=A.+D.+Kangauthor=K.+A.+Robellauthor=M.+V.+Reddyauthor=E.+P.+Reddy&title=A+non-ATP-competitive+inhibitor+of+BCR-ABL+overrides+imatinib+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGumireddy%26aufirst%3DK.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DJohn%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DA.%2BD.%26aulast%3DRobell%26aufirst%3DK.%2BA.%26aulast%3DReddy%26aufirst%3DM.%2BV.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DA%2520non-ATP-competitive%2520inhibitor%2520of%2520BCR-ABL%2520overrides%2520imatinib%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D1992%26epage%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barr, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlanson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fahr, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDowell, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, S. K.</span><span> </span><span class="NLM_article-title">Allosteric inhibition of protein tyrosine phosphatase 1B</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">737</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnsmb803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=15258570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVamtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=730-737&author=C.+Wiesmannauthor=K.+J.+Barrauthor=J.+Kungauthor=J.+Zhuauthor=D.+A.+Erlansonauthor=W.+Shenauthor=B.+J.+Fahrauthor=M.+Zhongauthor=L.+Taylorauthor=M.+Randalauthor=R.+S.+McDowellauthor=S.+K.+Hansen&title=Allosteric+inhibition+of+protein+tyrosine+phosphatase+1B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibition of protein tyrosine phosphatase 1B</span></div><div class="casAuthors">Wiesmann, Christian; Barr, Kenneth J.; Kung, Jenny; Zhu, Jiang; Erlanson, Daniel A.; Shen, Wang; Fahr, Bruce J.; Zhong, Min; Taylor, Lisa; Randal, Mike; McDowell, Robert S.; Hansen, Stig K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">730-737</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Obesity and type II diabetes are closely linked metabolic syndromes that afflict >100 million people worldwide.  Although protein tyrosine phosphatase 1B (PTP1B) has emerged as a promising target for the treatment of both syndromes, the discovery of pharmaceutically acceptable inhibitors that bind at the active site remains a substantial challenge.  Here we describe the discovery of an allosteric site in PTP1B.  Crystal structures of PTP1B in complex with allosteric inhibitors reveal a novel site located ∼20 Å from the catalytic site.  We show that allosteric inhibitors prevent formation of the active form of the enzyme by blocking mobility of the catalytic loop, thereby exploiting a general mechanism used by tyrosine phosphatases.  Notably, these inhibitors exhibit selectivity for PTP1B and enhance insulin signaling in cells.  Allosteric inhibition is a promising strategy for targeting PTP1B and constitutes a mechanism that may be applicable to other tyrosine phosphatases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv2mAdfb7Ou7Vg90H21EOLACvtfcHk0lhkjpabjb5Zdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVamtrc%253D&md5=abf4042d5dd49fa810ced16426d2bcb5</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fnsmb803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb803%26sid%3Dliteratum%253Aachs%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DBarr%26aufirst%3DK.%2BJ.%26aulast%3DKung%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DFahr%26aufirst%3DB.%2BJ.%26aulast%3DZhong%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DL.%26aulast%3DRandal%26aufirst%3DM.%26aulast%3DMcDowell%26aufirst%3DR.%2BS.%26aulast%3DHansen%26aufirst%3DS.%2BK.%26atitle%3DAllosteric%2520inhibition%2520of%2520protein%2520tyrosine%2520phosphatase%25201B%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D730%26epage%3D737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Diskin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livnah, O.</span><span> </span><span class="NLM_article-title">A novel lipid binding site formed by the MAP kinase insert in p38α</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">375</span><span class="NLM_x">, </span> <span class="NLM_fpage">70</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2Fj.jmb.2007.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17999933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlylu7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2008&pages=70-79&author=R.+Diskinauthor=D.+Engelbergauthor=O.+Livnah&title=A+novel+lipid+binding+site+formed+by+the+MAP+kinase+insert+in+p38%CE%B1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Lipid Binding Site Formed by the MAP Kinase Insert in p38α</span></div><div class="casAuthors">Diskin, Ron; Engelberg, David; Livnah, Oded</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70-79</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The p38 mitogen-activated protein (MAP) kinases function as signaling mols. essential for many cellular processes, particularly mediating stress response.  The activity of p38 MAP kinases is meticulously regulated to reach the desired cellular phenotype.  Several alternative activation and attenuation mechanisms have been characterized recently which include new phosphorylation sites.  Here we present the crystal structure of p38α MAP kinase in complex with n-octyl-β-glucopyranoside (β-OG) detergent.  The complex unveils a novel lipid-binding site formed by a local conformational change of the MAP kinase insert.  This binding is the first evidence of a possible role for the MAP kinase insert in p38.  The binding site can accommodate a large selection of lipidic mols.  In addn., we also show via biophys. methods that arachidonic acid (AA) and its derivs. bind p38α in vitro.  Based on our anal. we propose that the binding of lipids could fine-tune p38α catalytic activity towards a preferred phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6J5fd2Jqe77Vg90H21EOLACvtfcHk0lhQ2Z0LAMnStQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlylu7vI&md5=88b97152503182d41fa0ea7b53271229</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2007.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2007.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DDiskin%26aufirst%3DR.%26aulast%3DEngelberg%26aufirst%3DD.%26aulast%3DLivnah%26aufirst%3DO.%26atitle%3DA%2520novel%2520lipid%2520binding%2520site%2520formed%2520by%2520the%2520MAP%2520kinase%2520insert%2520in%2520p38%25CE%25B1%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2008%26volume%3D375%26spage%3D70%26epage%3D79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Barnett, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Defeo-Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haskell, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahana, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kral, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leander, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malinowski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAvoy, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nahas, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, H. E.</span><span> </span><span class="NLM_article-title">Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific AKT inhibitors</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">408</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=399-408&author=S.+F.+Barnettauthor=D.+Defeo-Jonesauthor=S.+Fuauthor=P.+J.+Hancockauthor=K.+M.+Haskellauthor=R.+E.+Jonesauthor=J.+A.+Kahanaauthor=A.+M.+Kralauthor=K.+Leanderauthor=L.+L.+Leeauthor=J.+Malinowskiauthor=E.+M.+McAvoyauthor=D.+D.+Nahasauthor=R.+G.+Robinsonauthor=H.+E.+Huber&title=Identification+and+characterization+of+pleckstrin-homology-domain-dependent+and+isoenzyme-specific+AKT+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBarnett%26aufirst%3DS.%2BF.%26aulast%3DDefeo-Jones%26aufirst%3DD.%26aulast%3DFu%26aufirst%3DS.%26aulast%3DHancock%26aufirst%3DP.%2BJ.%26aulast%3DHaskell%26aufirst%3DK.%2BM.%26aulast%3DJones%26aufirst%3DR.%2BE.%26aulast%3DKahana%26aufirst%3DJ.%2BA.%26aulast%3DKral%26aufirst%3DA.%2BM.%26aulast%3DLeander%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DL.%2BL.%26aulast%3DMalinowski%26aufirst%3DJ.%26aulast%3DMcAvoy%26aufirst%3DE.%2BM.%26aulast%3DNahas%26aufirst%3DD.%2BD.%26aulast%3DRobinson%26aufirst%3DR.%2BG.%26aulast%3DHuber%26aufirst%3DH.%2BE.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520pleckstrin-homology-domain-dependent%2520and%2520isoenzyme-specific%2520AKT%2520inhibitors%26jtitle%3DBiochem.%2520J.%26date%3D2005%26volume%3D15%26spage%3D399%26epage%3D408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Stebbins, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machleidt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becattini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vazquez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuntzen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cellitti, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riel-Mehan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emdadi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solinas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellecchia, M.</span><span> </span><span class="NLM_article-title">Identification of a new JNK inhibitor targeting the JNK-JIP interaction site</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">16809</span><span class="NLM_x">–</span> <span class="NLM_lpage">16813</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1073%2Fpnas.0805677105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=18922779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlertbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=16809-16813&author=J.+L.+Stebbinsauthor=S.+K.+Deauthor=T.+Machleidtauthor=B.+Becattiniauthor=J.+Vazquezauthor=C.+Kuntzenauthor=L.+H.+Chenauthor=J.+F.+Cellittiauthor=M.+Riel-Mehanauthor=A.+Emdadiauthor=G.+Solinasauthor=M.+Karinauthor=M.+Pellecchia&title=Identification+of+a+new+JNK+inhibitor+targeting+the+JNK-JIP+interaction+site"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a new JNK inhibitor targeting the JNK-JIP interaction site</span></div><div class="casAuthors">Stebbins, John L.; De, Surya K.; Machleidt, Thomas; Becattini, Barbara; Vazquez, Jesus; Kuntzen, Christian; Chen, Li-Hsing; Cellitti, Jason F.; Riel-Mehan, Megan; Emdadi, Aras; Solinas, Giovanni; Karin, Michael; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">16809-16813</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">JNK is a stress-activated protein kinase that modulates pathways implicated in a variety of disease states.  JNK-interacting protein-1 (JIP1) is a scaffolding protein that enhances JNK signaling by creating a proximity effect between JNK and upstream kinases.  A minimal peptide region derived from JIP1 is able to inhibit JNK activity both in vitro and in cell.  We report here a series of small mols. JIP1 mimics that function as substrate competitive inhibitors of JNK.  One such compd., BI-78D3, dose-dependently inhibits the phosphorylation of JNK substrates both in vitro and in cell.  In animal studies, BI-78D3 not only blocks JNK dependent Con A-induced liver damage but also restores insulin sensitivity in mouse models of type 2 diabetes.  Our findings open the way for the development of protein kinase inhibitors targeting substrate specific docking sites, rather than the highly conserved ATP binding sites.  In view of its favorable inhibition profile, selectivity, and ability to function in the cellular milieu and in vivo, BI-78D3 represents not only a JNK inhibitor, but also a promising stepping stone toward the development of an innovative class of therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5qVRg8EpCvbVg90H21EOLACvtfcHk0lhQ2Z0LAMnStQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlertbvM&md5=8fef92335594787de91361c5b1683f5e</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0805677105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0805677105%26sid%3Dliteratum%253Aachs%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DDe%26aufirst%3DS.%2BK.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DBecattini%26aufirst%3DB.%26aulast%3DVazquez%26aufirst%3DJ.%26aulast%3DKuntzen%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DL.%2BH.%26aulast%3DCellitti%26aufirst%3DJ.%2BF.%26aulast%3DRiel-Mehan%26aufirst%3DM.%26aulast%3DEmdadi%26aufirst%3DA.%26aulast%3DSolinas%26aufirst%3DG.%26aulast%3DKarin%26aufirst%3DM.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520a%2520new%2520JNK%2520inhibitor%2520targeting%2520the%2520JNK-JIP%2520interaction%2520site%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D16809%26epage%3D16813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the erbB family of protein tyrosine kinases</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2FS0163-7258%2802%2900194-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=12191617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVShurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2002&pages=253-261&author=W.+A.+Denny&title=Irreversible+inhibitors+of+the+erbB+family+of+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible inhibitors of the erbB family of protein tyrosine kinases</span></div><div class="casAuthors">Denny, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">253-261</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  The erbB family of transmembrane receptor tyrosine kinases initiates a large no. of cellular signaling pathways.  Their over-expression in human tumors correlates with poor prognosis, and they have become important targets for drug development.  The 4-anilinoquinazolines are potent and selective ATP site inhibitors of these enzymes, esp. erbB1 (epidermal growth factor receptor).  Structure-activity studies for binding at the ATP site are narrow, consistent with homol. and crystal structure-binding models.  Combinations of small lipophilic groups at the 3'-position of the aniline and electron-donating groups at the 6- or 7-positions of the quinazoline result in extremely potent (picomolar) reversible inhibitors, several of which are in clin. trial.  Observation that the erbB family of enzymes contains a unique Cys residue (Cys773) close to the ATP-binding site prompted the development of irreversible inhibitors, the most successful being 6-acrylamides and related butynamides, which show significantly improved in vivo antitumor activity compared with closely related reversibly binding compds.  Solubilizing side chains can be placed either at the terminus of the alkylating unit or at the quinazoline C-7, and examples of both types are in clin. trial.  Both reversible and irreversible inhibitors synergize with a variety of DNA-damaging anticancer drugs, and it is likely that the greatest impact of these agents will be in combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwN71GFZA09rVg90H21EOLACvtfcHk0lhQ2Z0LAMnStQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVShurk%253D&md5=7937e2efbf606734ae781554e7c26d15</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2802%2900194-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252802%252900194-8%26sid%3Dliteratum%253Aachs%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520erbB%2520family%2520of%2520protein%2520tyrosine%2520kinases%26jtitle%3DPharmacol.%2520Ther.%26date%3D2002%26volume%3D93%26spage%3D253%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenschein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadimitrakopoulou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbst, R.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor inhibitors in development for the treatment of non small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">4441</span><span class="NLM_x">–</span> <span class="NLM_lpage">4445</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1158%2F1078-0432.CCR-06-0286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFSmtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=4441-4445&author=J.+V.+Heymachauthor=M.+Nilssonauthor=G.+Blumenscheinauthor=V.+Papadimitrakopoulouauthor=R.+Herbst&title=Epidermal+growth+factor+receptor+inhibitors+in+development+for+the+treatment+of+non+small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Heymach, John V.; Nilsson, Monique; Blumenschein, George; Papadimitrakopoulou, Vassiliki; Herbst, Roy</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">14, Pt. 2</span>),
    <span class="NLM_cas:pages">4441s-4445s</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) inhibitors erlotinib, gefitinib, and cetuximab have undergone extensive clin. testing and have established clin. activity in non-small cell lung cancer and other types of solid tumors.  A no. of newer inhibitors are currently in clin. development with different spectra of activity or mechanisms of receptor inhibition.  These include monoclonal antibodies, such as panitumumab and matuzumab; dual inhibitors of EGFR and vascular endothelial growth factor receptor, such as ZD6474 and AEE788; inhibitors of multiple EGFR family members, such as lapatinib; and irreversible inhibitors, such as canertinib and HKI272.  Preclin. studies suggest that several of these agents may have activity in tumors refractory to erlotinib or gefitinib.  Among these agents, ZD6474 has undergone the most extensive clin. testing.  The antitumor activity of ZD6474 in these two randomized phase II clin. trials in patients with non-small cell lung cancer was felt to be sufficiently promising to warrant phase III clin. testing.  Several of the other EGFR inhibitors are also undergoing advanced clin. testing, either alone or in combination with other agents.  EGFR has now been validated as a clin. relevant target, and several different types of agents inhibiting this receptor are currently in development.  Future research will be needed to elucidate the role of these agents in patients with EGFR inhibitor-naive and EGFR inhibitor-refractory disease, to define the mol. characteristics that predict response, and to det. whether these drugs should be used in combination with other targeted agents or chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdonmx9qlZZLVg90H21EOLACvtfcHk0lielelHm2K5bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFSmtrc%253D&md5=24c5413d2d0e2a46921d22dba474fa89</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0286%26sid%3Dliteratum%253Aachs%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DBlumenschein%26aufirst%3DG.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DHerbst%26aufirst%3DR.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520inhibitors%2520in%2520development%2520for%2520the%2520treatment%2520of%2520non%2520small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D4441%26epage%3D4445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingalls, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dushin, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nittoli, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravi, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loganzo, F.</span><span> </span><span class="NLM_article-title">Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">3635</span><span class="NLM_x">–</span> <span class="NLM_lpage">3648</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=3635-3648&author=A.+Wissnerauthor=H.+L.+Fraserauthor=C.+L.+Ingallsauthor=R.+G.+Dushinauthor=M.+B.+Floydauthor=K.+Cheungauthor=T.+Nittoliauthor=M.+R.+Raviauthor=X.+Tanauthor=F.+Loganzo&title=Dual+irreversible+kinase+inhibitors%3A+quinazoline-based+inhibitors+incorporating+two+independent+reactive+centers+with+each+targeting+different+cysteine+residues+in+the+kinase+domains+of+EGFR+and+VEGFR-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DFraser%26aufirst%3DH.%2BL.%26aulast%3DIngalls%26aufirst%3DC.%2BL.%26aulast%3DDushin%26aufirst%3DR.%2BG.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DCheung%26aufirst%3DK.%26aulast%3DNittoli%26aufirst%3DT.%26aulast%3DRavi%26aufirst%3DM.%2BR.%26aulast%3DTan%26aufirst%3DX.%26aulast%3DLoganzo%26aufirst%3DF.%26atitle%3DDual%2520irreversible%2520kinase%2520inhibitors%253A%2520quinazoline-based%2520inhibitors%2520incorporating%2520two%2520independent%2520reactive%2520centers%2520with%2520each%2520targeting%2520different%2520cysteine%2520residues%2520in%2520the%2520kinase%2520domains%2520of%2520EGFR%2520and%2520VEGFR-2%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D3635%26epage%3D3648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Vieth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgs, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gragg, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemmerle, H.</span><span> </span><span class="NLM_article-title">Kinomics: structural biology and chemogenomics of kinase inhibitors and targets</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Proteins Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">1697</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2Fj.bbapap.2003.11.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=15023365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitFKlsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1697&publication_year=2004&pages=243-257&author=M.+Viethauthor=R.+E.+Higgsauthor=D.+H.+Robertsonauthor=M.+Shapiroauthor=E.+A.+Graggauthor=H.+Hemmerle&title=Kinomics%3A+structural+biology+and+chemogenomics+of+kinase+inhibitors+and+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Kinomics-structural biology and chemogenomics of kinase inhibitors and targets</span></div><div class="casAuthors">Vieth, Michal; Higgs, Richard E.; Robertson, Daniel H.; Shapiro, Michael; Gragg, Ellen A.; Hemmerle, Horst</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1697</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">243-257</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Classifying kinases based entirely on small mol. selectivity data is a new approach to drug discovery that allows scientists to understand relationships between targets.  This approach combines the understanding of small mols. and targets, and thereby assists the researcher in finding new targets for existing mols. or understanding selectivity and polypharmacol. of mols. in related targets.  Currently, structural information is available for relatively few of the protein kinases encoded in the human genome (7% of the estd. 518); however, even the current knowledge base, when paired with structure-based design techniques, can assist in the identification and optimization of novel kinase inhibitors across the entire protein class.  Chemogenomics attempts to combine genomic data, structural biol. data, classical dendrograms, and selectivity data to explore, define, and classify the medicinally relevant kinase space.  Exploitation of this information in the discovery of kinase inhibitors defines practical kinase chemogenomics (kinomics).  In this paper, the authors review the available information on kinase targets and their inhibitors, and present the relationships between the various classification schema for kinase space.  In particular, the authors present the first dendrogram of kinases based entirely on small mol. selectivity data.  The authors find that the selectivity dendrogram differs from sequence-based clustering mostly in the higher-level groupings of the smaller clusters, and remains very comparable for closely homologous targets.  Highly homologous kinases are, on av., inhibited comparably by small mols.  This observation, although intuitive, is very important to the process of target selection, as one would expect difficulty in achieving inhibitor selectivity for kinases that share high sequence identity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1jGPlCWLR5LVg90H21EOLACvtfcHk0lielelHm2K5bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitFKlsLk%253D&md5=2742824cbdc8acc8660113547160a012</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2003.11.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2003.11.028%26sid%3Dliteratum%253Aachs%26aulast%3DVieth%26aufirst%3DM.%26aulast%3DHiggs%26aufirst%3DR.%2BE.%26aulast%3DRobertson%26aufirst%3DD.%2BH.%26aulast%3DShapiro%26aufirst%3DM.%26aulast%3DGragg%26aufirst%3DE.%2BA.%26aulast%3DHemmerle%26aufirst%3DH.%26atitle%3DKinomics%253A%2520structural%2520biology%2520and%2520chemogenomics%2520of%2520kinase%2520inhibitors%2520and%2520targets%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2004%26volume%3D1697%26spage%3D243%26epage%3D257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Vieth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, R. M.</span><span> </span><span class="NLM_article-title">Kinomics: characterizing the therapeutically validated kinase space</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">839</span><span class="NLM_x">–</span> <span class="NLM_lpage">846</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=839-846&author=M.+Viethauthor=J.+J.+Sutherlandauthor=D.+H.+Robertsonauthor=R.+M.+Campbell&title=Kinomics%3A+characterizing+the+therapeutically+validated+kinase+space"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVieth%26aufirst%3DM.%26aulast%3DSutherland%26aufirst%3DJ.%2BJ.%26aulast%3DRobertson%26aufirst%3DD.%2BH.%26aulast%3DCampbell%26aufirst%3DR.%2BM.%26atitle%3DKinomics%253A%2520characterizing%2520the%2520therapeutically%2520validated%2520kinase%2520space%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D839%26epage%3D846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Apsel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazif, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aizenstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span> </span><span class="NLM_article-title">Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">699</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnchembio.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=18849971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=691-699&author=B.+Apselauthor=J.+A.+Blairauthor=B.+Gonzalezauthor=T.+M.+Nazifauthor=M.+E.+Feldmanauthor=B.+Aizensteinauthor=R.+Hoffmanauthor=R.+L.+Williamsauthor=K.+M.+Shokatauthor=Z.+A.+Knight&title=Targeted+polypharmacology%3A+discovery+of+dual+inhibitors+of+tyrosine+and+phosphoinositide+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases</span></div><div class="casAuthors">Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">691-699</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. success of multitargeted kinase inhibitors has stimulated efforts to identify promiscuous drugs with optimal selectivity profiles.  It remains unclear to what extent such drugs can be rationally designed, particularly for combinations of targets that are structurally divergent.  Here we report the systematic discovery of mols. that potently inhibit both tyrosine kinases and phosphatidylinositol-3-OH kinases, two protein families that are among the most intensely pursued cancer drug targets.  Through iterative chem. synthesis, X-ray crystallog. and kinome-level biochem. profiling, we identified compds. that inhibit a spectrum of new target combinations in these two families.  Crystal structures revealed that the dual selectivity of these mols. is controlled by a hydrophobic pocket conserved in both enzyme classes and accessible through a rotatable bond in the drug skeleton.  We show that compd. I blocks the proliferation of tumor cells by direct inhibition of oncogenic tyrosine kinases and phosphatidylinositol-3-OH kinases.  These mols. demonstrate the feasibility of accessing a chem. space that intersects two families of oncogenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7xlegha5YF7Vg90H21EOLACvtfcHk0lhwKF_T-VUmPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF&md5=4da10a973f6895f92a644ca82ca5cdcd</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.117%26sid%3Dliteratum%253Aachs%26aulast%3DApsel%26aufirst%3DB.%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DNazif%26aufirst%3DT.%2BM.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DAizenstein%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26atitle%3DTargeted%2520polypharmacology%253A%2520discovery%2520of%2520dual%2520inhibitors%2520of%2520tyrosine%2520and%2520phosphoinositide%2520kinases%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D691%26epage%3D699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Sergina, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rausch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moasser, M. M.</span><span> </span><span class="NLM_article-title">Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">445</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">441</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=445&publication_year=2007&pages=437-441&author=N.+V.+Serginaauthor=M.+Rauschauthor=D.+Wangauthor=J.+Blairauthor=B.+Hannauthor=K.+M.+Shokatauthor=M.+M.+Moasser&title=Escape+from+HER-family+tyrosine+kinase+inhibitor+therapy+by+the+kinase-inactive+HER3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSergina%26aufirst%3DN.%2BV.%26aulast%3DRausch%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DBlair%26aufirst%3DJ.%26aulast%3DHann%26aufirst%3DB.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DMoasser%26aufirst%3DM.%2BM.%26atitle%3DEscape%2520from%2520HER-family%2520tyrosine%2520kinase%2520inhibitor%2520therapy%2520by%2520the%2520kinase-inactive%2520HER3%26jtitle%3DNature%26date%3D2007%26volume%3D445%26spage%3D437%26epage%3D441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Mohi, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sternberg, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neel, B. G.</span><span> </span><span class="NLM_article-title">Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">3130</span><span class="NLM_x">–</span> <span class="NLM_lpage">3135</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=3130-3135&author=M.+G.+Mohiauthor=C.+Boultonauthor=T.+L.+Guauthor=D.+W.+Sternbergauthor=D.+Neubergauthor=J.+D.+Griffinauthor=D.+G.+Gillilandauthor=B.+G.+Neel&title=Combination+of+rapamycin+and+protein+tyrosine+kinase+%28PTK%29+inhibitors+for+the+treatment+of+leukemias+caused+by+oncogenic+PTKs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMohi%26aufirst%3DM.%2BG.%26aulast%3DBoulton%26aufirst%3DC.%26aulast%3DGu%26aufirst%3DT.%2BL.%26aulast%3DSternberg%26aufirst%3DD.%2BW.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DCombination%2520of%2520rapamycin%2520and%2520protein%2520tyrosine%2520kinase%2520%2528PTK%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520leukemias%2520caused%2520by%2520oncogenic%2520PTKs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D3130%26epage%3D3135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Sutherland, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgs, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vieth, M.</span><span> </span><span class="NLM_article-title">Chemical fragments as foundations for understanding target space and activity prediction</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2689</span><span class="NLM_x">–</span> <span class="NLM_lpage">2700</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701399f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2689-2700&author=J.+J.+Sutherlandauthor=R.+E.+Higgsauthor=I.+Watsonauthor=M.+Vieth&title=Chemical+fragments+as+foundations+for+understanding+target+space+and+activity+prediction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Fjm701399f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701399f%26sid%3Dliteratum%253Aachs%26aulast%3DSutherland%26aufirst%3DJ.%2BJ.%26aulast%3DHiggs%26aufirst%3DR.%2BE.%26aulast%3DWatson%26aufirst%3DI.%26aulast%3DVieth%26aufirst%3DM.%26atitle%3DChemical%2520fragments%2520as%2520foundations%2520for%2520understanding%2520target%2520space%2520and%2520activity%2520prediction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2689%26epage%3D2700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Parkkila, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Innocenti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallio, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilvo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scozzafava, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supuran, C. T.</span><span> </span><span class="NLM_article-title">The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4102</span><span class="NLM_x">–</span> <span class="NLM_lpage">4106</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4102-4106&author=S.+Parkkilaauthor=A.+Innocentiauthor=H.+Kallioauthor=M.+Hilvoauthor=A.+Scozzafavaauthor=C.+T.+Supuran&title=The+protein+tyrosine+kinase+inhibitors+imatinib+and+nilotinib+strongly+inhibit+several+mammalian+alpha-carbonic+anhydrase+isoforms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DParkkila%26aufirst%3DS.%26aulast%3DInnocenti%26aufirst%3DA.%26aulast%3DKallio%26aufirst%3DH.%26aulast%3DHilvo%26aufirst%3DM.%26aulast%3DScozzafava%26aufirst%3DA.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26atitle%3DThe%2520protein%2520tyrosine%2520kinase%2520inhibitors%2520imatinib%2520and%2520nilotinib%2520strongly%2520inhibit%2520several%2520mammalian%2520alpha-carbonic%2520anhydrase%2520isoforms%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4102%26epage%3D4106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihnat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnke, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisliuk, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, F. T.</span><span> </span><span class="NLM_article-title">Novel 5-substituted 2,4-diaminofuro[2,3-<i>d</i>]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">5475</span><span class="NLM_x">–</span> <span class="NLM_lpage">5491</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=5475-5491&author=A.+Gangjeeauthor=Y.+Zengauthor=M.+Ihnatauthor=L.+A.+Warnkeauthor=D.+W.+Greenauthor=R.+L.+Kisliukauthor=F.+T.+Lin&title=Novel+5-substituted+2%2C4-diaminofuro%5B2%2C3-d%5Dpyrimidines+as+multireceptor+tyrosine+kinase+and+dihydrofolate+reductase+inhibitors+with+antiangiogenic+and+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DWarnke%26aufirst%3DL.%2BA.%26aulast%3DGreen%26aufirst%3DD.%2BW.%26aulast%3DKisliuk%26aufirst%3DR.%2BL.%26aulast%3DLin%26aufirst%3DF.%2BT.%26atitle%3DNovel%25205-substituted%25202%252C4-diaminofuro%255B2%252C3-d%255Dpyrimidines%2520as%2520multireceptor%2520tyrosine%2520kinase%2520and%2520dihydrofolate%2520reductase%2520inhibitors%2520with%2520antiangiogenic%2520and%2520antitumor%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26spage%3D5475%26epage%3D5491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Mahboobi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dove, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellmer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichhorn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pongratz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciossek, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckers, T.</span><span> </span><span class="NLM_article-title">Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrids as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rβ, and histone deacetylases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2265</span><span class="NLM_x">–</span> <span class="NLM_lpage">2279</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800988r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2265-2279&author=S.+Mahboobiauthor=S.+Doveauthor=A.+Sellmerauthor=M.+Winklerauthor=E.+Eichhornauthor=H.+Pongratzauthor=T.+Ciossekauthor=T.+Baerauthor=T.+Maierauthor=T.+Beckers&title=Design+of+chimeric+histone+deacetylase-+and+tyrosine+kinase-inhibitors%3A+a+series+of+imatinib+hybrids+as+potent+inhibitors+of+wild-type+and+mutant+BCR-ABL%2C+PDGF-R%CE%B2%2C+and+histone+deacetylases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fjm800988r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800988r%26sid%3Dliteratum%253Aachs%26aulast%3DMahboobi%26aufirst%3DS.%26aulast%3DDove%26aufirst%3DS.%26aulast%3DSellmer%26aufirst%3DA.%26aulast%3DWinkler%26aufirst%3DM.%26aulast%3DEichhorn%26aufirst%3DE.%26aulast%3DPongratz%26aufirst%3DH.%26aulast%3DCiossek%26aufirst%3DT.%26aulast%3DBaer%26aufirst%3DT.%26aulast%3DMaier%26aufirst%3DT.%26aulast%3DBeckers%26aufirst%3DT.%26atitle%3DDesign%2520of%2520chimeric%2520histone%2520deacetylase-%2520and%2520tyrosine%2520kinase-inhibitors%253A%2520a%2520series%2520of%2520imatinib%2520hybrids%2520as%2520potent%2520inhibitors%2520of%2520wild-type%2520and%2520mutant%2520BCR-ABL%252C%2520PDGF-R%25CE%25B2%252C%2520and%2520histone%2520deacetylases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2265%26epage%3D2279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span>Presented at the 235th National Meeting of the American Chemical Society, New Orleans, LA, April 6−10,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>Poster from Curis Inc.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Presented+at+the+235th+National+Meeting+of+the+American+Chemical+Society%2C+New+Orleans%2C+LA%2C+April+6%E2%88%9210%2C+2008%3B+Poster+from+Curis+Inc."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Triola, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetzel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellinger, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldmann, H.</span><span> </span><span class="NLM_article-title">ATP competitive inhibitors of <span class="smallcaps smallerCapital">d</span>-alanine−<span class="smallcaps smallerCapital">d</span>-alanine ligase based on protein kinase inhibitor scaffolds</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1079</span><span class="NLM_x">–</span> <span class="NLM_lpage">1087</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=1079-1087&author=G.+Triolaauthor=S.+Wetzelauthor=B.+Ellingerauthor=M.+A.+Kochauthor=K.+H%C3%BCbelauthor=D.+Rauhauthor=H.+Waldmann&title=ATP+competitive+inhibitors+of+d-alanine%E2%88%92d-alanine+ligase+based+on+protein+kinase+inhibitor+scaffolds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTriola%26aufirst%3DG.%26aulast%3DWetzel%26aufirst%3DS.%26aulast%3DEllinger%26aufirst%3DB.%26aulast%3DKoch%26aufirst%3DM.%2BA.%26aulast%3DH%25C3%25BCbel%26aufirst%3DK.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DWaldmann%26aufirst%3DH.%26atitle%3DATP%2520competitive%2520inhibitors%2520of%2520d-alanine%25E2%2588%2592d-alanine%2520ligase%2520based%2520on%2520protein%2520kinase%2520inhibitor%2520scaffolds%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D1079%26epage%3D1087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Miller, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mochalkin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banotai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunkle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harwood, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huband, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karnovsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Limberakis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehrens, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogden, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasad, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelly, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skerlos, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulavik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, V. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanderRoest, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stover, C. K.</span><span> </span><span class="NLM_article-title">A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">1737</span><span class="NLM_x">–</span> <span class="NLM_lpage">1742</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1073%2Fpnas.0811275106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=19164768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitV2jurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=1737-1742&author=J.+R.+Millerauthor=S.+Dunhamauthor=I.+Mochalkinauthor=C.+Banotaiauthor=M.+Bowmanauthor=S.+Buistauthor=B.+Dunkleauthor=D.+Hannaauthor=H.+J.+Harwoodauthor=M.+D.+Hubandauthor=A.+Karnovskyauthor=M.+Kuhnauthor=C.+Limberakisauthor=J.+Y.+Liuauthor=S.+Mehrensauthor=W.+T.+Muellerauthor=L.+Narasimhanauthor=A.+Ogdenauthor=J.+Ohrenauthor=J.+V.+Prasadauthor=J.+A.+Shellyauthor=L.+Skerlosauthor=M.+Sulavikauthor=V.+H.+Thomasauthor=S.+VanderRoestauthor=L.+Wangauthor=Z.+Wangauthor=A.+Whittonauthor=T.+Zhuauthor=C.+K.+Stover&title=A+class+of+selective+antibacterials+derived+from+a+protein+kinase+inhibitor+pharmacophore"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore</span></div><div class="casAuthors">Miller, J. Richard; Dunham, Steve; Mochalkin, Igor; Banotai, Craig; Bowman, Matthew; Buist, Susan; Dunkle, Bill; Hanna, Debra; Harwood, James; Huband, Michael D.; Karnovsky, Alla; Kuhn, Michael; Limberakis, Chris; Liu, Jia Y.; Mehrens, Shawn; Mueller, W. Thomas; Narasimhan, Lakshmi; Ogden, Adam; Ohren, Jeff; Vara Prasad, J. V. N.; Shelly, John A.; Skerlos, Laura; Sulavik, Mark; Thomas, V. Hayden; VanderRoest, Steve; Wang, LiAnn; Wang, Zhigang; Whitton, Amy; Zhu, Tong; Stover, C. Kendall</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1737-1742</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">As the need for novel antibiotic classes to combat bacterial drug resistance increases, the paucity of leads resulting from target-based antibacterial screening of pharmaceutical compd. libraries is of major concern.  One explanation for this lack of success is that antibacterial screening efforts have not leveraged the eukaryotic bias resulting from more extensive chem. efforts targeting eukaryotic gene families such as G protein-coupled receptors and protein kinases.  Consistent with a focus on antibacterial target space resembling these eukaryotic targets, we used whole-cell screening to identify a series of antibacterial pyridopyrimidines derived from a protein kinase inhibitor pharmacophore.  In bacteria, the pyridopyrimidines target the ATP-binding site of biotin carboxylase (BC), which catalyzes the first enzymic step of fatty acid biosynthesis.  These inhibitors are effective in vitro and in vivo against fastidious Gram-neg. pathogens including Haemophilus influenzae.  Although the BC active site has architectural similarity to those of eukaryotic protein kinases, inhibitor binding to the BC ATP-binding site is distinct from the protein kinase-binding mode, such that the inhibitors are selective for bacterial BC.  In summary, the authors have discovered a promising class of potent antibacterials with a previously undescribed mechanism of action.  In consideration of the eukaryotic bias of pharmaceutical libraries, the findings also suggest that pursuit of a novel inhibitor leads for antibacterial targets with active-site structural similarity to known human targets will likely be more fruitful than the traditional focus on unique bacterial target space, particularly when structure-based and computational methodologies are applied to ensure bacterial selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8jpj8EOtRo7Vg90H21EOLACvtfcHk0licmqHltU_dXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitV2jurk%253D&md5=06758ee5befbe847825ec35adb177006</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0811275106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0811275106%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DJ.%2BR.%26aulast%3DDunham%26aufirst%3DS.%26aulast%3DMochalkin%26aufirst%3DI.%26aulast%3DBanotai%26aufirst%3DC.%26aulast%3DBowman%26aufirst%3DM.%26aulast%3DBuist%26aufirst%3DS.%26aulast%3DDunkle%26aufirst%3DB.%26aulast%3DHanna%26aufirst%3DD.%26aulast%3DHarwood%26aufirst%3DH.%2BJ.%26aulast%3DHuband%26aufirst%3DM.%2BD.%26aulast%3DKarnovsky%26aufirst%3DA.%26aulast%3DKuhn%26aufirst%3DM.%26aulast%3DLimberakis%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DJ.%2BY.%26aulast%3DMehrens%26aufirst%3DS.%26aulast%3DMueller%26aufirst%3DW.%2BT.%26aulast%3DNarasimhan%26aufirst%3DL.%26aulast%3DOgden%26aufirst%3DA.%26aulast%3DOhren%26aufirst%3DJ.%26aulast%3DPrasad%26aufirst%3DJ.%2BV.%26aulast%3DShelly%26aufirst%3DJ.%2BA.%26aulast%3DSkerlos%26aufirst%3DL.%26aulast%3DSulavik%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DV.%2BH.%26aulast%3DVanderRoest%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWhitton%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DStover%26aufirst%3DC.%2BK.%26atitle%3DA%2520class%2520of%2520selective%2520antibacterials%2520derived%2520from%2520a%2520protein%2520kinase%2520inhibitor%2520pharmacophore%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D1737%26epage%3D1742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Lazareno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birdsall, N. J.</span><span> </span><span class="NLM_article-title">Allosteric interactions of staurosporine and other indolocarbazoles with <i>N</i>-[methyl-3<i>H</i>]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">194</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2000&pages=194-207&author=S.+Lazarenoauthor=A.+Pophamauthor=N.+J.+Birdsall&title=Allosteric+interactions+of+staurosporine+and+other+indolocarbazoles+with+N-%5Bmethyl-3H%5Dscopolamine+and+acetylcholine+at+muscarinic+receptor+subtypes%3A+identification+of+a+second+allosteric+site"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLazareno%26aufirst%3DS.%26aulast%3DPopham%26aufirst%3DA.%26aulast%3DBirdsall%26aufirst%3DN.%2BJ.%26atitle%3DAllosteric%2520interactions%2520of%2520staurosporine%2520and%2520other%2520indolocarbazoles%2520with%2520N-%255Bmethyl-3H%255Dscopolamine%2520and%2520acetylcholine%2520at%2520muscarinic%2520receptor%2520subtypes%253A%2520identification%2520of%2520a%2520second%2520allosteric%2520site%26jtitle%3DMol.%2520Pharmacol.%26date%3D2000%26volume%3D58%26spage%3D194%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Nobeli, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favia, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornton, J. M.</span><span> </span><span class="NLM_article-title">Protein promiscuity and its implications for biotechnology</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnbt1519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=19204698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Cktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=157-167&author=I.+Nobeliauthor=A.+D.+Faviaauthor=J.+M.+Thornton&title=Protein+promiscuity+and+its+implications+for+biotechnology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Protein promiscuity and its implications for biotechnology</span></div><div class="casAuthors">Nobeli, Irene; Favia, Angelo D.; Thornton, Janet M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-167</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mol. recognition between proteins and their interacting partners underlies the biochem. of living organisms.  Specificity in this recognition is thought to be essential, whereas promiscuity is often assocd. with unwanted side-effects, poor catalytic properties, and errors in biol. function.  Recent exptl. evidence suggests that promiscuity, not only in interactions but also in the actual function of proteins, is not as rare as was previously thought.  This has implications not only for the fundamental understanding of mol. recognition and how protein function has evolved over time, but also in the realm of biotechnol.  Understanding protein promiscuity is becoming increasingly important not only to optimize protein engineering applications in areas as diverse as synthetic biol. and metagenomics, but also to lower attrition rates in drug discovery programs, identify drug interaction surfaces less susceptible to escape mutations, and potentiate the power of polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdzkMBuUqOqLVg90H21EOLACvtfcHk0licmqHltU_dXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Cktrc%253D&md5=1e72967accb88b6183ec882a4cba2571</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fnbt1519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1519%26sid%3Dliteratum%253Aachs%26aulast%3DNobeli%26aufirst%3DI.%26aulast%3DFavia%26aufirst%3DA.%2BD.%26aulast%3DThornton%26aufirst%3DJ.%2BM.%26atitle%3DProtein%2520promiscuity%2520and%2520its%2520implications%2520for%2520biotechnology%26jtitle%3DNat.%2520Biotechnol.%26date%3D2009%26volume%3D27%26spage%3D157%26epage%3D167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Winger, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hantschel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)</span> <span class="citation_source-journal">BMC Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">7</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1186%2F1472-6807-9-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=19236722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A280%3ADC%252BD1M3gslyhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=7-18&author=J.+A.+Wingerauthor=O.+Hantschelauthor=G.+Superti-Furgaauthor=J.+Kuriyan&title=The+structure+of+the+leukemia+drug+imatinib+bound+to+human+quinone+reductase+2+%28NQO2%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)</span></div><div class="casAuthors">Winger Jonathan A; Hantschel Oliver; Superti-Furga Giulio; Kuriyan John</div><div class="citationInfo"><span class="NLM_cas:title">BMC structural biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Imatinib represents the first in a class of drugs targeted against chronic myelogenous leukemia to enter the clinic, showing excellent efficacy and specificity for Abl, Kit, and PDGFR kinases.  Recent screens carried out to find off-target proteins that bind to imatinib identified the oxidoreductase NQO2, a flavoprotein that is phosphorylated in a chronic myelogenous leukemia cell line.  RESULTS:  We examined the inhibition of NQO2 activity by the Abl kinase inhibitors imatinib, nilotinib, and dasatinib, and obtained IC50 values of 80 nM, 380 nM, and >100 microM, respectively.  Using electronic absorption spectroscopy, we show that imatinib binding results in a perturbation of the protein environment around the flavin prosthetic group in NQO2.  We have determined the crystal structure of the complex of imatinib with human NQO2 at 1.75 A resolution, which reveals that imatinib binds in the enzyme active site, adjacent to the flavin isoalloxazine ring.  We find that phosphorylation of NQO2 has little effect on enzyme activity and is therefore likely to regulate other aspects of NQO2 function.  CONCLUSION:  The structure of the imatinib-NQO2 complex demonstrates that imatinib inhibits NQO2 activity by competing with substrate for the active site.  The overall conformation of imatinib when bound to NQO2 resembles the folded conformation observed in some kinase complexes.  Interactions made by imatinib with residues at the rim of the active site provide an explanation for the binding selectivity of NQO2 for imatinib, nilotinib, and dasatinib.  These interactions also provide a rationale for the lack of inhibition of the related oxidoreductase NQO1 by these compounds.  Taken together, these studies provide insight into the mechanism of NQO2 inhibition by imatinib, with potential implications for drug design and treatment of chronic myelogenous leukemia in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRO2EpZRmfn9zW1zwg2yUK5fW6udTcc2eaWEymdSG4vGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3gslyhsQ%253D%253D&md5=a19609238b7de880d6680048b15941c1</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1186%2F1472-6807-9-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6807-9-7%26sid%3Dliteratum%253Aachs%26aulast%3DWinger%26aufirst%3DJ.%2BA.%26aulast%3DHantschel%26aufirst%3DO.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DThe%2520structure%2520of%2520the%2520leukemia%2520drug%2520imatinib%2520bound%2520to%2520human%2520quinone%2520reductase%25202%2520%2528NQO2%2529%26jtitle%3DBMC%2520Struct.%2520Biol.%26date%3D2009%26volume%3D9%26spage%3D7%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Stockwell, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornton, J. M.</span><span> </span><span class="NLM_article-title">Conformational diversity of ligands bound to proteins</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">928</span><span class="NLM_x">–</span> <span class="NLM_lpage">944</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2Fj.jmb.2005.12.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=16405908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XotVOitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2006&pages=928-944&author=G.+R.+Stockwellauthor=J.+M.+Thornton&title=Conformational+diversity+of+ligands+bound+to+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational Diversity of Ligands Bound to Proteins</span></div><div class="casAuthors">Stockwell, Gareth R.; Thornton, Janet M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">928-944</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The phenomenon of mol. recognition, which underpins almost all biol. processes, is dynamic, complex and subtle.  Establishing an interaction between a pair of mols. involves mutual structural rearrangements guided by a highly convoluted energy landscape, the accurate mapping of which continues to elude us.  Increased understanding of the degree to which the conformational space of a ligand is restricted upon binding may have important implications for docking studies, structure refinement and for function prediction methods based on geometrical comparisons of ligands or their binding sites.  Here, we present an anal. of the conformational variability exhibited by three of the most ubiquitous biol. ligands in nature, ATP, NAD and FAD.  First, we demonstrate qual. that these ligands bind to proteins in widely varying conformations, including several cases in which parts of the mol. assume energetically unfavorable orientations.  Next, by comparing the distribution of bound ligand shapes with the set of all possible mol. conformations, we provide a quant. assessment of previous observations that ligands tend to unfold when binding to proteins.  We show that, while extended forms of ligands are indeed common in ligand-protein structures, instances of ligands in almost maximally compact arrangements can also be found.  Thirdly, we compare the conformational variation in two sets of ligand mols., those bound to homologous proteins, and those bound to unrelated proteins.  Although most superfamilies bind ligands in a fairly conserved manner, we find several cases in which significant variation in ligand configuration is obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfZf7uuw0-gLVg90H21EOLACvtfcHk0lhdezTkpS7p6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotVOitA%253D%253D&md5=581db35cc9e2a3fb061ef00321566fc3</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2005.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2005.12.012%26sid%3Dliteratum%253Aachs%26aulast%3DStockwell%26aufirst%3DG.%2BR.%26aulast%3DThornton%26aufirst%3DJ.%2BM.%26atitle%3DConformational%2520diversity%2520of%2520ligands%2520bound%2520to%2520proteins%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2006%26volume%3D356%26spage%3D928%26epage%3D944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Weber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supuran, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scozzafava, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebe, G.</span><span> </span><span class="NLM_article-title">Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">550</span><span class="NLM_x">–</span> <span class="NLM_lpage">557</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=550-557&author=A.+Weberauthor=A.+Casiniauthor=A.+Heineauthor=D.+Kuhnauthor=C.+T.+Supuranauthor=A.+Scozzafavaauthor=G.+Klebe&title=Unexpected+nanomolar+inhibition+of+carbonic+anhydrase+by+COX-2-selective+celecoxib%3A+new+pharmacological+opportunities+due+to+related+binding+site+recognition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DA.%26aulast%3DCasini%26aufirst%3DA.%26aulast%3DHeine%26aufirst%3DA.%26aulast%3DKuhn%26aufirst%3DD.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26aulast%3DScozzafava%26aufirst%3DA.%26aulast%3DKlebe%26aufirst%3DG.%26atitle%3DUnexpected%2520nanomolar%2520inhibition%2520of%2520carbonic%2520anhydrase%2520by%2520COX-2-selective%2520celecoxib%253A%2520new%2520pharmacological%2520opportunities%2520due%2520to%2520related%2520binding%2520site%2520recognition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D550%26epage%3D557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Jenwitheesuk, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horst, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivas, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Voorhis, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samudrala, R.</span><span> </span><span class="NLM_article-title">Novel paradigms for drug discovery: computational multitarget screening</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">62</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2Fj.tips.2007.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=18190973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhslOjsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=62-71&author=E.+Jenwitheesukauthor=J.+A.+Horstauthor=K.+L.+Rivasauthor=W.+C.+Van+Voorhisauthor=R.+Samudrala&title=Novel+paradigms+for+drug+discovery%3A+computational+multitarget+screening"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Novel paradigms for drug discovery: computational multitarget screening</span></div><div class="casAuthors">Jenwitheesuk, Ekachai; Horst, Jeremy A.; Rivas, Kasey L.; Van Voorhis, Wesley C.; Samudrala, Ram</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">62-71</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  An established paradigm in current drug development is (i) to identify a single protein target whose inhibition is likely to result in the successful treatment of a disease of interest; (ii) to assay exptl. large libraries of small-mol. compds. in vitro and in vivo to identify promising inhibitors in model systems; and (iii) to det. whether the findings are extensible to humans.  This complex process, which is largely based on trial and error, is risk-, time- and cost-intensive.  Computational (virtual) screening of drug-like compds. simultaneously against the at. structures of multiple protein targets, taking into account protein-inhibitor dynamics, might help to identify lead inhibitors more efficiently, particularly for complex drug-resistant diseases.  Here we discuss the potential benefits of this approach, using HIV-1 and Plasmodium falciparum infections as examples.  We propose a virtual drug discovery pipeline' that will not only identify lead inhibitors efficiently, but also help minimize side-effects and toxicity, thereby increasing the likelihood of successful therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcA1qFl-hV8bVg90H21EOLACvtfcHk0lgHbMDjdFIhYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhslOjsLo%253D&md5=0dd3e34e8bf4a9799194d7add9ff7343</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DJenwitheesuk%26aufirst%3DE.%26aulast%3DHorst%26aufirst%3DJ.%2BA.%26aulast%3DRivas%26aufirst%3DK.%2BL.%26aulast%3DVan%2BVoorhis%26aufirst%3DW.%2BC.%26aulast%3DSamudrala%26aufirst%3DR.%26atitle%3DNovel%2520paradigms%2520for%2520drug%2520discovery%253A%2520computational%2520multitarget%2520screening%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2008%26volume%3D29%26spage%3D62%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group">Bender, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettles, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, J. W.</span><span> </span><span class="NLM_article-title">Bayes affinity fingerprints improve retrieval rates in virtual screening and define orthogonal bioactivity space: When are multitarget drugs a feasible concept?</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2445</span><span class="NLM_x">–</span> <span class="NLM_lpage">2456</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci600197y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpt1yqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=2445-2456&author=A.+Benderauthor=J.+L.+Jenkinsauthor=M.+Glickauthor=Z.+Dengauthor=J.+H.+Nettlesauthor=J.+W.+Davies&title=Bayes+affinity+fingerprints+improve+retrieval+rates+in+virtual+screening+and+define+orthogonal+bioactivity+space%3A+When+are+multitarget+drugs+a+feasible+concept%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">"Bayes Affinity Fingerprints" Improve Retrieval Rates in Virtual Screening and Define Orthogonal Bioactivity Space: When Are Multitarget Drugs a Feasible Concept?</span></div><div class="casAuthors">Bender, Andreas; Jenkins, Jeremy L.; Glick, Meir; Deng, Zhan; Nettles, James H.; Davies, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2445-2456</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Conventional similarity searching of mols. compares single (or multiple) active query structures to each other in a relative framework, by means of a structural descriptor and a similarity measure.  While this often works well, depending on the target, the authors show here that retrieval rates can be improved considerably by incorporating an external framework describing ligand bioactivity space for comparisons ("Bayes affinity fingerprints").  Structures are described by Bayes scores for a ligand panel comprising about 1000 activity classes extd. from the WOMBAT database.  The comparison of structures is performed via the Pearson correlation coeff. of activity classes, i.e., the order in which two structures are similar to the panel activity classes.  Compd. retrieval on a recently published data set could be improved by as much as 24% relative (9% abs.).  Knowledge about the shape of the "bioactive chem. universe" is thus beneficial to identifying similar bioactivities.  Principal component anal. was employed to further analyze activity space with the objective to define orthogonal ligand bioactive chem. space, leading to nine major (roughly orthogonal) activity axes.  Employing only those nine activity classes, retrieval rates are still comparable to original Bayes affinity fingerprints; thus, the concept of orthogonal bioactive ligand chem. space was validated as being an information-rich but low-dimensional representation of bioactivity space.  Correlations between activity classes are a major determinant to gauge whether the desired multitarget activity of drugs is (on the basis of current knowledge) a feasible concept because it measures the extent to which activities can be optimized independently, or only by strongly influencing one another.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6IjlYwYDTwLVg90H21EOLACvtfcHk0lgHbMDjdFIhYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpt1yqsrs%253D&md5=47adb720154f45bda1738963d54c70a5</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1021%2Fci600197y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci600197y%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DZ.%26aulast%3DNettles%26aufirst%3DJ.%2BH.%26aulast%3DDavies%26aufirst%3DJ.%2BW.%26atitle%3DBayes%2520affinity%2520fingerprints%2520improve%2520retrieval%2520rates%2520in%2520virtual%2520screening%2520and%2520define%2520orthogonal%2520bioactivity%2520space%253A%2520When%2520are%2520multitarget%2520drugs%2520a%2520feasible%2520concept%253F%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2006%26volume%3D46%26spage%3D2445%26epage%3D2456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armbruster, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernsberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span> </span><span class="NLM_article-title">Relating protein pharmacology by ligand chemistry</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnbt1284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17287757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOrsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=197-206&author=M.+J.+Keiserauthor=B.+L.+Rothauthor=B.+N.+Armbrusterauthor=P.+Ernsbergerauthor=J.+J.+Irwinauthor=B.+K.+Shoichet&title=Relating+protein+pharmacology+by+ligand+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Relating protein pharmacology by ligand chemistry</span></div><div class="casAuthors">Keiser, Michael J.; Roth, Bryan L.; Armbruster, Blaine N.; Ernsberger, Paul; Irwin, John J.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-206</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The identification of protein function based on biol. information is an area of intense research.  Here the authors consider a complementary technique that quant. groups and relates proteins based on the chem. similarity of their ligands.  The authors began with 65,000 ligands annotated into sets for hundreds of drug targets.  The similarity score between each set was calcd. using ligand topol.  A statistical model was developed to rank the significance of the resulting similarity scores, which are expressed as a min. spanning tree to map the sets together.  Although these maps are connected solely by chem. similarity, biol. sensible clusters nevertheless emerged.  Links among unexpected targets also emerged, among them that methadone, emetine and loperamide (Imodium) may antagonize muscarinic M3, α2 adrenergic and neurokinin NK2 receptors, resp.  These predictions were subsequently confirmed exptl.  Relating receptors by ligand chem. organizes biol. to reveal unexpected relationships that may be assayed using the ligands themselves.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNKEMguhmluLVg90H21EOLACvtfcHk0lgHbMDjdFIhYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOrsLo%253D&md5=1b7373d52563fca5fe1e893d85f70573</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fnbt1284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1284%26sid%3Dliteratum%253Aachs%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DArmbruster%26aufirst%3DB.%2BN.%26aulast%3DErnsberger%26aufirst%3DP.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DRelating%2520protein%2520pharmacology%2520by%2520ligand%2520chemistry%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D197%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Network pharmacology: the next paradigm in drug discovery</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">682</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnchembio.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=18936753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=682-690&author=A.+L.+Hopkins&title=Network+pharmacology%3A+the+next+paradigm+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology: the next paradigm in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is the concept of designing maximally selective ligands to act on individual drug targets.  However, many effective drugs act via modulation of multiple proteins rather than single targets.  Advances in systems biol. are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compds., compared with multi-target drugs, may exhibit lower than desired clin. efficacy.  This new appreciation of the role of polypharmacol. has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity.  Integrating network biol. and polypharmacol. holds the promise of expanding the current opportunity space for druggable targets.  However, the rational design of polypharmacol. faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties.  Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqHy4FqkK-h7Vg90H21EOLACvtfcHk0lgHbMDjdFIhYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK&md5=03b8be3ddbcab7dc65afd17df7ee8395</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.118%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DNetwork%2520pharmacology%253A%2520the%2520next%2520paradigm%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D682%26epage%3D690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Lehár, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molnar, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ledell, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heilbut, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Short, G. F.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giusti, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolan, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magid, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borisy, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockwell, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, C. T.</span><span> </span><span class="NLM_article-title">Chemical combination effects predict connectivity in biological systems</span> <span class="citation_source-journal">Mol. Syst. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=80-93&author=J.+Leh%C3%A1rauthor=G.+R.+Zimmermannauthor=A.+S.+Kruegerauthor=R.+A.+Molnarauthor=J.+T.+Ledellauthor=A.+M.+Heilbutauthor=G.+F.+Shortauthor=L.+C.+Giustiauthor=G.+P.+Nolanauthor=O.+A.+Magidauthor=M.+S.+Leeauthor=A.+A.+Borisyauthor=B.+R.+Stockwellauthor=C.+T.+Keith&title=Chemical+combination+effects+predict+connectivity+in+biological+systems"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeh%25C3%25A1r%26aufirst%3DJ.%26aulast%3DZimmermann%26aufirst%3DG.%2BR.%26aulast%3DKrueger%26aufirst%3DA.%2BS.%26aulast%3DMolnar%26aufirst%3DR.%2BA.%26aulast%3DLedell%26aufirst%3DJ.%2BT.%26aulast%3DHeilbut%26aufirst%3DA.%2BM.%26aulast%3DShort%26aufirst%3DG.%2BF.%26aulast%3DGiusti%26aufirst%3DL.%2BC.%26aulast%3DNolan%26aufirst%3DG.%2BP.%26aulast%3DMagid%26aufirst%3DO.%2BA.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DBorisy%26aufirst%3DA.%2BA.%26aulast%3DStockwell%26aufirst%3DB.%2BR.%26aulast%3DKeith%26aufirst%3DC.%2BT.%26atitle%3DChemical%2520combination%2520effects%2520predict%2520connectivity%2520in%2520biological%2520systems%26jtitle%3DMol.%2520Syst.%2520Biol.%26date%3D2007%26volume%3D3%26spage%3D80%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group">Okuzumi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiedler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aizenstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Inhibitor hijacking of AKT activation</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">484</span><span class="NLM_x">–</span> <span class="NLM_lpage">493</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnchembio.183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=19465931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtlarsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=484-493&author=T.+Okuzumiauthor=D.+Fiedlerauthor=C.+Zhangauthor=D.+C.+Grayauthor=B.+Aizensteinauthor=R.+Hoffmanauthor=K.+M.+Shokat&title=Inhibitor+hijacking+of+AKT+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitor hijacking of Akt activation</span></div><div class="casAuthors">Okuzumi, Tatsuya; Fiedler, Dorothea; Zhang, Chao; Gray, Daniel C.; Aizenstein, Brian; Hoffman, Randy; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">484-493</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The kinase Akt plays a central role as a regulator of multiple growth factor input signals, thus making it an attractive anticancer drug target.  A-443654 is an ATP-competitive Akt inhibitor.  Unexpectedly, treatment of cells with A-443654 causes paradoxical hyperphosphorylation of Akt at its two regulatory sites (Thr308 and Ser473).  We explored whether inhibitor-induced hyperphosphorylation of Akt by A-443654 is a consequence of disrupted feedback regulation at a pathway level or whether it is a direct consequence of inhibitor binding to the ATP binding site of Akt.  Catalytically inactive mutants of Akt revealed that binding of an inhibitor to the ATP site of Akt is sufficient to directly cause hyperphosphorylation of the kinase in the absence of any pathway feedback effects.  We conclude that ATP-competitive Akt inhibitors impart regulatory phosphorylation of their target kinase Akt.  These results provide new insights into both natural regulation of Akt activation and Akt inhibitors entering the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWNjUB9YVue7Vg90H21EOLACvtfcHk0liH294O0AGubw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtlarsrY%253D&md5=4edb5a0457fd9378850102a6414bfdb5</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.183%26sid%3Dliteratum%253Aachs%26aulast%3DOkuzumi%26aufirst%3DT.%26aulast%3DFiedler%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DGray%26aufirst%3DD.%2BC.%26aulast%3DAizenstein%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DInhibitor%2520hijacking%2520of%2520AKT%2520activation%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D484%26epage%3D493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Fan, Q. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mostov, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, W. A.</span><span> </span><span class="NLM_article-title">A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2006&pages=341-349&author=Q.+W.+Fanauthor=Z.+A.+Knightauthor=D.+D.+Goldenbergauthor=W.+Yuauthor=K.+E.+Mostovauthor=D.+Stokoeauthor=K.+M.+Shokatauthor=W.+A.+Weiss&title=A+dual+PI3+kinase%2FmTOR+inhibitor+reveals+emergent+efficacy+in+glioma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DQ.%2BW.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DGoldenberg%26aufirst%3DD.%2BD.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DMostov%26aufirst%3DK.%2BE.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26atitle%3DA%2520dual%2520PI3%2520kinase%252FmTOR%2520inhibitor%2520reveals%2520emergent%2520efficacy%2520in%2520glioma%26jtitle%3DCancer%2520Cell%26date%3D2006%26volume%3D9%26spage%3D341%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group">Sergina, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rausch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moasser, M. M.</span><span> </span><span class="NLM_article-title">Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">445</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">441</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=445&publication_year=2007&pages=437-441&author=N.+V.+Serginaauthor=M.+Rauschauthor=D.+Wangauthor=J.+Blairauthor=B.+Hannauthor=K.+M.+Shokatauthor=M.+M.+Moasser&title=Escape+from+HER-family+tyrosine+kinase+inhibitor+therapy+by+the+kinase-inactive+HER3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSergina%26aufirst%3DN.%2BV.%26aulast%3DRausch%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DBlair%26aufirst%3DJ.%26aulast%3DHann%26aufirst%3DB.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DMoasser%26aufirst%3DM.%2BM.%26atitle%3DEscape%2520from%2520HER-family%2520tyrosine%2520kinase%2520inhibitor%2520therapy%2520by%2520the%2520kinase-inactive%2520HER3%26jtitle%3DNature%26date%3D2007%26volume%3D445%26spage%3D437%26epage%3D441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">Fan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolaides, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, W. A.</span><span> </span><span class="NLM_article-title">A dual PI3K α/mTOR inhibitor cooperates with blockade of EGFR in PTEN-mutant glioma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">7960</span><span class="NLM_x">–</span> <span class="NLM_lpage">7965</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=7960-7965&author=Q.+Fanauthor=C.+K.+Chengauthor=T.+P.+Nicolaidesauthor=Z.+A.+Knightauthor=K.+M.+Shokatauthor=W.+A.+Weiss&title=A+dual+PI3K+%CE%B1%2FmTOR+inhibitor+cooperates+with+blockade+of+EGFR+in+PTEN-mutant+glioma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DQ.%26aulast%3DCheng%26aufirst%3DC.%2BK.%26aulast%3DNicolaides%26aufirst%3DT.%2BP.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26atitle%3DA%2520dual%2520PI3K%2520%25CE%25B1%252FmTOR%2520inhibitor%2520cooperates%2520with%2520blockade%2520of%2520EGFR%2520in%2520PTEN-mutant%2520glioma%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D7960%26epage%3D7965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1043</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1126%2Fscience.1141478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17463250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=1039-1043&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=T.+Mitsudomiauthor=Y.+Songauthor=C.+Hylandauthor=J.+O.+Parkauthor=N.+Lindemanauthor=C.+M.+Galeauthor=X.+Zhaoauthor=J.+Christensenauthor=T.+Kosakaauthor=A.+J.+Holmesauthor=A.+M.+Rogersauthor=F.+Cappuzzoauthor=T.+Mokauthor=C.+Leeauthor=B.+E.+Johnsonauthor=L.+C.+Cantleyauthor=P.+A.+J%C3%A4nne&title=MET+amplification+leads+to+gefitinib+resistance+in+lung+cancer+by+activating+ERBB3+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling</span></div><div class="casAuthors">Engelman, Jeffrey A.; Zejnullahu, Kreshnik; Mitsudomi, Tetsuya; Song, Youngchul; Hyland, Courtney; Park, Joon Oh; Lindeman, Neal; Gale, Christopher-Michael; Zhao, Xiaojun; Christensen, James; Kosaka, Takayuki; Holmes, Alison J.; Rogers, Andrew M.; Cappuzzo, Federico; Mok, Tony; Lee, Charles; Johnson, Bruce E.; Cantley, Lewis C.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">5827</span>),
    <span class="NLM_cas:pages">1039-1043</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance.  Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib.  MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib.  We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors.  Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr430gbvBeIoLVg90H21EOLACvtfcHk0lhnfQvhl9eN3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D&md5=3da9383b4acb965f57529b095f8f4686</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1126%2Fscience.1141478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1141478%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DHyland%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGale%26aufirst%3DC.%2BM.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DRogers%26aufirst%3DA.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DMET%2520amplification%2520leads%2520to%2520gefitinib%2520resistance%2520in%2520lung%2520cancer%2520by%2520activating%2520ERBB3%2520signaling%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D1039%26epage%3D1043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Gaestel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotlyarov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kracht, M.</span><span> </span><span class="NLM_article-title">Targeting innate immunity protein kinase signalling in inflammation</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">480</span><span class="NLM_x">–</span> <span class="NLM_lpage">499</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=480-499&author=M.+Gaestelauthor=A.+Kotlyarovauthor=M.+Kracht&title=Targeting+innate+immunity+protein+kinase+signalling+in+inflammation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGaestel%26aufirst%3DM.%26aulast%3DKotlyarov%26aufirst%3DA.%26aulast%3DKracht%26aufirst%3DM.%26atitle%3DTargeting%2520innate%2520immunity%2520protein%2520kinase%2520signalling%2520in%2520inflammation%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D480%26epage%3D499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">Ronkina, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotlyarov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittrich-Breiholz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kracht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milarski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Askew, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marusic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaestel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telliez, J. B.</span><span> </span><span class="NLM_article-title">The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">170</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1128%2FMCB.01456-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17030606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1Oh" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=170-181&author=N.+Ronkinaauthor=A.+Kotlyarovauthor=O.+Dittrich-Breiholzauthor=M.+Krachtauthor=E.+Hittiauthor=K.+Milarskiauthor=R.+Askewauthor=S.+Marusicauthor=L.+L.+Linauthor=M.+Gaestelauthor=J.+B.+Telliez&title=The+mitogen-activated+protein+kinase+%28MAPK%29-activated+protein+kinases+MK2+and+MK3+cooperate+in+stimulation+of+tumor+necrosis+factor+biosynthesis+and+stabilization+of+p38+MAPK"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK</span></div><div class="casAuthors">Ronkina, N.; Kotlyarov, A.; Dittrich-Breiholz, O.; Kracht, M.; Hitti, E.; Milarski, K.; Askew, R.; Marusic, S.; Lin, L.-L.; Gaestel, M.; Telliez, J.-B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">170-181</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">MK2 and MK3 represent protein kinases downstream of p38 mitogen-activated protein kinase (MAPK).  Deletion of the MK2 gene in mice resulted in an impaired inflammatory response although MK3, which displays extensive structural similarities and identical functional properties in vitro, is still present.  Here, the authors analyze tumor necrosis factor (TNF) prodn. and expression of p38 MAPK and tristetraprolin (TTP) in MK3-deficient mice and demonstrate that there are no significant differences with wild-type animals.  The authors show that in vivo MK2 and MK3 are expressed and activated in parallel.  However, the level of activity of MK2 is always significantly higher than that of MK3.  Accordingly, the authors hypothesized that MK3 could have significant effects only in an MK2-free background and generated MK2/MK3 double-knockout mice.  Unexpectedly, these mice are viable and show no obvious defects due to loss of compensation between MK2 and MK3.  However, there is a further redn. of TNF prodn. and expression of p38 and TTP in double-knockout mice compared to MK2-deficient mice.  This finding, together with the observation that ectopically expressed MK3 can rescue MK2 deficiency similarly to MK2, indicates that both kinases share the same physiol. function in vivo but are expressed to different levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdXOig9ZksrbVg90H21EOLACvtfcHk0lhnfQvhl9eN3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1Oh&md5=4dca45754c91bce57cf3c2063bf23a88</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1128%2FMCB.01456-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01456-06%26sid%3Dliteratum%253Aachs%26aulast%3DRonkina%26aufirst%3DN.%26aulast%3DKotlyarov%26aufirst%3DA.%26aulast%3DDittrich-Breiholz%26aufirst%3DO.%26aulast%3DKracht%26aufirst%3DM.%26aulast%3DHitti%26aufirst%3DE.%26aulast%3DMilarski%26aufirst%3DK.%26aulast%3DAskew%26aufirst%3DR.%26aulast%3DMarusic%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DL.%2BL.%26aulast%3DGaestel%26aufirst%3DM.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26atitle%3DThe%2520mitogen-activated%2520protein%2520kinase%2520%2528MAPK%2529-activated%2520protein%2520kinases%2520MK2%2520and%2520MK3%2520cooperate%2520in%2520stimulation%2520of%2520tumor%2520necrosis%2520factor%2520biosynthesis%2520and%2520stabilization%2520of%2520p38%2520MAPK%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2007%26volume%3D27%26spage%3D170%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">Herrick, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Million, R. P.</span><span> </span><span class="NLM_article-title">From the analyst's couch: tapping the potential of fixed-dose combinations</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">513</span><span class="NLM_x">–</span> <span class="NLM_lpage">514</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=513-514&author=T.+M.+Herrickauthor=R.+P.+Million&title=From+the+analyst%27s+couch%3A+tapping+the+potential+of+fixed-dose+combinations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHerrick%26aufirst%3DT.%2BM.%26aulast%3DMillion%26aufirst%3DR.%2BP.%26atitle%3DFrom%2520the%2520analyst%2527s%2520couch%253A%2520tapping%2520the%2520potential%2520of%2520fixed-dose%2520combinations%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D513%26epage%3D514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span> </span><span class="NLM_article-title">From Pioneering Collaboration to Investigate Novel Combination Anticancer Regimen</span>. Press Release; AstraZeneca and Merck & Co., Inc., June 1,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span><a href="http://www.merck.com" class="extLink">www.merck.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=From+Pioneering+Collaboration+to+Investigate+Novel+Combination+Anticancer+Regimen.+Press+Release%3B+AstraZeneca+and+Merck+%26+Co.%2C+Inc.%2C+June+1%2C+2009%3B+www.merck.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DFrom%2520Pioneering%2520Collaboration%2520to%2520Investigate%2520Novel%2520Combination%2520Anticancer%2520Regimen%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">Cannon, C. P.</span><span> </span><span class="NLM_article-title">Can the polypill save the world from heart disease?</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">1341</span><span class="NLM_x">–</span> <span class="NLM_lpage">1351</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2009&pages=1341-1351&author=C.+P.+Cannon&title=Can+the+polypill+save+the+world+from+heart+disease%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCannon%26aufirst%3DC.%2BP.%26atitle%3DCan%2520the%2520polypill%2520save%2520the%2520world%2520from%2520heart%2520disease%253F%26jtitle%3DLancet%26date%3D2009%26volume%3D373%26spage%3D1341%26epage%3D1351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">Frantz, S.</span><span> </span><span class="NLM_article-title">The trouble with making combination drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">882</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=881-882&author=S.+Frantz&title=The+trouble+with+making+combination+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFrantz%26aufirst%3DS.%26atitle%3DThe%2520trouble%2520with%2520making%2520combination%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D881%26epage%3D882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Rokosz, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beasley, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appell, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, M. L.</span><span> </span><span class="NLM_article-title">Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges</span> <span class="citation_source-journal">Expert Opin. Ther Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">883</span><span class="NLM_x">–</span> <span class="NLM_lpage">903</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1517%2F14728222.12.7.883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=18554156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntFylsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=883-903&author=L.+L.+Rokoszauthor=J.+R.+Beasleyauthor=C.+D.+Carrollauthor=T.+Linauthor=J.+Zhaoauthor=K.+C.+Appellauthor=M.+L.+Webb&title=Kinase+inhibitors+as+drugs+for+chronic+inflammatory+and+immunological+diseases%3A+progress+and+challenges"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges</span></div><div class="casAuthors">Rokosz, Laura L.; Beasley, James R.; Carroll, Carolyn DiIanni; Lin, Tsung; Zhao, Jiuqiao; Appell, Kenneth C.; Webb, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">883-903</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  At the time of writing, there are seven marketed kinase inhibitor drugs.  The first kinase inhibitor, imatinib mesilate (Gleevec, Novartis), came to market in 2001, an inhibitor of the breakpoint cluster region (BCR)/Abelson murine leukemia oncogene homolog (ABL) fusion, platelet-derived growth factor (PDGF) receptor, and c-kit kinases.  The most recent kinase inhibitor to come to market, disatinib (Sprycel, Bristol-Myers Squibb), acts on c-SRC, ABL and Bruton's tyrosine kinase.  To date, kinase inhibitor drugs are approved for oncol. and demonstrate that it is possible to develop compds. with relative selectivity for the target kinase against the broader kinome.  However, the use of kinase inhibitors in chronic inflammatory and immunol. diseases may require greater selectivity for the target kinase.  This review addresses the opportunities and challenges of kinase inhibition as a therapeutic approach in chronic immune and inflammatory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq458NGQKTbcbVg90H21EOLACvtfcHk0liUJvK0x61OVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntFylsLY%253D&md5=6db3fdcc34b3ec97394c9dc6cdca8b99</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1517%2F14728222.12.7.883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.12.7.883%26sid%3Dliteratum%253Aachs%26aulast%3DRokosz%26aufirst%3DL.%2BL.%26aulast%3DBeasley%26aufirst%3DJ.%2BR.%26aulast%3DCarroll%26aufirst%3DC.%2BD.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DAppell%26aufirst%3DK.%2BC.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26atitle%3DKinase%2520inhibitors%2520as%2520drugs%2520for%2520chronic%2520inflammatory%2520and%2520immunological%2520diseases%253A%2520progress%2520and%2520challenges%26jtitle%3DExpert%2520Opin.%2520Ther%2520Targets%26date%3D2008%26volume%3D12%26spage%3D883%26epage%3D903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">ter Haar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazhanisamy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taslimi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bemis, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harbeson, S. L.</span><span> </span><span class="NLM_article-title">Kinase chemogenomics: targeting the human kinome for target validation and drug discovery</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=235-253&author=E.+ter+Haarauthor=W.+P.+Waltersauthor=S.+Pazhanisamyauthor=P.+Taslimiauthor=A.+C.+Pierceauthor=G.+W.+Bemisauthor=F.+G.+Salituroauthor=S.+L.+Harbeson&title=Kinase+chemogenomics%3A+targeting+the+human+kinome+for+target+validation+and+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dter%2BHaar%26aufirst%3DE.%26aulast%3DWalters%26aufirst%3DW.%2BP.%26aulast%3DPazhanisamy%26aufirst%3DS.%26aulast%3DTaslimi%26aufirst%3DP.%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DHarbeson%26aufirst%3DS.%2BL.%26atitle%3DKinase%2520chemogenomics%253A%2520targeting%2520the%2520human%2520kinome%2520for%2520target%2520validation%2520and%2520drug%2520discovery%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D235%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group">Camins, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdaguer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canudas, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallas, M.</span><span> </span><span class="NLM_article-title">The role of CDK5/P25 formation/inhibition in neurodegeneration</span> <span class="citation_source-journal">Drug News Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">453</span><span class="NLM_x">–</span> <span class="NLM_lpage">460</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1358%2Fdnp.2006.19.8.1043961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17160145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXls1Cktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=453-460&author=A.+Caminsauthor=E.+Verdaguerauthor=J.+Folchauthor=A.+M.+Canudasauthor=M.+Pallas&title=The+role+of+CDK5%2FP25+formation%2Finhibition+in+neurodegeneration"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">The role of CDK5/P25 formation/inhibition in neurodegeneration</span></div><div class="casAuthors">Camins, Antoni; Verdaguer, Ester; Folch, Jaume; Canudas, Anna Maria; Pallas, Merce</div><div class="citationInfo"><span class="NLM_cas:title">Drug News & Perspectives</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">453-460</span>CODEN:
                <span class="NLM_cas:coden">DNPEED</span>;
        ISSN:<span class="NLM_cas:issn">0214-0934</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Cdk5 is an atypical cyclin-dependent kinase localized in the brain, and its activity is dependent upon binding to p35/p39.  In addn., while cdk5 has important physiol. functions related to brain development, the breakdown of cdk5/p35 into cdk5/p25 increases its kinase activity and neurotoxicity.  Interestingly, in recent years increased cdk5/p25 expression has been demonstrated in the brains of patients with Alzheimer's and Parkinson's diseases.  Exptl. studies performed in neuronal cell cultures indicate that cdk5/p25 plays a prominent role in apoptosis.  Moreover, an apoptotic pathway, via an intracellular calcium increase following calpain activation and cdk5/p25 formation, has been postulated.  Cdk5/p25 subsequently phosphorylates the nuclear transcription factor myocyte enhancer factor (MEF2), thereby inhibiting its prosurvival activity.  However, cdk5/p25 could phosphorylate other substrates such as tau and p53, as well as the retinoblastoma protein pRb.  All these data lend credence to the hypothesis that cdk5/p25 acts as a master regulator of neuronal cell death.  In addn., cdk5/p25 might also interact with other pathways such as glycogen synthetase kinase 3β (GSK3β) and c-JUN kinase.  Drugs like roscovitine, flavopiridol, calpain inhibitors, kenpaullone and induribins, which inhibit cdk5/p25 formation, constitute potential drugs for the treatment of neurol. disorders.  Furthermore, the dual inhibitory effect of some of these drugs on cdk5 and GSK3β could be beneficial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwOxQ0IEe0BrVg90H21EOLACvtfcHk0liUJvK0x61OVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXls1Cktw%253D%253D&md5=7cc22392cdc933c8aac503cbb8a0cede</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1358%2Fdnp.2006.19.8.1043961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdnp.2006.19.8.1043961%26sid%3Dliteratum%253Aachs%26aulast%3DCamins%26aufirst%3DA.%26aulast%3DVerdaguer%26aufirst%3DE.%26aulast%3DFolch%26aufirst%3DJ.%26aulast%3DCanudas%26aufirst%3DA.%2BM.%26aulast%3DPallas%26aufirst%3DM.%26atitle%3DThe%2520role%2520of%2520CDK5%252FP25%2520formation%252Finhibition%2520in%2520neurodegeneration%26jtitle%3DDrug%2520News%2520Perspect.%26date%3D2006%26volume%3D19%26spage%3D453%26epage%3D460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Aulia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, B. L.</span><span> </span><span class="NLM_article-title">Cdh1-APC/C, cyclin B-Cdc2, and Alzheimer’s disease pathology</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">339</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2006&pages=1-6&author=S.+Auliaauthor=B.+L.+Tang&title=Cdh1-APC%2FC%2C+cyclin+B-Cdc2%2C+and+Alzheimer%E2%80%99s+disease+pathology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAulia%26aufirst%3DS.%26aulast%3DTang%26aufirst%3DB.%2BL.%26atitle%3DCdh1-APC%252FC%252C%2520cyclin%2520B-Cdc2%252C%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%2520pathology%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2006%26volume%3D339%26spage%3D1%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Takashima, A.</span><span> </span><span class="NLM_article-title">GSK-3 is essential in the pathogenesis of Alzheimer’s disease</span> <span class="citation_source-journal">J. Alzheimer's Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=16914869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFKktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2006&pages=309-317&author=A.+Takashima&title=GSK-3+is+essential+in+the+pathogenesis+of+Alzheimer%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3 is essential in the pathogenesis of Alzheimer's disease</span></div><div class="casAuthors">Takashima, Akihiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">Suppl. 3</span>),
    <span class="NLM_cas:pages">309-317</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">A review.  Glycogen synthase kinase-3 (GSK-3) is a pivotal mol. in the development of Alzheimer's disease (AD).  GSK-3β is involved in the formation of paired helical filament (PHF)-tau, which is an integral component of the neurofibrillary tangle (NFT) deposits that disrupt neuronal function, and a marker of neurodegeneration in AD.  GSK-3β has exactly the same oligonucleotide sequence as tau-protein kinase I (TPKI), which was first purified from the microtubule fraction of bovine brain.  Initially, we discovered that GSK-3β was involved in amyloid-β (Aβ)-induced neuronal death in rat hippocampal cultures.  In the present review, we discuss our initial in vitro results and addnl. investigations showing that Aβ activates GSK-3β through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Aβ-activated GSK-3β induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3β can induce memory deficits in vivo; and that inhibition of GSK-3α (an isoform of GSK-3β) reduces Aβ prodn.  These combined results strongly suggest that GSK-3 activation is a crit. step in brain aging and the cascade of detrimental events in AD, preceding both the NFT and neuronal death pathways.  Therefore, therapeutics targeted to inhibiting GSK-3 may be beneficial in the treatment of this devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP4pguAPgiQLVg90H21EOLACvtfcHk0liUJvK0x61OVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFKktLo%253D&md5=d7157eb2d6a985a3489bb143113d7500</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakashima%26aufirst%3DA.%26atitle%3DGSK-3%2520is%2520essential%2520in%2520the%2520pathogenesis%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2006%26volume%3D9%26spage%3D309%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group">Flajolet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heiman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nairn, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greengard, P.</span><span> </span><span class="NLM_article-title">Regulation of Alzheimer’s disease amyloid-beta formation by casein kinase I</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">4159</span><span class="NLM_x">–</span> <span class="NLM_lpage">4164</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=4159-4164&author=M.+Flajoletauthor=G.+Heauthor=M.+Heimanauthor=A.+Linauthor=A.+C.+Nairnauthor=P.+Greengard&title=Regulation+of+Alzheimer%E2%80%99s+disease+amyloid-beta+formation+by+casein+kinase+I"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFlajolet%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DHeiman%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DA.%26aulast%3DNairn%26aufirst%3DA.%2BC.%26aulast%3DGreengard%26aufirst%3DP.%26atitle%3DRegulation%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520amyloid-beta%2520formation%2520by%2520casein%2520kinase%2520I%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D4159%26epage%3D4164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Oumata, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bettayeb, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferandin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demange, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Giral, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goddard, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myrianthopoulos, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikros, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flajolet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greengard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galons, H.</span><span> </span><span class="NLM_article-title">Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5229</span><span class="NLM_x">–</span> <span class="NLM_lpage">5242</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800109e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5229-5242&author=N.+Oumataauthor=K.+Bettayebauthor=Y.+Ferandinauthor=L.+Demangeauthor=A.+Lopez-Giralauthor=M.+L.+Goddardauthor=V.+Myrianthopoulosauthor=E.+Mikrosauthor=M.+Flajoletauthor=P.+Greengardauthor=L.+Meijerauthor=H.+Galons&title=Roscovitine-derived%2C+dual-specificity+inhibitors+of+cyclin-dependent+kinases+and+casein+kinases+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1021%2Fjm800109e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800109e%26sid%3Dliteratum%253Aachs%26aulast%3DOumata%26aufirst%3DN.%26aulast%3DBettayeb%26aufirst%3DK.%26aulast%3DFerandin%26aufirst%3DY.%26aulast%3DDemange%26aufirst%3DL.%26aulast%3DLopez-Giral%26aufirst%3DA.%26aulast%3DGoddard%26aufirst%3DM.%2BL.%26aulast%3DMyrianthopoulos%26aufirst%3DV.%26aulast%3DMikros%26aufirst%3DE.%26aulast%3DFlajolet%26aufirst%3DM.%26aulast%3DGreengard%26aufirst%3DP.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DGalons%26aufirst%3DH.%26atitle%3DRoscovitine-derived%252C%2520dual-specificity%2520inhibitors%2520of%2520cyclin-dependent%2520kinases%2520and%2520casein%2520kinases%25201%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5229%26epage%3D5242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group">Chioua, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samadi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lozach, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marco-Contelles, J.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 3,6-diamino-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine derivatives as protein kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4566</span><span class="NLM_x">–</span> <span class="NLM_lpage">4569</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4566-4569&author=M.+Chiouaauthor=A.+Samadiauthor=E.+Sorianoauthor=O.+Lozachauthor=L.+Meijerauthor=J.+Marco-Contelles&title=Synthesis+and+biological+evaluation+of+3%2C6-diamino-1H-pyrazolo%5B3%2C4-b%5Dpyridine+derivatives+as+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChioua%26aufirst%3DM.%26aulast%3DSamadi%26aufirst%3DA.%26aulast%3DSoriano%26aufirst%3DE.%26aulast%3DLozach%26aufirst%3DO.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25203%252C6-diamino-1H-pyrazolo%255B3%252C4-b%255Dpyridine%2520derivatives%2520as%2520protein%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4566%26epage%3D4569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 203 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xingye Chen, Wuchen Xie, Yan Yang, Yi Hua, GuoMeng Xing, Li Liang, Chenglong Deng, Yuchen Wang, Yuanrong Fan, Haichun Liu, Tao Lu, Yadong Chen, <span class="NLM_string-name hlFld-ContribAuthor">Yanmin Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Dual FGFR4 and EGFR Inhibitors by Machine Learning and Biological Evaluation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (10)
                                     , 4640-4652. <a href="https://doi.org/10.1021/acs.jcim.0c00652" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c00652</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c00652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c00652%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DDiscovery%252Bof%252BDual%252BFGFR4%252Band%252BEGFR%252BInhibitors%252Bby%252BMachine%252BLearning%252Band%252BBiological%252BEvaluation%26aulast%3DChen%26aufirst%3DXingye%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09062020%26date%3D24092020%26date%3D14092020%26volume%3D60%26issue%3D10%26spage%3D4640%26epage%3D4652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Maria Laura Bolognesi</span>. </span><span class="cited-content_cbyCitation_article-title">Harnessing Polypharmacology with Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (3)
                                     , 273-275. <a href="https://doi.org/10.1021/acsmedchemlett.9b00039" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00039%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DHarnessing%252BPolypharmacology%252Bwith%252BMedicinal%252BChemistry%26aulast%3DBolognesi%26aufirst%3DMaria%2BLaura%26date%3D2019%26date%3D2019%26date%3D15022019%26volume%3D10%26issue%3D3%26spage%3D273%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> David C.    Blakemore    </span><span class="hlFld-ContribAuthor "> Thomas    Brandt </span><span class="hlFld-ContribAuthor "> Craig    Knight    </span><span class="hlFld-ContribAuthor "> Sarah E.    Skerratt </span>. </span><span class="cited-content_cbyCitation_article-title">The Discovery and Chemical Development of PF-06273340: A Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor for Pain. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 155-183. <a href="https://doi.org/10.1021/bk-2019-1332.ch007" title="DOI URL">https://doi.org/10.1021/bk-2019-1332.ch007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2019-1332.ch007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2019-1332.ch007%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BDiscovery%252Band%252BChemical%252BDevelopment%252Bof%252BPF-06273340%25253A%252BA%252BPotent%25252C%252BSelective%25252C%252Band%252BPeripherally%252BRestricted%252BPan-Trk%252BInhibitor%252Bfor%252BPain%26aulast%3DBlakemore%26aufirst%3DDavid%2BC.%26date%3D2019%26date%3D2019%26spage%3D155%26epage%3D183%26atitle%3DComplete%252BAccounts%252Bof%252BIntegrated%252BDrug%252BDiscovery%252Band%252BDevelopment%25253A%252BRecent%252BExamples%252Bfrom%252Bthe%252BPharmaceutical%252BIndustry%252BVolume%252B2%26aulast%3DPesti%26aufirst%3DJaan%2BA.%26date%3D2019%26date%3D2019%26volume%3D1332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, <span class="hlFld-ContribAuthor ">Danfeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, and <span class="hlFld-ContribAuthor ">Yu  Jiao</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (1)
                                     , 140-157. <a href="https://doi.org/10.1021/acs.jmedchem.7b01091" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01091</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01091%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BPotent%252BVEGFR-2%252BInhibitors%252BExerting%252BSignificant%252BAntiproliferative%252BActivity%252Bagainst%252BCancer%252BCell%252BLines%26aulast%3DZhang%26aufirst%3DYanmin%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D25072017%26date%3D19122017%26date%3D11012018%26date%3D30112017%26volume%3D61%26issue%3D1%26spage%3D140%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shunzhou  Wan</span>, <span class="hlFld-ContribAuthor ">Agastya P.  Bhati</span>, <span class="hlFld-ContribAuthor ">Sarah  Skerratt</span>, <span class="hlFld-ContribAuthor ">Kiyoyuki  Omoto</span>, <span class="hlFld-ContribAuthor ">Veerabahu  Shanmugasundaram</span>, <span class="hlFld-ContribAuthor ">Sharan K.  Bagal</span>, and <span class="hlFld-ContribAuthor ">Peter V.  Coveney</span>  . </span><span class="cited-content_cbyCitation_article-title">Evaluation and Characterization of Trk Kinase Inhibitors for the Treatment of Pain: Reliable Binding Affinity Predictions from Theory and Computation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2017,</strong> <em>57 </em>
                                    (4)
                                     , 897-909. <a href="https://doi.org/10.1021/acs.jcim.6b00780" title="DOI URL">https://doi.org/10.1021/acs.jcim.6b00780</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.6b00780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.6b00780%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DEvaluation%252Band%252BCharacterization%252Bof%252BTrk%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BPain%25253A%252BReliable%252BBinding%252BAffinity%252BPredictions%252Bfrom%252BTheory%252Band%252BComputation%26aulast%3DWan%26aufirst%3DShunzhou%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D21122016%26date%3D04042017%26date%3D24042017%26date%3D20032017%26volume%3D57%26issue%3D4%26spage%3D897%26epage%3D909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weilin  Zhang</span>, <span class="hlFld-ContribAuthor ">Jianfeng  Pei</span>, and <span class="hlFld-ContribAuthor ">Luhua  Lai</span>  . </span><span class="cited-content_cbyCitation_article-title">Computational Multitarget Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2017,</strong> <em>57 </em>
                                    (3)
                                     , 403-412. <a href="https://doi.org/10.1021/acs.jcim.6b00491" title="DOI URL">https://doi.org/10.1021/acs.jcim.6b00491</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.6b00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.6b00491%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DComputational%252BMultitarget%252BDrug%252BDesign%26aulast%3DZhang%26aufirst%3DWeilin%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D19082016%26date%3D23022017%26date%3D27032017%26date%3D06022017%26volume%3D57%26issue%3D3%26spage%3D403%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sarah E.  Skerratt</span>, <span class="hlFld-ContribAuthor ">Mark  Andrews</span>, <span class="hlFld-ContribAuthor ">Sharan K.  Bagal</span>, <span class="hlFld-ContribAuthor ">James  Bilsland</span>, <span class="hlFld-ContribAuthor ">David  Brown</span>, <span class="hlFld-ContribAuthor ">Peter J.  Bungay</span>, <span class="hlFld-ContribAuthor ">Susan  Cole</span>, <span class="hlFld-ContribAuthor ">Karl R  Gibson</span>, <span class="hlFld-ContribAuthor ">Russell  Jones</span>, <span class="hlFld-ContribAuthor ">Inaki  Morao</span>, <span class="hlFld-ContribAuthor ">Angus  Nedderman</span>, <span class="hlFld-ContribAuthor ">Kiyoyuki  Omoto</span>, <span class="hlFld-ContribAuthor ">Colin  Robinson</span>, <span class="hlFld-ContribAuthor ">Thomas  Ryckmans</span>, <span class="hlFld-ContribAuthor ">Kimberly  Skinner</span>, <span class="hlFld-ContribAuthor ">Paul  Stupple</span>, and <span class="hlFld-ContribAuthor ">Gareth  Waldron</span>  . </span><span class="cited-content_cbyCitation_article-title">The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (22)
                                     , 10084-10099. <a href="https://doi.org/10.1021/acs.jmedchem.6b00850" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00850</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00850%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BDiscovery%252Bof%252Ba%252BPotent%25252C%252BSelective%25252C%252Band%252BPeripherally%252BRestricted%252BPan-Trk%252BInhibitor%252B%252528PF-06273340%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BPain%26aulast%3DSkerratt%26aufirst%3DSarah%2BE.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D07062016%26date%3D04112016%26date%3D23112016%26date%3D21102016%26volume%3D59%26issue%3D22%26spage%3D10084%26epage%3D10099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luca  Carlino</span> and <span class="hlFld-ContribAuthor ">Giulio  Rastelli</span>  . </span><span class="cited-content_cbyCitation_article-title">Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (20)
                                     , 9305-9320. <a href="https://doi.org/10.1021/acs.jmedchem.6b00438" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00438</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00438%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252BKinase-Bromodomain%252BInhibitors%252Bin%252BAnticancer%252BDrug%252BDiscovery%25253A%252BA%252BStructural%252Band%252BPharmacological%252BPerspective%26aulast%3DCarlino%26aufirst%3DLuca%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D24032016%26date%3D07092016%26date%3D27102016%26date%3D25082016%26volume%3D59%26issue%3D20%26spage%3D9305%26epage%3D9320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Serge  Christmann-Franck</span>, <span class="hlFld-ContribAuthor ">Gerard J. P.  van Westen</span>, <span class="hlFld-ContribAuthor ">George  Papadatos</span>, <span class="hlFld-ContribAuthor ">Fanny  Beltran Escudie</span>, <span class="hlFld-ContribAuthor ">Alexander  Roberts</span>, <span class="hlFld-ContribAuthor ">John P.  Overington</span>, and <span class="hlFld-ContribAuthor ">Daniel  Domine</span>  . </span><span class="cited-content_cbyCitation_article-title">Unprecedently Large-Scale Kinase Inhibitor Set Enabling the Accurate Prediction of Compound–Kinase Activities: A Way toward Selective Promiscuity by Design?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (9)
                                     , 1654-1675. <a href="https://doi.org/10.1021/acs.jcim.6b00122" title="DOI URL">https://doi.org/10.1021/acs.jcim.6b00122</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.6b00122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.6b00122%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DUnprecedently%252BLarge-Scale%252BKinase%252BInhibitor%252BSet%252BEnabling%252Bthe%252BAccurate%252BPrediction%252Bof%252BCompound%2525E2%252580%252593Kinase%252BActivities%25253A%252BA%252BWay%252Btoward%252BSelective%252BPromiscuity%252Bby%252BDesign%25253F%26aulast%3DChristmann-Franck%26aufirst%3DSerge%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D03032016%26date%3D11082016%26date%3D26092016%26date%3D02082016%26volume%3D56%26issue%3D9%26spage%3D1654%26epage%3D1675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Frank E.  Kwarcinski</span>, <span class="hlFld-ContribAuthor ">Kristoffer R.  Brandvold</span>, <span class="hlFld-ContribAuthor ">Sameer  Phadke</span>, <span class="hlFld-ContribAuthor ">Omar M.  Beleh</span>, <span class="hlFld-ContribAuthor ">Taylor K.  Johnson</span>, <span class="hlFld-ContribAuthor ">Jennifer L.  Meagher</span>, <span class="hlFld-ContribAuthor ">Markus A.  Seeliger</span>, <span class="hlFld-ContribAuthor ">Jeanne A.  Stuckey</span>, and <span class="hlFld-ContribAuthor ">Matthew B.  Soellner</span>  . </span><span class="cited-content_cbyCitation_article-title">Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2016,</strong> <em>11 </em>
                                    (5)
                                     , 1296-1304. <a href="https://doi.org/10.1021/acschembio.5b01018" title="DOI URL">https://doi.org/10.1021/acschembio.5b01018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.5b01018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.5b01018%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DConformation-Selective%252BAnalogues%252Bof%252BDasatinib%252BReveal%252BInsight%252Binto%252BKinase%252BInhibitor%252BBinding%252Band%252BSelectivity%26aulast%3DKwarcinski%26aufirst%3DFrank%2BE.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D10122015%26date%3D19022016%26date%3D01032016%26date%3D20052016%26date%3D19022016%26volume%3D11%26issue%3D5%26spage%3D1296%26epage%3D1304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiyong  Park</span>, <span class="hlFld-ContribAuthor ">Joseph J.  McDonald</span>, <span class="hlFld-ContribAuthor ">Russell C.  Petter</span>, and <span class="hlFld-ContribAuthor ">K. N.  Houk</span>  . </span><span class="cited-content_cbyCitation_article-title">Molecular Dynamics Analysis of Binding of Kinase Inhibitors to WT EGFR and the T790M Mutant. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Theory and Computation</span><span> <strong>2016,</strong> <em>12 </em>
                                    (4)
                                     , 2066-2078. <a href="https://doi.org/10.1021/acs.jctc.5b01221" title="DOI URL">https://doi.org/10.1021/acs.jctc.5b01221</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jctc.5b01221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jctc.5b01221%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Theory%2520and%2520Computation%26atitle%3DMolecular%252BDynamics%252BAnalysis%252Bof%252BBinding%252Bof%252BKinase%252BInhibitors%252Bto%252BWT%252BEGFR%252Band%252Bthe%252BT790M%252BMutant%26aulast%3DPark%26aufirst%3DJiyong%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D24122015%26date%3D04042016%26date%3D12042016%26date%3D24032016%26volume%3D12%26issue%3D4%26spage%3D2066%26epage%3D2078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stuart T.  Onions</span>, <span class="hlFld-ContribAuthor ">Kazuhiro  Ito</span>, <span class="hlFld-ContribAuthor ">Catherine E.  Charron</span>, <span class="hlFld-ContribAuthor ">Richard J.  Brown</span>, <span class="hlFld-ContribAuthor ">Marie  Colucci</span>, <span class="hlFld-ContribAuthor ">Fritz  Frickel</span>, <span class="hlFld-ContribAuthor ">George  Hardy</span>, <span class="hlFld-ContribAuthor ">Kevin  Joly</span>, <span class="hlFld-ContribAuthor ">John  King-Underwood</span>, <span class="hlFld-ContribAuthor ">Yasuo  Kizawa</span>, <span class="hlFld-ContribAuthor ">Ian  Knowles</span>, <span class="hlFld-ContribAuthor ">P. John  Murray</span>, <span class="hlFld-ContribAuthor ">Andrew  Novak</span>, <span class="hlFld-ContribAuthor ">Anjna  Rani</span>, <span class="hlFld-ContribAuthor ">Garth  Rapeport</span>, <span class="hlFld-ContribAuthor ">Alun  Smith</span>, <span class="hlFld-ContribAuthor ">Peter  Strong</span>, <span class="hlFld-ContribAuthor ">David M.  Taddei</span>, and <span class="hlFld-ContribAuthor ">Jonathan G.  Williams</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Narrow Spectrum Kinase Inhibitors: New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (5)
                                     , 1727-1746. <a href="https://doi.org/10.1021/acs.jmedchem.5b01029" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01029%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNarrow%252BSpectrum%252BKinase%252BInhibitors%25253A%252BNew%252BTherapeutic%252BAgents%252Bfor%252Bthe%252BTreatment%252Bof%252BCOPD%252Band%252BSteroid-Resistant%252BAsthma%26aulast%3DOnions%26aufirst%3DStuart%2BT.%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D01072015%26date%3D04022016%26date%3D10032016%26date%3D22012016%26volume%3D59%26issue%3D5%26spage%3D1727%26epage%3D1746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrea  Volkamer</span>, <span class="hlFld-ContribAuthor ">Sameh  Eid</span>, <span class="hlFld-ContribAuthor ">Samo  Turk</span>, <span class="hlFld-ContribAuthor ">Friedrich  Rippmann</span>, and <span class="hlFld-ContribAuthor ">Simone  Fulle</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification and Visualization of Kinase-Specific Subpockets. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (2)
                                     , 335-346. <a href="https://doi.org/10.1021/acs.jcim.5b00627" title="DOI URL">https://doi.org/10.1021/acs.jcim.5b00627</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.5b00627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.5b00627%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DIdentification%252Band%252BVisualization%252Bof%252BKinase-Specific%252BSubpockets%26aulast%3DVolkamer%26aufirst%3DAndrea%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D15102015%26date%3D29012016%26date%3D22022016%26date%3D06012016%26volume%3D56%26issue%3D2%26spage%3D335%26epage%3D346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peng  Zhan</span>, <span class="hlFld-ContribAuthor ">Yukihiro  Itoh</span>, <span class="hlFld-ContribAuthor ">Takayoshi  Suzuki</span>, and <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>  . </span><span class="cited-content_cbyCitation_article-title">Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (19)
                                     , 7611-7633. <a href="https://doi.org/10.1021/acs.jmedchem.5b00229" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00229</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00229%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStrategies%252Bfor%252Bthe%252BDiscovery%252Bof%252BTarget-Specific%252Bor%252BIsoform-Selective%252BModulators%26aulast%3DZhan%26aufirst%3DPeng%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D09022015%26date%3D01072015%26date%3D08102015%26date%3D18062015%26volume%3D58%26issue%3D19%26spage%3D7611%26epage%3D7633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Frank E.  Kwarcinski</span>, <span class="hlFld-ContribAuthor ">Michael E.  Steffey</span>, <span class="hlFld-ContribAuthor ">Christel C.  Fox</span>, and <span class="hlFld-ContribAuthor ">Matthew B.  Soellner</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Bivalent Kinase Inhibitors via Enzyme-Templated Fragment Elaboration. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (8)
                                     , 898-901. <a href="https://doi.org/10.1021/acsmedchemlett.5b00167" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00167</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00167%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BBivalent%252BKinase%252BInhibitors%252Bvia%252BEnzyme-Templated%252BFragment%252BElaboration%26aulast%3DKwarcinski%26aufirst%3DFrank%2BE.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D21042015%26date%3D13072015%26date%3D16072015%26date%3D13082015%26date%3D13072015%26volume%3D6%26issue%3D8%26spage%3D898%26epage%3D901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guillaume  Médard</span>, <span class="hlFld-ContribAuthor ">Fiona  Pachl</span>, <span class="hlFld-ContribAuthor ">Benjamin  Ruprecht</span>, <span class="hlFld-ContribAuthor ">Susan  Klaeger</span>, <span class="hlFld-ContribAuthor ">Stephanie  Heinzlmeir</span>, <span class="hlFld-ContribAuthor ">Dominic  Helm</span>, <span class="hlFld-ContribAuthor ">Huichao  Qiao</span>, <span class="hlFld-ContribAuthor ">Xin  Ku</span>, <span class="hlFld-ContribAuthor ">Mathias  Wilhelm</span>, <span class="hlFld-ContribAuthor ">Thomas  Kuehne</span>, <span class="hlFld-ContribAuthor ">Zhixiang  Wu</span>, <span class="hlFld-ContribAuthor ">Antje  Dittmann</span>, <span class="hlFld-ContribAuthor ">Carsten  Hopf</span>, <span class="hlFld-ContribAuthor ">Karl  Kramer</span>, and <span class="hlFld-ContribAuthor ">Bernhard  Kuster</span>  . </span><span class="cited-content_cbyCitation_article-title">Optimized Chemical Proteomics Assay for Kinase Inhibitor Profiling. </span><span class="cited-content_cbyCitation_journal-name">Journal of Proteome Research</span><span> <strong>2015,</strong> <em>14 </em>
                                    (3)
                                     , 1574-1586. <a href="https://doi.org/10.1021/pr5012608" title="DOI URL">https://doi.org/10.1021/pr5012608</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/pr5012608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fpr5012608%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Proteome%2520Research%26atitle%3DOptimized%252BChemical%252BProteomics%252BAssay%252Bfor%252BKinase%252BInhibitor%252BProfiling%26aulast%3DM%25C3%25A9dard%26aufirst%3DGuillaume%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D05122014%26date%3D20022015%26date%3D06032015%26date%3D08022015%26volume%3D14%26issue%3D3%26spage%3D1574%26epage%3D1586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chudi  Ndubaku</span> and <span class="hlFld-ContribAuthor ">Vickie  Tsui</span>  . </span><span class="cited-content_cbyCitation_article-title">Inhibiting the Deubiquitinating Enzymes (DUBs). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (4)
                                     , 1581-1595. <a href="https://doi.org/10.1021/jm501061a" title="DOI URL">https://doi.org/10.1021/jm501061a</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501061a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501061a%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DInhibiting%252Bthe%252BDeubiquitinating%252BEnzymes%252B%252528DUBs%252529%26aulast%3DNdubaku%26aufirst%3DChudi%26date%3D2015%26date%3D2014%26date%3D2014%26date%3D15072014%26date%3D14112014%26date%3D26022015%26date%3D03112014%26volume%3D58%26issue%3D4%26spage%3D1581%26epage%3D1595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher  Merritt</span>, <span class="hlFld-ContribAuthor ">Lisseth E.  Silva</span>, <span class="hlFld-ContribAuthor ">Angela L.  Tanner</span>, <span class="hlFld-ContribAuthor ">Kenneth  Stuart</span>, and <span class="hlFld-ContribAuthor ">Michael P.  Pollastri</span>  . </span><span class="cited-content_cbyCitation_article-title">Kinases as Druggable Targets in Trypanosomatid Protozoan Parasites. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2014,</strong> <em>114 </em>
                                    (22)
                                     , 11280-11304. <a href="https://doi.org/10.1021/cr500197d" title="DOI URL">https://doi.org/10.1021/cr500197d</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/cr500197d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fcr500197d%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DKinases%252Bas%252BDruggable%252BTargets%252Bin%252BTrypanosomatid%252BProtozoan%252BParasites%26aulast%3DMerritt%26aufirst%3DChristopher%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D07042014%26date%3D07102014%26date%3D26112014%26volume%3D114%26issue%3D22%26spage%3D11280%26epage%3D11304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jonghoon  Kim</span>, <span class="hlFld-ContribAuthor ">Heejun  Kim</span>, and <span class="hlFld-ContribAuthor ">Seung Bum  Park</span>  . </span><span class="cited-content_cbyCitation_article-title">Privileged Structures: Efficient Chemical “Navigators” toward Unexplored Biologically Relevant Chemical Spaces. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2014,</strong> <em>136 </em>
                                    (42)
                                     , 14629-14638. <a href="https://doi.org/10.1021/ja508343a" title="DOI URL">https://doi.org/10.1021/ja508343a</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ja508343a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fja508343a%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DPrivileged%252BStructures%25253A%252BEfficient%252BChemical%252B%2525E2%252580%25259CNavigators%2525E2%252580%25259D%252Btoward%252BUnexplored%252BBiologically%252BRelevant%252BChemical%252BSpaces%26aulast%3DKim%26aufirst%3DJonghoon%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D14082014%26date%3D13102014%26date%3D22102014%26volume%3D136%26issue%3D42%26spage%3D14629%26epage%3D14638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrea  Unzue</span>, <span class="hlFld-ContribAuthor ">Jing  Dong</span>, <span class="hlFld-ContribAuthor ">Karine  Lafleur</span>, <span class="hlFld-ContribAuthor ">Hongtao  Zhao</span>, <span class="hlFld-ContribAuthor ">Emilie  Frugier</span>, <span class="hlFld-ContribAuthor ">Amedeo  Caflisch</span>, and <span class="hlFld-ContribAuthor ">Cristina  Nevado</span>  . </span><span class="cited-content_cbyCitation_article-title">Pyrrolo[3,2-b]quinoxaline Derivatives as Types I1/2 and II Eph Tyrosine Kinase Inhibitors: Structure-Based Design, Synthesis, and in Vivo Validation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (15)
                                     , 6834-6844. <a href="https://doi.org/10.1021/jm5009242" title="DOI URL">https://doi.org/10.1021/jm5009242</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm5009242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm5009242%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrrolo%25255B3%25252C2-b%25255Dquinoxaline%252BDerivatives%252Bas%252BTypes%252BI1%25252F2%252Band%252BII%252BEph%252BTyrosine%252BKinase%252BInhibitors%25253A%252BStructure-Based%252BDesign%25252C%252BSynthesis%25252C%252Band%252Bin%252BVivo%252BValidation%26aulast%3DUnzue%26aufirst%3DAndrea%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D18062014%26date%3D30072014%26date%3D14082014%26volume%3D57%26issue%3D15%26spage%3D6834%26epage%3D6844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maurizio  Botta</span> (<span class="NLM_role">Editor</span>). </span><span class="cited-content_cbyCitation_article-title">New Frontiers in Kinases: Special Issue. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>5 </em>
                                    (4)
                                     , 270-270. <a href="https://doi.org/10.1021/ml500071m" title="DOI URL">https://doi.org/10.1021/ml500071m</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml500071m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml500071m%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNew%252BFrontiers%252Bin%252BKinases%25253A%252BSpecial%252BIssue%26aulast%3DBotta%26aufirst%3DMaurizio%26date%3D2014%26date%3D2014%26date%3D14022014%26date%3D18022014%26date%3D10042014%26volume%3D5%26issue%3D4%26spage%3D270%26epage%3D270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oscar P. J.  van Linden</span>, <span class="hlFld-ContribAuthor ">Albert J.  Kooistra</span>, <span class="hlFld-ContribAuthor ">Rob  Leurs</span>, <span class="hlFld-ContribAuthor ">Iwan J. P.  de Esch</span>, and <span class="hlFld-ContribAuthor ">Chris  de Graaf</span>  . </span><span class="cited-content_cbyCitation_article-title">KLIFS: A Knowledge-Based Structural Database To Navigate Kinase–Ligand Interaction Space. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (2)
                                     , 249-277. <a href="https://doi.org/10.1021/jm400378w" title="DOI URL">https://doi.org/10.1021/jm400378w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400378w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400378w%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKLIFS%25253A%252BA%252BKnowledge-Based%252BStructural%252BDatabase%252BTo%252BNavigate%252BKinase%2525E2%252580%252593Ligand%252BInteraction%252BSpace%26aulast%3Dvan%2BLinden%26aufirst%3DOscar%2BP.%2BJ.%26date%3D2014%26date%3D2013%26date%3D2013%26date%3D14032013%26date%3D20092013%26date%3D23012014%26date%3D13082013%26volume%3D57%26issue%3D2%26spage%3D249%26epage%3D277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vigneshwari  Subramanian</span>, <span class="hlFld-ContribAuthor ">Peteris  Prusis</span>, <span class="hlFld-ContribAuthor ">Lars-Olof  Pietilä</span>, <span class="hlFld-ContribAuthor ">Henri  Xhaard</span>, and <span class="hlFld-ContribAuthor ">Gerd  Wohlfahrt</span>  . </span><span class="cited-content_cbyCitation_article-title">Visually Interpretable Models of Kinase Selectivity Related Features Derived from Field-Based Proteochemometrics. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2013,</strong> <em>53 </em>
                                    (11)
                                     , 3021-3030. <a href="https://doi.org/10.1021/ci400369z" title="DOI URL">https://doi.org/10.1021/ci400369z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci400369z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci400369z%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DVisually%252BInterpretable%252BModels%252Bof%252BKinase%252BSelectivity%252BRelated%252BFeatures%252BDerived%252Bfrom%252BField-Based%252BProteochemometrics%26aulast%3DSubramanian%26aufirst%3DVigneshwari%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D27062013%26date%3D25102013%26date%3D25112013%26date%3D12102013%26volume%3D53%26issue%3D11%26spage%3D3021%26epage%3D3030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Val S.  Goodfellow</span>, <span class="hlFld-ContribAuthor ">Colin J.  Loweth</span>, <span class="hlFld-ContribAuthor ">Satheesh B.  Ravula</span>, <span class="hlFld-ContribAuthor ">Torsten  Wiemann</span>, <span class="hlFld-ContribAuthor ">Thong  Nguyen</span>, <span class="hlFld-ContribAuthor ">Yang  Xu</span>, <span class="hlFld-ContribAuthor ">Daniel E.  Todd</span>, <span class="hlFld-ContribAuthor ">David  Sheppard</span>, <span class="hlFld-ContribAuthor ">Scott  Pollack</span>, <span class="hlFld-ContribAuthor ">Oksana  Polesskaya</span>, <span class="hlFld-ContribAuthor ">Daniel F.  Marker</span>, <span class="hlFld-ContribAuthor ">Stephen  Dewhurst</span>, and <span class="hlFld-ContribAuthor ">Harris A.  Gelbard</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery, Synthesis, and Characterization of an Orally Bioavailable, Brain Penetrant Inhibitor of Mixed Lineage Kinase 3. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (20)
                                     , 8032-8048. <a href="https://doi.org/10.1021/jm401094t" title="DOI URL">https://doi.org/10.1021/jm401094t</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm401094t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm401094t%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%25252C%252BSynthesis%25252C%252Band%252BCharacterization%252Bof%252Ban%252BOrally%252BBioavailable%25252C%252BBrain%252BPenetrant%252BInhibitor%252Bof%252BMixed%252BLineage%252BKinase%252B3%26aulast%3DGoodfellow%26aufirst%3DVal%2BS.%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D18072013%26date%3D03102013%26date%3D24102013%26date%3D17092013%26volume%3D56%26issue%3D20%26spage%3D8032%26epage%3D8048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ken-ichi  Kusakabe</span>, <span class="hlFld-ContribAuthor ">Nobuyuki  Ide</span>, <span class="hlFld-ContribAuthor ">Yataro  Daigo</span>, <span class="hlFld-ContribAuthor ">Yuki  Tachibana</span>, <span class="hlFld-ContribAuthor ">Takeshi,  Itoh</span>, <span class="hlFld-ContribAuthor ">Takahiko  Yamamoto</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Hashizume</span>, <span class="hlFld-ContribAuthor ">Yoshio  Hato</span>, <span class="hlFld-ContribAuthor ">Kenichi  Higashino</span>, <span class="hlFld-ContribAuthor ">Yousuke  Okano</span>, <span class="hlFld-ContribAuthor ">Yuji  Sato</span>, <span class="hlFld-ContribAuthor ">Makiko  Inoue</span>, <span class="hlFld-ContribAuthor ">Motofumi  Iguchi</span>, <span class="hlFld-ContribAuthor ">Takayuki  Kanazawa</span>, <span class="hlFld-ContribAuthor ">Yukichi  Ishioka</span>, <span class="hlFld-ContribAuthor ">Keiji  Dohi</span>, <span class="hlFld-ContribAuthor ">Yasuto  Kido</span>, <span class="hlFld-ContribAuthor ">Shingo  Sakamoto</span>, <span class="hlFld-ContribAuthor ">Kazuya  Yasuo</span>, <span class="hlFld-ContribAuthor ">Masahiro  Maeda</span>, <span class="hlFld-ContribAuthor ">Masayo  Higaki</span>, <span class="hlFld-ContribAuthor ">Kazuo  Ueda</span>, <span class="hlFld-ContribAuthor ">Hidenori  Yoshizawa</span>, <span class="hlFld-ContribAuthor ">Yoshiyasu  Baba</span>, <span class="hlFld-ContribAuthor ">Takeshi  Shiota</span>, <span class="hlFld-ContribAuthor ">Hitoshi  Murai</span>, and <span class="hlFld-ContribAuthor ">Yusuke  Nakamura</span>  . </span><span class="cited-content_cbyCitation_article-title">Indazole-Based Potent and Cell-Active Mps1 Kinase Inhibitors: Rational Design from Pan-Kinase Inhibitor Anthrapyrazolone (SP600125). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (11)
                                     , 4343-4356. <a href="https://doi.org/10.1021/jm4000215" title="DOI URL">https://doi.org/10.1021/jm4000215</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm4000215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm4000215%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIndazole-Based%252BPotent%252Band%252BCell-Active%252BMps1%252BKinase%252BInhibitors%25253A%252BRational%252BDesign%252Bfrom%252BPan-Kinase%252BInhibitor%252BAnthrapyrazolone%252B%252528SP600125%252529%26aulast%3DKusakabe%26aufirst%3DKen-ichi%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D04012013%26date%3D24052013%26date%3D13062013%26date%3D01052013%26volume%3D56%26issue%3D11%26spage%3D4343%26epage%3D4356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shunye  Zhou</span>, <span class="hlFld-ContribAuthor ">Youyong  Li</span>, and <span class="hlFld-ContribAuthor ">Tingjun  Hou</span>  . </span><span class="cited-content_cbyCitation_article-title">Feasibility of Using Molecular Docking-Based Virtual Screening for Searching Dual Target Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2013,</strong> <em>53 </em>
                                    (4)
                                     , 982-996. <a href="https://doi.org/10.1021/ci400065e" title="DOI URL">https://doi.org/10.1021/ci400065e</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci400065e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci400065e%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DFeasibility%252Bof%252BUsing%252BMolecular%252BDocking-Based%252BVirtual%252BScreening%252Bfor%252BSearching%252BDual%252BTarget%252BKinase%252BInhibitors%26aulast%3DZhou%26aufirst%3DShunye%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D28012013%26date%3D03042013%26date%3D22042013%26date%3D18032013%26volume%3D53%26issue%3D4%26spage%3D982%26epage%3D996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaobo  Wan</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Li  Li</span>, <span class="hlFld-ContribAuthor ">Yuting  Xie</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, and <span class="hlFld-ContribAuthor ">Niu  Huang</span>  . </span><span class="cited-content_cbyCitation_article-title">A New Target for an Old Drug: Identifying Mitoxantrone as a Nanomolar Inhibitor of PIM1 Kinase via Kinome-Wide Selectivity Modeling. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (6)
                                     , 2619-2629. <a href="https://doi.org/10.1021/jm400045y" title="DOI URL">https://doi.org/10.1021/jm400045y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400045y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400045y%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BNew%252BTarget%252Bfor%252Ban%252BOld%252BDrug%25253A%252BIdentifying%252BMitoxantrone%252Bas%252Ba%252BNanomolar%252BInhibitor%252Bof%252BPIM1%252BKinase%252Bvia%252BKinome-Wide%252BSelectivity%252BModeling%26aulast%3DWan%26aufirst%3DXiaobo%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D09012013%26date%3D15032013%26date%3D28032013%26date%3D26022013%26volume%3D56%26issue%3D6%26spage%3D2619%26epage%3D2629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephan C.  Schürer</span> and <span class="hlFld-ContribAuthor ">Steven M.  Muskal</span>  . </span><span class="cited-content_cbyCitation_article-title">Kinome-wide Activity Modeling from Diverse Public High-Quality Data Sets. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2013,</strong> <em>53 </em>
                                    (1)
                                     , 27-38. <a href="https://doi.org/10.1021/ci300403k" title="DOI URL">https://doi.org/10.1021/ci300403k</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci300403k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci300403k%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DKinome-wide%252BActivity%252BModeling%252Bfrom%252BDiverse%252BPublic%252BHigh-Quality%252BData%252BSets%26aulast%3DSch%25C3%25BCrer%26aufirst%3DStephan%2BC.%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D24082012%26date%3D09012013%26date%3D28012013%26date%3D21122012%26volume%3D53%26issue%3D1%26spage%3D27%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lina  Yin</span>, <span class="hlFld-ContribAuthor ">Qingzhong  Hu</span>, and <span class="hlFld-ContribAuthor ">Rolf W.  Hartmann</span>  . </span><span class="cited-content_cbyCitation_article-title">Tetrahydropyrroloquinolinone Type Dual Inhibitors of Aromatase/Aldosterone Synthase as a Novel Strategy for Breast Cancer Patients with Elevated Cardiovascular Risks. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (2)
                                     , 460-470. <a href="https://doi.org/10.1021/jm301408t" title="DOI URL">https://doi.org/10.1021/jm301408t</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301408t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301408t%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTetrahydropyrroloquinolinone%252BType%252BDual%252BInhibitors%252Bof%252BAromatase%25252FAldosterone%252BSynthase%252Bas%252Ba%252BNovel%252BStrategy%252Bfor%252BBreast%252BCancer%252BPatients%252Bwith%252BElevated%252BCardiovascular%252BRisks%26aulast%3DYin%26aufirst%3DLina%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D27092012%26date%3D03012013%26date%3D24012013%26volume%3D56%26issue%3D2%26spage%3D460%26epage%3D470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kristoffer R.  Brandvold</span>, <span class="hlFld-ContribAuthor ">Michael E.  Steffey</span>, <span class="hlFld-ContribAuthor ">Christel C.  Fox</span>, and <span class="hlFld-ContribAuthor ">Matthew B.  Soellner</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of a Highly Selective c-Src Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2012,</strong> <em>7 </em>
                                    (8)
                                     , 1393-1398. <a href="https://doi.org/10.1021/cb300172e" title="DOI URL">https://doi.org/10.1021/cb300172e</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/cb300172e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fcb300172e%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DDevelopment%252Bof%252Ba%252BHighly%252BSelective%252Bc-Src%252BKinase%252BInhibitor%26aulast%3DBrandvold%26aufirst%3DKristoffer%2BR.%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D11042012%26date%3D17052012%26date%3D04062012%26date%3D17082012%26date%3D17052012%26volume%3D7%26issue%3D8%26spage%3D1393%26epage%3D1398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard A.  Norman</span>, <span class="hlFld-ContribAuthor ">Anne-Kathrin  Schott</span>, <span class="hlFld-ContribAuthor ">David M.  Andrews</span>, <span class="hlFld-ContribAuthor ">Jason  Breed</span>, <span class="hlFld-ContribAuthor ">Kevin M.  Foote</span>, <span class="hlFld-ContribAuthor ">Andrew P.  Garner</span>, <span class="hlFld-ContribAuthor ">Derek  Ogg</span>, <span class="hlFld-ContribAuthor ">Jonathon P.  Orme</span>, <span class="hlFld-ContribAuthor ">Jennifer H.  Pink</span>, <span class="hlFld-ContribAuthor ">Karen  Roberts</span>, <span class="hlFld-ContribAuthor ">David A.  Rudge</span>, <span class="hlFld-ContribAuthor ">Andrew P.  Thomas</span>, and <span class="hlFld-ContribAuthor ">Andrew G.  Leach</span>  . </span><span class="cited-content_cbyCitation_article-title">Protein–Ligand Crystal Structures Can Guide the Design of Selective Inhibitors of the FGFR Tyrosine Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (11)
                                     , 5003-5012. <a href="https://doi.org/10.1021/jm3004043" title="DOI URL">https://doi.org/10.1021/jm3004043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm3004043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm3004043%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DProtein%2525E2%252580%252593Ligand%252BCrystal%252BStructures%252BCan%252BGuide%252Bthe%252BDesign%252Bof%252BSelective%252BInhibitors%252Bof%252Bthe%252BFGFR%252BTyrosine%252BKinase%26aulast%3DNorman%26aufirst%3DRichard%2BA.%26date%3D2012%26date%3D2012%26date%3D2011%26date%3D15112011%26date%3D21052012%26date%3D14062012%26volume%3D55%26issue%3D11%26spage%3D5003%26epage%3D5012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jamel  Meslamani</span>, <span class="hlFld-ContribAuthor ">Jiabo  Li</span>, <span class="hlFld-ContribAuthor ">Jon  Sutter</span>, <span class="hlFld-ContribAuthor ">Adrian  Stevens</span>, <span class="hlFld-ContribAuthor ">Hugues-Olivier  Bertrand</span>, and <span class="hlFld-ContribAuthor ">Didier  Rognan</span>  . </span><span class="cited-content_cbyCitation_article-title">Protein–Ligand-Based Pharmacophores: Generation and Utility Assessment in Computational Ligand Profiling. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2012,</strong> <em>52 </em>
                                    (4)
                                     , 943-955. <a href="https://doi.org/10.1021/ci300083r" title="DOI URL">https://doi.org/10.1021/ci300083r</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci300083r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci300083r%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DProtein%2525E2%252580%252593Ligand-Based%252BPharmacophores%25253A%252BGeneration%252Band%252BUtility%252BAssessment%252Bin%252BComputational%252BLigand%252BProfiling%26aulast%3DMeslamani%26aufirst%3DJamel%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D10022012%26date%3D11042012%26date%3D23042012%26date%3D05042012%26volume%3D52%26issue%3D4%26spage%3D943%26epage%3D955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">Dong Joon  Kim</span>, <span class="hlFld-ContribAuthor ">Weiya  Ma</span>, <span class="hlFld-ContribAuthor ">Ronald A.  Lubet</span>, <span class="hlFld-ContribAuthor ">Ann M.  Bode</span>, and <span class="hlFld-ContribAuthor ">Zigang  Dong</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Checkpoint Kinase 1 Inhibitors by Virtual Screening Based on Multiple Crystal Structures. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2011,</strong> <em>51 </em>
                                    (11)
                                     , 2904-2914. <a href="https://doi.org/10.1021/ci200257b" title="DOI URL">https://doi.org/10.1021/ci200257b</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci200257b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci200257b%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DDiscovery%252Bof%252BNovel%252BCheckpoint%252BKinase%252B1%252BInhibitors%252Bby%252BVirtual%252BScreening%252BBased%252Bon%252BMultiple%252BCrystal%252BStructures%26aulast%3DLi%26aufirst%3DYan%26date%3D2011%26date%3D2011%26date%3D2011%26date%3D10062011%26date%3D12102011%26date%3D28112011%26date%3D28092011%26volume%3D51%26issue%3D11%26spage%3D2904%26epage%3D2914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Delvare</span>, <span class="hlFld-ContribAuthor ">Craig S.  Harris</span>, <span class="hlFld-ContribAuthor ">Laurent  Hennequin</span>, <span class="hlFld-ContribAuthor ">Patrice  Koza</span>, <span class="hlFld-ContribAuthor ">Christine  Lambert-van der Brempt</span>, <span class="hlFld-ContribAuthor ">Jacques  Pelleter</span>, and <span class="hlFld-ContribAuthor ">Olivier  Willerval</span>  . </span><span class="cited-content_cbyCitation_article-title">Efficient Three-Step One-Pot Synthesis of a Novel 2,3,5-Substituted Pyrazine Library. </span><span class="cited-content_cbyCitation_journal-name">ACS Combinatorial Science</span><span> <strong>2011,</strong> <em>13 </em>
                                    (5)
                                     , 449-452. <a href="https://doi.org/10.1021/co200062n" title="DOI URL">https://doi.org/10.1021/co200062n</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/co200062n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fco200062n%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Combinatorial%2520Science%26atitle%3DEfficient%252BThree-Step%252BOne-Pot%252BSynthesis%252Bof%252Ba%252BNovel%252B2%25252C3%25252C5-Substituted%252BPyrazine%252BLibrary%26aulast%3DDelvare%26aufirst%3DChristian%26date%3D2011%26date%3D2011%26date%3D2011%26date%3D2011%26date%3D03042011%26date%3D06062011%26date%3D01072011%26date%3D12092011%26date%3D07062011%26volume%3D13%26issue%3D5%26spage%3D449%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ye  Hu</span>, <span class="hlFld-ContribAuthor ">Dagmar  Stumpfe</span>, and <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>  . </span><span class="cited-content_cbyCitation_article-title">Lessons Learned from Molecular Scaffold Analysis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2011,</strong> <em>51 </em>
                                    (8)
                                     , 1742-1753. <a href="https://doi.org/10.1021/ci200179y" title="DOI URL">https://doi.org/10.1021/ci200179y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci200179y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci200179y%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DLessons%252BLearned%252Bfrom%252BMolecular%252BScaffold%252BAnalysis%26aulast%3DHu%26aufirst%3DYe%26date%3D2011%26date%3D2011%26date%3D2011%26date%3D19042011%26date%3D28072011%26date%3D22082011%26date%3D14072011%26volume%3D51%26issue%3D8%26spage%3D1742%26epage%3D1753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Preethi  Badrinarayan</span> and <span class="hlFld-ContribAuthor ">G. Narahari  Sastry</span>. </span><span class="cited-content_cbyCitation_article-title">Sequence, Structure, and Active Site Analyses of p38 MAP Kinase: Exploiting DFG-out Conformation as a Strategy to Design New Type II Leads. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2011,</strong> <em>51 </em>
                                    (1)
                                     , 115-129. <a href="https://doi.org/10.1021/ci100340w" title="DOI URL">https://doi.org/10.1021/ci100340w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci100340w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci100340w%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DSequence%25252C%252BStructure%25252C%252Band%252BActive%252BSite%252BAnalyses%252Bof%252Bp38%252BMAP%252BKinase%25253A%252BExploiting%252BDFG-out%252BConformation%252Bas%252Ba%252BStrategy%252Bto%252BDesign%252BNew%252BType%252BII%252BLeads%26aulast%3DBadrinarayan%26aufirst%3DPreethi%26date%3D2011%26date%3D2010%26date%3D2010%26date%3D1%252009%25202010%26date%3D08122010%26date%3D24012011%26volume%3D51%26issue%3D1%26spage%3D115%26epage%3D129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ye  Hu</span> and <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Polypharmacology Directed Compound Data Mining: Identification of Promiscuous Chemotypes with Different Activity Profiles and Comparison to Approved Drugs. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2010,</strong> <em>50 </em>
                                    (12)
                                     , 2112-2118. <a href="https://doi.org/10.1021/ci1003637" title="DOI URL">https://doi.org/10.1021/ci1003637</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci1003637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci1003637%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DPolypharmacology%252BDirected%252BCompound%252BData%252BMining%25253A%252BIdentification%252Bof%252BPromiscuous%252BChemotypes%252Bwith%252BDifferent%252BActivity%252BProfiles%252Band%252BComparison%252Bto%252BApproved%252BDrugs%26aulast%3DHu%26aufirst%3DYe%26date%3D2010%26date%3D2010%26date%3D2010%26date%3D13%252009%25202010%26date%3D12112010%26date%3D27122010%26volume%3D50%26issue%3D12%26spage%3D2112%26epage%3D2118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elisa  Barile</span>, <span class="hlFld-ContribAuthor ">Surya K.  De</span>, <span class="hlFld-ContribAuthor ">Coby B.  Carlson</span>, <span class="hlFld-ContribAuthor ">Vida  Chen</span>, <span class="hlFld-ContribAuthor ">Christine  Knutzen</span>, <span class="hlFld-ContribAuthor ">Megan  Riel-Mehan</span>, <span class="hlFld-ContribAuthor ">Li  Yang</span>, <span class="hlFld-ContribAuthor ">Russell  Dahl</span>, <span class="hlFld-ContribAuthor ">Gary  Chiang</span>, and <span class="hlFld-ContribAuthor ">Maurizio  Pellecchia</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Structure−Activity Relationships of 3-Ethynyl-1H-indazoles as Inhibitors of the Phosphatidylinositol 3-Kinase Signaling Pathway. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2010,</strong> <em>53 </em>
                                    (23)
                                     , 8368-8375. <a href="https://doi.org/10.1021/jm100825h" title="DOI URL">https://doi.org/10.1021/jm100825h</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm100825h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm100825h%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BStructure%2525E2%252588%252592Activity%252BRelationships%252Bof%252B3-Ethynyl-1H-indazoles%252Bas%252BInhibitors%252Bof%252Bthe%252BPhosphatidylinositol%252B3-Kinase%252BSignaling%252BPathway%26aulast%3DBarile%26aufirst%3DElisa%26date%3D2010%26date%3D2010%26date%3D2010%26date%3D02072010%26date%3D09112010%26date%3D09122010%26volume%3D53%26issue%3D23%26spage%3D8368%26epage%3D8375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michal  Brylinski</span> and <span class="hlFld-ContribAuthor ">Jeffrey  Skolnick</span>. </span><span class="cited-content_cbyCitation_article-title">Cross-Reactivity Virtual Profiling of the Human Kinome by X-ReactKIN: A Chemical Systems Biology Approach. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2010,</strong> <em>7 </em>
                                    (6)
                                     , 2324-2333. <a href="https://doi.org/10.1021/mp1002976" title="DOI URL">https://doi.org/10.1021/mp1002976</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/mp1002976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fmp1002976%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DCross-Reactivity%252BVirtual%252BProfiling%252Bof%252Bthe%252BHuman%252BKinome%252Bby%252BX-ReactKIN%25253A%252BA%252BChemical%252BSystems%252BBiology%252BApproach%26aulast%3DBrylinski%26aufirst%3DMichal%26date%3D2010%26date%3D2010%26date%3D2010%26date%3D2010%26date%3D2010%26date%3D31%252008%25202010%26date%3D19%252010%25202010%26date%3D30%252009%25202010%26date%3D08112010%26date%3D06122010%26date%3D19102010%26volume%3D7%26issue%3D6%26spage%3D2324%26epage%3D2333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fraser F.  Fleming</span>, <span class="hlFld-ContribAuthor ">Lihua  Yao</span>, <span class="hlFld-ContribAuthor ">P. C.  Ravikumar</span>, <span class="hlFld-ContribAuthor ">Lee  Funk</span>, and <span class="hlFld-ContribAuthor ">Brian C.  Shook</span>  . </span><span class="cited-content_cbyCitation_article-title">Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2010,</strong> <em>53 </em>
                                    (22)
                                     , 7902-7917. <a href="https://doi.org/10.1021/jm100762r" title="DOI URL">https://doi.org/10.1021/jm100762r</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm100762r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm100762r%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNitrile-Containing%252BPharmaceuticals%25253A%252BEfficacious%252BRoles%252Bof%252Bthe%252BNitrile%252BPharmacophore%26aulast%3DFleming%26aufirst%3DFraser%2BF.%26date%3D2010%26date%3D2010%26date%3D2010%26date%3D23062010%26date%3D30082010%26date%3D25112010%26volume%3D53%26issue%3D22%26spage%3D7902%26epage%3D7917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Govindan  Subramanian</span> and <span class="hlFld-ContribAuthor ">Manish  Sud</span>  . </span><span class="cited-content_cbyCitation_article-title">Computational Modeling of Kinase Inhibitor Selectivity. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2010,</strong> <em>1 </em>
                                    (8)
                                     , 395-399. <a href="https://doi.org/10.1021/ml1001097" title="DOI URL">https://doi.org/10.1021/ml1001097</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml1001097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml1001097%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DComputational%252BModeling%252Bof%252BKinase%252BInhibitor%252BSelectivity%26aulast%3DSubramanian%26aufirst%3DGovindan%26date%3D2010%26date%3D2010%26date%3D2010%26date%3D2010%26date%3D11052010%26date%3D26072010%26date%3D28072010%26date%3D11112010%26volume%3D1%26issue%3D8%26spage%3D395%26epage%3D399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fabio  Zuccotto</span>, <span class="hlFld-ContribAuthor ">Elena  Ardini</span>, <span class="hlFld-ContribAuthor ">Elena  Casale</span> and <span class="hlFld-ContribAuthor ">Mauro  Angiolini</span>  . </span><span class="cited-content_cbyCitation_article-title">Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2010,</strong> <em>53 </em>
                                    (7)
                                     , 2681-2694. <a href="https://doi.org/10.1021/jm901443h" title="DOI URL">https://doi.org/10.1021/jm901443h</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm901443h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm901443h%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThrough%252Bthe%252B%2525E2%252580%25259CGatekeeper%252BDoor%2525E2%252580%25259D%25253A%252BExploiting%252Bthe%252BActive%252BKinase%252BConformation%26aulast%3DZuccotto%26aufirst%3DFabio%26date%3D2010%26date%3D2009%26date%3D2009%26date%3D29092009%26date%3D14122009%26date%3D08042010%26volume%3D53%26issue%3D7%26spage%3D2681%26epage%3D2694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Feldmann</span>, <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Machine learning reveals that structural features distinguishing promiscuous and non-promiscuous compounds depend on target combinations. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-021-87042-z" title="DOI URL">https://doi.org/10.1038/s41598-021-87042-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-021-87042-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-021-87042-z%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DMachine%252Blearning%252Breveals%252Bthat%252Bstructural%252Bfeatures%252Bdistinguishing%252Bpromiscuous%252Band%252Bnon-promiscuous%252Bcompounds%252Bdepend%252Bon%252Btarget%252Bcombinations%26aulast%3DFeldmann%26aufirst%3DChristian%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Feldmann</span>, <span class="hlFld-ContribAuthor ">Dimitar  Yonchev</span>, <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Structured data sets of compounds with multi-target and corresponding single-target activity from biological assays. </span><span class="cited-content_cbyCitation_journal-name">Future Science OA</span><span> <strong>2021,</strong> <em>7 </em>
                                    (5)
                                     , FSO685. <a href="https://doi.org/10.2144/fsoa-2020-0209" title="DOI URL">https://doi.org/10.2144/fsoa-2020-0209</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2144/fsoa-2020-0209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2144%2Ffsoa-2020-0209%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Science%2520OA%26atitle%3DStructured%252Bdata%252Bsets%252Bof%252Bcompounds%252Bwith%252Bmulti-target%252Band%252Bcorresponding%252Bsingle-target%252Bactivity%252Bfrom%252Bbiological%252Bassays%26aulast%3DFeldmann%26aufirst%3DChristian%26date%3D2021%26volume%3D7%26issue%3D5%26spage%3DFSO685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Patricia  Saenz-Méndez</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-Target Drugs as Master Keys to Complex Diseases: Inverse Docking Strategies and Opportunities. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 295-311. <a href="https://doi.org/10.1016/B978-0-12-822312-3.00005-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-822312-3.00005-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-822312-3.00005-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-822312-3.00005-9%26sid%3Dliteratum%253Aachs%26atitle%3DMulti-Target%252BDrugs%252Bas%252BMaster%252BKeys%252Bto%252BComplex%252BDiseases%25253A%252BInverse%252BDocking%252BStrategies%252Band%252BOpportunities%26aulast%3DSaenz-M%25C3%25A9ndez%26aufirst%3DPatricia%26date%3D2021%26spage%3D295%26epage%3D311%26pub%3DElsevier%26atitle%3DMolecular%252BDocking%252Bfor%252BComputer-Aided%252BDrug%252BDesign%26date%3D2021%26volume%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Borgo</span>, <span class="hlFld-ContribAuthor ">Maria  Ruzzene</span>. </span><span class="cited-content_cbyCitation_article-title">Protein kinase CK2 inhibition as a pharmacological strategy. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 23-46. <a href="https://doi.org/10.1016/bs.apcsb.2020.09.003" title="DOI URL">https://doi.org/10.1016/bs.apcsb.2020.09.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.apcsb.2020.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.apcsb.2020.09.003%26sid%3Dliteratum%253Aachs%26atitle%3DProtein%252Bkinase%252BCK2%252Binhibition%252Bas%252Ba%252Bpharmacological%252Bstrategy%26aulast%3DBorgo%26aufirst%3DChristian%26date%3D2021%26spage%3D23%26epage%3D46%26pub%3DElsevier%26atitle%3DProtein%252BKinases%252Bin%252BDrug%252BDiscovery%26date%3D2021%26volume%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carrow I.  Wells</span>, <span class="hlFld-ContribAuthor ">Hassan  Al-Ali</span>, <span class="hlFld-ContribAuthor ">David M.  Andrews</span>, <span class="hlFld-ContribAuthor ">Christopher R. M.  Asquith</span>, <span class="hlFld-ContribAuthor ">Alison D.  Axtman</span>, <span class="hlFld-ContribAuthor ">Ivan  Dikic</span>, <span class="hlFld-ContribAuthor ">Daniel  Ebner</span>, <span class="hlFld-ContribAuthor ">Peter  Ettmayer</span>, <span class="hlFld-ContribAuthor ">Christian  Fischer</span>, <span class="hlFld-ContribAuthor ">Mathias  Frederiksen</span>, <span class="hlFld-ContribAuthor ">Robert E.  Futrell</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>, <span class="hlFld-ContribAuthor ">Stephanie B.  Hatch</span>, <span class="hlFld-ContribAuthor ">Stefan  Knapp</span>, <span class="hlFld-ContribAuthor ">Ulrich  Lücking</span>, <span class="hlFld-ContribAuthor ">Michael  Michaelides</span>, <span class="hlFld-ContribAuthor ">Caitlin E.  Mills</span>, <span class="hlFld-ContribAuthor ">Susanne  Müller</span>, <span class="hlFld-ContribAuthor ">Dafydd  Owen</span>, <span class="hlFld-ContribAuthor ">Alfredo  Picado</span>, <span class="hlFld-ContribAuthor ">Kumar S.  Saikatendu</span>, <span class="hlFld-ContribAuthor ">Martin  Schröder</span>, <span class="hlFld-ContribAuthor ">Alexandra  Stolz</span>, <span class="hlFld-ContribAuthor ">Mariana  Tellechea</span>, <span class="hlFld-ContribAuthor ">Brandon J.  Turunen</span>, <span class="hlFld-ContribAuthor ">Santiago  Vilar</span>, <span class="hlFld-ContribAuthor ">Jinhua  Wang</span>, <span class="hlFld-ContribAuthor ">William J.  Zuercher</span>, <span class="hlFld-ContribAuthor ">Timothy M.  Willson</span>, <span class="hlFld-ContribAuthor ">David H.  Drewry</span>. </span><span class="cited-content_cbyCitation_article-title">The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (2)
                                     , 566. <a href="https://doi.org/10.3390/ijms22020566" title="DOI URL">https://doi.org/10.3390/ijms22020566</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22020566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22020566%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DThe%252BKinase%252BChemogenomic%252BSet%252B%252528KCGS%252529%25253A%252BAn%252BOpen%252BScience%252BResource%252Bfor%252BKinase%252BVulnerability%252BIdentification%26aulast%3DWells%26aufirst%3DCarrow%2BI.%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D2%26spage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Feldmann</span>, <span class="hlFld-ContribAuthor ">Dimitar  Yonchev</span>, <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Analysis of Biological Screening Compounds with Single- or Multi-Target Activity via Diagnostic Machine Learning. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2020,</strong> <em>10 </em>
                                    (12)
                                     , 1605. <a href="https://doi.org/10.3390/biom10121605" title="DOI URL">https://doi.org/10.3390/biom10121605</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom10121605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom10121605%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DAnalysis%252Bof%252BBiological%252BScreening%252BCompounds%252Bwith%252BSingle-%252Bor%252BMulti-Target%252BActivity%252Bvia%252BDiagnostic%252BMachine%252BLearning%26aulast%3DFeldmann%26aufirst%3DChristian%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D12%26spage%3D1605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yunxin  Duan</span>, <span class="hlFld-ContribAuthor ">Jie  Wang</span>, <span class="hlFld-ContribAuthor ">Sihua  Zhu</span>, <span class="hlFld-ContribAuthor ">Zheng-Chao  Tu</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Shingpan  Chan</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and Structure–Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>203 </em>, 112552. <a href="https://doi.org/10.1016/j.ejmech.2020.112552" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112552</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112552%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationships%252B%252528SAR%252529%252Bof%252B3-vinylindazole%252Bderivatives%252Bas%252Bnew%252Bselective%252Btropomyosin%252Breceptor%252Bkinases%252B%252528Trk%252529%252Binhibitors%26aulast%3DDuan%26aufirst%3DYunxin%26date%3D2020%26volume%3D203%26spage%3D112552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francis E  Agamah</span>, <span class="hlFld-ContribAuthor ">Gaston K  Mazandu</span>, <span class="hlFld-ContribAuthor ">Radia  Hassan</span>, <span class="hlFld-ContribAuthor ">Christian D  Bope</span>, <span class="hlFld-ContribAuthor ">Nicholas E  Thomford</span>, <span class="hlFld-ContribAuthor ">Anita  Ghansah</span>, <span class="hlFld-ContribAuthor ">Emile R  Chimusa</span>. </span><span class="cited-content_cbyCitation_article-title">Computational/in silico methods in drug target and lead prediction. </span><span class="cited-content_cbyCitation_journal-name">Briefings in Bioinformatics</span><span> <strong>2020,</strong> <em>21 </em>
                                    (5)
                                     , 1663-1675. <a href="https://doi.org/10.1093/bib/bbz103" title="DOI URL">https://doi.org/10.1093/bib/bbz103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/bib/bbz103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fbib%2Fbbz103%26sid%3Dliteratum%253Aachs%26jtitle%3DBriefings%2520in%2520Bioinformatics%26atitle%3DComputational%25252Fin%252Bsilico%252Bmethods%252Bin%252Bdrug%252Btarget%252Band%252Blead%252Bprediction%26aulast%3DAgamah%26aufirst%3DFrancis%2BE%26date%3D2020%26date%3D2019%26volume%3D21%26issue%3D5%26spage%3D1663%26epage%3D1675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zuha  Imtiyaz</span>, <span class="hlFld-ContribAuthor ">Yi-Tzu  Lin</span>, <span class="hlFld-ContribAuthor ">Ut-Hang  Cheong</span>, <span class="hlFld-ContribAuthor ">Alagie  Jassey</span>, <span class="hlFld-ContribAuthor ">Hui-Kang  Liu</span>, <span class="hlFld-ContribAuthor ">Mei-Hsien  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Compounds isolated from Euonymus spraguei Hayata induce ossification through multiple pathways. </span><span class="cited-content_cbyCitation_journal-name">Saudi Journal of Biological Sciences</span><span> <strong>2020,</strong> <em>27 </em>
                                    (9)
                                     , 2227-2237. <a href="https://doi.org/10.1016/j.sjbs.2020.06.036" title="DOI URL">https://doi.org/10.1016/j.sjbs.2020.06.036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.sjbs.2020.06.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.sjbs.2020.06.036%26sid%3Dliteratum%253Aachs%26jtitle%3DSaudi%2520Journal%2520of%2520Biological%2520Sciences%26atitle%3DCompounds%252Bisolated%252Bfrom%252BEuonymus%252Bspraguei%252BHayata%252Binduce%252Bossification%252Bthrough%252Bmultiple%252Bpathways%26aulast%3DImtiyaz%26aufirst%3DZuha%26date%3D2020%26volume%3D27%26issue%3D9%26spage%3D2227%26epage%3D2237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian B.  Hasinoff</span>, <span class="hlFld-ContribAuthor ">Daywin  Patel</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib. </span><span class="cited-content_cbyCitation_journal-name">Cardiovascular Toxicology</span><span> <strong>2020,</strong> <em>20 </em>
                                    (4)
                                     , 380-389. <a href="https://doi.org/10.1007/s12012-020-09565-7" title="DOI URL">https://doi.org/10.1007/s12012-020-09565-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12012-020-09565-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12012-020-09565-7%26sid%3Dliteratum%253Aachs%26jtitle%3DCardiovascular%2520Toxicology%26atitle%3DMechanisms%252Bof%252Bthe%252BCardiac%252BMyocyte-Damaging%252BEffects%252Bof%252BDasatinib%26aulast%3DHasinoff%26aufirst%3DBrian%2BB.%26date%3D2020%26date%3D2020%26volume%3D20%26issue%3D4%26spage%3D380%26epage%3D389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zh. V.  Ignatovich</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of chimeric amides of 2-arilaminopyrimidine series. </span><span class="cited-content_cbyCitation_journal-name">Proceedings of the National Academy of Sciences of Belarus, Chemical Series</span><span> <strong>2020,</strong> <em>56 </em>
                                    (2)
                                     , 166-180. <a href="https://doi.org/10.29235/1561-8331-2020-56-2-38-166-180" title="DOI URL">https://doi.org/10.29235/1561-8331-2020-56-2-38-166-180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.29235/1561-8331-2020-56-2-38-166-180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.29235%2F1561-8331-2020-56-2-38-166-180%26sid%3Dliteratum%253Aachs%26jtitle%3DProceedings%2520of%2520the%2520National%2520Academy%2520of%2520Sciences%2520of%2520Belarus%252C%2520Chemical%2520Series%26atitle%3DSynthesis%252Bof%252Bchimeric%252Bamides%252Bof%252B2-arilaminopyrimidine%252Bseries%26aulast%3DIgnatovich%26aufirst%3DZh.%2BV.%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D2%26spage%3D166%26epage%3D180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria L  Bolognesi</span>, <span class="hlFld-ContribAuthor ">Michele  Rossi</span>. </span><span class="cited-content_cbyCitation_article-title">Multitarget Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 1-7. <a href="https://doi.org/10.1002/9780470015902.a0028845" title="DOI URL">https://doi.org/10.1002/9780470015902.a0028845</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9780470015902.a0028845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9780470015902.a0028845%26sid%3Dliteratum%253Aachs%26atitle%3DMultitarget%252BDrug%252BDiscovery%26aulast%3DBolognesi%26aufirst%3DMaria%2BL%26date%3D2020%26date%3D2020%26spage%3D1%26epage%3D7%26pub%3DWiley%26atitle%3DeLS%26aulast%3DJohn%2BWiley%2B%2526%2BSons%252C%2BLtd%26date%3D2001%26date%3D2001%26volume%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mauro  Angiolini</span>. </span><span class="cited-content_cbyCitation_article-title">The Role of Structural Biology in Kinase Inhibitor Drug Discovery Success. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 363-393. <a href="https://doi.org/10.1002/9781118681121.ch16" title="DOI URL">https://doi.org/10.1002/9781118681121.ch16</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118681121.ch16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118681121.ch16%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BRole%252Bof%252BStructural%252BBiology%252Bin%252BKinase%252BInhibitor%252BDrug%252BDiscovery%252BSuccess%26aulast%3DAngiolini%26aufirst%3DMauro%26date%3D2020%26date%3D2020%26spage%3D363%26epage%3D393%26pub%3DWiley%26atitle%3DStructural%252BBiology%252Bin%252BDrug%252BDiscovery%26aulast%3DRenaud%26aufirst%3DJean%25E2%2580%2590Paul%26date%3D2020%26date%3D2020%26volume%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laurent  Schio</span>, <span class="hlFld-ContribAuthor ">Herve  Minoux</span>. </span><span class="cited-content_cbyCitation_article-title">Achieving High Levels of Selectivity for Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 95-123. <a href="https://doi.org/10.1007/7355_2020_99" title="DOI URL">https://doi.org/10.1007/7355_2020_99</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2020_99&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2020_99%26sid%3Dliteratum%253Aachs%26atitle%3DAchieving%252BHigh%252BLevels%252Bof%252BSelectivity%252Bfor%252BKinase%252BInhibitors%26aulast%3DSchio%26aufirst%3DLaurent%26date%3D2020%26date%3D2020%26spage%3D95%26epage%3D123%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DProteinkinase%252BInhibitors%26aulast%3DLaufer%26aufirst%3DStefan%26date%3D2021%26volume%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hailin  Zheng</span>, <span class="hlFld-ContribAuthor ">Tamar  Amit</span>, <span class="hlFld-ContribAuthor ">Orit  Bar-Am</span>, <span class="hlFld-ContribAuthor ">Mati  Fridkin</span>, <span class="hlFld-ContribAuthor ">Silvia A.  Mandel</span>, <span class="hlFld-ContribAuthor ">Moussa B. H.  Youdim</span>. </span><span class="cited-content_cbyCitation_article-title">From Anti-Parkinson’s Drug Rasagiline to Novel Multitarget Iron Chelators with Acetylcholinesterase and Monoamine Oxidase Inhibitory and Neuroprotective Properties for Alzheimer’s Disease. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 1-26. <a href="https://doi.org/10.1007/978-3-319-56015-1_234-1" title="DOI URL">https://doi.org/10.1007/978-3-319-56015-1_234-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-56015-1_234-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-56015-1_234-1%26sid%3Dliteratum%253Aachs%26atitle%3DFrom%252BAnti-Parkinson%2525E2%252580%252599s%252BDrug%252BRasagiline%252Bto%252BNovel%252BMultitarget%252BIron%252BChelators%252Bwith%252BAcetylcholinesterase%252Band%252BMonoamine%252BOxidase%252BInhibitory%252Band%252BNeuroprotective%252BProperties%252Bfor%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DZheng%26aufirst%3DHailin%26date%3D2020%26date%3D2020%26spage%3D1%26epage%3D26%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DNeuroPsychopharmacotherapy%26aulast%3DRiederer%26aufirst%3DPeter%26date%3D2020%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiao  Han</span>, <span class="hlFld-ContribAuthor ">You-Wei  Xu</span>, <span class="hlFld-ContribAuthor ">Xue-Ming  Wang</span>, <span class="hlFld-ContribAuthor ">Lei  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiang-Ping  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Copper-catalyzed formal propargylic [3 + 2] cycloaddition for stereoselective construction of (E)-β-pyrazolylacrylates. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2020,</strong> <em>61 </em>
                                    (3)
                                     , 151409. <a href="https://doi.org/10.1016/j.tetlet.2019.151409" title="DOI URL">https://doi.org/10.1016/j.tetlet.2019.151409</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2019.151409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2019.151409%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DCopper-catalyzed%252Bformal%252Bpropargylic%252B%25255B3%2525E2%252580%2525AF%25252B%2525E2%252580%2525AF2%25255D%252Bcycloaddition%252Bfor%252Bstereoselective%252Bconstruction%252Bof%252B%252528E%252529-%2525CE%2525B2-pyrazolylacrylates%26aulast%3DHan%26aufirst%3DJiao%26date%3D2020%26volume%3D61%26issue%3D3%26spage%3D151409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel Nascimento  do Amaral</span>, <span class="hlFld-ContribAuthor ">Jonas  Lategahn</span>, <span class="hlFld-ContribAuthor ">Harold Hilarion  Fokoue</span>, <span class="hlFld-ContribAuthor ">Eduardo Miguez Bastos  da Silva</span>, <span class="hlFld-ContribAuthor ">Carlos Mauricio R.  Sant’Anna</span>, <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>, <span class="hlFld-ContribAuthor ">Eliezer J.  Barreiro</span>, <span class="hlFld-ContribAuthor ">Stefan  Laufer</span>, <span class="hlFld-ContribAuthor ">Lidia Moreira  Lima</span>. </span><span class="cited-content_cbyCitation_article-title">A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2019,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-018-36846-7" title="DOI URL">https://doi.org/10.1038/s41598-018-36846-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-018-36846-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-018-36846-7%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DA%252Bnovel%252Bscaffold%252Bfor%252BEGFR%252Binhibition%25253A%252BIntroducing%252BN-%2525283-%2525283-phenylureido%252529quinoxalin-6-yl%252529%252Bacrylamide%252Bderivatives%26aulast%3Ddo%2BAmaral%26aufirst%3DDaniel%2BNascimento%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Georgi K.  Kanev</span>, <span class="hlFld-ContribAuthor ">Chris  de Graaf</span>, <span class="hlFld-ContribAuthor ">Iwan J.P.  de Esch</span>, <span class="hlFld-ContribAuthor ">Rob  Leurs</span>, <span class="hlFld-ContribAuthor ">Thomas  Würdinger</span>, <span class="hlFld-ContribAuthor ">Bart A.  Westerman</span>, <span class="hlFld-ContribAuthor ">Albert J.  Kooistra</span>. </span><span class="cited-content_cbyCitation_article-title">The Landscape of Atypical and Eukaryotic Protein Kinases. </span><span class="cited-content_cbyCitation_journal-name">Trends in Pharmacological Sciences</span><span> <strong>2019,</strong> <em>40 </em>
                                    (11)
                                     , 818-832. <a href="https://doi.org/10.1016/j.tips.2019.09.002" title="DOI URL">https://doi.org/10.1016/j.tips.2019.09.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tips.2019.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tips.2019.09.002%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Pharmacological%2520Sciences%26atitle%3DThe%252BLandscape%252Bof%252BAtypical%252Band%252BEukaryotic%252BProtein%252BKinases%26aulast%3DKanev%26aufirst%3DGeorgi%2BK.%26date%3D2019%26volume%3D40%26issue%3D11%26spage%3D818%26epage%3D832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna Rita  Bilia</span>, <span class="hlFld-ContribAuthor ">Vieri  Piazzini</span>, <span class="hlFld-ContribAuthor ">Laura  Risaliti</span>, <span class="hlFld-ContribAuthor ">Giulia  Vanti</span>, <span class="hlFld-ContribAuthor ">Marta  Casamonti</span>, <span class="hlFld-ContribAuthor ">Meng  Wang</span>, <span class="hlFld-ContribAuthor ">Maria Camilla  Bergonzi</span>. </span><span class="cited-content_cbyCitation_article-title">Nanocarriers: A Successful Tool to Increase Solubility, Stability and Optimise Bioefficacy of Natural Constituents. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2019,</strong> <em>26 </em>
                                    (24)
                                     , 4631-4656. <a href="https://doi.org/10.2174/0929867325666181101110050" title="DOI URL">https://doi.org/10.2174/0929867325666181101110050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867325666181101110050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867325666181101110050%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DNanocarriers%25253A%252BA%252BSuccessful%252BTool%252Bto%252BIncrease%252BSolubility%25252C%252BStability%252Band%252BOptimise%252BBioefficacy%252Bof%252BNatural%252BConstituents%26aulast%3DBilia%26aufirst%3DAnna%2BRita%26date%3D2019%26volume%3D26%26issue%3D24%26spage%3D4631%26epage%3D4656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Supaphorn  Seetaha</span>, <span class="hlFld-ContribAuthor ">Siriluk  Ratanabanyong</span>, <span class="hlFld-ContribAuthor ">Kiattawee  Choowongkomon</span>. </span><span class="cited-content_cbyCitation_article-title">Expression, purification, and characterization of the native intracellular domain of human epidermal growth factor receptors 1 and 2 in Escherichia coli. </span><span class="cited-content_cbyCitation_journal-name">Applied Microbiology and Biotechnology</span><span> <strong>2019,</strong> <em>103 </em>
                                    (20)
                                     , 8427-8438. <a href="https://doi.org/10.1007/s00253-019-10116-6" title="DOI URL">https://doi.org/10.1007/s00253-019-10116-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00253-019-10116-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00253-019-10116-6%26sid%3Dliteratum%253Aachs%26jtitle%3DApplied%2520Microbiology%2520and%2520Biotechnology%26atitle%3DExpression%25252C%252Bpurification%25252C%252Band%252Bcharacterization%252Bof%252Bthe%252Bnative%252Bintracellular%252Bdomain%252Bof%252Bhuman%252Bepidermal%252Bgrowth%252Bfactor%252Breceptors%252B1%252Band%252B2%252Bin%252BEscherichia%252Bcoli%26aulast%3DSeetaha%26aufirst%3DSupaphorn%26date%3D2019%26date%3D2019%26volume%3D103%26issue%3D20%26spage%3D8427%26epage%3D8438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Melania  Poratti</span>, <span class="hlFld-ContribAuthor ">Giovanni  Marzaro</span>. </span><span class="cited-content_cbyCitation_article-title">Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>172 </em>, 143-153. <a href="https://doi.org/10.1016/j.ejmech.2019.03.064" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.03.064</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.03.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.03.064%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThird-generation%252BCDK%252Binhibitors%25253A%252BA%252Breview%252Bon%252Bthe%252Bsynthesis%252Band%252Bbinding%252Bmodes%252Bof%252BPalbociclib%25252C%252BRibociclib%252Band%252BAbemaciclib%26aulast%3DPoratti%26aufirst%3DMelania%26date%3D2019%26volume%3D172%26spage%3D143%26epage%3D153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christophe  Michon</span>, <span class="hlFld-ContribAuthor ">Joachim  Gilbert</span>, <span class="hlFld-ContribAuthor ">Xavier  Trivelli</span>, <span class="hlFld-ContribAuthor ">Fady  Nahra</span>, <span class="hlFld-ContribAuthor ">Catherine S. J.  Cazin</span>, <span class="hlFld-ContribAuthor ">Francine  Agbossou-Niedercorn</span>, <span class="hlFld-ContribAuthor ">Steven P.  Nolan</span>. </span><span class="cited-content_cbyCitation_article-title">Gold(
              i
              ) catalysed regio- and stereoselective intermolecular hydroamination of internal alkynes: towards functionalised azoles. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (15)
                                     , 3805-3811. <a href="https://doi.org/10.1039/C9OB00587K" title="DOI URL">https://doi.org/10.1039/C9OB00587K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9OB00587K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9OB00587K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DGold%252528%252Bi%252B%252529%252Bcatalysed%252Bregio-%252Band%252Bstereoselective%252Bintermolecular%252Bhydroamination%252Bof%252Binternal%252Balkynes%25253A%252Btowards%252Bfunctionalised%252Bazoles%26aulast%3DMichon%26aufirst%3DChristophe%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D15%26spage%3D3805%26epage%3D3811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aslı  Türe</span>, <span class="hlFld-ContribAuthor ">Deniz Cansen  Kahraman</span>, <span class="hlFld-ContribAuthor ">Rengul  Cetin-Atalay</span>, <span class="hlFld-ContribAuthor ">Sinem  Helvacıoğlu</span>, <span class="hlFld-ContribAuthor ">Mohammad  Charehsaz</span>, <span class="hlFld-ContribAuthor ">İlkay  Küçükgüzel</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, anticancer activity, toxicity evaluation and molecular docking studies of novel phenylaminopyrimidine—(thio)urea hybrids as potential kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Computational Biology and Chemistry</span><span> <strong>2019,</strong> <em>78 </em>, 227-241. <a href="https://doi.org/10.1016/j.compbiolchem.2018.12.003" title="DOI URL">https://doi.org/10.1016/j.compbiolchem.2018.12.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.compbiolchem.2018.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.compbiolchem.2018.12.003%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520Biology%2520and%2520Chemistry%26atitle%3DSynthesis%25252C%252Banticancer%252Bactivity%25252C%252Btoxicity%252Bevaluation%252Band%252Bmolecular%252Bdocking%252Bstudies%252Bof%252Bnovel%252Bphenylaminopyrimidine%2525E2%252580%252594%252528thio%252529urea%252Bhybrids%252Bas%252Bpotential%252Bkinase%252Binhibitors%26aulast%3DT%25C3%25BCre%26aufirst%3DAsl%25C4%25B1%26date%3D2019%26volume%3D78%26spage%3D227%26epage%3D241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">[Special Issue for Honor Award dedicating to Prof Kimito Funatsu]Exploring Polypharmacology and Molecular Promiscuity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computer Aided Chemistry</span><span> <strong>2019,</strong> <em>20 </em>
                                    (0)
                                     , 43-46. <a href="https://doi.org/10.2751/jcac.20.43" title="DOI URL">https://doi.org/10.2751/jcac.20.43</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2751/jcac.20.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2751%2Fjcac.20.43%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computer%2520Aided%2520Chemistry%26atitle%3D%25255BSpecial%252BIssue%252Bfor%252BHonor%252BAward%252Bdedicating%252Bto%252BProf%252BKimito%252BFunatsu%25255DExploring%252BPolypharmacology%252Band%252BMolecular%252BPromiscuity%26aulast%3DBajorath%26aufirst%3DJ%25C3%25BCrgen%26date%3D2019%26volume%3D20%26issue%3D0%26spage%3D43%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zh. V.  Ignatovich</span>, <span class="hlFld-ContribAuthor ">A. L.  Ermolinskaya</span>, <span class="hlFld-ContribAuthor ">A. V.  Kletskov</span>, <span class="hlFld-ContribAuthor ">V. I.  Potkin</span>, <span class="hlFld-ContribAuthor ">E. V.  Koroleva</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of New Amides of Isoxazole- and Isothiazole-Substituted Carboxylic Acids Containing an Arylaminopyrimidine Fragment. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>54 </em>
                                    (8)
                                     , 1218-1222. <a href="https://doi.org/10.1134/S107042801808016X" title="DOI URL">https://doi.org/10.1134/S107042801808016X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S107042801808016X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS107042801808016X%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BNew%252BAmides%252Bof%252BIsoxazole-%252Band%252BIsothiazole-Substituted%252BCarboxylic%252BAcids%252BContaining%252Ban%252BArylaminopyrimidine%252BFragment%26aulast%3DIgnatovich%26aufirst%3DZh.%2BV.%26date%3D2018%26date%3D2018%26volume%3D54%26issue%3D8%26spage%3D1218%26epage%3D1222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mehmet Erman  Erdemli</span>, <span class="hlFld-ContribAuthor ">Ramin  Ekhteiari Salmas</span>, <span class="hlFld-ContribAuthor ">Serdar  Durdagi</span>, <span class="hlFld-ContribAuthor ">Hasan  Akgul</span>, <span class="hlFld-ContribAuthor ">Mehmet  Demirkol</span>, <span class="hlFld-ContribAuthor ">Zeynep  Aksungur</span>, <span class="hlFld-ContribAuthor ">Zeliha  Selamoglu</span>. </span><span class="cited-content_cbyCitation_article-title">Biochemical changes induced by grape seed extract and low level laser therapy administration during intraoral wound healing in rat liver: an experimental and in silico study. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2018,</strong> <em>36 </em>
                                    (4)
                                     , 993-1008. <a href="https://doi.org/10.1080/07391102.2017.1305297" title="DOI URL">https://doi.org/10.1080/07391102.2017.1305297</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2017.1305297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2017.1305297%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DBiochemical%252Bchanges%252Binduced%252Bby%252Bgrape%252Bseed%252Bextract%252Band%252Blow%252Blevel%252Blaser%252Btherapy%252Badministration%252Bduring%252Bintraoral%252Bwound%252Bhealing%252Bin%252Brat%252Bliver%25253A%252Ban%252Bexperimental%252Band%252Bin%252Bsilico%252Bstudy%26aulast%3DErdemli%26aufirst%3DMehmet%2BErman%26date%3D2018%26date%3D2017%26volume%3D36%26issue%3D4%26spage%3D993%26epage%3D1008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martin  Prause</span>, <span class="hlFld-ContribAuthor ">Sabrina  Niedermoser</span>, <span class="hlFld-ContribAuthor ">Carmen  Wängler</span>, <span class="hlFld-ContribAuthor ">Clemens  Decristoforo</span>, <span class="hlFld-ContribAuthor ">Uwe  Seibold</span>, <span class="hlFld-ContribAuthor ">Stephanie  Riester</span>, <span class="hlFld-ContribAuthor ">Takahiro  Taguchi</span>, <span class="hlFld-ContribAuthor ">Ralf  Schirrmacher</span>, <span class="hlFld-ContribAuthor ">Gert  Fricker</span>, <span class="hlFld-ContribAuthor ">Björn  Wängler</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, in vitro and in vivo evaluation of 18 F-fluoronorimatinib as radiotracer for Imatinib-sensitive gastrointestinal stromal tumors. </span><span class="cited-content_cbyCitation_journal-name">Nuclear Medicine and Biology</span><span> <strong>2018,</strong> <em>57 </em>, 1-11. <a href="https://doi.org/10.1016/j.nucmedbio.2017.11.004" title="DOI URL">https://doi.org/10.1016/j.nucmedbio.2017.11.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.nucmedbio.2017.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.nucmedbio.2017.11.004%26sid%3Dliteratum%253Aachs%26jtitle%3DNuclear%2520Medicine%2520and%2520Biology%26atitle%3DSynthesis%25252C%252Bin%252Bvitro%252Band%252Bin%252Bvivo%252Bevaluation%252Bof%252B18%252BF-fluoronorimatinib%252Bas%252Bradiotracer%252Bfor%252BImatinib-sensitive%252Bgastrointestinal%252Bstromal%252Btumors%26aulast%3DPrause%26aufirst%3DMartin%26date%3D2018%26volume%3D57%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mange Ram  Yadav</span>, <span class="hlFld-ContribAuthor ">Mahesh A.  Barmade</span>, <span class="hlFld-ContribAuthor ">Rupesh V.  Chikhale</span>, <span class="hlFld-ContribAuthor ">Prashant R.  Murumkar</span>. </span><span class="cited-content_cbyCitation_article-title">Computational Modelling of Kinase Inhibitors as Anti-Alzheimer Agents. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 347-417. <a href="https://doi.org/10.1007/978-1-4939-7404-7_14" title="DOI URL">https://doi.org/10.1007/978-1-4939-7404-7_14</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-4939-7404-7_14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-4939-7404-7_14%26sid%3Dliteratum%253Aachs%26atitle%3DComputational%252BModelling%252Bof%252BKinase%252BInhibitors%252Bas%252BAnti-Alzheimer%252BAgents%26aulast%3DYadav%26aufirst%3DMange%2BRam%26date%3D2018%26date%3D2017%26spage%3D347%26epage%3D417%26pub%3DSpringer%2520New%2520York%26atitle%3DComputational%252BModeling%252Bof%252BDrugs%252BAgainst%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DRoy%26aufirst%3DKunal%26date%3D2018%26volume%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Akhil  Kumar</span>, <span class="hlFld-ContribAuthor ">Ashok  Sharma</span>. </span><span class="cited-content_cbyCitation_article-title">Computational Modeling of Multi-target-Directed Inhibitors Against Alzheimer’s Disease. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 533-571. <a href="https://doi.org/10.1007/978-1-4939-7404-7_19" title="DOI URL">https://doi.org/10.1007/978-1-4939-7404-7_19</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-4939-7404-7_19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-4939-7404-7_19%26sid%3Dliteratum%253Aachs%26atitle%3DComputational%252BModeling%252Bof%252BMulti-target-Directed%252BInhibitors%252BAgainst%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DKumar%26aufirst%3DAkhil%26date%3D2018%26date%3D2017%26spage%3D533%26epage%3D571%26pub%3DSpringer%2520New%2520York%26atitle%3DComputational%252BModeling%252Bof%252BDrugs%252BAgainst%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DRoy%26aufirst%3DKunal%26date%3D2018%26volume%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luciana  Scotti</span>, <span class="hlFld-ContribAuthor ">Hamilton Mitsugu  Ishiki</span>, <span class="hlFld-ContribAuthor ">Marcelo Cavalcante  Duarte</span>, <span class="hlFld-ContribAuthor ">Tiago Branquinho  Oliveira</span>, <span class="hlFld-ContribAuthor ">Marcus T.  Scotti</span>. </span><span class="cited-content_cbyCitation_article-title">Computational Approaches in Multitarget Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 327-345. <a href="https://doi.org/10.1007/978-1-4939-7899-1_16" title="DOI URL">https://doi.org/10.1007/978-1-4939-7899-1_16</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-4939-7899-1_16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-4939-7899-1_16%26sid%3Dliteratum%253Aachs%26atitle%3DComputational%252BApproaches%252Bin%252BMultitarget%252BDrug%252BDiscovery%26aulast%3DScotti%26aufirst%3DLuciana%26date%3D2018%26date%3D2018%26spage%3D327%26epage%3D345%26pub%3DSpringer%2520New%2520York%26atitle%3DComputational%252BToxicology%26aulast%3DNicolotti%26aufirst%3DOrazio%26date%3D2018%26volume%3D1800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pankaj K.  Singh</span>, <span class="hlFld-ContribAuthor ">Om  Silakari</span>. </span><span class="cited-content_cbyCitation_article-title">Multitargeting Heterocycles. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 1-29. <a href="https://doi.org/10.1016/B978-0-08-102083-8.00001-7" title="DOI URL">https://doi.org/10.1016/B978-0-08-102083-8.00001-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102083-8.00001-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102083-8.00001-7%26sid%3Dliteratum%253Aachs%26atitle%3DMultitargeting%252BHeterocycles%26aulast%3DSingh%26aufirst%3DPankaj%2BK.%26date%3D2018%26spage%3D1%26epage%3D29%26pub%3DElsevier%26atitle%3DKey%252BHeterocycle%252BCores%252Bfor%252BDesigning%252BMultitargeting%252BMolecules%26date%3D2018%26volume%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James L.  Gleason</span>, <span class="hlFld-ContribAuthor ">John H.  White</span>. </span><span class="cited-content_cbyCitation_article-title">Bifunctional Vitamin D Hybrid Molecules. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 647-655. <a href="https://doi.org/10.1016/B978-0-12-809963-6.00089-4" title="DOI URL">https://doi.org/10.1016/B978-0-12-809963-6.00089-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-809963-6.00089-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-809963-6.00089-4%26sid%3Dliteratum%253Aachs%26atitle%3DBifunctional%252BVitamin%252BD%252BHybrid%252BMolecules%26aulast%3DGleason%26aufirst%3DJames%2BL.%26date%3D2018%26spage%3D647%26epage%3D655%26pub%3DElsevier%26atitle%3DVitamin%252BD%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang-Ye  Jiang</span>, <span class="hlFld-ContribAuthor ">Gui-Yuan  Dou</span>, <span class="hlFld-ContribAuthor ">Kun  Xu</span>, <span class="hlFld-ContribAuthor ">Cheng-Chu  Zeng</span>. </span><span class="cited-content_cbyCitation_article-title">Bromide-catalyzed electrochemical trifluoromethylation/cyclization of
              N
              -arylacrylamides with low catalyst loading. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2018,</strong> <em>5 </em>
                                    (17)
                                     , 2573-2577. <a href="https://doi.org/10.1039/C8QO00645H" title="DOI URL">https://doi.org/10.1039/C8QO00645H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8QO00645H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8QO00645H%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DBromide-catalyzed%252Belectrochemical%252Btrifluoromethylation%25252Fcyclization%252Bof%252BN%252B-arylacrylamides%252Bwith%252Blow%252Bcatalyst%252Bloading%26aulast%3DJiang%26aufirst%3DYang-Ye%26date%3D2018%26date%3D2018%26volume%3D5%26issue%3D17%26spage%3D2573%26epage%3D2577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ж.В.  Игнатович</span>, <span class="hlFld-ContribAuthor ">А. Л.  Ермолинская</span>, <span class="hlFld-ContribAuthor ">А.В.  Клецков</span>, <span class="hlFld-ContribAuthor ">В.И.  Поткин</span>, <span class="hlFld-ContribAuthor ">Е.В.  Королева</span>. </span><span class="cited-content_cbyCitation_article-title">СИНТЕЗ НОВЫХ АМИДОВ ИЗОКСАЗОЛ- И ИЗОТИАЗОЛ- ЗАМЕЩЕННЫХ КАРБОНОВЫХ КИСЛОТ, СОДЕРЖАЩИХ АРИЛАМИНОПИРИМИДИНОВЫЙ ФРАГМЕНТ, "Журнал органической химии". </span><span class="cited-content_cbyCitation_journal-name">Журнал органической химии</span><span> <strong>2018,</strong> <em> </em>
                                    (8)
                                     , 1207-1210. <a href="https://doi.org/10.7868/S0514749218080162" title="DOI URL">https://doi.org/10.7868/S0514749218080162</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.7868/S0514749218080162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.7868%2FS0514749218080162%26sid%3Dliteratum%253Aachs%26jtitle%3D%25D0%2596%25D1%2583%25D1%2580%25D0%25BD%25D0%25B0%25D0%25BB%2520%25D0%25BE%25D1%2580%25D0%25B3%25D0%25B0%25D0%25BD%25D0%25B8%25D1%2587%25D0%25B5%25D1%2581%25D0%25BA%25D0%25BE%25D0%25B9%2520%25D1%2585%25D0%25B8%25D0%25BC%25D0%25B8%25D0%25B8%26atitle%3D%2525D0%2525A1%2525D0%252598%2525D0%25259D%2525D0%2525A2%2525D0%252595%2525D0%252597%252B%2525D0%25259D%2525D0%25259E%2525D0%252592%2525D0%2525AB%2525D0%2525A5%252B%2525D0%252590%2525D0%25259C%2525D0%252598%2525D0%252594%2525D0%25259E%2525D0%252592%252B%2525D0%252598%2525D0%252597%2525D0%25259E%2525D0%25259A%2525D0%2525A1%2525D0%252590%2525D0%252597%2525D0%25259E%2525D0%25259B-%252B%2525D0%252598%252B%2525D0%252598%2525D0%252597%2525D0%25259E%2525D0%2525A2%2525D0%252598%2525D0%252590%2525D0%252597%2525D0%25259E%2525D0%25259B-%252B%2525D0%252597%2525D0%252590%2525D0%25259C%2525D0%252595%2525D0%2525A9%2525D0%252595%2525D0%25259D%2525D0%25259D%2525D0%2525AB%2525D0%2525A5%252B%2525D0%25259A%2525D0%252590%2525D0%2525A0%2525D0%252591%2525D0%25259E%2525D0%25259D%2525D0%25259E%2525D0%252592%2525D0%2525AB%2525D0%2525A5%252B%2525D0%25259A%2525D0%252598%2525D0%2525A1%2525D0%25259B%2525D0%25259E%2525D0%2525A2%25252C%252B%2525D0%2525A1%2525D0%25259E%2525D0%252594%2525D0%252595%2525D0%2525A0%2525D0%252596%2525D0%252590%2525D0%2525A9%2525D0%252598%2525D0%2525A5%252B%2525D0%252590%2525D0%2525A0%2525D0%252598%2525D0%25259B%2525D0%252590%2525D0%25259C%2525D0%252598%2525D0%25259D%2525D0%25259E%2525D0%25259F%2525D0%252598%2525D0%2525A0%2525D0%252598%2525D0%25259C%2525D0%252598%2525D0%252594%2525D0%252598%2525D0%25259D%2525D0%25259E%2525D0%252592%2525D0%2525AB%2525D0%252599%252B%2525D0%2525A4%2525D0%2525A0%2525D0%252590%2525D0%252593%2525D0%25259C%2525D0%252595%2525D0%25259D%2525D0%2525A2%25252C%252B%252522%2525D0%252596%2525D1%252583%2525D1%252580%2525D0%2525BD%2525D0%2525B0%2525D0%2525BB%252B%2525D0%2525BE%2525D1%252580%2525D0%2525B3%2525D0%2525B0%2525D0%2525BD%2525D0%2525B8%2525D1%252587%2525D0%2525B5%2525D1%252581%2525D0%2525BA%2525D0%2525BE%2525D0%2525B9%252B%2525D1%252585%2525D0%2525B8%2525D0%2525BC%2525D0%2525B8%2525D0%2525B8%252522%26aulast%3D%25D0%2598%25D0%25B3%25D0%25BD%25D0%25B0%25D1%2582%25D0%25BE%25D0%25B2%25D0%25B8%25D1%2587%26aufirst%3D%25D0%2596.%25D0%2592.%26date%3D2018%26issue%3D8%26spage%3D1207%26epage%3D1210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oscar  Méndez-Lucio</span>, <span class="hlFld-ContribAuthor ">J. Jesús  Naveja</span>, <span class="hlFld-ContribAuthor ">Hugo  Vite-Caritino</span>, <span class="hlFld-ContribAuthor ">Fernando D.  Prieto-Martínez</span>, <span class="hlFld-ContribAuthor ">José L.  Medina-Franco</span>. </span><span class="cited-content_cbyCitation_article-title">Polypharmacology in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 1-29. <a href="https://doi.org/10.1002/9783527674381.ch1" title="DOI URL">https://doi.org/10.1002/9783527674381.ch1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527674381.ch1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527674381.ch1%26sid%3Dliteratum%253Aachs%26atitle%3DPolypharmacology%252Bin%252BDrug%252BDiscovery%26aulast%3DM%25C3%25A9ndez-Lucio%26aufirst%3DOscar%26date%3D2017%26date%3D2017%26spage%3D1%26epage%3D29%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DDrug%252BSelectivity%26aulast%3DHandler%26aufirst%3DNorbert%26date%3D2017%26volume%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dilip  Narayanan</span>, <span class="hlFld-ContribAuthor ">Osman A. B. S. M.  Gani</span>, <span class="hlFld-ContribAuthor ">Franz X. E.  Gruber</span>, <span class="hlFld-ContribAuthor ">Richard A.  Engh</span>. </span><span class="cited-content_cbyCitation_article-title">Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cheminformatics</span><span> <strong>2017,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13321-017-0229-8" title="DOI URL">https://doi.org/10.1186/s13321-017-0229-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13321-017-0229-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13321-017-0229-8%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cheminformatics%26atitle%3DData%252Bdriven%252Bpolypharmacological%252Bdrug%252Bdesign%252Bfor%252Blung%252Bcancer%25253A%252Banalyses%252Bfor%252Btargeting%252BALK%25252C%252BMET%25252C%252Band%252BEGFR%26aulast%3DNarayanan%26aufirst%3DDilip%26date%3D2017%26date%3D2017%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nesrine S.  El-Mezayen</span>, <span class="hlFld-ContribAuthor ">Wessam F.  El-Hadidy</span>, <span class="hlFld-ContribAuthor ">Wessam M.  El-Refaie</span>, <span class="hlFld-ContribAuthor ">Th.I.  Shalaby</span>, <span class="hlFld-ContribAuthor ">Mahmoud M.  Khattab</span>, <span class="hlFld-ContribAuthor ">Aiman S.  El-Khatib</span>. </span><span class="cited-content_cbyCitation_article-title">Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Controlled Release</span><span> <strong>2017,</strong> <em>266 </em>, 226-237. <a href="https://doi.org/10.1016/j.jconrel.2017.09.035" title="DOI URL">https://doi.org/10.1016/j.jconrel.2017.09.035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jconrel.2017.09.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jconrel.2017.09.035%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Controlled%2520Release%26atitle%3DHepatic%252Bstellate%252Bcell-targeted%252Bimatinib%252Bnanomedicine%252Bversus%252Bconventional%252Bimatinib%25253A%252BA%252Bnovel%252Bstrategy%252Bwith%252Bpotent%252Befficacy%252Bin%252Bexperimental%252Bliver%252Bfibrosis%26aulast%3DEl-Mezayen%26aufirst%3DNesrine%2BS.%26date%3D2017%26volume%3D266%26spage%3D226%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gaganpreet  Kaur</span>, <span class="hlFld-ContribAuthor ">Om  Silakari</span>. </span><span class="cited-content_cbyCitation_article-title">Multiple target-centric strategy to tame inflammation. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2017,</strong> <em>9 </em>
                                    (12)
                                     , 1361-1376. <a href="https://doi.org/10.4155/fmc-2017-0050" title="DOI URL">https://doi.org/10.4155/fmc-2017-0050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2017-0050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2017-0050%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DMultiple%252Btarget-centric%252Bstrategy%252Bto%252Btame%252Binflammation%26aulast%3DKaur%26aufirst%3DGaganpreet%26date%3D2017%26volume%3D9%26issue%3D12%26spage%3D1361%26epage%3D1376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Didier  Rognan</span>. </span><span class="cited-content_cbyCitation_article-title">The impact of in silico screening in the discovery of novel and safer drug candidates. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2017,</strong> <em>175 </em>, 47-66. <a href="https://doi.org/10.1016/j.pharmthera.2017.02.034" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2017.02.034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2017.02.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2017.02.034%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DThe%252Bimpact%252Bof%252Bin%252Bsilico%252Bscreening%252Bin%252Bthe%252Bdiscovery%252Bof%252Bnovel%252Band%252Bsafer%252Bdrug%252Bcandidates%26aulast%3DRognan%26aufirst%3DDidier%26date%3D2017%26volume%3D175%26spage%3D47%26epage%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Axel  Kleemann</span>. </span><span class="cited-content_cbyCitation_article-title">Antineoplastic and Immunomodulating Agents (L). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 1-56. <a href="https://doi.org/10.1002/14356007.a05_001.pub3" title="DOI URL">https://doi.org/10.1002/14356007.a05_001.pub3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/14356007.a05_001.pub3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F14356007.a05_001.pub3%26sid%3Dliteratum%253Aachs%26atitle%3DAntineoplastic%252Band%252BImmunomodulating%252BAgents%252B%252528L%252529%26aulast%3DKleemann%26aufirst%3DAxel%26date%3D2017%26date%3D2017%26spage%3D1%26epage%3D56%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DUllmann%252527s%252BEncyclopedia%252Bof%252BIndustrial%252BChemistry%26date%3D2000%26date%3D2000%26volume%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria  Ruzzene</span>, <span class="hlFld-ContribAuthor ">Jessika  Bertacchini</span>, <span class="hlFld-ContribAuthor ">Alex  Toker</span>, <span class="hlFld-ContribAuthor ">Sandra  Marmiroli</span>. </span><span class="cited-content_cbyCitation_article-title">Cross-talk between the CK2 and AKT signaling pathways in cancer. </span><span class="cited-content_cbyCitation_journal-name">Advances in Biological Regulation</span><span> <strong>2017,</strong> <em>64 </em>, 1-8. <a href="https://doi.org/10.1016/j.jbior.2017.03.002" title="DOI URL">https://doi.org/10.1016/j.jbior.2017.03.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jbior.2017.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jbior.2017.03.002%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvances%2520in%2520Biological%2520Regulation%26atitle%3DCross-talk%252Bbetween%252Bthe%252BCK2%252Band%252BAKT%252Bsignaling%252Bpathways%252Bin%252Bcancer%26aulast%3DRuzzene%26aufirst%3DMaria%26date%3D2017%26volume%3D64%26spage%3D1%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ye  Hu</span>, <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Entering the ‘big data’ era in medicinal chemistry: molecular promiscuity analysis revisited. </span><span class="cited-content_cbyCitation_journal-name">Future Science OA</span><span> <strong>2017,</strong> <em>3 </em>
                                    (2)
                                     , FSO179. <a href="https://doi.org/10.4155/fsoa-2017-0001" title="DOI URL">https://doi.org/10.4155/fsoa-2017-0001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fsoa-2017-0001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffsoa-2017-0001%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Science%2520OA%26atitle%3DEntering%252Bthe%252B%2525E2%252580%252598big%252Bdata%2525E2%252580%252599%252Bera%252Bin%252Bmedicinal%252Bchemistry%25253A%252Bmolecular%252Bpromiscuity%252Banalysis%252Brevisited%26aulast%3DHu%26aufirst%3DYe%26date%3D2017%26volume%3D3%26issue%3D2%26spage%3DFSO179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter M.  Fischer</span>. </span><span class="cited-content_cbyCitation_article-title">Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2017,</strong> <em>37 </em>
                                    (2)
                                     , 314-367. <a href="https://doi.org/10.1002/med.21409" title="DOI URL">https://doi.org/10.1002/med.21409</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21409%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DApproved%252Band%252BExperimental%252BSmall-Molecule%252BOncology%252BKinase%252BInhibitor%252BDrugs%25253A%252BA%252BMid-2016%252BOverview%26aulast%3DFischer%26aufirst%3DPeter%2BM.%26date%3D2017%26date%3D2016%26volume%3D37%26issue%3D2%26spage%3D314%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zh. V.  Ignatovich</span>, <span class="hlFld-ContribAuthor ">E. V.  Koroleva</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of functionalized amides of 2-(arylamino)pyrimidine series. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>53 </em>
                                    (2)
                                     , 251-257. <a href="https://doi.org/10.1134/S1070428017020191" title="DOI URL">https://doi.org/10.1134/S1070428017020191</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428017020191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428017020191%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252Bfunctionalized%252Bamides%252Bof%252B2-%252528arylamino%252529pyrimidine%252Bseries%26aulast%3DIgnatovich%26aufirst%3DZh.%2BV.%26date%3D2017%26date%3D2017%26volume%3D53%26issue%3D2%26spage%3D251%26epage%3D257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giovanni  Bottegoni</span>, <span class="hlFld-ContribAuthor ">Andrea  Cavalli</span>. </span><span class="cited-content_cbyCitation_article-title">Computational Methods in Multitarget Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 239-258. <a href="https://doi.org/10.1016/B978-0-08-101011-2.00009-X" title="DOI URL">https://doi.org/10.1016/B978-0-08-101011-2.00009-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-101011-2.00009-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-101011-2.00009-X%26sid%3Dliteratum%253Aachs%26atitle%3DComputational%252BMethods%252Bin%252BMultitarget%252BDrug%252BDiscovery%26aulast%3DBottegoni%26aufirst%3DGiovanni%26date%3D2017%26spage%3D239%26epage%3D258%26pub%3DElsevier%26atitle%3DDesign%252Bof%252BHybrid%252BMolecules%252Bfor%252BDrug%252BDevelopment%26date%3D2017%26volume%3D303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elisa  Uliassi</span>, <span class="hlFld-ContribAuthor ">Federica  Prati</span>, <span class="hlFld-ContribAuthor ">Salvatore  Bongarzone</span>, <span class="hlFld-ContribAuthor ">Maria Laura  Bolognesi</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal Chemistry of Hybrids for Neurodegenerative Diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 259-277. <a href="https://doi.org/10.1016/B978-0-08-101011-2.00010-6" title="DOI URL">https://doi.org/10.1016/B978-0-08-101011-2.00010-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-101011-2.00010-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-101011-2.00010-6%26sid%3Dliteratum%253Aachs%26atitle%3DMedicinal%252BChemistry%252Bof%252BHybrids%252Bfor%252BNeurodegenerative%252BDiseases%26aulast%3DUliassi%26aufirst%3DElisa%26date%3D2017%26spage%3D259%26epage%3D277%26pub%3DElsevier%26atitle%3DDesign%252Bof%252BHybrid%252BMolecules%252Bfor%252BDrug%252BDevelopment%26date%3D2017%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M.P.  Gleeson</span>, <span class="hlFld-ContribAuthor ">D.  Montanari</span>. </span><span class="cited-content_cbyCitation_article-title">Multiobjective Optimization of Biological and Physical Properties in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 64-93. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12315-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12315-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12315-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12315-7%26sid%3Dliteratum%253Aachs%26atitle%3DMultiobjective%252BOptimization%252Bof%252BBiological%252Band%252BPhysical%252BProperties%252Bin%252BDrug%252BDiscovery%26aulast%3DGleeson%26aufirst%3DM.P.%26date%3D2017%26spage%3D64%26epage%3D93%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Albert J.  Kooistra</span>, <span class="hlFld-ContribAuthor ">Andrea  Volkamer</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase-Centric Computational Drug Development. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 197-236. <a href="https://doi.org/10.1016/bs.armc.2017.08.001" title="DOI URL">https://doi.org/10.1016/bs.armc.2017.08.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.armc.2017.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.armc.2017.08.001%26sid%3Dliteratum%253Aachs%26atitle%3DKinase-Centric%252BComputational%252BDrug%252BDevelopment%26aulast%3DKooistra%26aufirst%3DAlbert%2BJ.%26date%3D2017%26spage%3D197%26epage%3D236%26pub%3DElsevier%26atitle%3DPlatform%252BTechnologies%252Bin%252BDrug%252BDiscovery%252Band%252BValidation%26date%3D2017%26volume%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vishal  Nemaysh</span>, <span class="hlFld-ContribAuthor ">Pratibha Mehta  Luthra</span>. </span><span class="cited-content_cbyCitation_article-title">Computational analysis revealing that K634 and T681 mutations modulate the 3D-structure of PDGFR-β and lead to sunitinib resistance. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2017,</strong> <em>7 </em>
                                    (60)
                                     , 37612-37626. <a href="https://doi.org/10.1039/C7RA01305A" title="DOI URL">https://doi.org/10.1039/C7RA01305A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7RA01305A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7RA01305A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DComputational%252Banalysis%252Brevealing%252Bthat%252BK634%252Band%252BT681%252Bmutations%252Bmodulate%252Bthe%252B3D-structure%252Bof%252BPDGFR-%2525CE%2525B2%252Band%252Blead%252Bto%252Bsunitinib%252Bresistance%26aulast%3DNemaysh%26aufirst%3DVishal%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D60%26spage%3D37612%26epage%3D37626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yung  Chang Hsu</span>, <span class="hlFld-ContribAuthor ">Mohane  Selvaraj Coumar</span>, <span class="hlFld-ContribAuthor ">Wen-Chieh  Wang</span>, <span class="hlFld-ContribAuthor ">Hui-Yi  Shiao</span>, <span class="hlFld-ContribAuthor ">Yi-Yu  Ke</span>, <span class="hlFld-ContribAuthor ">Wen-Hsing  Lin</span>, <span class="hlFld-ContribAuthor ">Ching-Chuan  Kuo</span>, <span class="hlFld-ContribAuthor ">Chun-Wei  Chang</span>, <span class="hlFld-ContribAuthor ">Fu-Ming  Kuo</span>, <span class="hlFld-ContribAuthor ">Pei-Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Sing-Yi  Wang</span>, <span class="hlFld-ContribAuthor ">An-Siou  Li</span>, <span class="hlFld-ContribAuthor ">Chun-Hwa  Chen</span>, <span class="hlFld-ContribAuthor ">Po-Chu  Kuo</span>, <span class="hlFld-ContribAuthor ">Ching-Ping  Chen</span>, <span class="hlFld-ContribAuthor ">Ming-Hsine  Wu</span>, <span class="hlFld-ContribAuthor ">Chen-Lung  Huang</span>, <span class="hlFld-ContribAuthor ">Kuei-Jung  Yen</span>, <span class="hlFld-ContribAuthor ">Yun-I  Chang</span>, <span class="hlFld-ContribAuthor ">John T.-A.  Hsu</span>, <span class="hlFld-ContribAuthor ">Chiung-Tong  Chen</span>, <span class="hlFld-ContribAuthor ">Teng-Kuang  Yeh</span>, <span class="hlFld-ContribAuthor ">Jen-Shin  Song</span>, <span class="hlFld-ContribAuthor ">Chuan  Shih</span>, <span class="hlFld-ContribAuthor ">Hsing-Pang  Hsieh</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of BPR1K871, a quinazoline based,  multi-kinase inhibitor for the treatment of AML and solid tumors: Rational  design, synthesis,
              in vitro
              and
              in vivo
              evaluation. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2016,</strong> <em>7 </em>
                                    (52)
                                     , 86239-86256. <a href="https://doi.org/10.18632/oncotarget.13369" title="DOI URL">https://doi.org/10.18632/oncotarget.13369</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.13369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.13369%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DDiscovery%252Bof%252BBPR1K871%25252C%252Ba%252Bquinazoline%252Bbased%25252C%252Bmulti-kinase%252Binhibitor%252Bfor%252Bthe%252Btreatment%252Bof%252BAML%252Band%252Bsolid%252Btumors%25253A%252BRational%252Bdesign%25252C%252Bsynthesis%25252C%252Bin%252Bvitro%252Band%252Bin%252Bvivo%252Bevaluation%26aulast%3DChang%2BHsu%26aufirst%3DYung%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D52%26spage%3D86239%26epage%3D86256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.  Österroos</span>, <span class="hlFld-ContribAuthor ">M.  Kashif</span>, <span class="hlFld-ContribAuthor ">C.  Haglund</span>, <span class="hlFld-ContribAuthor ">K.  Blom</span>, <span class="hlFld-ContribAuthor ">M.  Höglund</span>, <span class="hlFld-ContribAuthor ">C.  Andersson</span>, <span class="hlFld-ContribAuthor ">M.G.  Gustafsson</span>, <span class="hlFld-ContribAuthor ">A.  Eriksson</span>, <span class="hlFld-ContribAuthor ">R.  Larsson</span>. </span><span class="cited-content_cbyCitation_article-title">Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2016,</strong> <em>118 </em>, 40-49. <a href="https://doi.org/10.1016/j.bcp.2016.08.020" title="DOI URL">https://doi.org/10.1016/j.bcp.2016.08.020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2016.08.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2016.08.020%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DCombination%252Bscreening%252Bin%252Bvitro%252Bidentifies%252Bsynergistically%252Bacting%252BKP372-1%252Band%252Bcytarabine%252Bagainst%252Bacute%252Bmyeloid%252Bleukemia%26aulast%3D%25C3%2596sterroos%26aufirst%3DA.%26date%3D2016%26volume%3D118%26spage%3D40%26epage%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter J.  Barnes</span>, . </span><span class="cited-content_cbyCitation_article-title">Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Reviews</span><span> <strong>2016,</strong> <em>68 </em>
                                    (3)
                                     , 788-815. <a href="https://doi.org/10.1124/pr.116.012518" title="DOI URL">https://doi.org/10.1124/pr.116.012518</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/pr.116.012518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fpr.116.012518%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Reviews%26atitle%3DKinases%252Bas%252BNovel%252BTherapeutic%252BTargets%252Bin%252BAsthma%252Band%252BChronic%252BObstructive%252BPulmonary%252BDisease%26aulast%3DBarnes%26aufirst%3DPeter%2BJ.%26date%3D2016%26date%3D2016%26volume%3D68%26issue%3D3%26spage%3D788%26epage%3D815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ran  Cao</span>, <span class="hlFld-ContribAuthor ">Yanli  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Predicting Molecular Targets for Small-Molecule Drugs with a Ligand-Based Interaction Fingerprint Approach. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2016,</strong> <em>11 </em>
                                    (12)
                                     , 1352-1361. <a href="https://doi.org/10.1002/cmdc.201500228" title="DOI URL">https://doi.org/10.1002/cmdc.201500228</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201500228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201500228%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DPredicting%252BMolecular%252BTargets%252Bfor%252BSmall-Molecule%252BDrugs%252Bwith%252Ba%252BLigand-Based%252BInteraction%252BFingerprint%252BApproach%26aulast%3DCao%26aufirst%3DRan%26date%3D2016%26date%3D2015%26volume%3D11%26issue%3D12%26spage%3D1352%26epage%3D1361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gennady B.  Lapa</span>, <span class="hlFld-ContribAuthor ">Toshiyuki  Tsunoda</span>, <span class="hlFld-ContribAuthor ">Senji  Shirasawa</span>, <span class="hlFld-ContribAuthor ">Maria A.  Baryshnikova</span>, <span class="hlFld-ContribAuthor ">Gregory G.  Evseev</span>, <span class="hlFld-ContribAuthor ">Daria A.  Afanasyeva</span>, <span class="hlFld-ContribAuthor ">Elena A.  Chigorina</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of New Congeners of 1-methyl-3-aminoisoquinolines, Evaluation of Their Cytotoxic Activity,
              In Silico
              and
              In Vitro
              Study of Their Molecular Targets as PDE4B. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2016,</strong> <em>87 </em>
                                    (4)
                                     , 575-582. <a href="https://doi.org/10.1111/cbdd.12691" title="DOI URL">https://doi.org/10.1111/cbdd.12691</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12691%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DSynthesis%252Bof%252BNew%252BCongeners%252Bof%252B1-methyl-3-aminoisoquinolines%25252C%252BEvaluation%252Bof%252BTheir%252BCytotoxic%252BActivity%25252C%252BIn%252BSilico%252Band%252BIn%252BVitro%252BStudy%252Bof%252BTheir%252BMolecular%252BTargets%252Bas%252BPDE4B%26aulast%3DLapa%26aufirst%3DGennady%2BB.%26date%3D2016%26date%3D2015%26volume%3D87%26issue%3D4%26spage%3D575%26epage%3D582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yonghe  Li</span>, <span class="hlFld-ContribAuthor ">Wenyan  Lu</span>, <span class="hlFld-ContribAuthor ">Surendra K.  Saini</span>, <span class="hlFld-ContribAuthor ">Omar  Moukha-Chafiq</span>, <span class="hlFld-ContribAuthor ">Vibha  Pathak</span>, <span class="hlFld-ContribAuthor ">Subramaniam  Ananthan</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of quinazoline compounds as novel potent inhibitors of Wnt/β-catenin signaling in colorectal cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2016,</strong> <em>7 </em>
                                    (10)
                                     , 11263-11270. <a href="https://doi.org/10.18632/oncotarget.7019" title="DOI URL">https://doi.org/10.18632/oncotarget.7019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.7019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.7019%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DIdentification%252Bof%252Bquinazoline%252Bcompounds%252Bas%252Bnovel%252Bpotent%252Binhibitors%252Bof%252BWnt%25252F%2525CE%2525B2-catenin%252Bsignaling%252Bin%252Bcolorectal%252Bcancer%252Bcells%26aulast%3DLi%26aufirst%3DYonghe%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D10%26spage%3D11263%26epage%3D11270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hai-Qi  Zhang</span>, <span class="hlFld-ContribAuthor ">Fei-Hu  Gong</span>, <span class="hlFld-ContribAuthor ">Chuan-Gui  Li</span>, <span class="hlFld-ContribAuthor ">Chi  Zhang</span>, <span class="hlFld-ContribAuthor ">Yan-Jie  Wang</span>, <span class="hlFld-ContribAuthor ">Yun-Gen  Xu</span>, <span class="hlFld-ContribAuthor ">Li-Ping  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>109 </em>, 371-379. <a href="https://doi.org/10.1016/j.ejmech.2015.12.032" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.12.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.12.032%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bdiscovery%252Bof%252B4-anilinoquinazoline-acylamino%252Bderivatives%252Bas%252BEGFR%252Band%252BVEGFR-2%252Bdual%252BTK%252Binhibitors%26aulast%3DZhang%26aufirst%3DHai-Qi%26date%3D2016%26volume%3D109%26spage%3D371%26epage%3D379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E. V.  Koroleva</span>, <span class="hlFld-ContribAuthor ">Zh. I.  Ignatovich</span>, <span class="hlFld-ContribAuthor ">Yu. V.  Sinyutich</span>, <span class="hlFld-ContribAuthor ">K. N.  Gusak</span>. </span><span class="cited-content_cbyCitation_article-title">Aminopyrimidine derivatives as protein kinases inhibitors. Molecular design, synthesis, and biologic activity. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>52 </em>
                                    (2)
                                     , 139-177. <a href="https://doi.org/10.1134/S1070428016020019" title="DOI URL">https://doi.org/10.1134/S1070428016020019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428016020019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428016020019%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAminopyrimidine%252Bderivatives%252Bas%252Bprotein%252Bkinases%252Binhibitors.%252BMolecular%252Bdesign%25252C%252Bsynthesis%25252C%252Band%252Bbiologic%252Bactivity%26aulast%3DKoroleva%26aufirst%3DE.%2BV.%26date%3D2016%26date%3D2016%26volume%3D52%26issue%3D2%26spage%3D139%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sun  Hongmao</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Ligand Design II. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 61-108. <a href="https://doi.org/10.1016/B978-0-08-100098-4.00003-X" title="DOI URL">https://doi.org/10.1016/B978-0-08-100098-4.00003-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-100098-4.00003-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-100098-4.00003-X%26sid%3Dliteratum%253Aachs%26atitle%3DStructure-Based%252BLigand%252BDesign%252BII%26aulast%3DHongmao%26aufirst%3DSun%26date%3D2016%26spage%3D61%26epage%3D108%26pub%3DElsevier%26atitle%3DA%252BPractical%252BGuide%252Bto%252BRational%252BDrug%252BDesign%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Fjm901132v&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2010.53.issue-4%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Fjm901132v%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text&amp;citedByCount=203&amp;pagesCount=3&amp;pageNumber=2" title="Load more citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="”true”" class="icon-angle-double-down"></i><span>Load more citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="fig1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0013.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Overview of the terminology used in this article with examples.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0012.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Kinase inhibitors used for treating cancer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. EGFR family inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0010.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0009.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0008.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. ATP and inhibitor binding sites of kinases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Fragment-based approach to MTDD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Inhibitors with different binding modes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0004.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Network of disease-associated MKI connections.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0003.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0002.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/medium/jm-2009-01132v_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0001.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm901132v/production/images/large/jm-2009-01132v_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901132v&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27607" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27607" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 146 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Cohen, P.</span><span> </span><span class="NLM_article-title">Protein kinases: the major drug targets of the twenty-first century?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=309-315&author=P.+Cohen&title=Protein+kinases%3A+the+major+drug+targets+of+the+twenty-first+century%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DProtein%2520kinases%253A%2520the%2520major%2520drug%2520targets%2520of%2520the%2520twenty-first%2520century%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D309%26epage%3D315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">From magic bullets to designed multiple ligands</span> <span class="citation_source-journal">Drug Discovery Today.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">641</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+magic+bullets+to+designed+multiple+ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0ljhR0ES5lhTDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520magic%2520bullets%2520to%2520designed%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today.%26date%3D2004%26volume%3D9%26spage%3D641%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Millan, M. J.</span><span> </span><span class="NLM_article-title">Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2Fj.pharmthera.2005.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=16522330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtFCqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2006&pages=135-370&author=M.+J.+Millan&title=Multi-target+strategies+for+the+improved+treatment+of+depressive+states%3A+conceptual+foundations+and+neuronal+substrates%2C+drug+discovery+and+therapeutic+application"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application</span></div><div class="casAuthors">Millan, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-370</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Major depression is a debilitating and recurrent disorder with a substantial lifetime risk and a high social cost.  Depressed patients generally display co-morbid symptoms, and depression frequently accompanies other serious disorders.  Currently available drugs display limited efficacy and a pronounced delay to onset of action, and all provoke distressing side effects.  Cloning of the human genome has fuelled expectations that symptomatic treatment may soon become more rapid and effective, and that depressive states may ultimately be "prevented" or "cured".  In pursuing these objectives, in particular for genome-derived, non-monoaminergic targets, "specificity" of drug actions is often emphasized.  That is, priority is afforded to agents that interact exclusively with a single site hypothesized as critically involved in the pathogenesis and/or control of depression.  Certain highly selective drugs may prove effective, and they remain indispensable in the exptl. (and clin.) evaluation of the significance of novel mechanisms.  However, by analogy to other multifactorial disorders, "multi-target" agents may be better adapted to the improved treatment of depressive states.  Support for this contention is garnered from a broad palette of observations, ranging from mechanisms of action of adjunctive drug combinations and electroconvulsive therapy to "network theory" anal. of the etiol. and management of depressive states.  The review also outlines opportunities to be exploited, and challenges to be addressed, in the discovery and characterization of drugs recognizing multiple targets.  Finally, a diversity of multi-target strategies is proposed for the more efficacious and rapid control of core and co-morbid symptoms of depression, together with improved tolerance relative to currently available agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxf3nCB4E-O7Vg90H21EOLACvtfcHk0ljaXK-x3nK-bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtFCqtr4%253D&md5=dbca7f1b7bba52c69d9c6b95eea01d69</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2005.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2005.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26atitle%3DMulti-target%2520strategies%2520for%2520the%2520improved%2520treatment%2520of%2520depressive%2520states%253A%2520conceptual%2520foundations%2520and%2520neuronal%2520substrates%252C%2520drug%2520discovery%2520and%2520therapeutic%2520application%26jtitle%3DPharmacol.%2520Ther.%26date%3D2006%26volume%3D110%26spage%3D135%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6523</span><span class="NLM_x">–</span> <span class="NLM_lpage">6543</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0ljaXK-x3nK-bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eder, J. P.</span><span> </span><span class="NLM_article-title">Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1013</span><span class="NLM_x">–</span> <span class="NLM_lpage">1028</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=1013-1028&author=P.+M.+LoRussoauthor=J.+P.+Eder&title=Therapeutic+potential+of+novel+selective-spectrum+kinase+inhibitors+in+oncology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DEder%26aufirst%3DJ.%2BP.%26atitle%3DTherapeutic%2520potential%2520of%2520novel%2520selective-spectrum%2520kinase%2520inhibitors%2520in%2520oncology%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D17%26spage%3D1013%26epage%3D1028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Daub, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Specht, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Strategies to overcome resistance to targeted protein kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1001</span><span class="NLM_x">–</span> <span class="NLM_lpage">1010</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=1001-1010&author=H.+Daubauthor=K.+Spechtauthor=A.+Ullrich&title=Strategies+to+overcome+resistance+to+targeted+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDaub%26aufirst%3DH.%26aulast%3DSpecht%26aufirst%3DK.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DStrategies%2520to%2520overcome%2520resistance%2520to%2520targeted%2520protein%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D12%26spage%3D1001%26epage%3D1010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soverini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarani, M.</span><span> </span><span class="NLM_article-title">Dual tyrosine kinase inhibitors in chronic myeloid leukemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1872</span><span class="NLM_x">–</span> <span class="NLM_lpage">1879</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1872-1879&author=G.+Martinelliauthor=S.+Soveriniauthor=G.+Rostiauthor=M.+Baccarani&title=Dual+tyrosine+kinase+inhibitors+in+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DSoverini%26aufirst%3DS.%26aulast%3DRosti%26aufirst%3DG.%26aulast%3DBaccarani%26aufirst%3DM.%26atitle%3DDual%2520tyrosine%2520kinase%2520inhibitors%2520in%2520chronic%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2005%26volume%3D19%26spage%3D1872%26epage%3D1879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Deininger, M. W.</span><span> </span><span class="NLM_article-title">Nilotinib</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">4027</span><span class="NLM_x">–</span> <span class="NLM_lpage">4031</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1158%2F1078-0432.CCR-07-5015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=18593977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvFyltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=4027-4031&author=M.+W.+Deininger&title=Nilotinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Nilotinib</span></div><div class="casAuthors">Deininger, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4027-4031</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review on the development of nilotinib.  Topics discussed include current landscape of chronic myeloid leukemia (CML) therapy, preclin. profiling, clin. activity, toxicity, pharmacokinetics, and selection of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnU21REG8aPrVg90H21EOLACvtfcHk0lgj6OYN59sfzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvFyltbc%253D&md5=9f2f33d264c28bbe84e70a72d6e425ee</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-5015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-5015%26sid%3Dliteratum%253Aachs%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DNilotinib%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D4027%26epage%3D4031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedman, S. J.</span><span> </span><span class="NLM_article-title">MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">500</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=500-502&author=F.+J.+Gilesauthor=J.+Cortesauthor=D.+Jonesauthor=D.+Bergstromauthor=H.+Kantarjianauthor=S.+J.+Freedman&title=MK-0457%2C+a+novel+kinase+inhibitor%2C+is+active+in+patients+with+chronic+myeloid+leukemia+or+acute+lymphocytic+leukemia+with+the+T315I+BCR-ABL+mutation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DBergstrom%26aufirst%3DD.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DFreedman%26aufirst%3DS.%2BJ.%26atitle%3DMK-0457%252C%2520a%2520novel%2520kinase%2520inhibitor%252C%2520is%2520active%2520in%2520patients%2520with%2520chronic%2520myeloid%2520leukemia%2520or%2520acute%2520lymphocytic%2520leukemia%2520with%2520the%2520T315I%2520BCR-ABL%2520mutation%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D500%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruemmendorf, T.</span><span> </span><span class="NLM_article-title">Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated among patients with AP and BP CML and Ph_ ALL</span> <span class="citation_source-journal">Blood (ASH Annu. Meet. Abstr.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">473</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=473&author=C.+Gambacorti-Passeriniauthor=H.+Kantarjianauthor=T.+Bruemmendorf&title=Bosutinib+%28SKI-606%29+demonstrates+clinical+activity+and+is+well+tolerated+among+patients+with+AP+and+BP+CML+and+Ph_+ALL"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DBruemmendorf%26aufirst%3DT.%26atitle%3DBosutinib%2520%2528SKI-606%2529%2520demonstrates%2520clinical%2520activity%2520and%2520is%2520well%2520tolerated%2520among%2520patients%2520with%2520AP%2520and%2520BP%2520CML%2520and%2520Ph_%2520ALL%26jtitle%3DBlood%2520%2528ASH%2520Annu.%2520Meet.%2520Abstr.%2529%26date%3D2007%26volume%3D110%26spage%3D473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Blackledge, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Averbuch, S.</span><span> </span><span class="NLM_article-title">Gefitinib (“Iressa”, ZD1839) and new epidermal growth factor receptor inhibitors</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">566</span><span class="NLM_x">–</span> <span class="NLM_lpage">572</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fsj.bjc.6601550" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=14760365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2cXoslKjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2004&pages=566-572&author=G.+Blackledgeauthor=S.+Averbuch&title=Gefitinib+%28%E2%80%9CIressa%E2%80%9D%2C+ZD1839%29+and+new+epidermal+growth+factor+receptor+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib ( Iressa', ZD1839) and new epidermal growth factor receptor inhibitors</span></div><div class="casAuthors">Blackledge, G.; Averbuch, S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">566-572</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) is a promising target for cancer therapy and a no. of EGFR-targeted agents have been developed.  Those most advanced in development are the EGFR tyrosine kinase inhibitors gefitinib ('Tarceva', ZD1839) and erlotinib ('Tarceva', OSI-774), and the monoclonal antibody cetuximab ('Erbitux', IMC-C225).  This review provides a clin. overview of these agents, highlighting their antitumor activities in different tumor types.  Epidermal growth factor receptor-targeted agents are generally well tolerated and are not typically assocd. with the severe adverse events often seen with cytotoxic chemotherapy.  Gefitinib is the agent with the most extensive clin. experience, particularly in non-small-cell lung cancer (NSCLC). Recently, gefitinib became the first-approved EGFR-targeted agent, for use in patients with previously treated advanced NSCLC in Japan, the USA and other countries.  Further studies are required to explore the full potential of these novel agents either as monotherapy or combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFcx_HdnziB7Vg90H21EOLACvtfcHk0lgj6OYN59sfzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXoslKjsA%253D%253D&md5=6fb4274fbf9f2a674053bb6030348167</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6601550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6601550%26sid%3Dliteratum%253Aachs%26aulast%3DBlackledge%26aufirst%3DG.%26aulast%3DAverbuch%26aufirst%3DS.%26atitle%3DGefitinib%2520%2528%25E2%2580%259CIressa%25E2%2580%259D%252C%2520ZD1839%2529%2520and%2520new%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitors%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2004%26volume%3D90%26spage%3D566%26epage%3D572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Rix, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span> </span><span class="NLM_article-title">Target profiling of small molecules by chemical proteomics</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">616</span><span class="NLM_x">–</span> <span class="NLM_lpage">625</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnchembio.216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=19690537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWhsb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=616-625&author=U.+Rixauthor=G.+Superti-Furga&title=Target+profiling+of+small+molecules+by+chemical+proteomics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Target profiling of small molecules by chemical proteomics</span></div><div class="casAuthors">Rix, Uwe; Superti-Furga, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">616-624</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The medical and pharmaceutical communities are facing a dire need for new druggable targets, while, paradoxically, the targets of some drugs that are in clin. use or development remain elusive.  Many compds. have been more promiscuous than originally anticipated, which can potentially lead to side effects, but which may also open up addnl. medical uses.  As we move toward systems biol. and personalized medicine, comprehensively detg. small mol.-target interaction profiles and mapping these on signaling and metabolic pathways will become increasingly necessary.  Chem. proteomics is a powerful mass spectrometry-based affinity chromatog. approach for identifying proteome-wide small mol.-protein interactions.  Here we will provide a crit. overview of the basic concepts and recent advances in chem. proteomics and review recent applications, with a particular emphasis on kinase inhibitors and natural products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBJz9OMT5Rp7Vg90H21EOLACvtfcHk0lgj6OYN59sfzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWhsb7K&md5=b357080902ea5e6cd6ab51792f327d0b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.216%26sid%3Dliteratum%253Aachs%26aulast%3DRix%26aufirst%3DU.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DTarget%2520profiling%2520of%2520small%2520molecules%2520by%2520chemical%2520proteomics%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D616%26epage%3D625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Kerbel, R. S.</span><span> </span><span class="NLM_article-title">Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents</span> <span class="citation_source-journal">BioEssays</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1991&pages=31-36&author=R.+S.+Kerbel&title=Inhibition+of+tumor+angiogenesis+as+a+strategy+to+circumvent+acquired+resistance+to+anti-cancer+therapeutic+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKerbel%26aufirst%3DR.%2BS.%26atitle%3DInhibition%2520of%2520tumor%2520angiogenesis%2520as%2520a%2520strategy%2520to%2520circumvent%2520acquired%2520resistance%2520to%2520anti-cancer%2520therapeutic%2520agents%26jtitle%3DBioEssays%26date%3D1991%26volume%3D13%26spage%3D31%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Boyer, S. J.</span><span> </span><span class="NLM_article-title">Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">973</span><span class="NLM_x">–</span> <span class="NLM_lpage">1000</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.2174%2F1568026023393273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=12171566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtVOitbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=973-1000&author=S.+J.+Boyer&title=Small+molecule+inhibitors+of+KDR+%28VEGFR-2%29+kinase%3A+an+overview+of+structure+activity+relationships"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships</span></div><div class="casAuthors">Boyer, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Hilversum, Netherlands)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">973-1000</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The Kinase insert Domain contg. Receptor (KDR), alternatively referred to as VEGFR-2, is a receptor for Vascular Endothelial Growth Factors (VEGFs) and functions as a key regulator of angiogenesis, the process by which new capillaries are created from preexisting blood vessels.  The induction of angiogenesis, or the "angiogenic switch," is a crit. step in tumor progression, and inhibitors of KDR have been demonstrated both to induce tumor regression and reduce metastatic potential in preclin. models.  In the last few years, medicinal chemists have expanded the kinase selectivity profile of known inhibitor classes to include KDR, and also identified novel classes of KDR inhibitors.  This review presents structure activity relationships (SAR) of small mol. inhibitors of KDR, with an emphasis on the pharmacophore elements of the scaffolds employed.  Binding hypotheses based on x-ray crystallog. analyses will also be described.  Addnl., the efficacy of representative compds. in in vitro and in vivo models of tumor progression and angiogenesis are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8iX5xdLgktLVg90H21EOLACvtfcHk0lh_BXaRtTHGWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtVOitbw%253D&md5=4c4445eac589bded1baed3140b918be8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F1568026023393273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026023393273%26sid%3Dliteratum%253Aachs%26aulast%3DBoyer%26aufirst%3DS.%2BJ.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520KDR%2520%2528VEGFR-2%2529%2520kinase%253A%2520an%2520overview%2520of%2520structure%2520activity%2520relationships%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2002%26volume%3D2%26spage%3D973%26epage%3D1000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H.-J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazlauskas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavenee, W. K.</span><span> </span><span class="NLM_article-title">Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1464</span><span class="NLM_x">–</span> <span class="NLM_lpage">1472</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=1464-1472&author=D.+Wangauthor=H.-J.+S.+Huangauthor=A.+Kazlauskasauthor=W.+K.+Cavenee&title=Induction+of+vascular+endothelial+growth+factor+expression+in+endothelial+cells+by+platelet-derived+growth+factor+through+the+activation+of+phosphatidylinositol+3-kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DH.-J.%2BS.%26aulast%3DKazlauskas%26aufirst%3DA.%26aulast%3DCavenee%26aufirst%3DW.%2BK.%26atitle%3DInduction%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520expression%2520in%2520endothelial%2520cells%2520by%2520platelet-derived%2520growth%2520factor%2520through%2520the%2520activation%2520of%2520phosphatidylinositol%25203-kinase%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D1464%26epage%3D1472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Mendel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreck, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngai, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carver, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haznedar, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sukbuntherng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span> </span><span class="NLM_article-title">In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">337</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=12538485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1OrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=327-337&author=D.+B.+Mendelauthor=A.+D.+Lairdauthor=X.+Xinauthor=S.+G.+Louieauthor=J.+G.+Christensenauthor=G.+Liauthor=R.+E.+Schreckauthor=T.+J.+Abramsauthor=T.+J.+Ngaiauthor=L.+B.+Leeauthor=L.+J.+Murrayauthor=J.+Carverauthor=E.+Chanauthor=K.+G.+Mossauthor=J.+O.+Haznedarauthor=J.+Sukbuntherngauthor=R.+A.+Blakeauthor=L.+Sunauthor=C.+Tangauthor=T.+Millerauthor=S.+Shirazianauthor=G.+McMahonauthor=J.+M.+Cherrington&title=In+vivo+antitumor+activity+of+SU11248%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+growth+factor+and+platelet-derived+growth+factor+receptors%3A+determination+of+a+pharmacokinetic%2Fpharmacodynamic+relationship"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship</span></div><div class="casAuthors">Mendel, Dirk B.; Laird, A. Douglas; Xin, Xiaohua; Louie, Sharianne G.; Christensen, James G.; Li, Guangmin; Schreck, Randall E.; Abrams, Tinya J.; Ngai, Theresa J.; Lee, Leslie B.; Murray, Lesley J.; Carver, Jeremy; Chan, Emily; Moss, Katherine G.; Haznedar, Joshua O.; Sukbuntherng, Juthamas; Blake, Robert A.; Sun, Li; Tang, Cho; Miller, Todd; Shirazian, Sheri; McMahon, Gerald; Cherrington, Julie M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">327-337</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">One challenging aspect in the clin. development of molecularly targeted therapies, which represent a new and promising approach to treating cancers, has been the identification of a biol. active dose rather than a max. tolerated dose.  The goal of the present study was to identify a pharmacokinetic/pharmacodynamic relationship in preclin. models that could be used to help guide selection of a clin. dose.  SU11248, a novel small mol. receptor tyrosine kinase inhibitor with direct antitumor as well as antiangiogenic activity via targeting the vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), KIT, and FLT3 receptor tyrosine kinases, was used as the pharmacol. agent in these studies.  In mouse xenograft models, SU11248 exhibited broad and potent antitumor activity causing regression, growth arrest, or substantially reduced growth of various established xenografts derived from human or rat tumor cell lines.  To predict the target SU11248 exposure required to achieve antitumor activity in mouse xenograft models, we directly measured target phosphorylation in tumor xenografts before and after SU11248 treatment and correlated this with plasma inhibitor levels.  In target modulation studies in vivo, SU11248 selectively inhibited Flk-1/KDR (VEGF receptor 2) and PDGF receptor β phosphorylation (in a time- and dose-dependent manner) when plasma concns. of inhibitor reached or exceeded 50-100 ng/mL.  Similar results were obtained in a functional assay of VEGF-induced vascular permeability in vivo.  Const. inhibition of VEGFR2 and PDGF receptor β phosphorylation was not required for efficacy; at highly efficacious doses, inhibition was sustained for 12 h of a 24-h dosing interval.  The pharmacokinetic/pharmacodynamic relationship established for SU11248 in these preclin. studies has aided in the design, selection, and evaluation of dosing regimens being tested in human trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH8BrUNdo50rVg90H21EOLACvtfcHk0lh_BXaRtTHGWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1OrtA%253D%253D&md5=faafdec68a96d6cdf02ab347f69422b6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMendel%26aufirst%3DD.%2BB.%26aulast%3DLaird%26aufirst%3DA.%2BD.%26aulast%3DXin%26aufirst%3DX.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DSchreck%26aufirst%3DR.%2BE.%26aulast%3DAbrams%26aufirst%3DT.%2BJ.%26aulast%3DNgai%26aufirst%3DT.%2BJ.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26aulast%3DCarver%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DMoss%26aufirst%3DK.%2BG.%26aulast%3DHaznedar%26aufirst%3DJ.%2BO.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26atitle%3DIn%2520vivo%2520antitumor%2520activity%2520of%2520SU11248%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520growth%2520factor%2520and%2520platelet-derived%2520growth%2520factor%2520receptors%253A%2520determination%2520of%2520a%2520pharmacokinetic%252Fpharmacodynamic%2520relationship%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D327%26epage%3D337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNabola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shujath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gawlak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eveleigh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auclair, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gedrich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voznesensky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, P. A.</span><span> </span><span class="NLM_article-title">BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">7099</span><span class="NLM_x">–</span> <span class="NLM_lpage">7109</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7099-7109&author=S.+M.+Wilhelmauthor=C.+Carterauthor=L.+Tangauthor=D.+Wilkieauthor=A.+McNabolaauthor=H.+Rongauthor=C.+Chenauthor=X.+Zhangauthor=P.+Vincentauthor=M.+McHughauthor=Y.+Caoauthor=J.+Shujathauthor=S.+Gawlakauthor=D.+Eveleighauthor=B.+Rowleyauthor=L.+Liuauthor=L.+Adnaneauthor=M.+Lynchauthor=D.+Auclairauthor=I.+Taylorauthor=R.+Gedrichauthor=A.+Voznesenskyauthor=B.+Riedlauthor=L.+E.+Postauthor=G.+Bollagauthor=P.+A.+Trail&title=BAY+43-9006+exhibits+broad+spectrum+oral+antitumor+activity+and+targets+the+RAF%2FMEK%2FERK+pathway+and+receptor+tyrosine+kinases+involved+in+tumor+progression+and+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DWilkie%26aufirst%3DD.%26aulast%3DMcNabola%26aufirst%3DA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DVincent%26aufirst%3DP.%26aulast%3DMcHugh%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DShujath%26aufirst%3DJ.%26aulast%3DGawlak%26aufirst%3DS.%26aulast%3DEveleigh%26aufirst%3DD.%26aulast%3DRowley%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DAuclair%26aufirst%3DD.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DGedrich%26aufirst%3DR.%26aulast%3DVoznesensky%26aufirst%3DA.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DPost%26aufirst%3DL.%2BE.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DBAY%252043-9006%2520exhibits%2520broad%2520spectrum%2520oral%2520antitumor%2520activity%2520and%2520targets%2520the%2520RAF%252FMEK%252FERK%2520pathway%2520and%2520receptor%2520tyrosine%2520kinases%2520involved%2520in%2520tumor%2520progression%2520and%2520angiogenesis%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D7099%26epage%3D7109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Sathornsumetee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reardon, D. A.</span><span> </span><span class="NLM_article-title">Targeting multiple kinases in glioblastoma multiforme</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">292</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=277-292&author=S.+Sathornsumeteeauthor=D.+A.+Reardon&title=Targeting+multiple+kinases+in+glioblastoma+multiforme"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSathornsumetee%26aufirst%3DS.%26aulast%3DReardon%26aufirst%3DD.%2BA.%26atitle%3DTargeting%2520multiple%2520kinases%2520in%2520glioblastoma%2520multiforme%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D277%26epage%3D292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowinger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simantov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, S.</span><span> </span><span class="NLM_article-title">Discovery and development of sorafenib: a multikinase inhibitor for treating cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnrd2130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17016424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVajsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=835-844&author=S.+Wilhelmauthor=C.+Carterauthor=M.+Lynchauthor=T.+Lowingerauthor=J.+Dumasauthor=R.+A.+Smithauthor=B.+Schwartzauthor=R.+Simantovauthor=S.+Kelley&title=Discovery+and+development+of+sorafenib%3A+a+multikinase+inhibitor+for+treating+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of sorafenib: a multikinase inhibitor for treating cancer</span></div><div class="casAuthors">Wilhelm, Scott; Carter, Christopher; Lynch, Mark; Lowinger, Timothy; Dumas, Jacques; Smith, Roger A.; Schwartz, Brian; Simantov, Ronit; Kelley, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">835-844</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the mol. revolution of the 1980s, knowledge of the etiol. of cancer has increased considerably, which has led to the discovery and development of targeted therapies tailored to inhibit cancer-specific pathways.  The introduction and refinement of rapid, high-throughput screening technologies over the past decade has greatly facilitated this targeted discovery and development process.  Here, the authors describe the discovery and continuing development of sorafenib (previously known as BAY 43-9006), the first oral multikinase inhibitor that targets Raf and affects tumor signaling and the tumor vasculature.  The discovery cycle of sorafenib (Nexavar; Bayer Pharmaceuticals) - from initial screening for a lead compd. to FDA approval for the treatment of advanced renal cell carcinoma in Dec. 2005 - was completed in just 11 years, with approval being received ∼5 years after the initiation of the first Phase I trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6WjjfgNSCtbVg90H21EOLACvtfcHk0lgv42YjoEZYCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVajsbbM&md5=490d4995170f3a7270ae9bbdd24b12e5</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrd2130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2130%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DLowinger%26aufirst%3DT.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DSimantov%26aufirst%3DR.%26aulast%3DKelley%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520development%2520of%2520sorafenib%253A%2520a%2520multikinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D835%26epage%3D844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Golas, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etienne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span> </span><span class="NLM_article-title">SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of SRC and ABL kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">381</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=12543790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1Krsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=375-381&author=J.+M.+Golasauthor=K.+Arndtauthor=C.+Etienneauthor=J.+Lucasauthor=D.+Nardinauthor=J.+Gibbonsauthor=P.+Frostauthor=F.+Yeauthor=D.+H.+Boschelliauthor=F.+Boschelli&title=SKI-606%2C+a+4-anilino-3-quinolinecarbonitrile+dual+inhibitor+of+SRC+and+ABL+kinases%2C+is+a+potent+antiproliferative+agent+against+chronic+myelogenous+leukemia+cells+in+culture+and+causes+regression+of+K562+xenografts+in+nude+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">SKI-606, a 4-Anilino-3-quinolinecarbonitrile Dual Inhibitor of Src and Abl Kinases, Is a Potent Antiproliferative Agent against Chronic Myelogenous Leukemia Cells in Culture and Causes Regression of K562 Xenografts in Nude Mice</span></div><div class="casAuthors">Golas, Jennifer M.; Arndt, Kim; Etienne, Carlo; Lucas, Judy; Nardin, Danielle; Gibbons, James; Frost, Philip; Ye, Fei; Boschelli, Diane H.; Boschelli, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">375-381</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Constitutive tyrosine kinase activity of Bcr-Abl promotes proliferation and survival of chronic myelogenous leukemia (CML) cells.  Inhibition of Bcr-Abl tyrosine kinase activity or signaling proteins activated by Bcr-Abl in CML cells blocks proliferation and causes apoptotic cell death.  The selective Abl kinase inhibitor, STI-571 (marketed as Gleevec), is toxic to CML cells in culture, causes regression of CML tumors in nude mice, and is currently used to treat CML patients.  Here we describe a p.o. active, dual Src/Abl kinase inhibitor with potent antiproliferative activity against CML cells in culture.  This 4-anilino-3-quinolinecarbonitrile (SKI-606) ablates tyrosine phosphorylation of Bcr-Abl in CML cells and of v-Abl expressed in fibroblasts.  SKI-606 inhibits phosphorylation of cellular proteins, including STAT5, at concns. that inhibit proliferation in CML cells.  Phosphorylation of the autoactivation site of the Src family kinases Lyn and/or Hck is also reduced by treatment with SKI-606.  Once daily oral administration of this compd. at 100 mg/kg for 5 days causes complete regression of large K562 xenografts in nude mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ0DM9Z0QjjLVg90H21EOLACvtfcHk0lgJG5yx4k5aiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1Krsg%253D%253D&md5=e7b5e5ffee0238543dc9c31b7e86b3d2</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGolas%26aufirst%3DJ.%2BM.%26aulast%3DArndt%26aufirst%3DK.%26aulast%3DEtienne%26aufirst%3DC.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DNardin%26aufirst%3DD.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DFrost%26aufirst%3DP.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DBoschelli%26aufirst%3DF.%26atitle%3DSKI-606%252C%2520a%25204-anilino-3-quinolinecarbonitrile%2520dual%2520inhibitor%2520of%2520SRC%2520and%2520ABL%2520kinases%252C%2520is%2520a%2520potent%2520antiproliferative%2520agent%2520against%2520chronic%2520myelogenous%2520leukemia%2520cells%2520in%2520culture%2520and%2520causes%2520regression%2520of%2520K562%2520xenografts%2520in%2520nude%2520mice%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D375%26epage%3D381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lgJG5yx4k5aiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nematalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sistla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4-dimethyl-1<i>H</i>-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">–</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.+Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=A.+Sistlaauthor=T.+C.+Luuauthor=F.+Tangauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-fluoro-2-oxo-1%2C2-dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.%2BY.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DA.%26aulast%3DLuu%26aufirst%3DT.%2BC.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-fluoro-2-oxo-1%252C2-dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D27%26spage%3D1116%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaneda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inigo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual SRC/ABL kinase inhibitor with potent antitumor activity in preclinical assays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6658</span><span class="NLM_x">–</span> <span class="NLM_lpage">6661</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049486a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6658-6661&author=L.+J.+Lombardoauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=J.+C.+Barrishauthor=K.+Behniaauthor=S.+Castanedaauthor=L.+A.+Corneliusauthor=J.+Dasauthor=A.+M.+Doweykoauthor=C.+Fairchildauthor=J.+T.+Huntauthor=I.+Inigoauthor=K.+Johnstonauthor=A.+Kamathauthor=D.+Kanauthor=H.+Kleiauthor=P.+Maratheauthor=S.+Pangauthor=R.+Petersonauthor=S.+Pittauthor=G.+L.+Schievenauthor=R.+J.+Schmidtauthor=J.+Tokarskiauthor=M.+L.+Wenauthor=J.+Wityakauthor=R.+M.+Borzilleri&title=Discovery+of+N-%282-chloro-6-methyl-phenyl%29-2-%286-%284-%282-hydroxyethyl%29-piperazin-1-yl%29-2-methylpyrimidin-4-ylamino%29thiazole-5-carboxamide+%28BMS-354825%29%2C+a+dual+SRC%2FABL+kinase+inhibitor+with+potent+antitumor+activity+in+preclinical+assays"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm049486a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049486a%26sid%3Dliteratum%253Aachs%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DCastaneda%26aufirst%3DS.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DFairchild%26aufirst%3DC.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DInigo%26aufirst%3DI.%26aulast%3DJohnston%26aufirst%3DK.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DKan%26aufirst%3DD.%26aulast%3DKlei%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DPeterson%26aufirst%3DR.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DTokarski%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DM.%2BL.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520N-%25282-chloro-6-methyl-phenyl%2529-2-%25286-%25284-%25282-hydroxyethyl%2529-piperazin-1-yl%2529-2-methylpyrimidin-4-ylamino%2529thiazole-5-carboxamide%2520%2528BMS-354825%2529%252C%2520a%2520dual%2520SRC%252FABL%2520kinase%2520inhibitor%2520with%2520potent%2520antitumor%2520activity%2520in%2520preclinical%2520assays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6658%26epage%3D6661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Lackey, K. E.</span><span> </span><span class="NLM_article-title">Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">435</span><span class="NLM_x">–</span> <span class="NLM_lpage">460</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.2174%2F156802606776743156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=16719802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtV2juro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=435-460&author=K.+E.+Lackey&title=Lessons+from+the+drug+discovery+of+lapatinib%2C+a+dual+ErbB1%2F2+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons from the drug discovery of Lapatinib, a dual ErbB1/2 tyrosine Kinase inhibitor</span></div><div class="casAuthors">Lackey, Karen E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">435-460</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein Kinases offer many opportunities for drug intervention points since phosphorylation is the most common post-translational modification.  Phosphorylation regulates activity, location, degrdn., and conformation and the aberrant activity is implicated in many diseases, including cancer, inflammation, cardiovascular, and central nervous system diseases.  The focus of this review will be on the generation of highly effective signaling inhibitors targeting members of the erbB family of receptor tyrosine kinases, EGFR and ErbB-2, also known as transmembrane Type 1 receptor tyrosine kinases of the HER family of receptors.  Ligand binding to the receptor causes a conformational change which activates the tyrosine kinase domain leading to autophosphorylation.  This autophosphorylation activates the RAS/mitogen-activated protein (MAP) kinase and phosphoinositol-3-kinase (PI3K) pathways leading to a myriad of signaling and cellular activities.  Type 1 receptors are overexpressed in a variety of cancers and generally correlate with poor prognosis.  For this reason, scientists at GlaxoSmithKline and many others in the scientific community target the ATP binding site of the intracellular portion of the protein to block the aberrant signaling event.  This review intends to cover the lessons learned in the discovery of Lapatinib (GW572016, GW2016) by pulling together the various different publications that have been generated in distinct disciplines on aspects of the drug discovery program.  Data analyses and correlation of assay data to help with the design of drug-like mols. are included and demonstrate a break from the traditional focus on abs. potency as a guiding factor in lead compd. selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnKhQE45WWsbVg90H21EOLACvtfcHk0lihfDaQQiVCOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtV2juro%253D&md5=5bb70c03abc1fb8c301cac0f5f713fbe</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F156802606776743156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802606776743156%26sid%3Dliteratum%253Aachs%26aulast%3DLackey%26aufirst%3DK.%2BE.%26atitle%3DLessons%2520from%2520the%2520drug%2520discovery%2520of%2520lapatinib%252C%2520a%2520dual%2520ErbB1%252F2%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2006%26volume%3D6%26spage%3D435%26epage%3D460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Zhang, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guntrip, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanderwall, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span> </span><span class="NLM_article-title">Synthesis and SAR of potent EGFR/erbB2 dual inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=111-114&author=Y.+M.+Zhangauthor=S.+Cockerillauthor=S.+B.+Guntripauthor=D.+Rusnakauthor=K.+Smithauthor=D.+Vanderwallauthor=E.+Woodauthor=K.+Lackey&title=Synthesis+and+SAR+of+potent+EGFR%2FerbB2+dual+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%2BM.%26aulast%3DCockerill%26aufirst%3DS.%26aulast%3DGuntrip%26aufirst%3DS.%2BB.%26aulast%3DRusnak%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DK.%26aulast%3DVanderwall%26aufirst%3DD.%26aulast%3DWood%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520potent%2520EGFR%252FerbB2%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D111%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Normanno, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianco, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strizzi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maiello, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luca, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caponigro, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salomon, D. S.</span><span> </span><span class="NLM_article-title">The ErbB receptors and their ligands in cancer: an overview</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.2174%2F1389450053765879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=15857286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktlansb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=243-257&author=N.+Normannoauthor=C.+Biancoauthor=L.+Strizziauthor=M.+Mancinoauthor=M.+R.+Maielloauthor=A.+D.+Lucaauthor=F.+Caponigroauthor=D.+S.+Salomon&title=The+ErbB+receptors+and+their+ligands+in+cancer%3A+an+overview"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The ErbB receptors and their ligands in cancer: An overview</span></div><div class="casAuthors">Normanno, N.; Bianco, C.; Strizzi, L.; Mancino, M.; Maiello, M. R.; De Luca, A.; Caponigro, F.; Salomon, D. S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">243-257</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">This review article provides an overview on the most recent advances on the role of ErbB receptors and growth factors of the epidermal growth factor (EGF)-family of peptides in cancer pathogenesis and progression.  The ErbB tyrosine kinases and the EGF-like peptides form a complex system.  In fact, the interactions occurring between receptors and ligands of these families affect the type and the duration of the intracellular signals that derive from receptor activation.  Interestingly, activation of ErbB receptors is also driven by different classes of membrane receptor, suggesting that ErbB kinases can amplify growth promoting signals carried by different pathways.  The importance of ErbB receptors and EGF-like peptides in development of organs and tissues has been demonstrated by using different mouse models.  In vitro and in vivo studies have also shown that ErbB receptors and their ligands can act as transforming genes.  However, evidence suggests that cooperation of different receptors and ligands is necessary to induce a fully transformed phenotype.  Indeed, co-expression of different ErbB receptors and EGF-like growth factors is a common phenomenon in human primary carcinomas.  This observation suggests that the growth and the survival of carcinoma cells is sustained by a network of receptors/ligands of the ErbB family.  In this respect, the contemporary expression of different ErbB tyrosine kinases and/or EGF-like growth factors in human carcinomas might also affect tumor response to target based agents directed against the ErbB receptor/ligand system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr40R-_wweKqbVg90H21EOLACvtfcHk0lihfDaQQiVCOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktlansb8%253D&md5=40abc678c508a318878d76da7c866420</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2174%2F1389450053765879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450053765879%26sid%3Dliteratum%253Aachs%26aulast%3DNormanno%26aufirst%3DN.%26aulast%3DBianco%26aufirst%3DC.%26aulast%3DStrizzi%26aufirst%3DL.%26aulast%3DMancino%26aufirst%3DM.%26aulast%3DMaiello%26aufirst%3DM.%2BR.%26aulast%3DLuca%26aufirst%3DA.%2BD.%26aulast%3DCaponigro%26aufirst%3DF.%26aulast%3DSalomon%26aufirst%3DD.%2BS.%26atitle%3DThe%2520ErbB%2520receptors%2520and%2520their%2520ligands%2520in%2520cancer%253A%2520an%2520overview%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2005%26volume%3D6%26spage%3D243%26epage%3D257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Petrov, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K. E.</span><span> </span><span class="NLM_article-title">Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4686</span><span class="NLM_x">–</span> <span class="NLM_lpage">4691</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2Fj.bmcl.2006.05.090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=16777410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFOlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4686-4691&author=K.+G.+Petrovauthor=Y.+M.+Zhangauthor=M.+Carterauthor=G.+S.+Cockerillauthor=S.+Dickersonauthor=C.+A.+Gauthierauthor=Y.+Guoauthor=R.+A.+Mookauthor=D.+W.+Rusnakauthor=A.+L.+Walkerauthor=E.+R.+Woodauthor=K.+E.+Lackey&title=Optimization+and+SAR+for+dual+ErbB-1%2FErbB-2+tyrosine+kinase+inhibition+in+the+6-furanylquinazoline+series"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series</span></div><div class="casAuthors">Petrov, Kimberly G.; Zhang, Yue-Mei; Carter, Malcolm; Cockerill, G. Stuart; Dickerson, Scott; Gauthier, Cassandra A.; Guo, Yu; Mook, Robert A.; Rusnak, David W.; Walker, Ann L.; Wood, Edgar R.; Lackey, Karen E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4686-4691</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthetic modifications on a 6-furanylquinazoline scaffold to optimize the dual ErbB-1/ErbB-2 tyrosine kinase inhibition afforded consistent SAR whereby a 4-(3-fluorobenzyloxy)-3-haloanilino structure provided the best enzyme potency and cellular selectivity.  Changes made to the 6-furanyl group had little impact on the enzyme activity, but appeared to dramatically affect the cellular efficacy.  The discovery of lapatinib emerged from this work.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtejUjyH9in7Vg90H21EOLACvtfcHk0lgib_aOo-_Svg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFOlu7o%253D&md5=946712927ab1a7940ea3ef2fea7574b5</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.05.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.05.090%26sid%3Dliteratum%253Aachs%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DZhang%26aufirst%3DY.%2BM.%26aulast%3DCarter%26aufirst%3DM.%26aulast%3DCockerill%26aufirst%3DG.%2BS.%26aulast%3DDickerson%26aufirst%3DS.%26aulast%3DGauthier%26aufirst%3DC.%2BA.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DWalker%26aufirst%3DA.%2BL.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DLackey%26aufirst%3DK.%2BE.%26atitle%3DOptimization%2520and%2520SAR%2520for%2520dual%2520ErbB-1%252FErbB-2%2520tyrosine%2520kinase%2520inhibition%2520in%2520the%25206-furanylquinazoline%2520series%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4686%26epage%3D4691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Xu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Searle, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abad, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neeper, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struble, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emanuel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruninger, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandey, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno-Mazza, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuentes-Pesquera, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span> </span><span class="NLM_article-title">Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3495</span><span class="NLM_x">–</span> <span class="NLM_lpage">3499</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3495-3499&author=G.+Xuauthor=L.+L.+Searleauthor=T.+V.+Hughesauthor=A.+K.+Beckauthor=P.+J.+Connollyauthor=M.+C.+Abadauthor=M.+P.+Neeperauthor=G.+T.+Strubleauthor=B.+A.+Springerauthor=S.+L.+Emanuelauthor=R.+H.+Gruningerauthor=N.+Pandeyauthor=M.+Adamsauthor=S.+Moreno-Mazzaauthor=A.+R.+Fuentes-Pesqueraauthor=S.+A.+Middletonauthor=L.+M.+Greenberger&title=Discovery+of+novel+4-amino-6-arylaminopyrimidine-5-carbaldehyde+oximes+as+dual+inhibitors+of+EGFR+and+ErbB-2+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DG.%26aulast%3DSearle%26aufirst%3DL.%2BL.%26aulast%3DHughes%26aufirst%3DT.%2BV.%26aulast%3DBeck%26aufirst%3DA.%2BK.%26aulast%3DConnolly%26aufirst%3DP.%2BJ.%26aulast%3DAbad%26aufirst%3DM.%2BC.%26aulast%3DNeeper%26aufirst%3DM.%2BP.%26aulast%3DStruble%26aufirst%3DG.%2BT.%26aulast%3DSpringer%26aufirst%3DB.%2BA.%26aulast%3DEmanuel%26aufirst%3DS.%2BL.%26aulast%3DGruninger%26aufirst%3DR.%2BH.%26aulast%3DPandey%26aufirst%3DN.%26aulast%3DAdams%26aufirst%3DM.%26aulast%3DMoreno-Mazza%26aufirst%3DS.%26aulast%3DFuentes-Pesquera%26aufirst%3DA.%2BR.%26aulast%3DMiddleton%26aufirst%3DS.%2BA.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26atitle%3DDiscovery%2520of%2520novel%25204-amino-6-arylaminopyrimidine-5-carbaldehyde%2520oximes%2520as%2520dual%2520inhibitors%2520of%2520EGFR%2520and%2520ErbB-2%2520protein%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3495%26epage%3D3499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Hubbard, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamaung, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidanze, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palazzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilsbacher, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheppard, G. S.</span><span> </span><span class="NLM_article-title">Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1718</span><span class="NLM_x">–</span> <span class="NLM_lpage">1721</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1718-1721&author=R.+D.+Hubbardauthor=N.+Y.+Bamaungauthor=S.+D.+Fidanzeauthor=S.+A.+Ericksonauthor=F.+Palazzoauthor=J.+L.+Wilsbacherauthor=Q.+Zhangauthor=L.+A.+Tuckerauthor=X.+Huauthor=P.+Kovarauthor=D.+J.+Osterlingauthor=E.+F.+Johnsonauthor=J.+Bouskaauthor=J.+Wangauthor=S.+K.+Davidsenauthor=R.+L.+Bellauthor=G.+S.+Sheppard&title=Development+of+multitargeted+inhibitors+of+both+the+insulin-like+growth+factor+receptor+%28IGF-IR%29+and+members+of+the+epidermal+growth+factor+family+of+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DR.%2BD.%26aulast%3DBamaung%26aufirst%3DN.%2BY.%26aulast%3DFidanze%26aufirst%3DS.%2BD.%26aulast%3DErickson%26aufirst%3DS.%2BA.%26aulast%3DPalazzo%26aufirst%3DF.%26aulast%3DWilsbacher%26aufirst%3DJ.%2BL.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DTucker%26aufirst%3DL.%2BA.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DKovar%26aufirst%3DP.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DBouska%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DBell%26aufirst%3DR.%2BL.%26aulast%3DSheppard%26aufirst%3DG.%2BS.%26atitle%3DDevelopment%2520of%2520multitargeted%2520inhibitors%2520of%2520both%2520the%2520insulin-like%2520growth%2520factor%2520receptor%2520%2528IGF-IR%2529%2520and%2520members%2520of%2520the%2520epidermal%2520growth%2520factor%2520family%2520of%2520receptor%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1718%26epage%3D1721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Boschelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span> </span><span class="NLM_article-title">7-Alkoxy-4-phenylamino-3-quinolinecarbonitriles as dual inhibitors of SRC and ABL kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1599</span><span class="NLM_x">–</span> <span class="NLM_lpage">1601</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0499458" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1599-1601&author=D.+Boschelliauthor=Y.+Wangauthor=S.+Johnsonauthor=B.+Wuauthor=F.+Yeauthor=A.+Sosaauthor=J.+Golasauthor=F.+Boschelli&title=7-Alkoxy-4-phenylamino-3-quinolinecarbonitriles+as+dual+inhibitors+of+SRC+and+ABL+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm0499458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0499458%26sid%3Dliteratum%253Aachs%26aulast%3DBoschelli%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DSosa%26aufirst%3DA.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DBoschelli%26aufirst%3DF.%26atitle%3D7-Alkoxy-4-phenylamino-3-quinolinecarbonitriles%2520as%2520dual%2520inhibitors%2520of%2520SRC%2520and%2520ABL%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1599%26epage%3D1601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Bamborough, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, K.</span><span> </span><span class="NLM_article-title">Assessment of chemical coverage of kinome space and its implications for kinase drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">7898</span><span class="NLM_x">–</span> <span class="NLM_lpage">7914</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8011036" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVequ7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7898-7914&author=P.+Bamboroughauthor=D.+Drewryauthor=G.+Harperauthor=G.+K.+Smithauthor=K.+Schneider&title=Assessment+of+chemical+coverage+of+kinome+space+and+its+implications+for+kinase+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of Chemical Coverage of Kinome Space and Its Implications for Kinase Drug Discovery</span></div><div class="casAuthors">Bamborough, Paul; Drewry, David; Harper, Gavin; Smith, Gary K.; Schneider, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7898-7914</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">More than 500 compds. chosen to represent kinase inhibitor space have been screened against a panel of over 200 protein kinases.  Significant results include the identification of hits against new kinases including PIM1 and MPSK1, and the expansion of the inhibition profiles of several literature compds.  A detailed anal. of the data through the use of affinity fingerprints has produced findings with implications for biol. target selection, the choice of tool compds. for target validation, and lead discovery and optimization.  In a detailed examn. of the tyrosine kinases, interesting relationships have been found between targets and compds.  Taken together, these results show how broad cross-profiling can provide important insights to assist kinase drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBRI-arQk3t7Vg90H21EOLACvtfcHk0ljzOZvEP5lBQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVequ7zI&md5=8d98c80fb157b987a19e32a1efb53103</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm8011036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8011036%26sid%3Dliteratum%253Aachs%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DDrewry%26aufirst%3DD.%26aulast%3DHarper%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DG.%2BK.%26aulast%3DSchneider%26aufirst%3DK.%26atitle%3DAssessment%2520of%2520chemical%2520coverage%2520of%2520kinome%2520space%2520and%2520its%2520implications%2520for%2520kinase%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7898%26epage%3D7914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Aronov, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murcko, M. A.</span><span> </span><span class="NLM_article-title">Toward a pharmacophore for kinase frequent hitters</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">5616</span><span class="NLM_x">–</span> <span class="NLM_lpage">5619</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049793g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=5616-5619&author=A.+M.+Aronovauthor=M.+A.+Murcko&title=Toward+a+pharmacophore+for+kinase+frequent+hitters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm049793g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049793g%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26aulast%3DMurcko%26aufirst%3DM.%2BA.%26atitle%3DToward%2520a%2520pharmacophore%2520for%2520kinase%2520frequent%2520hitters%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D5616%26epage%3D5619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Akritopoulou-Zanze, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajduk, P. J.</span><span> </span><span class="NLM_article-title">Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">297</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=291-297&author=I.+Akritopoulou-Zanzeauthor=P.+J.+Hajduk&title=Kinase-targeted+libraries%3A+the+design+and+synthesis+of+novel%2C+potent%2C+and+selective+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAkritopoulou-Zanze%26aufirst%3DI.%26aulast%3DHajduk%26aufirst%3DP.%2BJ.%26atitle%3DKinase-targeted%2520libraries%253A%2520the%2520design%2520and%2520synthesis%2520of%2520novel%252C%2520potent%252C%2520and%2520selective%2520kinase%2520inhibitors%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D291%26epage%3D297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Lindsley, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leister, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Defeo-Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huff, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, M. E.</span><span> </span><span class="NLM_article-title">Allosteric AKT (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">764</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=761-764&author=C.+W.+Lindsleyauthor=Z.+Zhaoauthor=W.+H.+Leisterauthor=R.+G.+Robinsonauthor=S.+F.+Barnettauthor=D.+Defeo-Jonesauthor=R.+E.+Jonesauthor=G.+D.+Hartmanauthor=J.+R.+Huffauthor=H.+E.+Huberauthor=M.+E.+Duggan&title=Allosteric+AKT+%28PKB%29+inhibitors%3A+discovery+and+SAR+of+isozyme+selective+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLeister%26aufirst%3DW.%2BH.%26aulast%3DRobinson%26aufirst%3DR.%2BG.%26aulast%3DBarnett%26aufirst%3DS.%2BF.%26aulast%3DDefeo-Jones%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DR.%2BE.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DHuff%26aufirst%3DJ.%2BR.%26aulast%3DHuber%26aufirst%3DH.%2BE.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DAllosteric%2520AKT%2520%2528PKB%2529%2520inhibitors%253A%2520discovery%2520and%2520SAR%2520of%2520isozyme%2520selective%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D761%26epage%3D764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leister, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Defeo-Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huff, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span> </span><span class="NLM_article-title">Discovery of 2,3,5-trisubstituted pyridine derivatives as potent AKT1 and AKT2 dual inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">909</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2Fj.bmcl.2004.12.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=15686884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2MXos1elug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=905-909&author=Z.+Zhaoauthor=W.+H.+Leisterauthor=R.+G.+Robinsonauthor=S.+F.+Barnettauthor=D.+Defeo-Jonesauthor=R.+E.+Jonesauthor=G.+D.+Hartmanauthor=J.+R.+Huffauthor=H.+E.+Huberauthor=M.+E.+Dugganauthor=C.+W.+Lindsley&title=Discovery+of+2%2C3%2C5-trisubstituted+pyridine+derivatives+as+potent+AKT1+and+AKT2+dual+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors</span></div><div class="casAuthors">Zhao, Zhijian; Leister, William H.; Robinson, Ronald G.; Barnett, Stanley F.; Defeo-Jones, Deborah; Jones, Raymond E.; Hartman, George D.; Huff, Joel R.; Huber, Hans E.; Duggan, Mark E.; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">905-909</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This letter describes the discovery of a novel series of dual Akt1/Akt2 kinase inhibitors, based on a 2,3,5-trisubstituted pyridine scaffold.  Compds. from this series, which contain a 5-tetrazolyl moiety, exhibit more potent inhibition of Akt2 than Akt1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJOzjnuD-86LVg90H21EOLACvtfcHk0ljzOZvEP5lBQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXos1elug%253D%253D&md5=a61e2d83a2d7ffdb660255e341deaa9c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.12.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.12.062%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLeister%26aufirst%3DW.%2BH.%26aulast%3DRobinson%26aufirst%3DR.%2BG.%26aulast%3DBarnett%26aufirst%3DS.%2BF.%26aulast%3DDefeo-Jones%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DR.%2BE.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DHuff%26aufirst%3DJ.%2BR.%26aulast%3DHuber%26aufirst%3DH.%2BE.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DDiscovery%2520of%25202%252C3%252C5-trisubstituted%2520pyridine%2520derivatives%2520as%2520potent%2520AKT1%2520and%2520AKT2%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D905%26epage%3D909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Defeo-Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leander, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosford, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasit, P.</span><span> </span><span class="NLM_article-title">Allosteric inhibitors of AKT1 and AKT2: discovery of [1,2,4]triazolo[3,4-<i>f</i>][1,6]naphthyridines with potent and balanced activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">834</span><span class="NLM_x">–</span> <span class="NLM_lpage">836</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=834-836&author=Y.+Liauthor=J.+Liangauthor=T.+Siuauthor=E.+Huauthor=M.+A.+Rossiauthor=S.+F.+Barnettauthor=D.+Defeo-Jonesauthor=R.+E.+Jonesauthor=R.+G.+Robinsonauthor=K.+Leanderauthor=H.+E.+Huberauthor=S.+Mittalauthor=N.+Cosfordauthor=P.+Prasit&title=Allosteric+inhibitors+of+AKT1+and+AKT2%3A+discovery+of+%5B1%2C2%2C4%5Dtriazolo%5B3%2C4-f%5D%5B1%2C6%5Dnaphthyridines+with+potent+and+balanced+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DSiu%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DE.%26aulast%3DRossi%26aufirst%3DM.%2BA.%26aulast%3DBarnett%26aufirst%3DS.%2BF.%26aulast%3DDefeo-Jones%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DR.%2BE.%26aulast%3DRobinson%26aufirst%3DR.%2BG.%26aulast%3DLeander%26aufirst%3DK.%26aulast%3DHuber%26aufirst%3DH.%2BE.%26aulast%3DMittal%26aufirst%3DS.%26aulast%3DCosford%26aufirst%3DN.%26aulast%3DPrasit%26aufirst%3DP.%26atitle%3DAllosteric%2520inhibitors%2520of%2520AKT1%2520and%2520AKT2%253A%2520discovery%2520of%2520%255B1%252C2%252C4%255Dtriazolo%255B3%252C4-f%255D%255B1%252C6%255Dnaphthyridines%2520with%2520potent%2520and%2520balanced%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D834%26epage%3D836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span>NCT00670488: MK2206 in Patients with Locally Advanced or Metastatic Solid Tumors. <a href="http://www.clinicaltrials.gov" class="extLink">www.clinicaltrials.gov</a>,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NCT00670488%3A+MK2206+in+Patients+with+Locally+Advanced+or+Metastatic+Solid+Tumors.+www.clinicaltrials.gov%2C+2008."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Annis, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Athanasopoulos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felsch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalghatgi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orminati, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosner, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipps, G. W.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thaddupathy, G. R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyler, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilenchik, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, E. A.</span><span> </span><span class="NLM_article-title">An affinity selection-mass spectrometry method for the identification of small molecule ligands from self-encoded combinatorial libraries. Discovery of a novel antagonist of <i>E. coli</i> dihydrofolate reductase</span> <span class="citation_source-journal">Int. J. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">238</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">83</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=238&publication_year=2004&pages=77-83&author=D.+A.+Annisauthor=J.+Athanasopoulosauthor=P.+Curranauthor=J.+Felschauthor=K.+Kalghatgiauthor=W.+H.+Leeauthor=H.+Nashauthor=J.-P.+Orminatiauthor=K.+E.+Rosnerauthor=G.+W.+Shippsauthor=G.+R.+A.+Thaddupathyauthor=A.+N.+Tylerauthor=L.+Vilenchikauthor=E.+A.+Winter&title=An+affinity+selection-mass+spectrometry+method+for+the+identification+of+small+molecule+ligands+from+self-encoded+combinatorial+libraries.+Discovery+of+a+novel+antagonist+of+E.+coli+dihydrofolate+reductase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAnnis%26aufirst%3DD.%2BA.%26aulast%3DAthanasopoulos%26aufirst%3DJ.%26aulast%3DCurran%26aufirst%3DP.%26aulast%3DFelsch%26aufirst%3DJ.%26aulast%3DKalghatgi%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DW.%2BH.%26aulast%3DNash%26aufirst%3DH.%26aulast%3DOrminati%26aufirst%3DJ.-P.%26aulast%3DRosner%26aufirst%3DK.%2BE.%26aulast%3DShipps%26aufirst%3DG.%2BW.%26aulast%3DThaddupathy%26aufirst%3DG.%2BR.%2BA.%26aulast%3DTyler%26aufirst%3DA.%2BN.%26aulast%3DVilenchik%26aufirst%3DL.%26aulast%3DWinter%26aufirst%3DE.%2BA.%26atitle%3DAn%2520affinity%2520selection-mass%2520spectrometry%2520method%2520for%2520the%2520identification%2520of%2520small%2520molecule%2520ligands%2520from%2520self-encoded%2520combinatorial%2520libraries.%2520Discovery%2520of%2520a%2520novel%2520antagonist%2520of%2520E.%2520coli%2520dihydrofolate%2520reductase%26jtitle%3DInt.%2520J.%2520Mass%2520Spectrom.%26date%3D2004%26volume%3D238%26spage%3D77%26epage%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">Fragments, network biology and designing multiple ligands</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">156</span><span class="NLM_x">–</span> <span class="NLM_lpage">160</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=156-160&author=R.+Morphyauthor=Z.+Rankovic&title=Fragments%2C+network+biology+and+designing+multiple+ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFragments%252C%2520network%2520biology%2520and%2520designing%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D156%26epage%3D160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">McNeil, C.</span><span> </span><span class="NLM_article-title">Two targets, one drug for new EGFR inhibitors</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">1102</span><span class="NLM_x">–</span> <span class="NLM_lpage">1103</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1093%2Fjnci%2Fdjj350" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=16912259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A280%3ADC%252BD28vovVSqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2006&pages=1102-1103&author=C.+McNeil&title=Two+targets%2C+one+drug+for+new+EGFR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Two targets, one drug for new EGFR inhibitors</span></div><div class="casAuthors">McNeil Caroline</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1102-3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcbGu8z0PtTq69lAbTj9rGfW6udTcc2eb1NvwjRTKUdLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vovVSqtQ%253D%253D&md5=d18909cf12038eac649b05345b4bd51c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjj350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjj350%26sid%3Dliteratum%253Aachs%26aulast%3DMcNeil%26aufirst%3DC.%26atitle%3DTwo%2520targets%252C%2520one%2520drug%2520for%2520new%2520EGFR%2520inhibitors%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2006%26volume%3D98%26spage%3D1102%26epage%3D1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Factors underlying sensitivity of cancers to small-molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">709</span><span class="NLM_x">–</span> <span class="NLM_lpage">723</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=709-723&author=P.+A.+J%C3%A4nneauthor=N.+Grayauthor=J.+Settleman&title=Factors+underlying+sensitivity+of+cancers+to+small-molecule+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DFactors%2520underlying%2520sensitivity%2520of%2520cancers%2520to%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D709%26epage%3D723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguiz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title"><i>N</i>-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">2303</span><span class="NLM_x">–</span> <span class="NLM_lpage">2312</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2008&pages=2303-2312&author=N.+H.+Jensenauthor=R.+M.+Rodriguizauthor=M.+G.+Caronauthor=W.+C.+Wetselauthor=R.+B.+Rothmanauthor=B.+L.+Roth&title=N-Desalkylquetiapine%2C+a+potent+norepinephrine+reuptake+inhibitor+and+partial+5-HT1A+agonist%2C+as+a+putative+mediator+of+quetiapine%27s+antidepressant+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DN-Desalkylquetiapine%252C%2520a%2520potent%2520norepinephrine%2520reuptake%2520inhibitor%2520and%2520partial%25205-HT1A%2520agonist%252C%2520as%2520a%2520putative%2520mediator%2520of%2520quetiapine%2527s%2520antidepressant%2520activity%26jtitle%3DNeuropsychopharmacology%26date%3D2008%26volume%3D33%26spage%3D2303%26epage%3D2312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Medina, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodin, S.</span><span> </span><span class="NLM_article-title">Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1426</span><span class="NLM_x">–</span> <span class="NLM_lpage">1447</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2Fj.clinthera.2008.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=18803986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtF2rtLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2008&pages=1426-1447&author=P.+J.+Medinaauthor=S.+Goodin&title=Lapatinib%3A+a+dual+inhibitor+of+human+epidermal+growth+factor+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases</span></div><div class="casAuthors">Medina, Patrick J.; Goodin, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1426-1447</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Background: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.  It is indicated for use in combination with capecitabine for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress HER2 (ErbB2) and who have received previous treatment that included an anthracycline, a taxane, and trastuzumab.  Objective: This review summarizes the pharmacol., pharmacokinetics, clin. efficacy, and safety profile of lapatinib, and its current and potential role in the treatment of breast cancer and other malignancies.  Methods: Relevant English-language publications were identified through searches of MEDLINE (1966-May 2008), the American Society of Clin. Oncol. abstrs. database (2000-2007), abstrs. from the San Antonio Breast Cancer Symposium (2005-2007), and the FDA Web site (Jan. 2008).  Search terms included lapatinib, GW572016, HER2, EGFR, receptor tyrosine kinase, dual-receptor blockade, adverse events, and clin. trials.  Results: The Tmax of lapatinib after oral administration is 3 to 4 h.  Dividing the dose or administering it with food, particularly a high-fat meal, increases the AUC >2-fold.  Lapatinib is metabolized primarily by the cytochrome P 450 3A4 isoenzyme, with 1 metabolite remaining active against EGFR but not HER2.  Due to drug accumulation, the t1/2 of lapatinib is 24 h with continuous dosing.  In a Phase III trial comparing lapatinib and capecitabine with capecitabine alone in women with HER2-pos., locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of lapatinib and capecitabine was assocd. with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, resp.; P = NS) and a significant increase in time to progression (6.2 vs 4.3 mo; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).  Lapatinib has been reported to have antitumor activity in Phase II trials when used as first-line therapy for MBC, in patients with inflammatory breast cancer, and in patients with central nervous system metastases.  Phase II trials in other solid tumor types found modest activity.  The approved dosing of lapatinib is 1250 mg PO QD given continuously in combination with capecitabine 2000 mg/m2 daily administered in 2 divided doses on days 1 to 14 of a 21-day cycle.  The most common clin. toxicities of all grades assocd. with lapatinib used in combination with capecitabine in the pivotal clin. trial were diarrhea (65%), hand-foot syndrome (53%), nausea (44%), rash (29%), and fatigue (24%).  Cardiac toxicity appears to be less frequent with lapatinib than with trastuzumab.  Conclusions: Lapatinib is a dual inhibitor of the EGFR and HER2 tyrosine kinases.  It is approved by the FDA for use in combination with capecitabine for the treatment of HER2-pos. MBC that has progressed with std. treatment.  In clin. trials, this combination was assocd. with a significant improvement in the time to progression in patients with MBC.  Lapatinib's efficacy in other malignancies that overexpress EGFR and/or HER2 is under evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCjQ3-xYaNcbVg90H21EOLACvtfcHk0lhxKEUpaeQ6yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtF2rtLfL&md5=e2e7505d278f03060c4bf664994f1ae1</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2008.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2008.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DMedina%26aufirst%3DP.%2BJ.%26aulast%3DGoodin%26aufirst%3DS.%26atitle%3DLapatinib%253A%2520a%2520dual%2520inhibitor%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinases%26jtitle%3DClin.%2520Ther.%26date%3D2008%26volume%3D30%26spage%3D1426%26epage%3D1447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Houk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bello, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amantea, M.</span><span> </span><span class="NLM_article-title">A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2497</span><span class="NLM_x">–</span> <span class="NLM_lpage">2506</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1158%2F1078-0432.CCR-08-1893" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=19258444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvVWksLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=2497-2506&author=B.+E.+Houkauthor=C.+L.+Belloauthor=D.+Kangauthor=M.+Amantea&title=A+population+pharmacokinetic+meta-analysis+of+sunitinib+malate+%28SU11248%29+and+its+primary+metabolite+%28SU12662%29+in+healthy+volunteers+and+oncology+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients</span></div><div class="casAuthors">Houk, Brett E.; Bello, Carlo L.; Kang, Dongwoo; Amantea, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2497-2506</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor approved for advanced renal cell carcinoma and imatinib-resistant or imatinib-intolerant gastrointestinal stromal tumor.  Following administration, sunitinib is metabolized by cytochrome P 450 3A4 to an active metabolite (SU12662).  The objective of this anal. was to assess sunitinib and SU12662 pharmacokinetics and to identify covariates that might explain variability in exposure following oral administration.  Exptl. Design: Data from 590 subjects (73 volunteers and 517 patients) in 14 studies were analyzed.  Plasma concn.-time data were analyzed using nonlinear mixed-effects modeling to est. population pharmacokinetic parameters, as well as relationships between these parameters and gender, race, age, wt., creatinine clearance, Eastern Cooperative Oncol. Group score, and tumor type.  Simulations were done to det. the predicted effect of these covariates on exposure.  Results: Sep. models were developed for sunitinib and SU12662 (each a two-compartment model with first-order absorption and elimination).  Sunitinib parameters were estd. as CL/F, 51.8 L/h and Vd/Fcentral, 2,030 L.  SU12662 parameters were estd. as CL/F, 29.6 L/h and Vd/Fcentral, 3,080 L.  Tumor type (except acute myeloid leukemia), Asian race, gender, body wt., and elevated Eastern Cooperative Oncol. Group score described a portion of the variability in CL/F for sunitinib and metabolite; gender and body wt. explained some of the variability in Vd/Fcentral for sunitinib and metabolite.  Among patients, the predicted changes in sunitinib and metabolite AUC and Cmax as a result of the individual covariates ranged up to 17%.  Conclusion: The magnitude of the predicted changes in exposure with the covariates studied minimizes the necessity for dose adjustment in any of these subpopulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrSL9u0xSIEbVg90H21EOLACvtfcHk0lhxKEUpaeQ6yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvVWksLg%253D&md5=f970bf4524041d44f349f03aed344595</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1893%26sid%3Dliteratum%253Aachs%26aulast%3DHouk%26aufirst%3DB.%2BE.%26aulast%3DBello%26aufirst%3DC.%2BL.%26aulast%3DKang%26aufirst%3DD.%26aulast%3DAmantea%26aufirst%3DM.%26atitle%3DA%2520population%2520pharmacokinetic%2520meta-analysis%2520of%2520sunitinib%2520malate%2520%2528SU11248%2529%2520and%2520its%2520primary%2520metabolite%2520%2528SU12662%2529%2520in%2520healthy%2520volunteers%2520and%2520oncology%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D2497%26epage%3D2506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Lipinski, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominy, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, P. J.</span><span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0lhxKEUpaeQ6yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26spage%3D3%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Morphy, J. R.</span><span> </span><span class="NLM_article-title">The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2969</span><span class="NLM_x">–</span> <span class="NLM_lpage">2978</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0512185" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtlOit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=2969-2978&author=J.+R.+Morphy&title=The+influence+of+target+family+and+functional+activity+on+the+physicochemical+properties+of+pre-clinical+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The Influence of Target Family and Functional Activity on the Physicochemical Properties of Pre-Clinical Compounds</span></div><div class="casAuthors">Morphy, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2969-2978</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The target families of greatest interest in drug discovery can be differentiated on the basis of the physicochem. properties of their preclin. ligands.  The ligands for peptidergic targets, such as peptide G protein-coupled receptors (GPCRs) and integrin receptors, possess significantly higher median property values than those for aminergic targets, such as monoamine transporters and GPCRs.  The ligands for peptide GPCRs were found to be less efficient, in terms of their binding energy per unit of mol. wt. or lipophilicity, than ligands for monoamine GPCRs.  The changes in the property values during the optimization process were found to vary only slightly across the target families, with the main determinant of the drug-likeness of the optimized compds. being the profile of the starting compds.  Agonists for monoamine GPCRs, opioid receptors and ion channels were typically smaller and less lipophilic than the antagonists, but there was no difference between the agonists and the antagonists for peptide GPCRs and nuclear receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0EegclZUHNbVg90H21EOLACvtfcHk0lgU5XC-WPZ3sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtlOit7g%253D&md5=fcf63bff570d58d56492b46ddecb5eb1</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm0512185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0512185%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520influence%2520of%2520target%2520family%2520and%2520functional%2520activity%2520on%2520the%2520physicochemical%2520properties%2520of%2520pre-clinical%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D2969%26epage%3D2978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Morphy, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">The physicochemical challenges of designing multiple ligands</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4961</span><span class="NLM_x">–</span> <span class="NLM_lpage">4970</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0603015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4961-4970&author=J.+R.+Morphyauthor=Z.+Rankovic&title=The+physicochemical+challenges+of+designing+multiple+ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The Physicochemical Challenges of Designing Multiple Ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4961-4970</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compds. designed to bind more than one target can provide a therapeutic benefit relative to highly target-selective ligands.  The physicochem. properties of designed multiple ligands were found to be less druglike than those for preclin. compds. in general.  These properties are controlled by the superfamily to which the targets belong and the lead discovery strategy that was followed.  The properties for peptide G-protein-coupled receptor (GPCR) ligands were the least favorable for oral delivery, whereas transporter, monoamine GPCR, and oxidase ligands were the most druglike.  The lead discovery strategy, framework combination or screening, exerts a profound influence on the property values.  Combining the frameworks from two selective ligands often results in large, complex dual ligands, but druglike ligands can be achieved if the degree of framework overlap is maximized and the size of the selective ligands minimized.  For some target combinations, a screening approach may provide a route to smaller, less complex leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonGHbXyxgv4LVg90H21EOLACvtfcHk0lgU5XC-WPZ3sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D&md5=c7a227848516d0aa58ed037a582943fe</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm0603015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603015%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DJ.%2BR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DThe%2520physicochemical%2520challenges%2520of%2520designing%2520multiple%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4961%26epage%3D4970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Dinges, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akritopoulou-Zanze, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumeister, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunha, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Djuric, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gracias, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafferty, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowin, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. Q.</span><span> </span><span class="NLM_article-title">1,4-Dihydroindeno[1,2-<i>c</i>]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4266</span><span class="NLM_x">–</span> <span class="NLM_lpage">4271</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4266-4271&author=J.+Dingesauthor=K.+L.+Ashworthauthor=I.+Akritopoulou-Zanzeauthor=L.+D.+Arnoldauthor=S.+A.+Baumeisterauthor=P.+F.+Bousquetauthor=G.+A.+Cunhaauthor=S.+K.+Davidsenauthor=S.+W.+Djuricauthor=V.+J.+Graciasauthor=M.+R.+Michaelidesauthor=P.+Raffertyauthor=T.+J.+Sowinauthor=K.+D.+Stewartauthor=Z.+Xiaauthor=H.+Q.+Zhang&title=1%2C4-Dihydroindeno%5B1%2C2-c%5Dpyrazoles+as+novel+multitargeted+receptor+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDinges%26aufirst%3DJ.%26aulast%3DAshworth%26aufirst%3DK.%2BL.%26aulast%3DAkritopoulou-Zanze%26aufirst%3DI.%26aulast%3DArnold%26aufirst%3DL.%2BD.%26aulast%3DBaumeister%26aufirst%3DS.%2BA.%26aulast%3DBousquet%26aufirst%3DP.%2BF.%26aulast%3DCunha%26aufirst%3DG.%2BA.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DDjuric%26aufirst%3DS.%2BW.%26aulast%3DGracias%26aufirst%3DV.%2BJ.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26aulast%3DRafferty%26aufirst%3DP.%26aulast%3DSowin%26aufirst%3DT.%2BJ.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DH.%2BQ.%26atitle%3D1%252C4-Dihydroindeno%255B1%252C2-c%255Dpyrazoles%2520as%2520novel%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4266%26epage%3D4271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. M.</span><span> </span><span class="NLM_article-title">Time-related differences in the physical property profiles of oral drugs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6338</span><span class="NLM_x">–</span> <span class="NLM_lpage">6348</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049717d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpt1Sksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6338-6348&author=P.+D.+Leesonauthor=A.+M.+Davis&title=Time-related+differences+in+the+physical+property+profiles+of+oral+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Time-Related Differences in the Physical Property Profiles of Oral Drugs</span></div><div class="casAuthors">Leeson, Paul D.; Davis, Andrew M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">6338-6348</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Comparisons of the calcd. physicochem. properties of oral drugs launched prior to 1983 (864 drugs) and between 1983 and 2002 (329 drugs) show that mean values of lipophilicity, percent polar surface area and H-bond donor count are the same, suggesting that these are the most important oral drug-like phys. properties.  In contrast, mean values of mol. wt. and the nos. of O + N atoms, H-bond acceptors, and rotatable bonds and rings have increased in 1983-2002 drugs (by 13-29%).  Anal. of the 1983-2002 oral drugs by therapy area shows that anti-infectives and nervous system drugs have the most extreme phys. property profiles.  Cardiovascular drugs show increasing mol. wt. with year of publication, primarily a consequence of focusing on clin. proven mechanisms, with limited chem. diversity.  Drug classes other than anti-infectives show comparable distributions of lipophilicity, suggesting that this property in oral drugs is important irresp. of the drug's target.  The results suggest that the balance between polar and nonpolar drug properties is an important, unchanging feature of oral drug mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtNkiWH6Bl6bVg90H21EOLACvtfcHk0lgU5XC-WPZ3sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpt1Sksbg%253D&md5=edd5cceab1ccfe3542cb4df180e3c160</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm049717d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049717d%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DDavis%26aufirst%3DA.%2BM.%26atitle%3DTime-related%2520differences%2520in%2520the%2520physical%2520property%2520profiles%2520of%2520oral%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6338%26epage%3D6348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Vieth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, R. M.</span><span> </span><span class="NLM_article-title">Kinomics: characterizing the therapeutically validated kinase space</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">839</span><span class="NLM_x">–</span> <span class="NLM_lpage">846</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=839-846&author=M.+Viethauthor=J.+J.+Sutherlandauthor=D.+H.+Robertsonauthor=R.+M.+Campbell&title=Kinomics%3A+characterizing+the+therapeutically+validated+kinase+space"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVieth%26aufirst%3DM.%26aulast%3DSutherland%26aufirst%3DJ.%2BJ.%26aulast%3DRobertson%26aufirst%3DD.%2BH.%26aulast%3DCampbell%26aufirst%3DR.%2BM.%26atitle%3DKinomics%253A%2520characterizing%2520the%2520therapeutically%2520validated%2520kinase%2520space%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D839%26epage%3D846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Waterson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornberger, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sammond, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickson, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caferro, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinkle, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spehar, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehling, D. E.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1332</span><span class="NLM_x">–</span> <span class="NLM_lpage">1336</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1332-1336&author=A.+G.+Watersonauthor=K.+G.+Petrovauthor=K.+R.+Hornbergerauthor=R.+D.+Hubbardauthor=D.+M.+Sammondauthor=S.+C.+Smithauthor=H.+D.+Dicksonauthor=T.+R.+Caferroauthor=K.+W.+Hinkleauthor=K.+L.+Stevensauthor=S.+H.+Dickersonauthor=D.+W.+Rusnakauthor=G.+M.+Speharauthor=E.+R.+Woodauthor=R.+J.+Griffinauthor=D.+E.+Uehling&title=Synthesis+and+evaluation+of+aniline+headgroups+for+alkynyl+thienopyrimidine+dual+EGFR%2FErbB-2+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DHornberger%26aufirst%3DK.%2BR.%26aulast%3DHubbard%26aufirst%3DR.%2BD.%26aulast%3DSammond%26aufirst%3DD.%2BM.%26aulast%3DSmith%26aufirst%3DS.%2BC.%26aulast%3DDickson%26aufirst%3DH.%2BD.%26aulast%3DCaferro%26aufirst%3DT.%2BR.%26aulast%3DHinkle%26aufirst%3DK.%2BW.%26aulast%3DStevens%26aufirst%3DK.%2BL.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DSpehar%26aufirst%3DG.%2BM.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DUehling%26aufirst%3DD.%2BE.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520aniline%2520headgroups%2520for%2520alkynyl%2520thienopyrimidine%2520dual%2520EGFR%252FErbB-2%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1332%26epage%3D1336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lioRtC34Y9h0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Peters, J. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnider, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattei, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span> </span><span class="NLM_article-title">Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">680</span><span class="NLM_x">–</span> <span class="NLM_lpage">686</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=680-686&author=J.+U.+Petersauthor=P.+Schniderauthor=P.+Matteiauthor=M.+Kansy&title=Pharmacological+promiscuity%3A+dependence+on+compound+properties+and+target+specificity+in+a+set+of+recent+Roche+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26aulast%3DSchnider%26aufirst%3DP.%26aulast%3DMattei%26aufirst%3DP.%26aulast%3DKansy%26aufirst%3DM.%26atitle%3DPharmacological%2520promiscuity%253A%2520dependence%2520on%2520compound%2520properties%2520and%2520target%2520specificity%2520in%2520a%2520set%2520of%2520recent%2520Roche%2520compounds%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D680%26epage%3D686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Whitlock, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fish, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fray, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stobie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakenhut, F.</span><span> </span><span class="NLM_article-title">Pyridyl-phenyl ether monoamine reuptake inhibitors: impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2896</span><span class="NLM_x">–</span> <span class="NLM_lpage">2899</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2Fj.bmcl.2008.03.082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=18417343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvVWjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2896-2899&author=G.+A.+Whitlockauthor=P.+V.+Fishauthor=M.+J.+Frayauthor=A.+Stobieauthor=F.+Wakenhut&title=Pyridyl-phenyl+ether+monoamine+reuptake+inhibitors%3A+impact+of+lipophilicity+on+dual+SNRI+pharmacology+and+off-target+promiscuity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity</span></div><div class="casAuthors">Whitlock, Gavin A.; Fish, Paul V.; Fray, M. Jonathan; Stobie, Alan; Wakenhut, Florian</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2896-2899</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A novel series of pyridyl-Ph ethers are disclosed, which possess dual 5-HT and NA reuptake pharmacol. with good selectivity over dopamine reuptake inhibition.  An anal. of the relationship between lipophilicity and pharmacol. highlighted that potent dual SNRI activity was only achievable at c log P > 3.5.  The series was found to possess significant polypharmacol. issues, and we concluded that this off-target promiscuity was related to lipophilicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq5leMowQeALVg90H21EOLACvtfcHk0lioRtC34Y9h0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvVWjsL0%253D&md5=0558e1795ceabcbda51c84708bca12ee</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.03.082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.03.082%26sid%3Dliteratum%253Aachs%26aulast%3DWhitlock%26aufirst%3DG.%2BA.%26aulast%3DFish%26aufirst%3DP.%2BV.%26aulast%3DFray%26aufirst%3DM.%2BJ.%26aulast%3DStobie%26aufirst%3DA.%26aulast%3DWakenhut%26aufirst%3DF.%26atitle%3DPyridyl-phenyl%2520ether%2520monoamine%2520reuptake%2520inhibitors%253A%2520impact%2520of%2520lipophilicity%2520on%2520dual%2520SNRI%2520pharmacology%2520and%2520off-target%2520promiscuity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D2896%26epage%3D2899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Polli, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmon, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castellino, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Mara, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">John-Williams, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serabjit-Singh, C. J.</span><span> </span><span class="NLM_article-title">The role of efflux and uptake transporters in [<i>N</i>-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">701</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=695-701&author=J.+W.+Polliauthor=J.+E.+Humphreysauthor=K.+A.+Harmonauthor=S.+Castellinoauthor=M.+J.+O%27Maraauthor=K.+L.+Olsonauthor=L.+S.+John-Williamsauthor=K.+M.+Kochauthor=C.+J.+Serabjit-Singh&title=The+role+of+efflux+and+uptake+transporters+in+%5BN-%7B3-chloro-4-%5B%283-fluorobenzyl%29oxy%5Dphenyl%7D-6-%5B5-%28%7B%5B2-%28methylsulfonyl%29ethyl%5Damino%7Dmethyl%29-2-furyl%5D-4-quinazolinamine+%28GW572016%2C+lapatinib%29+disposition+and+drug+interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26aulast%3DHumphreys%26aufirst%3DJ.%2BE.%26aulast%3DHarmon%26aufirst%3DK.%2BA.%26aulast%3DCastellino%26aufirst%3DS.%26aulast%3DO%2527Mara%26aufirst%3DM.%2BJ.%26aulast%3DOlson%26aufirst%3DK.%2BL.%26aulast%3DJohn-Williams%26aufirst%3DL.%2BS.%26aulast%3DKoch%26aufirst%3DK.%2BM.%26aulast%3DSerabjit-Singh%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520role%2520of%2520efflux%2520and%2520uptake%2520transporters%2520in%2520%255BN-%257B3-chloro-4-%255B%25283-fluorobenzyl%2529oxy%255Dphenyl%257D-6-%255B5-%2528%257B%255B2-%2528methylsulfonyl%2529ethyl%255Damino%257Dmethyl%2529-2-furyl%255D-4-quinazolinamine%2520%2528GW572016%252C%2520lapatinib%2529%2520disposition%2520and%2520drug%2520interactions%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D695%26epage%3D701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Oprea, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bologa, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curpan, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glen, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipinski, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostopovici-Halip, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rishton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ursu, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sklar, L. A.</span><span> </span><span class="NLM_article-title">A crowdsourcing evaluation of the NIH chemical probes</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnchembio0709-441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=19536101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsVags7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=441-447&author=T.+I.+Opreaauthor=C.+G.+Bologaauthor=S.+Boyerauthor=R.+F.+Curpanauthor=R.+C.+Glenauthor=A.+L.+Hopkinsauthor=C.+A.+Lipinskiauthor=G.+R.+Marshallauthor=Y.+C.+Martinauthor=L.+Ostopovici-Halipauthor=G.+Rishtonauthor=O.+Ursuauthor=R.+J.+Vazauthor=C.+Wallerauthor=H.+Waldmannauthor=L.+A.+Sklar&title=A+crowdsourcing+evaluation+of+the+NIH+chemical+probes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A crowdsourcing evaluation of the NIH chemical probes</span></div><div class="casAuthors">Oprea, Tudor I.; Bologa, Cristian G.; Boyer, Scott; Curpan, Ramona F.; Glen, Robert C.; Hopkins, Andrew L.; Lipinski, Christopher A.; Marshall, Garland R.; Martin, Yvonne C.; Ostopovici-Halip, Liliana; Rishton, Gilbert; Ursu, Oleg; Vaz, Roy J.; Waller, Chris; Waldmann, Herbert; Sklar, Larry A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">441-447</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with commentary.  Between 2004 and 2008, the US National Institutes of Health Mol. Libraries and Imaging initiative pilot phase funded 10 high-throughput screening centers, resulting in the deposition of 691 assays into PubChem and the nomination of 64 chem. probes.  We crowdsourced the Mol. Libraries and Imaging initiative output to 11 experts, who expressed medium or high levels of confidence in 48 of these 64 probes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2vr16pYCeybVg90H21EOLACvtfcHk0ljXiRHhP7RSng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsVags7k%253D&md5=adc3ed5b33cbd233ec6160c5465651b7</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnchembio0709-441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio0709-441%26sid%3Dliteratum%253Aachs%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DBologa%26aufirst%3DC.%2BG.%26aulast%3DBoyer%26aufirst%3DS.%26aulast%3DCurpan%26aufirst%3DR.%2BF.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DMarshall%26aufirst%3DG.%2BR.%26aulast%3DMartin%26aufirst%3DY.%2BC.%26aulast%3DOstopovici-Halip%26aufirst%3DL.%26aulast%3DRishton%26aufirst%3DG.%26aulast%3DUrsu%26aufirst%3DO.%26aulast%3DVaz%26aufirst%3DR.%2BJ.%26aulast%3DWaller%26aufirst%3DC.%26aulast%3DWaldmann%26aufirst%3DH.%26aulast%3DSklar%26aufirst%3DL.%2BA.%26atitle%3DA%2520crowdsourcing%2520evaluation%2520of%2520the%2520NIH%2520chemical%2520probes%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D441%26epage%3D447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsden, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pogacic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rellos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullock, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwaller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundström, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">20523</span><span class="NLM_x">–</span> <span class="NLM_lpage">20528</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=20523-20528&author=O.+Fedorovauthor=B.+Marsdenauthor=V.+Pogacicauthor=P.+Rellosauthor=S.+M%C3%BCllerauthor=A.+N.+Bullockauthor=J.+Schwallerauthor=M.+Sundstr%C3%B6mauthor=S.+Knapp&title=A+systematic+interaction+map+of+validated+kinase+inhibitors+with+Ser%2FThr+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DMarsden%26aufirst%3DB.%26aulast%3DPogacic%26aufirst%3DV.%26aulast%3DRellos%26aufirst%3DP.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DSchwaller%26aufirst%3DJ.%26aulast%3DSundstr%25C3%25B6m%26aufirst%3DM.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DA%2520systematic%2520interaction%2520map%2520of%2520validated%2520kinase%2520inhibitors%2520with%2520Ser%252FThr%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D20523%26epage%3D20528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Bamborough, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, K.</span><span> </span><span class="NLM_article-title">Assessment of chemical coverage of kinome space and its implications for kinase drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">7898</span><span class="NLM_x">–</span> <span class="NLM_lpage">7914</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8011036" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVequ7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7898-7914&author=P.+Bamboroughauthor=D.+Drewryauthor=G.+Harperauthor=G.+K.+Smithauthor=K.+Schneider&title=Assessment+of+chemical+coverage+of+kinome+space+and+its+implications+for+kinase+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of Chemical Coverage of Kinome Space and Its Implications for Kinase Drug Discovery</span></div><div class="casAuthors">Bamborough, Paul; Drewry, David; Harper, Gavin; Smith, Gary K.; Schneider, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7898-7914</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">More than 500 compds. chosen to represent kinase inhibitor space have been screened against a panel of over 200 protein kinases.  Significant results include the identification of hits against new kinases including PIM1 and MPSK1, and the expansion of the inhibition profiles of several literature compds.  A detailed anal. of the data through the use of affinity fingerprints has produced findings with implications for biol. target selection, the choice of tool compds. for target validation, and lead discovery and optimization.  In a detailed examn. of the tyrosine kinases, interesting relationships have been found between targets and compds.  Taken together, these results show how broad cross-profiling can provide important insights to assist kinase drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBRI-arQk3t7Vg90H21EOLACvtfcHk0ljXiRHhP7RSng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVequ7zI&md5=8d98c80fb157b987a19e32a1efb53103</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm8011036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8011036%26sid%3Dliteratum%253Aachs%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DDrewry%26aufirst%3DD.%26aulast%3DHarper%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DG.%2BK.%26aulast%3DSchneider%26aufirst%3DK.%26atitle%3DAssessment%2520of%2520chemical%2520coverage%2520of%2520kinome%2520space%2520and%2520its%2520implications%2520for%2520kinase%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7898%26epage%3D7914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lélias, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule−kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule%E2%88%92kinase+interaction+map+for+clinical+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule%25E2%2588%2592kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Bantscheff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberhard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastuck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boesche, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hobson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reader, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweetman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouwmeester, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopf, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neubauer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsden, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuster, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewes, G.</span><span> </span><span class="NLM_article-title">Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1035</span><span class="NLM_x">–</span> <span class="NLM_lpage">1044</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnbt1328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17721511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVWksLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=1035-1044&author=M.+Bantscheffauthor=D.+Eberhardauthor=Y.+Abrahamauthor=S.+Bastuckauthor=M.+Boescheauthor=S.+Hobsonauthor=T.+Mathiesonauthor=J.+Perrinauthor=M.+Raidaauthor=C.+Rauauthor=V.+Readerauthor=G.+Sweetmanauthor=A.+Bauerauthor=T.+Bouwmeesterauthor=C.+Hopfauthor=U.+Kruseauthor=G.+Neubauerauthor=N.+Ramsdenauthor=J.+Rickauthor=B.+Kusterauthor=G.+Drewes&title=Quantitative+chemical+proteomics+reveals+mechanisms+of+action+of+clinical+ABL+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors</span></div><div class="casAuthors">Bantscheff, Marcus; Eberhard, Dirk; Abraham, Yann; Bastuck, Sonja; Boesche, Markus; Hobson, Scott; Mathieson, Toby; Perrin, Jessica; Raida, Manfred; Rau, Christina; Reader, Valerie; Sweetman, Gavain; Bauer, Andreas; Bouwmeester, Tewis; Hopf, Carsten; Kruse, Ulrich; Neubauer, Gitte; Ramsden, Nigel; Rick, Jens; Kuster, Bernhard; Drewes, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1035-1044</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors describe a chem. proteomics approach to profile the interaction of small mols. with hundreds of endogenously expressed protein kinases and purine-binding proteins.  This subproteome is captured by immobilized nonselective kinase inhibitors (kinobeads), and the bound proteins are quantified in parallel by mass spectrometry using isobaric tags for relative and abs. quantification (iTRAQ).  By measuring the competition with the affinity matrix, the authors assess the binding of drugs to their targets in cell lysates and in cells.  By mapping drug-induced changes in the phosphorylation state of the captured proteome, the authors also analyze signaling pathways downstream of target kinases.  Quant. profiling of the drugs imatinib (Gleevec), dasatinib (Sprycel) and bosutinib in K562 cells confirms known targets including ABL and SRC family kinases and identifies the receptor tyrosine kinase DDR1 and the oxidoreductase NQO2 as novel targets of imatinib.  The data suggest that the approach is a valuable tool for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsC3OpIuhl8LVg90H21EOLACvtfcHk0lj5o3jyiS5VHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVWksLvF&md5=ed20d4684a8a6733aba24ca64602bae8</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnbt1328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1328%26sid%3Dliteratum%253Aachs%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DEberhard%26aufirst%3DD.%26aulast%3DAbraham%26aufirst%3DY.%26aulast%3DBastuck%26aufirst%3DS.%26aulast%3DBoesche%26aufirst%3DM.%26aulast%3DHobson%26aufirst%3DS.%26aulast%3DMathieson%26aufirst%3DT.%26aulast%3DPerrin%26aufirst%3DJ.%26aulast%3DRaida%26aufirst%3DM.%26aulast%3DRau%26aufirst%3DC.%26aulast%3DReader%26aufirst%3DV.%26aulast%3DSweetman%26aufirst%3DG.%26aulast%3DBauer%26aufirst%3DA.%26aulast%3DBouwmeester%26aufirst%3DT.%26aulast%3DHopf%26aufirst%3DC.%26aulast%3DKruse%26aufirst%3DU.%26aulast%3DNeubauer%26aufirst%3DG.%26aulast%3DRamsden%26aufirst%3DN.%26aulast%3DRick%26aufirst%3DJ.%26aulast%3DKuster%26aufirst%3DB.%26aulast%3DDrewes%26aufirst%3DG.%26atitle%3DQuantitative%2520chemical%2520proteomics%2520reveals%2520mechanisms%2520of%2520action%2520of%2520clinical%2520ABL%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D1035%26epage%3D1044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Force, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Etten, R. A.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">332</span><span class="NLM_x">–</span> <span class="NLM_lpage">344</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnrc2106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17457301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksFSiu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=332-344&author=T.+Forceauthor=D.+S.+Krauseauthor=R.+A.+Van+Etten&title=Molecular+mechanisms+of+cardiotoxicity+of+tyrosine+kinase+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition</span></div><div class="casAuthors">Force, Thomas; Krause, Daniela S.; Van Etten, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">332-344</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer therapy has progressed remarkably in recent years.  In no area has this been more apparent than in the development of 'targeted therapies', particularly those using drugs that inhibit the activity of certain tyrosine kinases, activating mutations or amplifications of which are causal, or strongly contributory, to tumorigenesis.  However, some of these therapies have been assocd. with toxicity to the heart.  Here we summarize what is known about the cardiotoxicity of cancer drugs that target tyrosine kinases.  We focus on basic mechanisms through which interruption of specific signalling pathways leads to cardiomyocyte dysfunction and/or death, and contrast this with therapeutic responses in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIyJIGdG9hv7Vg90H21EOLACvtfcHk0lj5o3jyiS5VHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksFSiu7w%253D&md5=b574f420e2a09de9bae3aa2313e76c3e</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fnrc2106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2106%26sid%3Dliteratum%253Aachs%26aulast%3DForce%26aufirst%3DT.%26aulast%3DKrause%26aufirst%3DD.%2BS.%26aulast%3DVan%2BEtten%26aufirst%3DR.%2BA.%26atitle%3DMolecular%2520mechanisms%2520of%2520cardiotoxicity%2520of%2520tyrosine%2520kinase%2520inhibition%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D332%26epage%3D344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Kerkelä, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grazette, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yacobi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iliescu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patten, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beahm, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shevtsov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesant, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clubb, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenzweig, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salomon, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Etten, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alroy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durand, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Force, T.</span><span> </span><span class="NLM_article-title">Cardiotoxicity of the cancer therapeutic agent imatinib mesylate</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">908</span><span class="NLM_x">–</span> <span class="NLM_lpage">916</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnm1446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=16862153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A280%3ADC%252BD28rhtlKrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=908-916&author=R.+Kerkel%C3%A4author=L.+Grazetteauthor=R.+Yacobiauthor=C.+Iliescuauthor=R.+Pattenauthor=C.+Beahmauthor=B.+Waltersauthor=S.+Shevtsovauthor=S.+Pesantauthor=F.+J.+Clubbauthor=A.+Rosenzweigauthor=R.+N.+Salomonauthor=R.+A.+Van+Ettenauthor=J.+Alroyauthor=J.+B.+Durandauthor=T.+Force&title=Cardiotoxicity+of+the+cancer+therapeutic+agent+imatinib+mesylate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiotoxicity of the cancer therapeutic agent imatinib mesylate</span></div><div class="casAuthors">Kerkela Risto; Grazette Luanda; Yacobi Rinat; Iliescu Cezar; Patten Richard; Beahm Cara; Walters Brian; Shevtsov Sergei; Pesant Stephanie; Clubb Fred J; Rosenzweig Anthony; Salomon Robert N; Van Etten Richard A; Alroy Joseph; Durand Jean-Bernard; Force Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">908-16</span>
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    </div><div class="casAbstract">Imatinib mesylate (Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia.  Here we report ten individuals who developed severe congestive heart failure while on imatinib and we show that imatinib-treated mice develop left ventricular contractile dysfunction.  Transmission electron micrographs from humans and mice treated with imatinib show mitochondrial abnormalities and accumulation of membrane whorls in both vacuoles and the sarco- (endo-) plasmic reticulum, findings suggestive of a toxic myopathy.  With imatinib treatment, cardiomyocytes in culture show activation of the endoplasmic reticulum (ER) stress response, collapse of the mitochondrial membrane potential, release of cytochrome c into the cytosol, reduction in cellular ATP content and cell death.  Retroviral gene transfer of an imatinib-resistant mutant of c-Abl, alleviation of ER stress or inhibition of Jun amino-terminal kinases, which are activated as a consequence of ER stress, largely rescues cardiomyocytes from imatinib-induced death.  Thus, cardiotoxicity is an unanticipated side effect of inhibition of c-Abl by imatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGHOTag-dpJhjv2lLSLOxFfW6udTcc2eZARqSl95AmS7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rhtlKrtg%253D%253D&md5=4012ddd42a942f1441abb54df1894db8</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fnm1446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1446%26sid%3Dliteratum%253Aachs%26aulast%3DKerkel%25C3%25A4%26aufirst%3DR.%26aulast%3DGrazette%26aufirst%3DL.%26aulast%3DYacobi%26aufirst%3DR.%26aulast%3DIliescu%26aufirst%3DC.%26aulast%3DPatten%26aufirst%3DR.%26aulast%3DBeahm%26aufirst%3DC.%26aulast%3DWalters%26aufirst%3DB.%26aulast%3DShevtsov%26aufirst%3DS.%26aulast%3DPesant%26aufirst%3DS.%26aulast%3DClubb%26aufirst%3DF.%2BJ.%26aulast%3DRosenzweig%26aufirst%3DA.%26aulast%3DSalomon%26aufirst%3DR.%2BN.%26aulast%3DVan%2BEtten%26aufirst%3DR.%2BA.%26aulast%3DAlroy%26aufirst%3DJ.%26aulast%3DDurand%26aufirst%3DJ.%2BB.%26aulast%3DForce%26aufirst%3DT.%26atitle%3DCardiotoxicity%2520of%2520the%2520cancer%2520therapeutic%2520agent%2520imatinib%2520mesylate%26jtitle%3DNat.%2520Med.%26date%3D2006%26volume%3D12%26spage%3D908%26epage%3D916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Qian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cywin, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farmer, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashem, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magboo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pack, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prokopowicz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welzel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morwick, T.</span><span> </span><span class="NLM_article-title">Hit to lead account of the discovery of a new class of inhibitors of PIM kinases and crystallographic studies revealing an unusual kinase binding mode</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1814</span><span class="NLM_x">–</span> <span class="NLM_lpage">1827</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801242y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1814-1827&author=K.+Qianauthor=L.+Wangauthor=C.+L.+Cywinauthor=B.+T.+Farmerauthor=E.+Hickeyauthor=C.+Homonauthor=S.+Jakesauthor=M.+A.+Kashemauthor=G.+Leeauthor=S.+Leonardauthor=J.+Liauthor=R.+Magbooauthor=W.+Maoauthor=E.+Packauthor=C.+Pengauthor=A.+Prokopowiczauthor=M.+Welzelauthor=J.+Wolakauthor=T.+Morwick&title=Hit+to+lead+account+of+the+discovery+of+a+new+class+of+inhibitors+of+PIM+kinases+and+crystallographic+studies+revealing+an+unusual+kinase+binding+mode"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm801242y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801242y%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DCywin%26aufirst%3DC.%2BL.%26aulast%3DFarmer%26aufirst%3DB.%2BT.%26aulast%3DHickey%26aufirst%3DE.%26aulast%3DHomon%26aufirst%3DC.%26aulast%3DJakes%26aufirst%3DS.%26aulast%3DKashem%26aufirst%3DM.%2BA.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DLeonard%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMagboo%26aufirst%3DR.%26aulast%3DMao%26aufirst%3DW.%26aulast%3DPack%26aufirst%3DE.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DProkopowicz%26aufirst%3DA.%26aulast%3DWelzel%26aufirst%3DM.%26aulast%3DWolak%26aufirst%3DJ.%26aulast%3DMorwick%26aufirst%3DT.%26atitle%3DHit%2520to%2520lead%2520account%2520of%2520the%2520discovery%2520of%2520a%2520new%2520class%2520of%2520inhibitors%2520of%2520PIM%2520kinases%2520and%2520crystallographic%2520studies%2520revealing%2520an%2520unusual%2520kinase%2520binding%2520mode%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1814%26epage%3D1827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Brandt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, J.</span><span> </span><span class="NLM_article-title">Small kinase assay panels can provide a measure of selectivity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5861</span><span class="NLM_x">–</span> <span class="NLM_lpage">5863</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5861-5863&author=P.+Brandtauthor=A.+J.+Jensenauthor=J.+Nilsson&title=Small+kinase+assay+panels+can+provide+a+measure+of+selectivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrandt%26aufirst%3DP.%26aulast%3DJensen%26aufirst%3DA.%2BJ.%26aulast%3DNilsson%26aufirst%3DJ.%26atitle%3DSmall%2520kinase%2520assay%2520panels%2520can%2520provide%2520a%2520measure%2520of%2520selectivity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5861%26epage%3D5863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Rix, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hantschel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dürnberger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remsing, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planyavsky, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernbach, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaupe, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colinge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Köcher, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span> </span><span class="NLM_article-title">Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">4055</span><span class="NLM_x">–</span> <span class="NLM_lpage">4063</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1182%2Fblood-2007-07-102061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17720881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtl2qsb%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=4055-4063&author=U.+Rixauthor=O.+Hantschelauthor=G.+D%C3%BCrnbergerauthor=L.+Remsingauthor=M.+Planyavskyauthor=N.+V.+Fernbachauthor=I.+Kaupeauthor=K.+L.+Bennettauthor=P.+Valentauthor=J.+Colingeauthor=T.+K%C3%B6cherauthor=G.+Superti-Furga&title=Chemical+proteomic+profiles+of+the+BCR-ABL+inhibitors+imatinib%2C+nilotinib%2C+and+dasatinib+reveal+novel+kinase+and+nonkinase+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets</span></div><div class="casAuthors">Rix, Uwe; Hantschel, Oliver; Duernberger, Gerhard; Rix, Lily L. Remsing; Planyavsky, Melanie; Fernbach, Nora V.; Kaupe, Ines; Bennett, Keiryn L.; Valent, Peter; Colinge, Jacques; Koecher, Thomas; Superti-Furga, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4055-4063</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The BCR-ABL tyrosine kinase inhibitor imatinib represents the current front-line therapy in chronic myeloid leukemia.  Because many patients develop imatinib resistance, 2 second-generation drugs, nilotinib and dasatinib, displaying increased potency against BCR-ABL were developed.  To predict potential side effects and novel medical uses, we generated comprehensive drug-protein interaction profiles by chem. proteomics for all 3 drugs.  Our studies yielded 4 major findings: (1) The interaction profiles of the 3 drugs displayed strong differences and only a small overlap covering the ABL kinases.  (2) Dasatinib bound in excess of 30 Tyr and Ser/Thr kinases, including major regulators of the immune system, suggesting that dasatinib might have a particular impact on immune function.  (3) Despite the high specificity of nilotinib, the receptor tyrosine kinase DDR1 was identified and validated as an addnl. major target.  (4) The oxidoreductase NQO2 was bound and inhibited by imatinib and nilotinib at physiol. relevant drug concns., representing the 1st nonkinase target of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe8e6qqCnkrrVg90H21EOLACvtfcHk0lirJMd28XLzUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtl2qsb%252FF&md5=ff968982e9c20806c0c5fe9612f88407</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-07-102061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-07-102061%26sid%3Dliteratum%253Aachs%26aulast%3DRix%26aufirst%3DU.%26aulast%3DHantschel%26aufirst%3DO.%26aulast%3DD%25C3%25BCrnberger%26aufirst%3DG.%26aulast%3DRemsing%26aufirst%3DL.%26aulast%3DPlanyavsky%26aufirst%3DM.%26aulast%3DFernbach%26aufirst%3DN.%2BV.%26aulast%3DKaupe%26aufirst%3DI.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DColinge%26aufirst%3DJ.%26aulast%3DK%25C3%25B6cher%26aufirst%3DT.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DChemical%2520proteomic%2520profiles%2520of%2520the%2520BCR-ABL%2520inhibitors%2520imatinib%252C%2520nilotinib%252C%2520and%2520dasatinib%2520reveal%2520novel%2520kinase%2520and%2520nonkinase%2520targets%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D4055%26epage%3D4063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Targeting cancer with small molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+cancer+with+small+molecule+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0lhnya9I-I8FDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520cancer%2520with%2520small%2520molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer.%26date%3D2009%26volume%3D9%26spage%3D28%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Scotlandi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manara, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoletti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lollini, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perdichizzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Echeverría, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picci, P.</span><span> </span><span class="NLM_article-title">Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">3868</span><span class="NLM_x">–</span> <span class="NLM_lpage">3876</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=3868-3876&author=K.+Scotlandiauthor=M.+C.+Manaraauthor=G.+Nicolettiauthor=P.+L.+Lolliniauthor=S.+Lukasauthor=S.+Beniniauthor=S.+Crociauthor=S.+Perdichizziauthor=D.+Zambelliauthor=M.+Serraauthor=C.+Garc%C3%ADa-Echeverr%C3%ADaauthor=F.+Hofmannauthor=P.+Picci&title=Antitumor+activity+of+the+insulin-like+growth+factor-I+receptor+kinase+inhibitor+NVP-AEW541+in+musculoskeletal+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScotlandi%26aufirst%3DK.%26aulast%3DManara%26aufirst%3DM.%2BC.%26aulast%3DNicoletti%26aufirst%3DG.%26aulast%3DLollini%26aufirst%3DP.%2BL.%26aulast%3DLukas%26aufirst%3DS.%26aulast%3DBenini%26aufirst%3DS.%26aulast%3DCroci%26aufirst%3DS.%26aulast%3DPerdichizzi%26aufirst%3DS.%26aulast%3DZambelli%26aufirst%3DD.%26aulast%3DSerra%26aufirst%3DM.%26aulast%3DGarc%25C3%25ADa-Echeverr%25C3%25ADa%26aufirst%3DC.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DPicci%26aufirst%3DP.%26atitle%3DAntitumor%2520activity%2520of%2520the%2520insulin-like%2520growth%2520factor-I%2520receptor%2520kinase%2520inhibitor%2520NVP-AEW541%2520in%2520musculoskeletal%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D3868%26epage%3D3876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrián, F.</span><span> </span><span class="NLM_article-title">Ba/F3 cells and their use in kinase drug discovery</span> <span class="citation_source-journal">Curr. Opin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1097%2FCCO.0b013e328011a25f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17133113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Cnt7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=55-60&author=M.+Warmuthauthor=S.+Kimauthor=X.+J.+Guauthor=G.+Xiaauthor=F.+Adri%C3%A1n&title=Ba%2FF3+cells+and+their+use+in+kinase+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Ba/F3 cells and their use in kinase drug discovery</span></div><div class="casAuthors">Warmuth, Markus; Kim, Sungjoon; Gu, Xiang-ju; Xia, Gang; Adrian, Francisco</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-60</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Purpose of review: Due to their ability to function as dominant oncogenes, protein kinases have become favored targets in the quest for 'molecularly-targeted' cancer chemotherapeutics.  The discovery of a large no. of cancer-assocd. mutations in the kinome, and the progress in developing specific small-mol. kinase inhibitors has increased the need for accurate, reproducible, and efficient kinase activity-dependent cellular assay systems.  Recent findings: Ba/F3, a murine interleukin-3 dependent pro-B cell line is increasingly popular as a model system for assessing both the potency and downstream signaling of kinase oncogenes, and the ability of small-mol. kinase inhibitors to block kinase activity.  Facilitated by their growth properties, Ba/F3 cells have recently been adapted to high-throughput assay formats for compd. profiling.  Further, several published approaches show promise in predicting resistance to small-mol. kinase inhibitors elicited by point mutations interfering with inhibitor binding.  Summary: Ba/F3 cells are an increasingly popular tool in kinase drug discovery.  The ability to test the transforming capacity of newly identified kinase mutations, and to profile drug candidates and compd. libraries in high-throughput fashion, combined with the use of Ba/F3 cells to predict clin. resistance will greatly facilitate developments in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXQmhiRwGlDLVg90H21EOLACvtfcHk0lhnya9I-I8FDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Cnt7%252FL&md5=a7f8d84dfedea69d408edb571e2eead9</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1097%2FCCO.0b013e328011a25f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0b013e328011a25f%26sid%3Dliteratum%253Aachs%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DX.%2BJ.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DAdri%25C3%25A1n%26aufirst%3DF.%26atitle%3DBa%252FF3%2520cells%2520and%2520their%2520use%2520in%2520kinase%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2007%26volume%3D19%26spage%3D55%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Remsing Rix, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colinge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hantschel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stranzl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgartner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augustin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Till, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span> </span><span class="NLM_article-title">Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">485</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fleu.2008.334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=19039322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVKhu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=477-485&author=L.+L.+Remsing+Rixauthor=U.+Rixauthor=J.+Colingeauthor=O.+Hantschelauthor=K.+L.+Bennettauthor=T.+Stranzlauthor=A.+M%C3%BCllerauthor=C.+Baumgartnerauthor=P.+Valentauthor=M.+Augustinauthor=J.+H.+Tillauthor=G.+Superti-Furga&title=Global+target+profile+of+the+kinase+inhibitor+bosutinib+in+primary+chronic+myeloid+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells</span></div><div class="casAuthors">Remsing Rix, L. L.; Rix, U.; Colinge, J.; Hantschel, O.; Bennett, K. L.; Stranzl, T.; Mueller, A.; Baumgartner, C.; Valent, P.; Augustin, M.; Till, J. H.; Superti-Furga, G.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">477-485</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The detailed mol. mechanism of action of second-generation BCR-ABL tyrosine kinase inhibitors, including perturbed targets and pathways, should contribute to rationalized therapy in chronic myeloid leukemia (CML) or in other affected diseases.  Here, we characterized the target profile of the dual SRC/ABL inhibitor bosutinib employing a two-tiered approach using chem. proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel.  The combined strategy resulted in a global survey of bosutinib targets comprised of over 45 novel tyrosine and serine/threonine kinases.  We have found clear differences in the target patterns of bosutinib in primary CML cells vs. the K562 cell line.  A comparison of bosutinib with dasatinib across the whole kinase panel revealed overlapping, but distinct, inhibition profiles.  Common among those were the SRC, ABL and TEC family kinases.  Bosutinib did not inhibit KIT or platelet-derived growth factor receptor, but prominently targeted the apoptosis-linked STE20 kinases.  Although in vivo bosutinib is inactive against ABL T315I, we found this clin. important mutant to be enzymically inhibited in the mid-nanomolar range.  Finally, bosutinib is the first kinase inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation.  Leukemia (2009) 23, 477-485; doi:10.1038/leu.2008.334; published online 27 Nov. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8u0ixFotIMLVg90H21EOLACvtfcHk0lhnya9I-I8FDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVKhu7w%253D&md5=b0d56d468ef66ddc2a6f012d08f8c1a4</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fleu.2008.334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2008.334%26sid%3Dliteratum%253Aachs%26aulast%3DRemsing%2BRix%26aufirst%3DL.%2BL.%26aulast%3DRix%26aufirst%3DU.%26aulast%3DColinge%26aufirst%3DJ.%26aulast%3DHantschel%26aufirst%3DO.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DStranzl%26aufirst%3DT.%26aulast%3DM%25C3%25BCller%26aufirst%3DA.%26aulast%3DBaumgartner%26aufirst%3DC.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DAugustin%26aufirst%3DM.%26aulast%3DTill%26aufirst%3DJ.%2BH.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DGlobal%2520target%2520profile%2520of%2520the%2520kinase%2520inhibitor%2520bosutinib%2520in%2520primary%2520chronic%2520myeloid%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D477%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Heerding, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leber, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keenan, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafrance, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safonov, I. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takata, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venslavsky, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choudhry, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaber, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tummino, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strum, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duckett, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberwein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knick, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lansing, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McConnell, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minthorn, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Concha, N. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span> </span><span class="NLM_article-title">Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3<i>S</i>)-3-piperidinylmethyl]oxy}-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5663</span><span class="NLM_x">–</span> <span class="NLM_lpage">5679</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8004527" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5663-5679&author=D.+A.+Heerdingauthor=N.+Rhodesauthor=J.+D.+Leberauthor=T.+J.+Clarkauthor=R.+M.+Keenanauthor=L.+V.+Lafranceauthor=M.+Liauthor=I.+G.+Safonovauthor=D.+T.+Takataauthor=J.+W.+Venslavskyauthor=D.+S.+Yamashitaauthor=A.+E.+Choudhryauthor=R.+A.+Copelandauthor=Z.+Laiauthor=M.+D.+Schaberauthor=P.+J.+Tumminoauthor=S.+L.+Strumauthor=E.+R.+Woodauthor=D.+R.+Duckettauthor=D.+Eberweinauthor=V.+B.+Knickauthor=T.+J.+Lansingauthor=R.+T.+McConnellauthor=S.+Zhangauthor=E.+A.+Minthornauthor=N.+O.+Conchaauthor=G.+L.+Warrenauthor=R.+Kumar&title=Identification+of+4-%282-%284-amino-1%2C2%2C5-oxadiazol-3-yl%29-1-ethyl-7-%7B%5B%283S%29-3-piperidinylmethyl%5Doxy%7D-1H-imidazo%5B4%2C5-c%5Dpyridin-4-yl%29-2-methyl-3-butyn-2-ol+%28GSK690693%29%2C+a+novel+inhibitor+of+AKT+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Fjm8004527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8004527%26sid%3Dliteratum%253Aachs%26aulast%3DHeerding%26aufirst%3DD.%2BA.%26aulast%3DRhodes%26aufirst%3DN.%26aulast%3DLeber%26aufirst%3DJ.%2BD.%26aulast%3DClark%26aufirst%3DT.%2BJ.%26aulast%3DKeenan%26aufirst%3DR.%2BM.%26aulast%3DLafrance%26aufirst%3DL.%2BV.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DSafonov%26aufirst%3DI.%2BG.%26aulast%3DTakata%26aufirst%3DD.%2BT.%26aulast%3DVenslavsky%26aufirst%3DJ.%2BW.%26aulast%3DYamashita%26aufirst%3DD.%2BS.%26aulast%3DChoudhry%26aufirst%3DA.%2BE.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DStrum%26aufirst%3DS.%2BL.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DDuckett%26aufirst%3DD.%2BR.%26aulast%3DEberwein%26aufirst%3DD.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLansing%26aufirst%3DT.%2BJ.%26aulast%3DMcConnell%26aufirst%3DR.%2BT.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DMinthorn%26aufirst%3DE.%2BA.%26aulast%3DConcha%26aufirst%3DN.%2BO.%26aulast%3DWarren%26aufirst%3DG.%2BL.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DIdentification%2520of%25204-%25282-%25284-amino-1%252C2%252C5-oxadiazol-3-yl%2529-1-ethyl-7-%257B%255B%25283S%2529-3-piperidinylmethyl%255Doxy%257D-1H-imidazo%255B4%252C5-c%255Dpyridin-4-yl%2529-2-methyl-3-butyn-2-ol%2520%2528GSK690693%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520AKT%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5663%26epage%3D5679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Fernández, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanguino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozturk, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crespo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wulf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shavrin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trent, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangala, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bankson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelovani, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samarel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sood, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Berestein, G.</span><span> </span><span class="NLM_article-title">An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">4044</span><span class="NLM_x">–</span> <span class="NLM_lpage">4054</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=4044-4054&author=A.+Fern%C3%A1ndezauthor=A.+Sanguinoauthor=Z.+Pengauthor=E.+Ozturkauthor=J.+Chenauthor=A.+Crespoauthor=S.+Wulfauthor=A.+Shavrinauthor=C.+Qinauthor=J.+Maauthor=J.+Trentauthor=Y.+Linauthor=H.+D.+Hanauthor=L.+S.+Mangalaauthor=J.+A.+Banksonauthor=J.+Gelovaniauthor=A.+Samarelauthor=W.+Bornmannauthor=A.+K.+Soodauthor=G.+Lopez-Berestein&title=An+anticancer+C-Kit+kinase+inhibitor+is+reengineered+to+make+it+more+active+and+less+cardiotoxic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DA.%26aulast%3DSanguino%26aufirst%3DA.%26aulast%3DPeng%26aufirst%3DZ.%26aulast%3DOzturk%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCrespo%26aufirst%3DA.%26aulast%3DWulf%26aufirst%3DS.%26aulast%3DShavrin%26aufirst%3DA.%26aulast%3DQin%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DTrent%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DH.%2BD.%26aulast%3DMangala%26aufirst%3DL.%2BS.%26aulast%3DBankson%26aufirst%3DJ.%2BA.%26aulast%3DGelovani%26aufirst%3DJ.%26aulast%3DSamarel%26aufirst%3DA.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DSood%26aufirst%3DA.%2BK.%26aulast%3DLopez-Berestein%26aufirst%3DG.%26atitle%3DAn%2520anticancer%2520C-Kit%2520kinase%2520inhibitor%2520is%2520reengineered%2520to%2520make%2520it%2520more%2520active%2520and%2520less%2520cardiotoxic%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26spage%3D4044%26epage%3D4054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Fernández, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crespo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiwari, A.</span><span> </span><span class="NLM_article-title">Is there a case for selectively promiscuous anticancer drugs?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">5</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1-5&author=A.+Fern%C3%A1ndezauthor=A.+Crespoauthor=A.+Tiwari&title=Is+there+a+case+for+selectively+promiscuous+anticancer+drugs%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DA.%26aulast%3DCrespo%26aufirst%3DA.%26aulast%3DTiwari%26aufirst%3DA.%26atitle%3DIs%2520there%2520a%2520case%2520for%2520selectively%2520promiscuous%2520anticancer%2520drugs%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D1%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Von Coburg, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kottke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weizel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ligneau, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, H.</span><span> </span><span class="NLM_article-title">Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">538</span><span class="NLM_x">–</span> <span class="NLM_lpage">542</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=538-542&author=Y.+Von+Coburgauthor=T.+Kottkeauthor=L.+Weizelauthor=X.+Ligneauauthor=H.+Stark&title=Potential+utility+of+histamine+H3+receptor+antagonist+pharmacophore+in+antipsychotics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVon%2BCoburg%26aufirst%3DY.%26aulast%3DKottke%26aufirst%3DT.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DLigneau%26aufirst%3DX.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DPotential%2520utility%2520of%2520histamine%2520H3%2520receptor%2520antagonist%2520pharmacophore%2520in%2520antipsychotics%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D538%26epage%3D542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chessari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tisi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhead, A. J.</span><span> </span><span class="NLM_article-title">Recent developments in fragment-based drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3661</span><span class="NLM_x">–</span> <span class="NLM_lpage">3680</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8000373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3661-3680&author=M.+Congreveauthor=G.+Chessariauthor=D.+Tisiauthor=A.+J.+Woodhead&title=Recent+developments+in+fragment-based+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fjm8000373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8000373%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DTisi%26aufirst%3DD.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26atitle%3DRecent%2520developments%2520in%2520fragment-based%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3661%26epage%3D3680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Paolini, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapland, R. H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Hoorn, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Global mapping of pharmacological space</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">805</span><span class="NLM_x">–</span> <span class="NLM_lpage">815</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnbt1228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=16841068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFansb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=805-815&author=G.+V.+Paoliniauthor=R.+H.+B.+Shaplandauthor=W.+P.+van+Hoornauthor=J.+S.+Masonauthor=A.+L.+Hopkins&title=Global+mapping+of+pharmacological+space"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Global mapping of pharmacological space</span></div><div class="casAuthors">Paolini, Gaia V.; Shapland, Richard H. B.; van Hoorn, Willem P.; Mason, Jonathan S.; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">805-815</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We present the global mapping of pharmacol. space by the integration of several vast sources of medicinal chem. structure-activity relationships (SAR) data.  Our comprehensive mapping of pharmacol. space enables us to identify confidently the human targets for which chem. tools and drugs have been discovered to date.  The integration of SAR data from diverse sources by unique canonical chem. structure, protein sequence and disease indication enables the construction of a ligand-target matrix to explore the global relationships between chem. structure and biol. targets.  Using the data matrix, we are able to catalog the links between proteins in chem. space as a polypharmacol. interaction network.  We demonstrate that probabilistic models can be used to predict pharmacol. from a large knowledge base.  The relationships between proteins, chem. structures and drug-like properties provide a framework for developing a probabilistic approach to drug discovery that can be exploited to increase research productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV_CE47zZq8LVg90H21EOLACvtfcHk0lg8NIBtcNIjuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFansb8%253D&md5=f559b34692cc903a1b503deb07030c5d</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1038%2Fnbt1228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1228%26sid%3Dliteratum%253Aachs%26aulast%3DPaolini%26aufirst%3DG.%2BV.%26aulast%3DShapland%26aufirst%3DR.%2BH.%2BB.%26aulast%3Dvan%2BHoorn%26aufirst%3DW.%2BP.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DGlobal%2520mapping%2520of%2520pharmacological%2520space%26jtitle%3DNat.%2520Biotechnol.%26date%3D2006%26volume%3D24%26spage%3D805%26epage%3D815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Radhakrishnan, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tidor, B.</span><span> </span><span class="NLM_article-title">Specificity in molecular design: a physical framework for probing the determinants of binding specificity and promiscuity in a biological environment</span> <span class="citation_source-journal">J. Phys. Chem. B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">13419</span><span class="NLM_x">–</span> <span class="NLM_lpage">13435</span></span><div class="citationLinks">[<a href="/doi/10.1021/jp074285e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2007&pages=13419-13435&author=M.+L.+Radhakrishnanauthor=B.+Tidor&title=Specificity+in+molecular+design%3A+a+physical+framework+for+probing+the+determinants+of+binding+specificity+and+promiscuity+in+a+biological+environment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fjp074285e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp074285e%26sid%3Dliteratum%253Aachs%26aulast%3DRadhakrishnan%26aufirst%3DM.%2BL.%26aulast%3DTidor%26aufirst%3DB.%26atitle%3DSpecificity%2520in%2520molecular%2520design%253A%2520a%2520physical%2520framework%2520for%2520probing%2520the%2520determinants%2520of%2520binding%2520specificity%2520and%2520promiscuity%2520in%2520a%2520biological%2520environment%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2007%26volume%3D111%26spage%3D13419%26epage%3D13435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehra, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perreault, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erbe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krupka, H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">England, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plotnikov, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Will, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Signaevsky, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kral, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantwell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settachatgull, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Womack, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milburn, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vlasuk, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobin, J. F.</span><span> </span><span class="NLM_article-title">Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">262</span><span class="NLM_x">–</span> <span class="NLM_lpage">267</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1073%2Fpnas.0811325106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=19116277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltF2rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=262-267&author=D.+R.+Artisauthor=J.+J.+Linauthor=C.+Zhangauthor=W.+Wangauthor=U.+Mehraauthor=M.+Perreaultauthor=D.+Erbeauthor=H.+I.+Krupkaauthor=B.+P.+Englandauthor=J.+Arnoldauthor=A.+N.+Plotnikovauthor=A.+Marimuthuauthor=H.+Nguyenauthor=S.+Willauthor=M.+Signaevskyauthor=J.+Kralauthor=J.+Cantwellauthor=C.+Settachatgullauthor=D.+S.+Yanauthor=D.+Fongauthor=A.+Ohauthor=S.+Shiauthor=P.+Womackauthor=B.+Powellauthor=G.+Habetsauthor=B.+L.+Westauthor=K.+Y.+Zhangauthor=M.+V.+Milburnauthor=G.+P.+Vlasukauthor=K.+P.+Hirthauthor=K.+Nolopauthor=G.+Bollagauthor=P.+N.+Ibrahimauthor=J.+F.+Tobin&title=Scaffold-based+discovery+of+indeglitazar%2C+a+PPAR+pan-active+anti-diabetic+agent"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent</span></div><div class="casAuthors">Artis, Dean R.; Lin, Jack J.; Zhang, Chao; Wang, Weiru; Mehra, Upasana; Perreault, Mylene; Erbe, David; Krupka, Heike I.; England, Bruce P.; Arnold, James; Plotnikov, Alexander N.; Marimuthu, Adhirai; Nguyen, Hoa; Will, Sarah; Signaevsky, Maxime; Kral, John; Cantwell, John; Settachatgull, Alvin; Yan, Douglas S.; Fong, Daniel; Oh, Angela; Shi, Shenghua; Womack, Patrick; Powell, Benjamin; Habets, Gaston; West, Brian L.; Zhang, Kam Y. J.; Milburn, Michael V.; Vlasuk, George P.; Hirth, K. Peter; Nolop, Keith; Bollag, Gideon; Ibrahim, Prabha N.; Tobin, James F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">262-267</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">In a search for more effective anti-diabetic treatment, we used a process coupling low-affinity biochem. screening with high-throughput co-crystallog. in the design of a series of compds. that selectively modulate the activities of all three peroxisome proliferator-activated receptors (PPARs), PPARα, PPARγ, and PPARδ.  Transcriptional transactivation assays were used to select compds. from this chem. series with a bias toward partial agonism toward PPARγ, to circumvent the clin. obsd. side effects of full PPARγ agonists.  Co-crystallog. characterization of the lead mol., indeglitazar, in complex with each of the 3 PPARs revealed the structural basis for its PPAR pan-activity and its partial agonistic response toward PPARγ.  Compared with full PPARγ-agonists, indeglitazar is less potent in promoting adipocyte differentiation and only partially effective in stimulating adiponectin gene expression.  Evaluation of the compd. in vivo confirmed the reduced adiponectin response in animal models of obesity and diabetes while revealing strong beneficial effects on glucose, triglycerides, cholesterol, body wt., and other metabolic parameters.  Indeglitazar has now progressed to Phase II clin. evaluations for Type 2 diabetes mellitus (T2DM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiPwFlRHVN2bVg90H21EOLACvtfcHk0lg8NIBtcNIjuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltF2rtg%253D%253D&md5=29503488bc79c51644c81d83add9040a</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0811325106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0811325106%26sid%3Dliteratum%253Aachs%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DLin%26aufirst%3DJ.%2BJ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DMehra%26aufirst%3DU.%26aulast%3DPerreault%26aufirst%3DM.%26aulast%3DErbe%26aufirst%3DD.%26aulast%3DKrupka%26aufirst%3DH.%2BI.%26aulast%3DEngland%26aufirst%3DB.%2BP.%26aulast%3DArnold%26aufirst%3DJ.%26aulast%3DPlotnikov%26aufirst%3DA.%2BN.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DWill%26aufirst%3DS.%26aulast%3DSignaevsky%26aufirst%3DM.%26aulast%3DKral%26aufirst%3DJ.%26aulast%3DCantwell%26aufirst%3DJ.%26aulast%3DSettachatgull%26aufirst%3DC.%26aulast%3DYan%26aufirst%3DD.%2BS.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DWomack%26aufirst%3DP.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DVlasuk%26aufirst%3DG.%2BP.%26aulast%3DHirth%26aufirst%3DK.%2BP.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DTobin%26aufirst%3DJ.%2BF.%26atitle%3DScaffold-based%2520discovery%2520of%2520indeglitazar%252C%2520a%2520PPAR%2520pan-active%2520anti-diabetic%2520agent%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D262%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Mueller, G.</span> (Proteros) From Kinase Inhibitor Chemistry. Presented at CHI's Inaugural Meeting, Charting the Chemical Space, San Diego, CA, April 7−8,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Mueller%2C+G.+%28Proteros%29+From+Kinase+Inhibitor+Chemistry.+Presented+at+CHI%27s+Inaugural+Meeting%2C+Charting+the+Chemical+Space%2C+San+Diego%2C+CA%2C+April+7%E2%88%928%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DMueller%26aufirst%3DG.%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Pargellis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Churchill, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pav, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regan, J.</span><span> </span><span class="NLM_article-title">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnsb770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=11896401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=268-272&author=C.+Pargellisauthor=L.+Tongauthor=L.+Churchillauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=P.+M.+Grobauthor=E.+R.+Hickeyauthor=N.+Mossauthor=S.+Pavauthor=J.+Regan&title=Inhibition+of+p38+MAP+kinase+by+utilizing+a+novel+allosteric+binding+site"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span></div><div class="casAuthors">Pargellis, Christopher; Tong, Liang; Churchill, Laurie; Cirillo, Pier F.; Gilmore, Thomas; Graham, Anne G.; Grob, Peter M.; Hickey, Eugene R.; Moss, Neil; Pav, Susan; Regan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-272</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The p38 MAP kinase plays a crucial role in regulating the prodn. of proinflammatory cytokines, such as tumor necrosis factor and interleukin-1.  Blocking this kinase may offer an effective therapy for treating many inflammatory diseases.  Here we report a new allosteric binding site for a diaryl urea class of highly potent and selective inhibitors against human p38 MAP kinase.  The formation of this binding site requires a large conformational change not obsd. previously for any of the protein Ser/Thr kinases.  This change is in the highly conserved Asp-Phe-Gly motif within the active site of the kinase.  Soln. studies demonstrate that this class of compds. has slow binding kinetics, consistent with the requirement for conformational change.  Improving interactions in this allosteric pocket, as well as establishing binding interactions in the ATP pocket, enhanced the affinity of the inhibitors by 12,000-fold.  One of the most potent compds. in this series, BIRB 796, has picomolar affinity for the kinase and low nanomolar inhibitory activity in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT8_QT7_pbYrVg90H21EOLACvtfcHk0li52q62vBs0qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D&md5=68850ecdbe08df4285ba38cfa2c93ea4</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1038%2Fnsb770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb770%26sid%3Dliteratum%253Aachs%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DRegan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520p38%2520MAP%2520kinase%2520by%2520utilizing%2520a%2520novel%2520allosteric%2520binding%2520site%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D268%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, L.</span><span> </span><span class="NLM_article-title">Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">7882</span><span class="NLM_x">–</span> <span class="NLM_lpage">7888</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8010096" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7882-7888&author=D.+Weiauthor=X.+Jiangauthor=L.+Zhouauthor=J.+Chenauthor=Z.+Chenauthor=C.+Heauthor=K.+Yangauthor=Y.+Liuauthor=J.+Peiauthor=L.+Lai&title=Discovery+of+multitarget+inhibitors+by+combining+molecular+docking+with+common+pharmacophore+matching"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjm8010096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010096%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520multitarget%2520inhibitors%2520by%2520combining%2520molecular%2520docking%2520with%2520common%2520pharmacophore%2520matching%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7882%26epage%3D7888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Alton, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunney, E. A.</span><span> </span><span class="NLM_article-title">Targeting the unactivated conformations of protein kinases for small molecule drug discovery</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">595</span><span class="NLM_x">–</span> <span class="NLM_lpage">605</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=595-605&author=G.+R.+Altonauthor=E.+A.+Lunney&title=Targeting+the+unactivated+conformations+of+protein+kinases+for+small+molecule+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlton%26aufirst%3DG.%2BR.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26atitle%3DTargeting%2520the%2520unactivated%2520conformations%2520of%2520protein%2520kinases%2520for%2520small%2520molecule%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D595%26epage%3D605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Freire, E.</span><span> </span><span class="NLM_article-title">Do enthalpy and entropy distinguish first in class from best in class?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">869</span><span class="NLM_x">–</span> <span class="NLM_lpage">874</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2Fj.drudis.2008.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=18703160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFCgu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=869-874&author=E.+Freire&title=Do+enthalpy+and+entropy+distinguish+first+in+class+from+best+in+class%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Do enthalpy and entropy distinguish first in class from best in class?</span></div><div class="casAuthors">Freire, Ernesto</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">19/20</span>),
    <span class="NLM_cas:pages">869-874</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  A drug mol. should bind to its target with high affinity and selectivity.  Because the binding affinity is a combined function of the binding enthalpy and the binding entropy, extremely high affinity requires that both terms contribute favorably to binding.  The binding enthalpy, however, is notoriously more difficult to optimize than the binding entropy, a fact that has resulted in thermodynamically unbalanced mols. that do not achieve optimal potency.  In fact, with current technologies, the enthalpic optimization of drug candidates may take years and only appear in second-generation products.  Within that context, it is not surprising that structure/activity relationships (SARs) that explicitly incorporate the interplay between enthalpy and entropy and accelerate the optimization process are being developed and gaining popularity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5swEhu922BbVg90H21EOLACvtfcHk0li52q62vBs0qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFCgu7fN&md5=357358107c5686a1863a83291c1cdd92</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2008.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2008.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DFreire%26aufirst%3DE.%26atitle%3DDo%2520enthalpy%2520and%2520entropy%2520distinguish%2520first%2520in%2520class%2520from%2520best%2520in%2520class%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2008%26volume%3D13%26spage%3D869%26epage%3D874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pompliano, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meek, T. D.</span><span> </span><span class="NLM_article-title">Drug−target residence time and its implications for lead optimization</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug%E2%88%92target+residence+time+and+its+implications+for+lead+optimization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug%25E2%2588%2592target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Backes, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zech, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, G.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1409</span><span class="NLM_x">–</span> <span class="NLM_lpage">1425</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1517%2F17460440802579975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=23506106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvFCmtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1409-1425&author=A.+C.+Backesauthor=B.+Zechauthor=B.+Felberauthor=B.+Kleblauthor=G.+M%C3%BCller&title=Small-molecule+inhibitors+binding+to+protein+kinases.+Part+I%3A+exceptions+from+the+traditional+pharmacophore+approach+of+type+I+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition</span></div><div class="casAuthors">Backes, A. C.; Zech, B.; Felber, B.; Klebl, B.; Mueller, G.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1409-1425</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Protein kinases are essential enzymes propagating cellular signal transduction processes and consequently have emerged as central targets for drug discovery against a wide range of diseases with a strong historical focus on oncol. disorders.  A large no. of high-resoln. crystal structures of various ATP-competitive inhibitors in complex with their target protein kinases have been detd. and present a wealth of detailed information about binding modes, inhibition mechanisms and assocd. structure-activity relationships of target-bound small mols.  Objective: In this first part of a two-part review, exceptions to the type I binding mode of kinase inhibitors that follow the traditional pharmacophore model are discussed, highlighting unexpected structural features.  Methods: The scope of this review covers published crystal structures of protein kinases in complex with various ligands.  Results: Structural parameters of both inhibitors and kinases contribute to the complexity of designing kinase inhibitors.  The continued study of high-resoln. structures of ligand-enzyme complexes in combination with a more dynamic understanding of accessible conformational states of the target proteins, supported by detailed kinetic studies, will in the long-term help in developing new low-mol. wt. kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgxVqECguWJbVg90H21EOLACvtfcHk0lha6dD_o_Ol0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvFCmtrk%253D&md5=705fa7e531ceced90ed86d0d2658766e</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1517%2F17460440802579975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460440802579975%26sid%3Dliteratum%253Aachs%26aulast%3DBackes%26aufirst%3DA.%2BC.%26aulast%3DZech%26aufirst%3DB.%26aulast%3DFelber%26aufirst%3DB.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DG.%26atitle%3DSmall-molecule%2520inhibitors%2520binding%2520to%2520protein%2520kinases.%2520Part%2520I%253A%2520exceptions%2520from%2520the%2520traditional%2520pharmacophore%2520approach%2520of%2520type%2520I%2520inhibition%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D1409%26epage%3D1425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Krug, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilgeroth, A.</span><span> </span><span class="NLM_article-title">Recent advances in the development of multi-kinase inhibitors</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1312</span><span class="NLM_x">–</span> <span class="NLM_lpage">1327</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1312-1327&author=M.+Krugauthor=A.+Hilgeroth&title=Recent+advances+in+the+development+of+multi-kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrug%26aufirst%3DM.%26aulast%3DHilgeroth%26aufirst%3DA.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520of%2520multi-kinase%2520inhibitors%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D1312%26epage%3D1327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Backes, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zech, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, G .</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1427</span><span class="NLM_x">–</span> <span class="NLM_lpage">1449</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1427-1449&author=A.+C.+Backesauthor=B.+Zechauthor=B.+Felberauthor=B.+Kleblauthor=G+.+M%C3%BCller&title=Small-molecule+inhibitors+binding+to+protein+kinase.+Part+II%3A+the+novel+pharmacophore+approach+of+type+II+and+type+III+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBackes%26aufirst%3DA.%2BC.%26aulast%3DZech%26aufirst%3DB.%26aulast%3DFelber%26aufirst%3DB.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DG%2B.%26atitle%3DSmall-molecule%2520inhibitors%2520binding%2520to%2520protein%2520kinase.%2520Part%2520II%253A%2520the%2520novel%2520pharmacophore%2520approach%2520of%2520type%2520II%2520and%2520type%2520III%2520inhibition%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D1427%26epage%3D1449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Bikker, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span> </span><span class="NLM_article-title">Kinase domain mutations in cancer: implications for small molecule drug design strategies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1493</span><span class="NLM_x">–</span> <span class="NLM_lpage">1509</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8010542" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVCisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1493-1509&author=J.+A.+Bikkerauthor=N.+Brooijmansauthor=A.+Wissnerauthor=T.+S.+Mansour&title=Kinase+domain+mutations+in+cancer%3A+implications+for+small+molecule+drug+design+strategies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies</span></div><div class="casAuthors">Bikker, Jack A.; Brooijmans, Natasja; Wissner, Allan; Mansour, Tarek S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1493-1509</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review will provide a brief overview of kinase structure and function as it pertains to drug discovery, describe the location and importance of clin. mutations, and review the emerging understanding of their impact based on sequence homol., protein crystal complexes, and biochem./biophys. information.  Underlying this discussion is our appreciation that the current clin. arsenal of small mol. kinase inhibitors only contains the first weapons to be deployed in a long war against drug resistance mutations occurring in multiple kinases that target multiple cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBBjVt8P6JI7Vg90H21EOLACvtfcHk0lha6dD_o_Ol0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVCisr0%253D&md5=fa09d8a6e553ccd1bb1f093176ecb366</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fjm8010542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010542%26sid%3Dliteratum%253Aachs%26aulast%3DBikker%26aufirst%3DJ.%2BA.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DKinase%2520domain%2520mutations%2520in%2520cancer%253A%2520implications%2520for%2520small%2520molecule%2520drug%2520design%2520strategies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1493%26epage%3D1509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structures of the kinase domain of c-ABL in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+structures+of+the+kinase+domain+of+c-ABL+in+complex+with+the+small+molecule+inhibitors+PD173955+and+imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0lha6dD_o_Ol0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520kinase%2520domain%2520of%2520c-ABL%2520in%2520complex%2520with%2520the%2520small%2520molecule%2520inhibitors%2520PD173955%2520and%2520imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Wan, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">764</span><span class="NLM_x">–</span> <span class="NLM_lpage">766</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=764-766&author=P.+T.+Wanauthor=M.+J.+Garnettauthor=S.+M.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=C.+M.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Marais&title=Mechanism+of+activation+of+the+RAF-ERK+signaling+pathway+by+oncogenic+mutations+of+B-RAF"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMechanism%2520of%2520activation%2520of%2520the%2520RAF-ERK%2520signaling%2520pathway%2520by%2520oncogenic%2520mutations%2520of%2520B-RAF%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D764%26epage%3D766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuck, L.</span><span> </span><span class="NLM_article-title">A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">66452</span><span class="NLM_x">–</span> <span class="NLM_lpage">66659</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=66452-66659&author=E.+R.+Woodauthor=A.+T.+Tuesdaleauthor=O.+B.+McDonaldauthor=D.+Yanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilbmerauthor=L.+Shewchuck&title=A+unique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTuesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilbmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuck%26aufirst%3DL.%26atitle%3DA%2520unique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D66452%26epage%3D66659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Pollard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortimore, M.</span><span> </span><span class="NLM_article-title">Discovery and development of aurora kinase inhibitors as anticancer agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2629</span><span class="NLM_x">–</span> <span class="NLM_lpage">2651</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8012129" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjs1Gmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2629-2651&author=J.+R.+Pollardauthor=M.+Mortimore&title=Discovery+and+development+of+aurora+kinase+inhibitors+as+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Aurora Kinase Inhibitors as Anticancer Agents</span></div><div class="casAuthors">Pollard, John R.; Mortimore, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2629-2651</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This article summarizes the roles that each of the Aurora kinases plays in mitosis and cancer biol. and discusses how different Aurora inhibition selectivity profiles impact the cellular and in vivo behavior of the drug candidates.  In addn., the wealth of structural biol. information for the Aurora kinases is reviewed.  This will be used to provide a rationale for the cross-reactivity profiles of some the Aurora kinase drug candidates and will review current theories for how selectivity within the Aurora kinase family has been achieved.  Finally the discovery and development of the clin. candidates targeting Aurora kinases will be summarized together with a brief discussion of notable structure-activity relationships (SAR).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojisjXqX2odrVg90H21EOLACvtfcHk0li4y1xP2anYEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjs1Gmtbc%253D&md5=bb59ec8929dd81ae89e606cfb84f18df</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Fjm8012129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8012129%26sid%3Dliteratum%253Aachs%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DMortimore%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520development%2520of%2520aurora%2520kinase%2520inhibitors%2520as%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2629%26epage%3D2651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broudy, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span> </span><span class="NLM_article-title">Novel N9-arenethenyl purines as potent dual SRC/ABL tyrosine kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4907</span><span class="NLM_x">–</span> <span class="NLM_lpage">4912</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4907-4912&author=Y.+Wangauthor=W.+C.+Shakespeareauthor=W.+S.+Huangauthor=R.+Sundaramoorthiauthor=S.+Lentiniauthor=S.+Dasauthor=S.+Liuauthor=G.+Bandaauthor=D.+Wenauthor=X.+Zhuauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=D.+Dalgarnoauthor=T.+Clacksonauthor=T.+K.+Sawyer&title=Novel+N9-arenethenyl+purines+as+potent+dual+SRC%2FABL+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DLentini%26aufirst%3DS.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26atitle%3DNovel%2520N9-arenethenyl%2520purines%2520as%2520potent%2520dual%2520SRC%252FABL%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4907%26epage%3D4912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broudy, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iuliucci, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">9-(Arenethenyl)purines as dual SRC/ABL kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4743</span><span class="NLM_x">–</span> <span class="NLM_lpage">4756</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900166t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4743-4756&author=W.+S.+Huangauthor=X.+Zhuauthor=Y.+Wangauthor=M.+Azamauthor=D.+Wenauthor=R.+Sundaramoorthiauthor=R.+M.+Thomasauthor=S.+Liuauthor=G.+Bandaauthor=S.+P.+Lentiniauthor=S.+Dasauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=G.+Q.+Daleyauthor=J.+Iuliucciauthor=D.+C.+Dalgarnoauthor=T.+Clacksonauthor=T.+K.+Sawyerauthor=W.+C.+Shakespeare&title=9-%28Arenethenyl%29purines+as+dual+SRC%2FABL+kinase+inhibitors+targeting+the+inactive+conformation%3A+design%2C+synthesis%2C+and+biological+evaluation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Fjm900166t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900166t%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DIuliucci%26aufirst%3DJ.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3D9-%2528Arenethenyl%2529purines%2520as%2520dual%2520SRC%252FABL%2520kinase%2520inhibitors%2520targeting%2520the%2520inactive%2520conformation%253A%2520design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4743%26epage%3D4756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grtter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robubi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3915</span><span class="NLM_x">–</span> <span class="NLM_lpage">3926</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9002928" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtlWgtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3915-3926&author=M.+Getlikauthor=C.+Grtterauthor=J.+R.+Simardauthor=S.+Klterauthor=M.+Rabillerauthor=H.+B.+Rodeauthor=A.+Robubiauthor=D.+Rauh&title=Hybrid+compound+design+to+overcome+the+gatekeeper+T338M+mutation+in+cSrc"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc</span></div><div class="casAuthors">Getlik, Matthaeus; Gruetter, Christian; Simard, Jeffrey R.; Kluter, Sabine; Rabiller, Matthias; Rode, Haridas B.; Robubi, Armin; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3915-3926</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The emergence of drug resistance remains a fundamental challenge in the development of kinase inhibitors that are effective over long-term treatments.  Allosteric inhibitors that bind to sites lying outside the highly conserved ATP pocket are thought to be more selective than ATP-competitive inhibitors and may circumvent some mechanisms of drug resistance.  Crystal structures of type I and allosteric type III inhibitors in complex with the tyrosine kinase cSrc allowed to develop these scaffolds into potent type II kinase inhibitors.  One of these compds., I (RL46), disrupts FAK-mediated focal adhesions in cancer cells via direct inhibition of cSrc.  Details gleaned from crystal structures revealed a key feature of a subset of these compds., a surprising flexibility in the vicinity of the gatekeeper residue that allows these compds. to overcome a dasatinib-resistant gatekeeper mutation emerging in cSrc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-72ZDo25pC7Vg90H21EOLACvtfcHk0lj6A2eRHdF_QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtlWgtbY%253D&md5=3ff187e49298ec4690c76a2bc2100274</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Fjm9002928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9002928%26sid%3Dliteratum%253Aachs%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DGrtter%26aufirst%3DC.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DKlter%26aufirst%3DS.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DRobubi%26aufirst%3DA.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DHybrid%2520compound%2520design%2520to%2520overcome%2520the%2520gatekeeper%2520T338M%2520mutation%2520in%2520cSrc%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3915%26epage%3D3926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smykla, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mastalerz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span> </span><span class="NLM_article-title">Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">6186</span><span class="NLM_x">–</span> <span class="NLM_lpage">6193</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1158%2F1078-0432.CCR-06-0642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17062696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWhsbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=6186-6193&author=T.+W.+Wongauthor=F.+Y.+Leeauthor=C.+Yuauthor=F.+R.+Luoauthor=S.+Oppenheimerauthor=H.+Zhangauthor=R.+A.+Smyklaauthor=H.+Mastalerzauthor=B.+E.+Finkauthor=J.+T.+Hunt&title=Preclinical+antitumor+activity+of+BMS-599626%2C+a+pan-HER+kinase+inhibitor+that+inhibits+HER1%2FHER2+homodimer+and+heterodimer+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling</span></div><div class="casAuthors">Wong, Tai W.; Lee, Francis Y.; Yu, Chiang; Luo, Feng R.; Oppenheimer, Simone; Zhang, Hongjian; Smykla, Richard A.; Mastalerz, Harold; Fink, Brian E.; Hunt, John T.; Gavai, Ashvinikumar V.; Vite, Gregory D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">20, Pt. 1</span>),
    <span class="NLM_cas:pages">6186-6193</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The studies described here are intended to characterize the ability of BMS-599626, a small-mol. inhibitor of the human epidermal growth factor receptor (HER) kinase family, to modulate signaling and growth of tumor cells that depend on HER1 and/or HER2.  Exptl. Design: The potency and selectivity of BMS-599626 were assessed in biochem. assays using recombinant protein kinases, as well as in cell proliferation assays using tumor cell lines with varying degrees of dependence on HER1 or HER2 signaling.  Modulation of receptor signaling was detd. in cell assays by Western blot analyses of receptor autophosphorylation and downstream signaling.  The ability of BMS-599626 to inhibit receptor heterodimer signaling in tumor cells was studied by receptor coimmunopptn.  Antitumor activity of BMS-599626 was evaluated using a no. of different xenograft models that represent a spectrum of human tumors with HER1 or HER2 overexpression.  Results: BMS-599626 inhibited HER1 and HER2 with IC50 of 20 and 30 nmol/L, resp., and was highly selective when tested against a broad panel of diverse protein kinases.  Biochem. studies suggested that BMS-599626 inhibited HER1 and HER2 through distinct mechanisms.  BMS-599626 abrogated HER1 and HER2 signaling and inhibited the proliferation of tumor cell lines that are dependent on these receptors, with IC50 in the range of 0.24 to 1 μmol/L.  BMS-599626 was highly selective for tumor cells that depend on HER1/HER2 and had no effect on the proliferation of cell lines that do not express these receptors.  In tumor cells that are capable of forming HER1/HER2 heterodimers, BMS-599626 inhibited heterodimerization and downstream signaling.  BMS-599626 had antitumor activity in models that overexpress HER1 (GEO), as well as in models that have HER2 gene amplification (KPL4) or overexpression (Sal2), and there was good correlation between the inhibition of receptor signaling and antitumor activity.  Conclusions: BMS-599626 is a highly selective and potent inhibitor of HER1 and HER2 kinases and inhibits tumor cell proliferation through modulation of receptor signaling.  BMS-599626 inhibits HER1/HER2 receptor heterodimerization and provides an addnl. mechanism of inhibiting tumors in which receptor coexpression and heterodimerization play a major role in driving tumor growth.  The preclin. data support the advancement of BMS-599626 into clin. development for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVgsCF6GDMPbVg90H21EOLACvtfcHk0lj6A2eRHdF_QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWhsbbK&md5=a8350e2eb304a091fa82f1159e44c119</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0642%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DF.%2BR.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSmykla%26aufirst%3DR.%2BA.%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DB.%2BE.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26atitle%3DPreclinical%2520antitumor%2520activity%2520of%2520BMS-599626%252C%2520a%2520pan-HER%2520kinase%2520inhibitor%2520that%2520inhibits%2520HER1%252FHER2%2520homodimer%2520and%2520heterodimer%2520signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D6186%26epage%3D6193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Bogoyevitch, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairlie, D. P.</span><span> </span><span class="NLM_article-title">A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">622</span><span class="NLM_x">–</span> <span class="NLM_lpage">633</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=622-633&author=M.+A.+Bogoyevitchauthor=D.+P.+Fairlie&title=A+new+paradigm+for+protein+kinase+inhibition%3A+blocking+phosphorylation+without+directly+targeting+ATP+binding"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBogoyevitch%26aufirst%3DM.%2BA.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26atitle%3DA%2520new%2520paradigm%2520for%2520protein%2520kinase%2520inhibition%253A%2520blocking%2520phosphorylation%2520without%2520directly%2520targeting%2520ATP%2520binding%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D622%26epage%3D633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Price, S.</span><span> </span><span class="NLM_article-title">Putative allosteric MEK1 and MEK2 inhibitors</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">603</span><span class="NLM_x">–</span> <span class="NLM_lpage">627</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1517%2F13543776.18.6.603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmt1Okt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=603-627&author=S.+Price&title=Putative+allosteric+MEK1+and+MEK2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Putative allosteric MEK1 and MEK2 inhibitors</span></div><div class="casAuthors">Price, Steve</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">603-627</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Over the last decade, the pharmaceutical industry has invested significantly in efforts to identify novel inhibitors of the mitogen-activated protein kinases MEK1 and MEK2.  Unsurprisingly, several ATP-competitive inhibitors have been identified, but the discovery of allosteric inhibitors has been the main focus for the development of novel therapies.  A no. of allosteric MEK1 and MEK2 inhibitors have been reported to exhibit exquisite selectivity when profiled against large panels of kinases.  Of the eight MEK inhibitors that have entered the clinic, it is believed that the majority, if not all, bind allosterically.  Objective: This review focuses on the patenting activity concerning putative allosteric MEK inhibitors, and their progression into the clinic.  Method: An anal. of the putative allosteric MEK inhibitor patent estate from the first-use application for PD-098059 in 1996 through to Feb. 2008 was undertaken.  An evaluation and summary of such therapies that have entered the clinic are provided.  Conclusion: The overwhelming majority of patents filed that describe putative allosteric MEK inhibitors are based on a diarylamine scaffold.  The ubiquitous expression of MEK throughout the body, and its central role in the cell signaling pathway, will undoubtedly ensure that inhibitors continue to be progressed into the clinic over the next decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrembLi7K41BrVg90H21EOLACvtfcHk0liIU4vKrUxIzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmt1Okt74%253D&md5=0ae01171b408bcd941d692fe57ae57ae</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1517%2F13543776.18.6.603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.18.6.603%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DS.%26atitle%3DPutative%2520allosteric%2520MEK1%2520and%2520MEK2%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2008%26volume%3D18%26spage%3D603%26epage%3D627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Gumireddy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosenza, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">John, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robell, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">1992</span><span class="NLM_x">–</span> <span class="NLM_lpage">1997</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=1992-1997&author=K.+Gumireddyauthor=S.+J.+Bakerauthor=S.+C.+Cosenzaauthor=P.+Johnauthor=A.+D.+Kangauthor=K.+A.+Robellauthor=M.+V.+Reddyauthor=E.+P.+Reddy&title=A+non-ATP-competitive+inhibitor+of+BCR-ABL+overrides+imatinib+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGumireddy%26aufirst%3DK.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DJohn%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DA.%2BD.%26aulast%3DRobell%26aufirst%3DK.%2BA.%26aulast%3DReddy%26aufirst%3DM.%2BV.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DA%2520non-ATP-competitive%2520inhibitor%2520of%2520BCR-ABL%2520overrides%2520imatinib%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D1992%26epage%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barr, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlanson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fahr, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDowell, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, S. K.</span><span> </span><span class="NLM_article-title">Allosteric inhibition of protein tyrosine phosphatase 1B</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">737</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnsmb803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=15258570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVamtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=730-737&author=C.+Wiesmannauthor=K.+J.+Barrauthor=J.+Kungauthor=J.+Zhuauthor=D.+A.+Erlansonauthor=W.+Shenauthor=B.+J.+Fahrauthor=M.+Zhongauthor=L.+Taylorauthor=M.+Randalauthor=R.+S.+McDowellauthor=S.+K.+Hansen&title=Allosteric+inhibition+of+protein+tyrosine+phosphatase+1B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibition of protein tyrosine phosphatase 1B</span></div><div class="casAuthors">Wiesmann, Christian; Barr, Kenneth J.; Kung, Jenny; Zhu, Jiang; Erlanson, Daniel A.; Shen, Wang; Fahr, Bruce J.; Zhong, Min; Taylor, Lisa; Randal, Mike; McDowell, Robert S.; Hansen, Stig K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">730-737</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Obesity and type II diabetes are closely linked metabolic syndromes that afflict >100 million people worldwide.  Although protein tyrosine phosphatase 1B (PTP1B) has emerged as a promising target for the treatment of both syndromes, the discovery of pharmaceutically acceptable inhibitors that bind at the active site remains a substantial challenge.  Here we describe the discovery of an allosteric site in PTP1B.  Crystal structures of PTP1B in complex with allosteric inhibitors reveal a novel site located ∼20 Å from the catalytic site.  We show that allosteric inhibitors prevent formation of the active form of the enzyme by blocking mobility of the catalytic loop, thereby exploiting a general mechanism used by tyrosine phosphatases.  Notably, these inhibitors exhibit selectivity for PTP1B and enhance insulin signaling in cells.  Allosteric inhibition is a promising strategy for targeting PTP1B and constitutes a mechanism that may be applicable to other tyrosine phosphatases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv2mAdfb7Ou7Vg90H21EOLACvtfcHk0liIU4vKrUxIzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVamtrc%253D&md5=abf4042d5dd49fa810ced16426d2bcb5</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fnsmb803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb803%26sid%3Dliteratum%253Aachs%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DBarr%26aufirst%3DK.%2BJ.%26aulast%3DKung%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DFahr%26aufirst%3DB.%2BJ.%26aulast%3DZhong%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DL.%26aulast%3DRandal%26aufirst%3DM.%26aulast%3DMcDowell%26aufirst%3DR.%2BS.%26aulast%3DHansen%26aufirst%3DS.%2BK.%26atitle%3DAllosteric%2520inhibition%2520of%2520protein%2520tyrosine%2520phosphatase%25201B%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D730%26epage%3D737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Diskin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livnah, O.</span><span> </span><span class="NLM_article-title">A novel lipid binding site formed by the MAP kinase insert in p38α</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">375</span><span class="NLM_x">, </span> <span class="NLM_fpage">70</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2Fj.jmb.2007.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17999933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlylu7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2008&pages=70-79&author=R.+Diskinauthor=D.+Engelbergauthor=O.+Livnah&title=A+novel+lipid+binding+site+formed+by+the+MAP+kinase+insert+in+p38%CE%B1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Lipid Binding Site Formed by the MAP Kinase Insert in p38α</span></div><div class="casAuthors">Diskin, Ron; Engelberg, David; Livnah, Oded</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70-79</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The p38 mitogen-activated protein (MAP) kinases function as signaling mols. essential for many cellular processes, particularly mediating stress response.  The activity of p38 MAP kinases is meticulously regulated to reach the desired cellular phenotype.  Several alternative activation and attenuation mechanisms have been characterized recently which include new phosphorylation sites.  Here we present the crystal structure of p38α MAP kinase in complex with n-octyl-β-glucopyranoside (β-OG) detergent.  The complex unveils a novel lipid-binding site formed by a local conformational change of the MAP kinase insert.  This binding is the first evidence of a possible role for the MAP kinase insert in p38.  The binding site can accommodate a large selection of lipidic mols.  In addn., we also show via biophys. methods that arachidonic acid (AA) and its derivs. bind p38α in vitro.  Based on our anal. we propose that the binding of lipids could fine-tune p38α catalytic activity towards a preferred phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6J5fd2Jqe77Vg90H21EOLACvtfcHk0liIU4vKrUxIzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlylu7vI&md5=88b97152503182d41fa0ea7b53271229</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2007.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2007.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DDiskin%26aufirst%3DR.%26aulast%3DEngelberg%26aufirst%3DD.%26aulast%3DLivnah%26aufirst%3DO.%26atitle%3DA%2520novel%2520lipid%2520binding%2520site%2520formed%2520by%2520the%2520MAP%2520kinase%2520insert%2520in%2520p38%25CE%25B1%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2008%26volume%3D375%26spage%3D70%26epage%3D79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Barnett, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Defeo-Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haskell, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahana, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kral, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leander, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malinowski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAvoy, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nahas, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, H. E.</span><span> </span><span class="NLM_article-title">Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific AKT inhibitors</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">408</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=399-408&author=S.+F.+Barnettauthor=D.+Defeo-Jonesauthor=S.+Fuauthor=P.+J.+Hancockauthor=K.+M.+Haskellauthor=R.+E.+Jonesauthor=J.+A.+Kahanaauthor=A.+M.+Kralauthor=K.+Leanderauthor=L.+L.+Leeauthor=J.+Malinowskiauthor=E.+M.+McAvoyauthor=D.+D.+Nahasauthor=R.+G.+Robinsonauthor=H.+E.+Huber&title=Identification+and+characterization+of+pleckstrin-homology-domain-dependent+and+isoenzyme-specific+AKT+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBarnett%26aufirst%3DS.%2BF.%26aulast%3DDefeo-Jones%26aufirst%3DD.%26aulast%3DFu%26aufirst%3DS.%26aulast%3DHancock%26aufirst%3DP.%2BJ.%26aulast%3DHaskell%26aufirst%3DK.%2BM.%26aulast%3DJones%26aufirst%3DR.%2BE.%26aulast%3DKahana%26aufirst%3DJ.%2BA.%26aulast%3DKral%26aufirst%3DA.%2BM.%26aulast%3DLeander%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DL.%2BL.%26aulast%3DMalinowski%26aufirst%3DJ.%26aulast%3DMcAvoy%26aufirst%3DE.%2BM.%26aulast%3DNahas%26aufirst%3DD.%2BD.%26aulast%3DRobinson%26aufirst%3DR.%2BG.%26aulast%3DHuber%26aufirst%3DH.%2BE.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520pleckstrin-homology-domain-dependent%2520and%2520isoenzyme-specific%2520AKT%2520inhibitors%26jtitle%3DBiochem.%2520J.%26date%3D2005%26volume%3D15%26spage%3D399%26epage%3D408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Stebbins, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machleidt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becattini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vazquez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuntzen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cellitti, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riel-Mehan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emdadi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solinas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellecchia, M.</span><span> </span><span class="NLM_article-title">Identification of a new JNK inhibitor targeting the JNK-JIP interaction site</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">16809</span><span class="NLM_x">–</span> <span class="NLM_lpage">16813</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1073%2Fpnas.0805677105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=18922779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlertbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=16809-16813&author=J.+L.+Stebbinsauthor=S.+K.+Deauthor=T.+Machleidtauthor=B.+Becattiniauthor=J.+Vazquezauthor=C.+Kuntzenauthor=L.+H.+Chenauthor=J.+F.+Cellittiauthor=M.+Riel-Mehanauthor=A.+Emdadiauthor=G.+Solinasauthor=M.+Karinauthor=M.+Pellecchia&title=Identification+of+a+new+JNK+inhibitor+targeting+the+JNK-JIP+interaction+site"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a new JNK inhibitor targeting the JNK-JIP interaction site</span></div><div class="casAuthors">Stebbins, John L.; De, Surya K.; Machleidt, Thomas; Becattini, Barbara; Vazquez, Jesus; Kuntzen, Christian; Chen, Li-Hsing; Cellitti, Jason F.; Riel-Mehan, Megan; Emdadi, Aras; Solinas, Giovanni; Karin, Michael; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">16809-16813</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">JNK is a stress-activated protein kinase that modulates pathways implicated in a variety of disease states.  JNK-interacting protein-1 (JIP1) is a scaffolding protein that enhances JNK signaling by creating a proximity effect between JNK and upstream kinases.  A minimal peptide region derived from JIP1 is able to inhibit JNK activity both in vitro and in cell.  We report here a series of small mols. JIP1 mimics that function as substrate competitive inhibitors of JNK.  One such compd., BI-78D3, dose-dependently inhibits the phosphorylation of JNK substrates both in vitro and in cell.  In animal studies, BI-78D3 not only blocks JNK dependent Con A-induced liver damage but also restores insulin sensitivity in mouse models of type 2 diabetes.  Our findings open the way for the development of protein kinase inhibitors targeting substrate specific docking sites, rather than the highly conserved ATP binding sites.  In view of its favorable inhibition profile, selectivity, and ability to function in the cellular milieu and in vivo, BI-78D3 represents not only a JNK inhibitor, but also a promising stepping stone toward the development of an innovative class of therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5qVRg8EpCvbVg90H21EOLACvtfcHk0lh51cchofIXkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlertbvM&md5=8fef92335594787de91361c5b1683f5e</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0805677105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0805677105%26sid%3Dliteratum%253Aachs%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DDe%26aufirst%3DS.%2BK.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DBecattini%26aufirst%3DB.%26aulast%3DVazquez%26aufirst%3DJ.%26aulast%3DKuntzen%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DL.%2BH.%26aulast%3DCellitti%26aufirst%3DJ.%2BF.%26aulast%3DRiel-Mehan%26aufirst%3DM.%26aulast%3DEmdadi%26aufirst%3DA.%26aulast%3DSolinas%26aufirst%3DG.%26aulast%3DKarin%26aufirst%3DM.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520a%2520new%2520JNK%2520inhibitor%2520targeting%2520the%2520JNK-JIP%2520interaction%2520site%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D16809%26epage%3D16813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the erbB family of protein tyrosine kinases</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2FS0163-7258%2802%2900194-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=12191617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVShurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2002&pages=253-261&author=W.+A.+Denny&title=Irreversible+inhibitors+of+the+erbB+family+of+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible inhibitors of the erbB family of protein tyrosine kinases</span></div><div class="casAuthors">Denny, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">253-261</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  The erbB family of transmembrane receptor tyrosine kinases initiates a large no. of cellular signaling pathways.  Their over-expression in human tumors correlates with poor prognosis, and they have become important targets for drug development.  The 4-anilinoquinazolines are potent and selective ATP site inhibitors of these enzymes, esp. erbB1 (epidermal growth factor receptor).  Structure-activity studies for binding at the ATP site are narrow, consistent with homol. and crystal structure-binding models.  Combinations of small lipophilic groups at the 3'-position of the aniline and electron-donating groups at the 6- or 7-positions of the quinazoline result in extremely potent (picomolar) reversible inhibitors, several of which are in clin. trial.  Observation that the erbB family of enzymes contains a unique Cys residue (Cys773) close to the ATP-binding site prompted the development of irreversible inhibitors, the most successful being 6-acrylamides and related butynamides, which show significantly improved in vivo antitumor activity compared with closely related reversibly binding compds.  Solubilizing side chains can be placed either at the terminus of the alkylating unit or at the quinazoline C-7, and examples of both types are in clin. trial.  Both reversible and irreversible inhibitors synergize with a variety of DNA-damaging anticancer drugs, and it is likely that the greatest impact of these agents will be in combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwN71GFZA09rVg90H21EOLACvtfcHk0lh51cchofIXkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVShurk%253D&md5=7937e2efbf606734ae781554e7c26d15</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2802%2900194-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252802%252900194-8%26sid%3Dliteratum%253Aachs%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520erbB%2520family%2520of%2520protein%2520tyrosine%2520kinases%26jtitle%3DPharmacol.%2520Ther.%26date%3D2002%26volume%3D93%26spage%3D253%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenschein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadimitrakopoulou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbst, R.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor inhibitors in development for the treatment of non small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">4441</span><span class="NLM_x">–</span> <span class="NLM_lpage">4445</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1158%2F1078-0432.CCR-06-0286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFSmtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=4441-4445&author=J.+V.+Heymachauthor=M.+Nilssonauthor=G.+Blumenscheinauthor=V.+Papadimitrakopoulouauthor=R.+Herbst&title=Epidermal+growth+factor+receptor+inhibitors+in+development+for+the+treatment+of+non+small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Heymach, John V.; Nilsson, Monique; Blumenschein, George; Papadimitrakopoulou, Vassiliki; Herbst, Roy</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">14, Pt. 2</span>),
    <span class="NLM_cas:pages">4441s-4445s</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) inhibitors erlotinib, gefitinib, and cetuximab have undergone extensive clin. testing and have established clin. activity in non-small cell lung cancer and other types of solid tumors.  A no. of newer inhibitors are currently in clin. development with different spectra of activity or mechanisms of receptor inhibition.  These include monoclonal antibodies, such as panitumumab and matuzumab; dual inhibitors of EGFR and vascular endothelial growth factor receptor, such as ZD6474 and AEE788; inhibitors of multiple EGFR family members, such as lapatinib; and irreversible inhibitors, such as canertinib and HKI272.  Preclin. studies suggest that several of these agents may have activity in tumors refractory to erlotinib or gefitinib.  Among these agents, ZD6474 has undergone the most extensive clin. testing.  The antitumor activity of ZD6474 in these two randomized phase II clin. trials in patients with non-small cell lung cancer was felt to be sufficiently promising to warrant phase III clin. testing.  Several of the other EGFR inhibitors are also undergoing advanced clin. testing, either alone or in combination with other agents.  EGFR has now been validated as a clin. relevant target, and several different types of agents inhibiting this receptor are currently in development.  Future research will be needed to elucidate the role of these agents in patients with EGFR inhibitor-naive and EGFR inhibitor-refractory disease, to define the mol. characteristics that predict response, and to det. whether these drugs should be used in combination with other targeted agents or chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdonmx9qlZZLVg90H21EOLACvtfcHk0ljizA1urLK_Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFSmtrc%253D&md5=24c5413d2d0e2a46921d22dba474fa89</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0286%26sid%3Dliteratum%253Aachs%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DBlumenschein%26aufirst%3DG.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DHerbst%26aufirst%3DR.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520inhibitors%2520in%2520development%2520for%2520the%2520treatment%2520of%2520non%2520small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D4441%26epage%3D4445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingalls, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dushin, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nittoli, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravi, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loganzo, F.</span><span> </span><span class="NLM_article-title">Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">3635</span><span class="NLM_x">–</span> <span class="NLM_lpage">3648</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=3635-3648&author=A.+Wissnerauthor=H.+L.+Fraserauthor=C.+L.+Ingallsauthor=R.+G.+Dushinauthor=M.+B.+Floydauthor=K.+Cheungauthor=T.+Nittoliauthor=M.+R.+Raviauthor=X.+Tanauthor=F.+Loganzo&title=Dual+irreversible+kinase+inhibitors%3A+quinazoline-based+inhibitors+incorporating+two+independent+reactive+centers+with+each+targeting+different+cysteine+residues+in+the+kinase+domains+of+EGFR+and+VEGFR-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DFraser%26aufirst%3DH.%2BL.%26aulast%3DIngalls%26aufirst%3DC.%2BL.%26aulast%3DDushin%26aufirst%3DR.%2BG.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DCheung%26aufirst%3DK.%26aulast%3DNittoli%26aufirst%3DT.%26aulast%3DRavi%26aufirst%3DM.%2BR.%26aulast%3DTan%26aufirst%3DX.%26aulast%3DLoganzo%26aufirst%3DF.%26atitle%3DDual%2520irreversible%2520kinase%2520inhibitors%253A%2520quinazoline-based%2520inhibitors%2520incorporating%2520two%2520independent%2520reactive%2520centers%2520with%2520each%2520targeting%2520different%2520cysteine%2520residues%2520in%2520the%2520kinase%2520domains%2520of%2520EGFR%2520and%2520VEGFR-2%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D3635%26epage%3D3648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Vieth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgs, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gragg, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemmerle, H.</span><span> </span><span class="NLM_article-title">Kinomics: structural biology and chemogenomics of kinase inhibitors and targets</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Proteins Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">1697</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2Fj.bbapap.2003.11.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=15023365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitFKlsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1697&publication_year=2004&pages=243-257&author=M.+Viethauthor=R.+E.+Higgsauthor=D.+H.+Robertsonauthor=M.+Shapiroauthor=E.+A.+Graggauthor=H.+Hemmerle&title=Kinomics%3A+structural+biology+and+chemogenomics+of+kinase+inhibitors+and+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Kinomics-structural biology and chemogenomics of kinase inhibitors and targets</span></div><div class="casAuthors">Vieth, Michal; Higgs, Richard E.; Robertson, Daniel H.; Shapiro, Michael; Gragg, Ellen A.; Hemmerle, Horst</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1697</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">243-257</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Classifying kinases based entirely on small mol. selectivity data is a new approach to drug discovery that allows scientists to understand relationships between targets.  This approach combines the understanding of small mols. and targets, and thereby assists the researcher in finding new targets for existing mols. or understanding selectivity and polypharmacol. of mols. in related targets.  Currently, structural information is available for relatively few of the protein kinases encoded in the human genome (7% of the estd. 518); however, even the current knowledge base, when paired with structure-based design techniques, can assist in the identification and optimization of novel kinase inhibitors across the entire protein class.  Chemogenomics attempts to combine genomic data, structural biol. data, classical dendrograms, and selectivity data to explore, define, and classify the medicinally relevant kinase space.  Exploitation of this information in the discovery of kinase inhibitors defines practical kinase chemogenomics (kinomics).  In this paper, the authors review the available information on kinase targets and their inhibitors, and present the relationships between the various classification schema for kinase space.  In particular, the authors present the first dendrogram of kinases based entirely on small mol. selectivity data.  The authors find that the selectivity dendrogram differs from sequence-based clustering mostly in the higher-level groupings of the smaller clusters, and remains very comparable for closely homologous targets.  Highly homologous kinases are, on av., inhibited comparably by small mols.  This observation, although intuitive, is very important to the process of target selection, as one would expect difficulty in achieving inhibitor selectivity for kinases that share high sequence identity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1jGPlCWLR5LVg90H21EOLACvtfcHk0ljizA1urLK_Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitFKlsLk%253D&md5=2742824cbdc8acc8660113547160a012</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2003.11.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2003.11.028%26sid%3Dliteratum%253Aachs%26aulast%3DVieth%26aufirst%3DM.%26aulast%3DHiggs%26aufirst%3DR.%2BE.%26aulast%3DRobertson%26aufirst%3DD.%2BH.%26aulast%3DShapiro%26aufirst%3DM.%26aulast%3DGragg%26aufirst%3DE.%2BA.%26aulast%3DHemmerle%26aufirst%3DH.%26atitle%3DKinomics%253A%2520structural%2520biology%2520and%2520chemogenomics%2520of%2520kinase%2520inhibitors%2520and%2520targets%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2004%26volume%3D1697%26spage%3D243%26epage%3D257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Vieth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, R. M.</span><span> </span><span class="NLM_article-title">Kinomics: characterizing the therapeutically validated kinase space</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">839</span><span class="NLM_x">–</span> <span class="NLM_lpage">846</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=839-846&author=M.+Viethauthor=J.+J.+Sutherlandauthor=D.+H.+Robertsonauthor=R.+M.+Campbell&title=Kinomics%3A+characterizing+the+therapeutically+validated+kinase+space"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVieth%26aufirst%3DM.%26aulast%3DSutherland%26aufirst%3DJ.%2BJ.%26aulast%3DRobertson%26aufirst%3DD.%2BH.%26aulast%3DCampbell%26aufirst%3DR.%2BM.%26atitle%3DKinomics%253A%2520characterizing%2520the%2520therapeutically%2520validated%2520kinase%2520space%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D839%26epage%3D846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Apsel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazif, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aizenstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span> </span><span class="NLM_article-title">Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">699</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnchembio.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=18849971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=691-699&author=B.+Apselauthor=J.+A.+Blairauthor=B.+Gonzalezauthor=T.+M.+Nazifauthor=M.+E.+Feldmanauthor=B.+Aizensteinauthor=R.+Hoffmanauthor=R.+L.+Williamsauthor=K.+M.+Shokatauthor=Z.+A.+Knight&title=Targeted+polypharmacology%3A+discovery+of+dual+inhibitors+of+tyrosine+and+phosphoinositide+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases</span></div><div class="casAuthors">Apsel, Beth; Blair, Jimmy A.; Gonzalez, Beatriz; Nazif, Tamim M.; Feldman, Morri E.; Aizenstein, Brian; Hoffman, Randy; Williams, Roger L.; Shokat, Kevan M.; Knight, Zachary A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">691-699</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. success of multitargeted kinase inhibitors has stimulated efforts to identify promiscuous drugs with optimal selectivity profiles.  It remains unclear to what extent such drugs can be rationally designed, particularly for combinations of targets that are structurally divergent.  Here we report the systematic discovery of mols. that potently inhibit both tyrosine kinases and phosphatidylinositol-3-OH kinases, two protein families that are among the most intensely pursued cancer drug targets.  Through iterative chem. synthesis, X-ray crystallog. and kinome-level biochem. profiling, we identified compds. that inhibit a spectrum of new target combinations in these two families.  Crystal structures revealed that the dual selectivity of these mols. is controlled by a hydrophobic pocket conserved in both enzyme classes and accessible through a rotatable bond in the drug skeleton.  We show that compd. I blocks the proliferation of tumor cells by direct inhibition of oncogenic tyrosine kinases and phosphatidylinositol-3-OH kinases.  These mols. demonstrate the feasibility of accessing a chem. space that intersects two families of oncogenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7xlegha5YF7Vg90H21EOLACvtfcHk0ljizA1urLK_Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7bF&md5=4da10a973f6895f92a644ca82ca5cdcd</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.117%26sid%3Dliteratum%253Aachs%26aulast%3DApsel%26aufirst%3DB.%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DNazif%26aufirst%3DT.%2BM.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DAizenstein%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26atitle%3DTargeted%2520polypharmacology%253A%2520discovery%2520of%2520dual%2520inhibitors%2520of%2520tyrosine%2520and%2520phosphoinositide%2520kinases%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D691%26epage%3D699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Sergina, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rausch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moasser, M. M.</span><span> </span><span class="NLM_article-title">Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">445</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">441</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=445&publication_year=2007&pages=437-441&author=N.+V.+Serginaauthor=M.+Rauschauthor=D.+Wangauthor=J.+Blairauthor=B.+Hannauthor=K.+M.+Shokatauthor=M.+M.+Moasser&title=Escape+from+HER-family+tyrosine+kinase+inhibitor+therapy+by+the+kinase-inactive+HER3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSergina%26aufirst%3DN.%2BV.%26aulast%3DRausch%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DBlair%26aufirst%3DJ.%26aulast%3DHann%26aufirst%3DB.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DMoasser%26aufirst%3DM.%2BM.%26atitle%3DEscape%2520from%2520HER-family%2520tyrosine%2520kinase%2520inhibitor%2520therapy%2520by%2520the%2520kinase-inactive%2520HER3%26jtitle%3DNature%26date%3D2007%26volume%3D445%26spage%3D437%26epage%3D441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Mohi, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sternberg, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neel, B. G.</span><span> </span><span class="NLM_article-title">Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">3130</span><span class="NLM_x">–</span> <span class="NLM_lpage">3135</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=3130-3135&author=M.+G.+Mohiauthor=C.+Boultonauthor=T.+L.+Guauthor=D.+W.+Sternbergauthor=D.+Neubergauthor=J.+D.+Griffinauthor=D.+G.+Gillilandauthor=B.+G.+Neel&title=Combination+of+rapamycin+and+protein+tyrosine+kinase+%28PTK%29+inhibitors+for+the+treatment+of+leukemias+caused+by+oncogenic+PTKs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMohi%26aufirst%3DM.%2BG.%26aulast%3DBoulton%26aufirst%3DC.%26aulast%3DGu%26aufirst%3DT.%2BL.%26aulast%3DSternberg%26aufirst%3DD.%2BW.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DCombination%2520of%2520rapamycin%2520and%2520protein%2520tyrosine%2520kinase%2520%2528PTK%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520leukemias%2520caused%2520by%2520oncogenic%2520PTKs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D3130%26epage%3D3135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Sutherland, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgs, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vieth, M.</span><span> </span><span class="NLM_article-title">Chemical fragments as foundations for understanding target space and activity prediction</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2689</span><span class="NLM_x">–</span> <span class="NLM_lpage">2700</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701399f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2689-2700&author=J.+J.+Sutherlandauthor=R.+E.+Higgsauthor=I.+Watsonauthor=M.+Vieth&title=Chemical+fragments+as+foundations+for+understanding+target+space+and+activity+prediction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Fjm701399f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701399f%26sid%3Dliteratum%253Aachs%26aulast%3DSutherland%26aufirst%3DJ.%2BJ.%26aulast%3DHiggs%26aufirst%3DR.%2BE.%26aulast%3DWatson%26aufirst%3DI.%26aulast%3DVieth%26aufirst%3DM.%26atitle%3DChemical%2520fragments%2520as%2520foundations%2520for%2520understanding%2520target%2520space%2520and%2520activity%2520prediction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2689%26epage%3D2700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Parkkila, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Innocenti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallio, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilvo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scozzafava, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supuran, C. T.</span><span> </span><span class="NLM_article-title">The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4102</span><span class="NLM_x">–</span> <span class="NLM_lpage">4106</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4102-4106&author=S.+Parkkilaauthor=A.+Innocentiauthor=H.+Kallioauthor=M.+Hilvoauthor=A.+Scozzafavaauthor=C.+T.+Supuran&title=The+protein+tyrosine+kinase+inhibitors+imatinib+and+nilotinib+strongly+inhibit+several+mammalian+alpha-carbonic+anhydrase+isoforms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DParkkila%26aufirst%3DS.%26aulast%3DInnocenti%26aufirst%3DA.%26aulast%3DKallio%26aufirst%3DH.%26aulast%3DHilvo%26aufirst%3DM.%26aulast%3DScozzafava%26aufirst%3DA.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26atitle%3DThe%2520protein%2520tyrosine%2520kinase%2520inhibitors%2520imatinib%2520and%2520nilotinib%2520strongly%2520inhibit%2520several%2520mammalian%2520alpha-carbonic%2520anhydrase%2520isoforms%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4102%26epage%3D4106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihnat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnke, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisliuk, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, F. T.</span><span> </span><span class="NLM_article-title">Novel 5-substituted 2,4-diaminofuro[2,3-<i>d</i>]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">5475</span><span class="NLM_x">–</span> <span class="NLM_lpage">5491</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=5475-5491&author=A.+Gangjeeauthor=Y.+Zengauthor=M.+Ihnatauthor=L.+A.+Warnkeauthor=D.+W.+Greenauthor=R.+L.+Kisliukauthor=F.+T.+Lin&title=Novel+5-substituted+2%2C4-diaminofuro%5B2%2C3-d%5Dpyrimidines+as+multireceptor+tyrosine+kinase+and+dihydrofolate+reductase+inhibitors+with+antiangiogenic+and+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DWarnke%26aufirst%3DL.%2BA.%26aulast%3DGreen%26aufirst%3DD.%2BW.%26aulast%3DKisliuk%26aufirst%3DR.%2BL.%26aulast%3DLin%26aufirst%3DF.%2BT.%26atitle%3DNovel%25205-substituted%25202%252C4-diaminofuro%255B2%252C3-d%255Dpyrimidines%2520as%2520multireceptor%2520tyrosine%2520kinase%2520and%2520dihydrofolate%2520reductase%2520inhibitors%2520with%2520antiangiogenic%2520and%2520antitumor%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26spage%3D5475%26epage%3D5491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Mahboobi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dove, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellmer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichhorn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pongratz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciossek, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckers, T.</span><span> </span><span class="NLM_article-title">Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrids as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rβ, and histone deacetylases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2265</span><span class="NLM_x">–</span> <span class="NLM_lpage">2279</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800988r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2265-2279&author=S.+Mahboobiauthor=S.+Doveauthor=A.+Sellmerauthor=M.+Winklerauthor=E.+Eichhornauthor=H.+Pongratzauthor=T.+Ciossekauthor=T.+Baerauthor=T.+Maierauthor=T.+Beckers&title=Design+of+chimeric+histone+deacetylase-+and+tyrosine+kinase-inhibitors%3A+a+series+of+imatinib+hybrids+as+potent+inhibitors+of+wild-type+and+mutant+BCR-ABL%2C+PDGF-R%CE%B2%2C+and+histone+deacetylases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fjm800988r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800988r%26sid%3Dliteratum%253Aachs%26aulast%3DMahboobi%26aufirst%3DS.%26aulast%3DDove%26aufirst%3DS.%26aulast%3DSellmer%26aufirst%3DA.%26aulast%3DWinkler%26aufirst%3DM.%26aulast%3DEichhorn%26aufirst%3DE.%26aulast%3DPongratz%26aufirst%3DH.%26aulast%3DCiossek%26aufirst%3DT.%26aulast%3DBaer%26aufirst%3DT.%26aulast%3DMaier%26aufirst%3DT.%26aulast%3DBeckers%26aufirst%3DT.%26atitle%3DDesign%2520of%2520chimeric%2520histone%2520deacetylase-%2520and%2520tyrosine%2520kinase-inhibitors%253A%2520a%2520series%2520of%2520imatinib%2520hybrids%2520as%2520potent%2520inhibitors%2520of%2520wild-type%2520and%2520mutant%2520BCR-ABL%252C%2520PDGF-R%25CE%25B2%252C%2520and%2520histone%2520deacetylases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2265%26epage%3D2279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span>Presented at the 235th National Meeting of the American Chemical Society, New Orleans, LA, April 6−10,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>Poster from Curis Inc.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Presented+at+the+235th+National+Meeting+of+the+American+Chemical+Society%2C+New+Orleans%2C+LA%2C+April+6%E2%88%9210%2C+2008%3B+Poster+from+Curis+Inc."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Triola, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetzel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellinger, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldmann, H.</span><span> </span><span class="NLM_article-title">ATP competitive inhibitors of <span class="smallcaps smallerCapital">d</span>-alanine−<span class="smallcaps smallerCapital">d</span>-alanine ligase based on protein kinase inhibitor scaffolds</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1079</span><span class="NLM_x">–</span> <span class="NLM_lpage">1087</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=1079-1087&author=G.+Triolaauthor=S.+Wetzelauthor=B.+Ellingerauthor=M.+A.+Kochauthor=K.+H%C3%BCbelauthor=D.+Rauhauthor=H.+Waldmann&title=ATP+competitive+inhibitors+of+d-alanine%E2%88%92d-alanine+ligase+based+on+protein+kinase+inhibitor+scaffolds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTriola%26aufirst%3DG.%26aulast%3DWetzel%26aufirst%3DS.%26aulast%3DEllinger%26aufirst%3DB.%26aulast%3DKoch%26aufirst%3DM.%2BA.%26aulast%3DH%25C3%25BCbel%26aufirst%3DK.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DWaldmann%26aufirst%3DH.%26atitle%3DATP%2520competitive%2520inhibitors%2520of%2520d-alanine%25E2%2588%2592d-alanine%2520ligase%2520based%2520on%2520protein%2520kinase%2520inhibitor%2520scaffolds%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D1079%26epage%3D1087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Miller, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mochalkin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banotai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunkle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harwood, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huband, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karnovsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Limberakis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehrens, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogden, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasad, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelly, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skerlos, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulavik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, V. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanderRoest, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stover, C. K.</span><span> </span><span class="NLM_article-title">A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">1737</span><span class="NLM_x">–</span> <span class="NLM_lpage">1742</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1073%2Fpnas.0811275106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=19164768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitV2jurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=1737-1742&author=J.+R.+Millerauthor=S.+Dunhamauthor=I.+Mochalkinauthor=C.+Banotaiauthor=M.+Bowmanauthor=S.+Buistauthor=B.+Dunkleauthor=D.+Hannaauthor=H.+J.+Harwoodauthor=M.+D.+Hubandauthor=A.+Karnovskyauthor=M.+Kuhnauthor=C.+Limberakisauthor=J.+Y.+Liuauthor=S.+Mehrensauthor=W.+T.+Muellerauthor=L.+Narasimhanauthor=A.+Ogdenauthor=J.+Ohrenauthor=J.+V.+Prasadauthor=J.+A.+Shellyauthor=L.+Skerlosauthor=M.+Sulavikauthor=V.+H.+Thomasauthor=S.+VanderRoestauthor=L.+Wangauthor=Z.+Wangauthor=A.+Whittonauthor=T.+Zhuauthor=C.+K.+Stover&title=A+class+of+selective+antibacterials+derived+from+a+protein+kinase+inhibitor+pharmacophore"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore</span></div><div class="casAuthors">Miller, J. Richard; Dunham, Steve; Mochalkin, Igor; Banotai, Craig; Bowman, Matthew; Buist, Susan; Dunkle, Bill; Hanna, Debra; Harwood, James; Huband, Michael D.; Karnovsky, Alla; Kuhn, Michael; Limberakis, Chris; Liu, Jia Y.; Mehrens, Shawn; Mueller, W. Thomas; Narasimhan, Lakshmi; Ogden, Adam; Ohren, Jeff; Vara Prasad, J. V. N.; Shelly, John A.; Skerlos, Laura; Sulavik, Mark; Thomas, V. Hayden; VanderRoest, Steve; Wang, LiAnn; Wang, Zhigang; Whitton, Amy; Zhu, Tong; Stover, C. Kendall</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1737-1742</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">As the need for novel antibiotic classes to combat bacterial drug resistance increases, the paucity of leads resulting from target-based antibacterial screening of pharmaceutical compd. libraries is of major concern.  One explanation for this lack of success is that antibacterial screening efforts have not leveraged the eukaryotic bias resulting from more extensive chem. efforts targeting eukaryotic gene families such as G protein-coupled receptors and protein kinases.  Consistent with a focus on antibacterial target space resembling these eukaryotic targets, we used whole-cell screening to identify a series of antibacterial pyridopyrimidines derived from a protein kinase inhibitor pharmacophore.  In bacteria, the pyridopyrimidines target the ATP-binding site of biotin carboxylase (BC), which catalyzes the first enzymic step of fatty acid biosynthesis.  These inhibitors are effective in vitro and in vivo against fastidious Gram-neg. pathogens including Haemophilus influenzae.  Although the BC active site has architectural similarity to those of eukaryotic protein kinases, inhibitor binding to the BC ATP-binding site is distinct from the protein kinase-binding mode, such that the inhibitors are selective for bacterial BC.  In summary, the authors have discovered a promising class of potent antibacterials with a previously undescribed mechanism of action.  In consideration of the eukaryotic bias of pharmaceutical libraries, the findings also suggest that pursuit of a novel inhibitor leads for antibacterial targets with active-site structural similarity to known human targets will likely be more fruitful than the traditional focus on unique bacterial target space, particularly when structure-based and computational methodologies are applied to ensure bacterial selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8jpj8EOtRo7Vg90H21EOLACvtfcHk0lhc7UdQK1vStg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitV2jurk%253D&md5=06758ee5befbe847825ec35adb177006</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0811275106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0811275106%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DJ.%2BR.%26aulast%3DDunham%26aufirst%3DS.%26aulast%3DMochalkin%26aufirst%3DI.%26aulast%3DBanotai%26aufirst%3DC.%26aulast%3DBowman%26aufirst%3DM.%26aulast%3DBuist%26aufirst%3DS.%26aulast%3DDunkle%26aufirst%3DB.%26aulast%3DHanna%26aufirst%3DD.%26aulast%3DHarwood%26aufirst%3DH.%2BJ.%26aulast%3DHuband%26aufirst%3DM.%2BD.%26aulast%3DKarnovsky%26aufirst%3DA.%26aulast%3DKuhn%26aufirst%3DM.%26aulast%3DLimberakis%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DJ.%2BY.%26aulast%3DMehrens%26aufirst%3DS.%26aulast%3DMueller%26aufirst%3DW.%2BT.%26aulast%3DNarasimhan%26aufirst%3DL.%26aulast%3DOgden%26aufirst%3DA.%26aulast%3DOhren%26aufirst%3DJ.%26aulast%3DPrasad%26aufirst%3DJ.%2BV.%26aulast%3DShelly%26aufirst%3DJ.%2BA.%26aulast%3DSkerlos%26aufirst%3DL.%26aulast%3DSulavik%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DV.%2BH.%26aulast%3DVanderRoest%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWhitton%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DStover%26aufirst%3DC.%2BK.%26atitle%3DA%2520class%2520of%2520selective%2520antibacterials%2520derived%2520from%2520a%2520protein%2520kinase%2520inhibitor%2520pharmacophore%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D1737%26epage%3D1742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Lazareno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birdsall, N. J.</span><span> </span><span class="NLM_article-title">Allosteric interactions of staurosporine and other indolocarbazoles with <i>N</i>-[methyl-3<i>H</i>]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">194</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2000&pages=194-207&author=S.+Lazarenoauthor=A.+Pophamauthor=N.+J.+Birdsall&title=Allosteric+interactions+of+staurosporine+and+other+indolocarbazoles+with+N-%5Bmethyl-3H%5Dscopolamine+and+acetylcholine+at+muscarinic+receptor+subtypes%3A+identification+of+a+second+allosteric+site"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLazareno%26aufirst%3DS.%26aulast%3DPopham%26aufirst%3DA.%26aulast%3DBirdsall%26aufirst%3DN.%2BJ.%26atitle%3DAllosteric%2520interactions%2520of%2520staurosporine%2520and%2520other%2520indolocarbazoles%2520with%2520N-%255Bmethyl-3H%255Dscopolamine%2520and%2520acetylcholine%2520at%2520muscarinic%2520receptor%2520subtypes%253A%2520identification%2520of%2520a%2520second%2520allosteric%2520site%26jtitle%3DMol.%2520Pharmacol.%26date%3D2000%26volume%3D58%26spage%3D194%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Nobeli, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favia, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornton, J. M.</span><span> </span><span class="NLM_article-title">Protein promiscuity and its implications for biotechnology</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnbt1519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=19204698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Cktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=157-167&author=I.+Nobeliauthor=A.+D.+Faviaauthor=J.+M.+Thornton&title=Protein+promiscuity+and+its+implications+for+biotechnology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Protein promiscuity and its implications for biotechnology</span></div><div class="casAuthors">Nobeli, Irene; Favia, Angelo D.; Thornton, Janet M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-167</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mol. recognition between proteins and their interacting partners underlies the biochem. of living organisms.  Specificity in this recognition is thought to be essential, whereas promiscuity is often assocd. with unwanted side-effects, poor catalytic properties, and errors in biol. function.  Recent exptl. evidence suggests that promiscuity, not only in interactions but also in the actual function of proteins, is not as rare as was previously thought.  This has implications not only for the fundamental understanding of mol. recognition and how protein function has evolved over time, but also in the realm of biotechnol.  Understanding protein promiscuity is becoming increasingly important not only to optimize protein engineering applications in areas as diverse as synthetic biol. and metagenomics, but also to lower attrition rates in drug discovery programs, identify drug interaction surfaces less susceptible to escape mutations, and potentiate the power of polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdzkMBuUqOqLVg90H21EOLACvtfcHk0lhc7UdQK1vStg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Cktrc%253D&md5=1e72967accb88b6183ec882a4cba2571</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fnbt1519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1519%26sid%3Dliteratum%253Aachs%26aulast%3DNobeli%26aufirst%3DI.%26aulast%3DFavia%26aufirst%3DA.%2BD.%26aulast%3DThornton%26aufirst%3DJ.%2BM.%26atitle%3DProtein%2520promiscuity%2520and%2520its%2520implications%2520for%2520biotechnology%26jtitle%3DNat.%2520Biotechnol.%26date%3D2009%26volume%3D27%26spage%3D157%26epage%3D167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Winger, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hantschel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)</span> <span class="citation_source-journal">BMC Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">7</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1186%2F1472-6807-9-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=19236722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A280%3ADC%252BD1M3gslyhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=7-18&author=J.+A.+Wingerauthor=O.+Hantschelauthor=G.+Superti-Furgaauthor=J.+Kuriyan&title=The+structure+of+the+leukemia+drug+imatinib+bound+to+human+quinone+reductase+2+%28NQO2%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)</span></div><div class="casAuthors">Winger Jonathan A; Hantschel Oliver; Superti-Furga Giulio; Kuriyan John</div><div class="citationInfo"><span class="NLM_cas:title">BMC structural biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Imatinib represents the first in a class of drugs targeted against chronic myelogenous leukemia to enter the clinic, showing excellent efficacy and specificity for Abl, Kit, and PDGFR kinases.  Recent screens carried out to find off-target proteins that bind to imatinib identified the oxidoreductase NQO2, a flavoprotein that is phosphorylated in a chronic myelogenous leukemia cell line.  RESULTS:  We examined the inhibition of NQO2 activity by the Abl kinase inhibitors imatinib, nilotinib, and dasatinib, and obtained IC50 values of 80 nM, 380 nM, and >100 microM, respectively.  Using electronic absorption spectroscopy, we show that imatinib binding results in a perturbation of the protein environment around the flavin prosthetic group in NQO2.  We have determined the crystal structure of the complex of imatinib with human NQO2 at 1.75 A resolution, which reveals that imatinib binds in the enzyme active site, adjacent to the flavin isoalloxazine ring.  We find that phosphorylation of NQO2 has little effect on enzyme activity and is therefore likely to regulate other aspects of NQO2 function.  CONCLUSION:  The structure of the imatinib-NQO2 complex demonstrates that imatinib inhibits NQO2 activity by competing with substrate for the active site.  The overall conformation of imatinib when bound to NQO2 resembles the folded conformation observed in some kinase complexes.  Interactions made by imatinib with residues at the rim of the active site provide an explanation for the binding selectivity of NQO2 for imatinib, nilotinib, and dasatinib.  These interactions also provide a rationale for the lack of inhibition of the related oxidoreductase NQO1 by these compounds.  Taken together, these studies provide insight into the mechanism of NQO2 inhibition by imatinib, with potential implications for drug design and treatment of chronic myelogenous leukemia in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRO2EpZRmfn9zW1zwg2yUK5fW6udTcc2ebKeO_OVLrvyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3gslyhsQ%253D%253D&md5=a19609238b7de880d6680048b15941c1</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1186%2F1472-6807-9-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6807-9-7%26sid%3Dliteratum%253Aachs%26aulast%3DWinger%26aufirst%3DJ.%2BA.%26aulast%3DHantschel%26aufirst%3DO.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DThe%2520structure%2520of%2520the%2520leukemia%2520drug%2520imatinib%2520bound%2520to%2520human%2520quinone%2520reductase%25202%2520%2528NQO2%2529%26jtitle%3DBMC%2520Struct.%2520Biol.%26date%3D2009%26volume%3D9%26spage%3D7%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Stockwell, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornton, J. M.</span><span> </span><span class="NLM_article-title">Conformational diversity of ligands bound to proteins</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">928</span><span class="NLM_x">–</span> <span class="NLM_lpage">944</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2Fj.jmb.2005.12.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=16405908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XotVOitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2006&pages=928-944&author=G.+R.+Stockwellauthor=J.+M.+Thornton&title=Conformational+diversity+of+ligands+bound+to+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational Diversity of Ligands Bound to Proteins</span></div><div class="casAuthors">Stockwell, Gareth R.; Thornton, Janet M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">928-944</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The phenomenon of mol. recognition, which underpins almost all biol. processes, is dynamic, complex and subtle.  Establishing an interaction between a pair of mols. involves mutual structural rearrangements guided by a highly convoluted energy landscape, the accurate mapping of which continues to elude us.  Increased understanding of the degree to which the conformational space of a ligand is restricted upon binding may have important implications for docking studies, structure refinement and for function prediction methods based on geometrical comparisons of ligands or their binding sites.  Here, we present an anal. of the conformational variability exhibited by three of the most ubiquitous biol. ligands in nature, ATP, NAD and FAD.  First, we demonstrate qual. that these ligands bind to proteins in widely varying conformations, including several cases in which parts of the mol. assume energetically unfavorable orientations.  Next, by comparing the distribution of bound ligand shapes with the set of all possible mol. conformations, we provide a quant. assessment of previous observations that ligands tend to unfold when binding to proteins.  We show that, while extended forms of ligands are indeed common in ligand-protein structures, instances of ligands in almost maximally compact arrangements can also be found.  Thirdly, we compare the conformational variation in two sets of ligand mols., those bound to homologous proteins, and those bound to unrelated proteins.  Although most superfamilies bind ligands in a fairly conserved manner, we find several cases in which significant variation in ligand configuration is obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfZf7uuw0-gLVg90H21EOLACvtfcHk0lgxm7rA5rd7Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotVOitA%253D%253D&md5=581db35cc9e2a3fb061ef00321566fc3</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2005.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2005.12.012%26sid%3Dliteratum%253Aachs%26aulast%3DStockwell%26aufirst%3DG.%2BR.%26aulast%3DThornton%26aufirst%3DJ.%2BM.%26atitle%3DConformational%2520diversity%2520of%2520ligands%2520bound%2520to%2520proteins%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2006%26volume%3D356%26spage%3D928%26epage%3D944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Weber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supuran, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scozzafava, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebe, G.</span><span> </span><span class="NLM_article-title">Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">550</span><span class="NLM_x">–</span> <span class="NLM_lpage">557</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=550-557&author=A.+Weberauthor=A.+Casiniauthor=A.+Heineauthor=D.+Kuhnauthor=C.+T.+Supuranauthor=A.+Scozzafavaauthor=G.+Klebe&title=Unexpected+nanomolar+inhibition+of+carbonic+anhydrase+by+COX-2-selective+celecoxib%3A+new+pharmacological+opportunities+due+to+related+binding+site+recognition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DA.%26aulast%3DCasini%26aufirst%3DA.%26aulast%3DHeine%26aufirst%3DA.%26aulast%3DKuhn%26aufirst%3DD.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26aulast%3DScozzafava%26aufirst%3DA.%26aulast%3DKlebe%26aufirst%3DG.%26atitle%3DUnexpected%2520nanomolar%2520inhibition%2520of%2520carbonic%2520anhydrase%2520by%2520COX-2-selective%2520celecoxib%253A%2520new%2520pharmacological%2520opportunities%2520due%2520to%2520related%2520binding%2520site%2520recognition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D550%26epage%3D557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Jenwitheesuk, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horst, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivas, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Voorhis, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samudrala, R.</span><span> </span><span class="NLM_article-title">Novel paradigms for drug discovery: computational multitarget screening</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">62</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1016%2Fj.tips.2007.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=18190973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhslOjsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=62-71&author=E.+Jenwitheesukauthor=J.+A.+Horstauthor=K.+L.+Rivasauthor=W.+C.+Van+Voorhisauthor=R.+Samudrala&title=Novel+paradigms+for+drug+discovery%3A+computational+multitarget+screening"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Novel paradigms for drug discovery: computational multitarget screening</span></div><div class="casAuthors">Jenwitheesuk, Ekachai; Horst, Jeremy A.; Rivas, Kasey L.; Van Voorhis, Wesley C.; Samudrala, Ram</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">62-71</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  An established paradigm in current drug development is (i) to identify a single protein target whose inhibition is likely to result in the successful treatment of a disease of interest; (ii) to assay exptl. large libraries of small-mol. compds. in vitro and in vivo to identify promising inhibitors in model systems; and (iii) to det. whether the findings are extensible to humans.  This complex process, which is largely based on trial and error, is risk-, time- and cost-intensive.  Computational (virtual) screening of drug-like compds. simultaneously against the at. structures of multiple protein targets, taking into account protein-inhibitor dynamics, might help to identify lead inhibitors more efficiently, particularly for complex drug-resistant diseases.  Here we discuss the potential benefits of this approach, using HIV-1 and Plasmodium falciparum infections as examples.  We propose a virtual drug discovery pipeline' that will not only identify lead inhibitors efficiently, but also help minimize side-effects and toxicity, thereby increasing the likelihood of successful therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcA1qFl-hV8bVg90H21EOLACvtfcHk0lgxm7rA5rd7Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhslOjsLo%253D&md5=0dd3e34e8bf4a9799194d7add9ff7343</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DJenwitheesuk%26aufirst%3DE.%26aulast%3DHorst%26aufirst%3DJ.%2BA.%26aulast%3DRivas%26aufirst%3DK.%2BL.%26aulast%3DVan%2BVoorhis%26aufirst%3DW.%2BC.%26aulast%3DSamudrala%26aufirst%3DR.%26atitle%3DNovel%2520paradigms%2520for%2520drug%2520discovery%253A%2520computational%2520multitarget%2520screening%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2008%26volume%3D29%26spage%3D62%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group">Bender, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettles, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, J. W.</span><span> </span><span class="NLM_article-title">Bayes affinity fingerprints improve retrieval rates in virtual screening and define orthogonal bioactivity space: When are multitarget drugs a feasible concept?</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2445</span><span class="NLM_x">–</span> <span class="NLM_lpage">2456</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci600197y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpt1yqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=2445-2456&author=A.+Benderauthor=J.+L.+Jenkinsauthor=M.+Glickauthor=Z.+Dengauthor=J.+H.+Nettlesauthor=J.+W.+Davies&title=Bayes+affinity+fingerprints+improve+retrieval+rates+in+virtual+screening+and+define+orthogonal+bioactivity+space%3A+When+are+multitarget+drugs+a+feasible+concept%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">"Bayes Affinity Fingerprints" Improve Retrieval Rates in Virtual Screening and Define Orthogonal Bioactivity Space: When Are Multitarget Drugs a Feasible Concept?</span></div><div class="casAuthors">Bender, Andreas; Jenkins, Jeremy L.; Glick, Meir; Deng, Zhan; Nettles, James H.; Davies, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2445-2456</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Conventional similarity searching of mols. compares single (or multiple) active query structures to each other in a relative framework, by means of a structural descriptor and a similarity measure.  While this often works well, depending on the target, the authors show here that retrieval rates can be improved considerably by incorporating an external framework describing ligand bioactivity space for comparisons ("Bayes affinity fingerprints").  Structures are described by Bayes scores for a ligand panel comprising about 1000 activity classes extd. from the WOMBAT database.  The comparison of structures is performed via the Pearson correlation coeff. of activity classes, i.e., the order in which two structures are similar to the panel activity classes.  Compd. retrieval on a recently published data set could be improved by as much as 24% relative (9% abs.).  Knowledge about the shape of the "bioactive chem. universe" is thus beneficial to identifying similar bioactivities.  Principal component anal. was employed to further analyze activity space with the objective to define orthogonal ligand bioactive chem. space, leading to nine major (roughly orthogonal) activity axes.  Employing only those nine activity classes, retrieval rates are still comparable to original Bayes affinity fingerprints; thus, the concept of orthogonal bioactive ligand chem. space was validated as being an information-rich but low-dimensional representation of bioactivity space.  Correlations between activity classes are a major determinant to gauge whether the desired multitarget activity of drugs is (on the basis of current knowledge) a feasible concept because it measures the extent to which activities can be optimized independently, or only by strongly influencing one another.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6IjlYwYDTwLVg90H21EOLACvtfcHk0lgXyBFjLxP8tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpt1yqsrs%253D&md5=47adb720154f45bda1738963d54c70a5</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1021%2Fci600197y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci600197y%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DZ.%26aulast%3DNettles%26aufirst%3DJ.%2BH.%26aulast%3DDavies%26aufirst%3DJ.%2BW.%26atitle%3DBayes%2520affinity%2520fingerprints%2520improve%2520retrieval%2520rates%2520in%2520virtual%2520screening%2520and%2520define%2520orthogonal%2520bioactivity%2520space%253A%2520When%2520are%2520multitarget%2520drugs%2520a%2520feasible%2520concept%253F%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2006%26volume%3D46%26spage%3D2445%26epage%3D2456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armbruster, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernsberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span> </span><span class="NLM_article-title">Relating protein pharmacology by ligand chemistry</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnbt1284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17287757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOrsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=197-206&author=M.+J.+Keiserauthor=B.+L.+Rothauthor=B.+N.+Armbrusterauthor=P.+Ernsbergerauthor=J.+J.+Irwinauthor=B.+K.+Shoichet&title=Relating+protein+pharmacology+by+ligand+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Relating protein pharmacology by ligand chemistry</span></div><div class="casAuthors">Keiser, Michael J.; Roth, Bryan L.; Armbruster, Blaine N.; Ernsberger, Paul; Irwin, John J.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-206</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The identification of protein function based on biol. information is an area of intense research.  Here the authors consider a complementary technique that quant. groups and relates proteins based on the chem. similarity of their ligands.  The authors began with 65,000 ligands annotated into sets for hundreds of drug targets.  The similarity score between each set was calcd. using ligand topol.  A statistical model was developed to rank the significance of the resulting similarity scores, which are expressed as a min. spanning tree to map the sets together.  Although these maps are connected solely by chem. similarity, biol. sensible clusters nevertheless emerged.  Links among unexpected targets also emerged, among them that methadone, emetine and loperamide (Imodium) may antagonize muscarinic M3, α2 adrenergic and neurokinin NK2 receptors, resp.  These predictions were subsequently confirmed exptl.  Relating receptors by ligand chem. organizes biol. to reveal unexpected relationships that may be assayed using the ligands themselves.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNKEMguhmluLVg90H21EOLACvtfcHk0lgXyBFjLxP8tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOrsLo%253D&md5=1b7373d52563fca5fe1e893d85f70573</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fnbt1284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1284%26sid%3Dliteratum%253Aachs%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DArmbruster%26aufirst%3DB.%2BN.%26aulast%3DErnsberger%26aufirst%3DP.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DRelating%2520protein%2520pharmacology%2520by%2520ligand%2520chemistry%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D197%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Network pharmacology: the next paradigm in drug discovery</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">682</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnchembio.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=18936753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=682-690&author=A.+L.+Hopkins&title=Network+pharmacology%3A+the+next+paradigm+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology: the next paradigm in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is the concept of designing maximally selective ligands to act on individual drug targets.  However, many effective drugs act via modulation of multiple proteins rather than single targets.  Advances in systems biol. are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compds., compared with multi-target drugs, may exhibit lower than desired clin. efficacy.  This new appreciation of the role of polypharmacol. has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity.  Integrating network biol. and polypharmacol. holds the promise of expanding the current opportunity space for druggable targets.  However, the rational design of polypharmacol. faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties.  Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqHy4FqkK-h7Vg90H21EOLACvtfcHk0lgXyBFjLxP8tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK&md5=03b8be3ddbcab7dc65afd17df7ee8395</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.118%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DNetwork%2520pharmacology%253A%2520the%2520next%2520paradigm%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D682%26epage%3D690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Lehár, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molnar, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ledell, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heilbut, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Short, G. F.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giusti, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolan, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magid, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borisy, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockwell, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, C. T.</span><span> </span><span class="NLM_article-title">Chemical combination effects predict connectivity in biological systems</span> <span class="citation_source-journal">Mol. Syst. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=80-93&author=J.+Leh%C3%A1rauthor=G.+R.+Zimmermannauthor=A.+S.+Kruegerauthor=R.+A.+Molnarauthor=J.+T.+Ledellauthor=A.+M.+Heilbutauthor=G.+F.+Shortauthor=L.+C.+Giustiauthor=G.+P.+Nolanauthor=O.+A.+Magidauthor=M.+S.+Leeauthor=A.+A.+Borisyauthor=B.+R.+Stockwellauthor=C.+T.+Keith&title=Chemical+combination+effects+predict+connectivity+in+biological+systems"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeh%25C3%25A1r%26aufirst%3DJ.%26aulast%3DZimmermann%26aufirst%3DG.%2BR.%26aulast%3DKrueger%26aufirst%3DA.%2BS.%26aulast%3DMolnar%26aufirst%3DR.%2BA.%26aulast%3DLedell%26aufirst%3DJ.%2BT.%26aulast%3DHeilbut%26aufirst%3DA.%2BM.%26aulast%3DShort%26aufirst%3DG.%2BF.%26aulast%3DGiusti%26aufirst%3DL.%2BC.%26aulast%3DNolan%26aufirst%3DG.%2BP.%26aulast%3DMagid%26aufirst%3DO.%2BA.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DBorisy%26aufirst%3DA.%2BA.%26aulast%3DStockwell%26aufirst%3DB.%2BR.%26aulast%3DKeith%26aufirst%3DC.%2BT.%26atitle%3DChemical%2520combination%2520effects%2520predict%2520connectivity%2520in%2520biological%2520systems%26jtitle%3DMol.%2520Syst.%2520Biol.%26date%3D2007%26volume%3D3%26spage%3D80%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group">Okuzumi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiedler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aizenstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Inhibitor hijacking of AKT activation</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">484</span><span class="NLM_x">–</span> <span class="NLM_lpage">493</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1038%2Fnchembio.183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=19465931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtlarsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=484-493&author=T.+Okuzumiauthor=D.+Fiedlerauthor=C.+Zhangauthor=D.+C.+Grayauthor=B.+Aizensteinauthor=R.+Hoffmanauthor=K.+M.+Shokat&title=Inhibitor+hijacking+of+AKT+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitor hijacking of Akt activation</span></div><div class="casAuthors">Okuzumi, Tatsuya; Fiedler, Dorothea; Zhang, Chao; Gray, Daniel C.; Aizenstein, Brian; Hoffman, Randy; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">484-493</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The kinase Akt plays a central role as a regulator of multiple growth factor input signals, thus making it an attractive anticancer drug target.  A-443654 is an ATP-competitive Akt inhibitor.  Unexpectedly, treatment of cells with A-443654 causes paradoxical hyperphosphorylation of Akt at its two regulatory sites (Thr308 and Ser473).  We explored whether inhibitor-induced hyperphosphorylation of Akt by A-443654 is a consequence of disrupted feedback regulation at a pathway level or whether it is a direct consequence of inhibitor binding to the ATP binding site of Akt.  Catalytically inactive mutants of Akt revealed that binding of an inhibitor to the ATP site of Akt is sufficient to directly cause hyperphosphorylation of the kinase in the absence of any pathway feedback effects.  We conclude that ATP-competitive Akt inhibitors impart regulatory phosphorylation of their target kinase Akt.  These results provide new insights into both natural regulation of Akt activation and Akt inhibitors entering the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWNjUB9YVue7Vg90H21EOLACvtfcHk0lio5z9sloH_PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtlarsrY%253D&md5=4edb5a0457fd9378850102a6414bfdb5</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.183%26sid%3Dliteratum%253Aachs%26aulast%3DOkuzumi%26aufirst%3DT.%26aulast%3DFiedler%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DGray%26aufirst%3DD.%2BC.%26aulast%3DAizenstein%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DInhibitor%2520hijacking%2520of%2520AKT%2520activation%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D484%26epage%3D493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Fan, Q. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mostov, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, W. A.</span><span> </span><span class="NLM_article-title">A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2006&pages=341-349&author=Q.+W.+Fanauthor=Z.+A.+Knightauthor=D.+D.+Goldenbergauthor=W.+Yuauthor=K.+E.+Mostovauthor=D.+Stokoeauthor=K.+M.+Shokatauthor=W.+A.+Weiss&title=A+dual+PI3+kinase%2FmTOR+inhibitor+reveals+emergent+efficacy+in+glioma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DQ.%2BW.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DGoldenberg%26aufirst%3DD.%2BD.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DMostov%26aufirst%3DK.%2BE.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26atitle%3DA%2520dual%2520PI3%2520kinase%252FmTOR%2520inhibitor%2520reveals%2520emergent%2520efficacy%2520in%2520glioma%26jtitle%3DCancer%2520Cell%26date%3D2006%26volume%3D9%26spage%3D341%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group">Sergina, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rausch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moasser, M. M.</span><span> </span><span class="NLM_article-title">Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">445</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">441</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=445&publication_year=2007&pages=437-441&author=N.+V.+Serginaauthor=M.+Rauschauthor=D.+Wangauthor=J.+Blairauthor=B.+Hannauthor=K.+M.+Shokatauthor=M.+M.+Moasser&title=Escape+from+HER-family+tyrosine+kinase+inhibitor+therapy+by+the+kinase-inactive+HER3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSergina%26aufirst%3DN.%2BV.%26aulast%3DRausch%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DBlair%26aufirst%3DJ.%26aulast%3DHann%26aufirst%3DB.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DMoasser%26aufirst%3DM.%2BM.%26atitle%3DEscape%2520from%2520HER-family%2520tyrosine%2520kinase%2520inhibitor%2520therapy%2520by%2520the%2520kinase-inactive%2520HER3%26jtitle%3DNature%26date%3D2007%26volume%3D445%26spage%3D437%26epage%3D441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">Fan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolaides, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, W. A.</span><span> </span><span class="NLM_article-title">A dual PI3K α/mTOR inhibitor cooperates with blockade of EGFR in PTEN-mutant glioma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">7960</span><span class="NLM_x">–</span> <span class="NLM_lpage">7965</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=7960-7965&author=Q.+Fanauthor=C.+K.+Chengauthor=T.+P.+Nicolaidesauthor=Z.+A.+Knightauthor=K.+M.+Shokatauthor=W.+A.+Weiss&title=A+dual+PI3K+%CE%B1%2FmTOR+inhibitor+cooperates+with+blockade+of+EGFR+in+PTEN-mutant+glioma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DQ.%26aulast%3DCheng%26aufirst%3DC.%2BK.%26aulast%3DNicolaides%26aufirst%3DT.%2BP.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26atitle%3DA%2520dual%2520PI3K%2520%25CE%25B1%252FmTOR%2520inhibitor%2520cooperates%2520with%2520blockade%2520of%2520EGFR%2520in%2520PTEN-mutant%2520glioma%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D7960%26epage%3D7965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1043</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1126%2Fscience.1141478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17463250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=1039-1043&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=T.+Mitsudomiauthor=Y.+Songauthor=C.+Hylandauthor=J.+O.+Parkauthor=N.+Lindemanauthor=C.+M.+Galeauthor=X.+Zhaoauthor=J.+Christensenauthor=T.+Kosakaauthor=A.+J.+Holmesauthor=A.+M.+Rogersauthor=F.+Cappuzzoauthor=T.+Mokauthor=C.+Leeauthor=B.+E.+Johnsonauthor=L.+C.+Cantleyauthor=P.+A.+J%C3%A4nne&title=MET+amplification+leads+to+gefitinib+resistance+in+lung+cancer+by+activating+ERBB3+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling</span></div><div class="casAuthors">Engelman, Jeffrey A.; Zejnullahu, Kreshnik; Mitsudomi, Tetsuya; Song, Youngchul; Hyland, Courtney; Park, Joon Oh; Lindeman, Neal; Gale, Christopher-Michael; Zhao, Xiaojun; Christensen, James; Kosaka, Takayuki; Holmes, Alison J.; Rogers, Andrew M.; Cappuzzo, Federico; Mok, Tony; Lee, Charles; Johnson, Bruce E.; Cantley, Lewis C.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">5827</span>),
    <span class="NLM_cas:pages">1039-1043</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance.  Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib.  MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib.  We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors.  Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr430gbvBeIoLVg90H21EOLACvtfcHk0lio5z9sloH_PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D&md5=3da9383b4acb965f57529b095f8f4686</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1126%2Fscience.1141478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1141478%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DHyland%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGale%26aufirst%3DC.%2BM.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DRogers%26aufirst%3DA.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DMET%2520amplification%2520leads%2520to%2520gefitinib%2520resistance%2520in%2520lung%2520cancer%2520by%2520activating%2520ERBB3%2520signaling%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D1039%26epage%3D1043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Gaestel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotlyarov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kracht, M.</span><span> </span><span class="NLM_article-title">Targeting innate immunity protein kinase signalling in inflammation</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">480</span><span class="NLM_x">–</span> <span class="NLM_lpage">499</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=480-499&author=M.+Gaestelauthor=A.+Kotlyarovauthor=M.+Kracht&title=Targeting+innate+immunity+protein+kinase+signalling+in+inflammation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGaestel%26aufirst%3DM.%26aulast%3DKotlyarov%26aufirst%3DA.%26aulast%3DKracht%26aufirst%3DM.%26atitle%3DTargeting%2520innate%2520immunity%2520protein%2520kinase%2520signalling%2520in%2520inflammation%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D480%26epage%3D499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">Ronkina, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotlyarov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittrich-Breiholz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kracht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milarski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Askew, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marusic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaestel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telliez, J. B.</span><span> </span><span class="NLM_article-title">The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">170</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1128%2FMCB.01456-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17030606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1Oh" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=170-181&author=N.+Ronkinaauthor=A.+Kotlyarovauthor=O.+Dittrich-Breiholzauthor=M.+Krachtauthor=E.+Hittiauthor=K.+Milarskiauthor=R.+Askewauthor=S.+Marusicauthor=L.+L.+Linauthor=M.+Gaestelauthor=J.+B.+Telliez&title=The+mitogen-activated+protein+kinase+%28MAPK%29-activated+protein+kinases+MK2+and+MK3+cooperate+in+stimulation+of+tumor+necrosis+factor+biosynthesis+and+stabilization+of+p38+MAPK"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK</span></div><div class="casAuthors">Ronkina, N.; Kotlyarov, A.; Dittrich-Breiholz, O.; Kracht, M.; Hitti, E.; Milarski, K.; Askew, R.; Marusic, S.; Lin, L.-L.; Gaestel, M.; Telliez, J.-B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">170-181</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">MK2 and MK3 represent protein kinases downstream of p38 mitogen-activated protein kinase (MAPK).  Deletion of the MK2 gene in mice resulted in an impaired inflammatory response although MK3, which displays extensive structural similarities and identical functional properties in vitro, is still present.  Here, the authors analyze tumor necrosis factor (TNF) prodn. and expression of p38 MAPK and tristetraprolin (TTP) in MK3-deficient mice and demonstrate that there are no significant differences with wild-type animals.  The authors show that in vivo MK2 and MK3 are expressed and activated in parallel.  However, the level of activity of MK2 is always significantly higher than that of MK3.  Accordingly, the authors hypothesized that MK3 could have significant effects only in an MK2-free background and generated MK2/MK3 double-knockout mice.  Unexpectedly, these mice are viable and show no obvious defects due to loss of compensation between MK2 and MK3.  However, there is a further redn. of TNF prodn. and expression of p38 and TTP in double-knockout mice compared to MK2-deficient mice.  This finding, together with the observation that ectopically expressed MK3 can rescue MK2 deficiency similarly to MK2, indicates that both kinases share the same physiol. function in vivo but are expressed to different levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdXOig9ZksrbVg90H21EOLACvtfcHk0ljwwse2A2LpCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1Oh&md5=4dca45754c91bce57cf3c2063bf23a88</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1128%2FMCB.01456-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01456-06%26sid%3Dliteratum%253Aachs%26aulast%3DRonkina%26aufirst%3DN.%26aulast%3DKotlyarov%26aufirst%3DA.%26aulast%3DDittrich-Breiholz%26aufirst%3DO.%26aulast%3DKracht%26aufirst%3DM.%26aulast%3DHitti%26aufirst%3DE.%26aulast%3DMilarski%26aufirst%3DK.%26aulast%3DAskew%26aufirst%3DR.%26aulast%3DMarusic%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DL.%2BL.%26aulast%3DGaestel%26aufirst%3DM.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26atitle%3DThe%2520mitogen-activated%2520protein%2520kinase%2520%2528MAPK%2529-activated%2520protein%2520kinases%2520MK2%2520and%2520MK3%2520cooperate%2520in%2520stimulation%2520of%2520tumor%2520necrosis%2520factor%2520biosynthesis%2520and%2520stabilization%2520of%2520p38%2520MAPK%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2007%26volume%3D27%26spage%3D170%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">Herrick, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Million, R. P.</span><span> </span><span class="NLM_article-title">From the analyst's couch: tapping the potential of fixed-dose combinations</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">513</span><span class="NLM_x">–</span> <span class="NLM_lpage">514</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=513-514&author=T.+M.+Herrickauthor=R.+P.+Million&title=From+the+analyst%27s+couch%3A+tapping+the+potential+of+fixed-dose+combinations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHerrick%26aufirst%3DT.%2BM.%26aulast%3DMillion%26aufirst%3DR.%2BP.%26atitle%3DFrom%2520the%2520analyst%2527s%2520couch%253A%2520tapping%2520the%2520potential%2520of%2520fixed-dose%2520combinations%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D513%26epage%3D514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span> </span><span class="NLM_article-title">From Pioneering Collaboration to Investigate Novel Combination Anticancer Regimen</span>. Press Release; AstraZeneca and Merck & Co., Inc., June 1,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span><a href="http://www.merck.com" class="extLink">www.merck.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=From+Pioneering+Collaboration+to+Investigate+Novel+Combination+Anticancer+Regimen.+Press+Release%3B+AstraZeneca+and+Merck+%26+Co.%2C+Inc.%2C+June+1%2C+2009%3B+www.merck.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DFrom%2520Pioneering%2520Collaboration%2520to%2520Investigate%2520Novel%2520Combination%2520Anticancer%2520Regimen%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">Cannon, C. P.</span><span> </span><span class="NLM_article-title">Can the polypill save the world from heart disease?</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">1341</span><span class="NLM_x">–</span> <span class="NLM_lpage">1351</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2009&pages=1341-1351&author=C.+P.+Cannon&title=Can+the+polypill+save+the+world+from+heart+disease%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCannon%26aufirst%3DC.%2BP.%26atitle%3DCan%2520the%2520polypill%2520save%2520the%2520world%2520from%2520heart%2520disease%253F%26jtitle%3DLancet%26date%3D2009%26volume%3D373%26spage%3D1341%26epage%3D1351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">Frantz, S.</span><span> </span><span class="NLM_article-title">The trouble with making combination drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">882</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=881-882&author=S.+Frantz&title=The+trouble+with+making+combination+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFrantz%26aufirst%3DS.%26atitle%3DThe%2520trouble%2520with%2520making%2520combination%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D881%26epage%3D882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Rokosz, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beasley, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appell, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, M. L.</span><span> </span><span class="NLM_article-title">Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges</span> <span class="citation_source-journal">Expert Opin. Ther Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">883</span><span class="NLM_x">–</span> <span class="NLM_lpage">903</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1517%2F14728222.12.7.883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=18554156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntFylsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=883-903&author=L.+L.+Rokoszauthor=J.+R.+Beasleyauthor=C.+D.+Carrollauthor=T.+Linauthor=J.+Zhaoauthor=K.+C.+Appellauthor=M.+L.+Webb&title=Kinase+inhibitors+as+drugs+for+chronic+inflammatory+and+immunological+diseases%3A+progress+and+challenges"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges</span></div><div class="casAuthors">Rokosz, Laura L.; Beasley, James R.; Carroll, Carolyn DiIanni; Lin, Tsung; Zhao, Jiuqiao; Appell, Kenneth C.; Webb, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">883-903</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  At the time of writing, there are seven marketed kinase inhibitor drugs.  The first kinase inhibitor, imatinib mesilate (Gleevec, Novartis), came to market in 2001, an inhibitor of the breakpoint cluster region (BCR)/Abelson murine leukemia oncogene homolog (ABL) fusion, platelet-derived growth factor (PDGF) receptor, and c-kit kinases.  The most recent kinase inhibitor to come to market, disatinib (Sprycel, Bristol-Myers Squibb), acts on c-SRC, ABL and Bruton's tyrosine kinase.  To date, kinase inhibitor drugs are approved for oncol. and demonstrate that it is possible to develop compds. with relative selectivity for the target kinase against the broader kinome.  However, the use of kinase inhibitors in chronic inflammatory and immunol. diseases may require greater selectivity for the target kinase.  This review addresses the opportunities and challenges of kinase inhibition as a therapeutic approach in chronic immune and inflammatory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq458NGQKTbcbVg90H21EOLACvtfcHk0ljwwse2A2LpCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntFylsLY%253D&md5=6db3fdcc34b3ec97394c9dc6cdca8b99</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1517%2F14728222.12.7.883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.12.7.883%26sid%3Dliteratum%253Aachs%26aulast%3DRokosz%26aufirst%3DL.%2BL.%26aulast%3DBeasley%26aufirst%3DJ.%2BR.%26aulast%3DCarroll%26aufirst%3DC.%2BD.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DAppell%26aufirst%3DK.%2BC.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26atitle%3DKinase%2520inhibitors%2520as%2520drugs%2520for%2520chronic%2520inflammatory%2520and%2520immunological%2520diseases%253A%2520progress%2520and%2520challenges%26jtitle%3DExpert%2520Opin.%2520Ther%2520Targets%26date%3D2008%26volume%3D12%26spage%3D883%26epage%3D903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">ter Haar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazhanisamy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taslimi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bemis, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harbeson, S. L.</span><span> </span><span class="NLM_article-title">Kinase chemogenomics: targeting the human kinome for target validation and drug discovery</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=235-253&author=E.+ter+Haarauthor=W.+P.+Waltersauthor=S.+Pazhanisamyauthor=P.+Taslimiauthor=A.+C.+Pierceauthor=G.+W.+Bemisauthor=F.+G.+Salituroauthor=S.+L.+Harbeson&title=Kinase+chemogenomics%3A+targeting+the+human+kinome+for+target+validation+and+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dter%2BHaar%26aufirst%3DE.%26aulast%3DWalters%26aufirst%3DW.%2BP.%26aulast%3DPazhanisamy%26aufirst%3DS.%26aulast%3DTaslimi%26aufirst%3DP.%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DHarbeson%26aufirst%3DS.%2BL.%26atitle%3DKinase%2520chemogenomics%253A%2520targeting%2520the%2520human%2520kinome%2520for%2520target%2520validation%2520and%2520drug%2520discovery%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D235%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group">Camins, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdaguer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canudas, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallas, M.</span><span> </span><span class="NLM_article-title">The role of CDK5/P25 formation/inhibition in neurodegeneration</span> <span class="citation_source-journal">Drug News Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">453</span><span class="NLM_x">–</span> <span class="NLM_lpage">460</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Fjm901132v&amp;key=10.1358%2Fdnp.2006.19.8.1043961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=17160145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXls1Cktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=453-460&author=A.+Caminsauthor=E.+Verdaguerauthor=J.+Folchauthor=A.+M.+Canudasauthor=M.+Pallas&title=The+role+of+CDK5%2FP25+formation%2Finhibition+in+neurodegeneration"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">The role of CDK5/P25 formation/inhibition in neurodegeneration</span></div><div class="casAuthors">Camins, Antoni; Verdaguer, Ester; Folch, Jaume; Canudas, Anna Maria; Pallas, Merce</div><div class="citationInfo"><span class="NLM_cas:title">Drug News & Perspectives</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">453-460</span>CODEN:
                <span class="NLM_cas:coden">DNPEED</span>;
        ISSN:<span class="NLM_cas:issn">0214-0934</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Cdk5 is an atypical cyclin-dependent kinase localized in the brain, and its activity is dependent upon binding to p35/p39.  In addn., while cdk5 has important physiol. functions related to brain development, the breakdown of cdk5/p35 into cdk5/p25 increases its kinase activity and neurotoxicity.  Interestingly, in recent years increased cdk5/p25 expression has been demonstrated in the brains of patients with Alzheimer's and Parkinson's diseases.  Exptl. studies performed in neuronal cell cultures indicate that cdk5/p25 plays a prominent role in apoptosis.  Moreover, an apoptotic pathway, via an intracellular calcium increase following calpain activation and cdk5/p25 formation, has been postulated.  Cdk5/p25 subsequently phosphorylates the nuclear transcription factor myocyte enhancer factor (MEF2), thereby inhibiting its prosurvival activity.  However, cdk5/p25 could phosphorylate other substrates such as tau and p53, as well as the retinoblastoma protein pRb.  All these data lend credence to the hypothesis that cdk5/p25 acts as a master regulator of neuronal cell death.  In addn., cdk5/p25 might also interact with other pathways such as glycogen synthetase kinase 3β (GSK3β) and c-JUN kinase.  Drugs like roscovitine, flavopiridol, calpain inhibitors, kenpaullone and induribins, which inhibit cdk5/p25 formation, constitute potential drugs for the treatment of neurol. disorders.  Furthermore, the dual inhibitory effect of some of these drugs on cdk5 and GSK3β could be beneficial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwOxQ0IEe0BrVg90H21EOLACvtfcHk0lhIZI1EWzG3Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXls1Cktw%253D%253D&md5=7cc22392cdc933c8aac503cbb8a0cede</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1358%2Fdnp.2006.19.8.1043961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdnp.2006.19.8.1043961%26sid%3Dliteratum%253Aachs%26aulast%3DCamins%26aufirst%3DA.%26aulast%3DVerdaguer%26aufirst%3DE.%26aulast%3DFolch%26aufirst%3DJ.%26aulast%3DCanudas%26aufirst%3DA.%2BM.%26aulast%3DPallas%26aufirst%3DM.%26atitle%3DThe%2520role%2520of%2520CDK5%252FP25%2520formation%252Finhibition%2520in%2520neurodegeneration%26jtitle%3DDrug%2520News%2520Perspect.%26date%3D2006%26volume%3D19%26spage%3D453%26epage%3D460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Aulia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, B. L.</span><span> </span><span class="NLM_article-title">Cdh1-APC/C, cyclin B-Cdc2, and Alzheimer’s disease pathology</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">339</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2006&pages=1-6&author=S.+Auliaauthor=B.+L.+Tang&title=Cdh1-APC%2FC%2C+cyclin+B-Cdc2%2C+and+Alzheimer%E2%80%99s+disease+pathology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAulia%26aufirst%3DS.%26aulast%3DTang%26aufirst%3DB.%2BL.%26atitle%3DCdh1-APC%252FC%252C%2520cyclin%2520B-Cdc2%252C%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%2520pathology%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2006%26volume%3D339%26spage%3D1%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Takashima, A.</span><span> </span><span class="NLM_article-title">GSK-3 is essential in the pathogenesis of Alzheimer’s disease</span> <span class="citation_source-journal">J. Alzheimer's Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Fjm901132v&amp;key=16914869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Fjm901132v&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFKktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2006&pages=309-317&author=A.+Takashima&title=GSK-3+is+essential+in+the+pathogenesis+of+Alzheimer%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">GSK-3 is essential in the pathogenesis of Alzheimer's disease</span></div><div class="casAuthors">Takashima, Akihiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">Suppl. 3</span>),
    <span class="NLM_cas:pages">309-317</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">A review.  Glycogen synthase kinase-3 (GSK-3) is a pivotal mol. in the development of Alzheimer's disease (AD).  GSK-3β is involved in the formation of paired helical filament (PHF)-tau, which is an integral component of the neurofibrillary tangle (NFT) deposits that disrupt neuronal function, and a marker of neurodegeneration in AD.  GSK-3β has exactly the same oligonucleotide sequence as tau-protein kinase I (TPKI), which was first purified from the microtubule fraction of bovine brain.  Initially, we discovered that GSK-3β was involved in amyloid-β (Aβ)-induced neuronal death in rat hippocampal cultures.  In the present review, we discuss our initial in vitro results and addnl. investigations showing that Aβ activates GSK-3β through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Aβ-activated GSK-3β induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3β can induce memory deficits in vivo; and that inhibition of GSK-3α (an isoform of GSK-3β) reduces Aβ prodn.  These combined results strongly suggest that GSK-3 activation is a crit. step in brain aging and the cascade of detrimental events in AD, preceding both the NFT and neuronal death pathways.  Therefore, therapeutics targeted to inhibiting GSK-3 may be beneficial in the treatment of this devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP4pguAPgiQLVg90H21EOLACvtfcHk0lhIZI1EWzG3Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFKktLo%253D&md5=d7157eb2d6a985a3489bb143113d7500</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakashima%26aufirst%3DA.%26atitle%3DGSK-3%2520is%2520essential%2520in%2520the%2520pathogenesis%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2006%26volume%3D9%26spage%3D309%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group">Flajolet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heiman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nairn, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greengard, P.</span><span> </span><span class="NLM_article-title">Regulation of Alzheimer’s disease amyloid-beta formation by casein kinase I</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">4159</span><span class="NLM_x">–</span> <span class="NLM_lpage">4164</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=4159-4164&author=M.+Flajoletauthor=G.+Heauthor=M.+Heimanauthor=A.+Linauthor=A.+C.+Nairnauthor=P.+Greengard&title=Regulation+of+Alzheimer%E2%80%99s+disease+amyloid-beta+formation+by+casein+kinase+I"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFlajolet%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DHeiman%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DA.%26aulast%3DNairn%26aufirst%3DA.%2BC.%26aulast%3DGreengard%26aufirst%3DP.%26atitle%3DRegulation%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520amyloid-beta%2520formation%2520by%2520casein%2520kinase%2520I%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D4159%26epage%3D4164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Oumata, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bettayeb, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferandin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demange, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Giral, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goddard, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myrianthopoulos, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikros, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flajolet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greengard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galons, H.</span><span> </span><span class="NLM_article-title">Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5229</span><span class="NLM_x">–</span> <span class="NLM_lpage">5242</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800109e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5229-5242&author=N.+Oumataauthor=K.+Bettayebauthor=Y.+Ferandinauthor=L.+Demangeauthor=A.+Lopez-Giralauthor=M.+L.+Goddardauthor=V.+Myrianthopoulosauthor=E.+Mikrosauthor=M.+Flajoletauthor=P.+Greengardauthor=L.+Meijerauthor=H.+Galons&title=Roscovitine-derived%2C+dual-specificity+inhibitors+of+cyclin-dependent+kinases+and+casein+kinases+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1021%2Fjm800109e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800109e%26sid%3Dliteratum%253Aachs%26aulast%3DOumata%26aufirst%3DN.%26aulast%3DBettayeb%26aufirst%3DK.%26aulast%3DFerandin%26aufirst%3DY.%26aulast%3DDemange%26aufirst%3DL.%26aulast%3DLopez-Giral%26aufirst%3DA.%26aulast%3DGoddard%26aufirst%3DM.%2BL.%26aulast%3DMyrianthopoulos%26aufirst%3DV.%26aulast%3DMikros%26aufirst%3DE.%26aulast%3DFlajolet%26aufirst%3DM.%26aulast%3DGreengard%26aufirst%3DP.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DGalons%26aufirst%3DH.%26atitle%3DRoscovitine-derived%252C%2520dual-specificity%2520inhibitors%2520of%2520cyclin-dependent%2520kinases%2520and%2520casein%2520kinases%25201%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5229%26epage%3D5242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group">Chioua, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samadi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lozach, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marco-Contelles, J.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 3,6-diamino-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine derivatives as protein kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4566</span><span class="NLM_x">–</span> <span class="NLM_lpage">4569</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4566-4569&author=M.+Chiouaauthor=A.+Samadiauthor=E.+Sorianoauthor=O.+Lozachauthor=L.+Meijerauthor=J.+Marco-Contelles&title=Synthesis+and+biological+evaluation+of+3%2C6-diamino-1H-pyrazolo%5B3%2C4-b%5Dpyridine+derivatives+as+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChioua%26aufirst%3DM.%26aulast%3DSamadi%26aufirst%3DA.%26aulast%3DSoriano%26aufirst%3DE.%26aulast%3DLozach%26aufirst%3DO.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25203%252C6-diamino-1H-pyrazolo%255B3%252C4-b%255Dpyridine%2520derivatives%2520as%2520protein%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4566%26epage%3D4569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm901132v&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2010.53.issue-4%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Fjm901132v%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm901132v" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a7ed86a833d48","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
